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Background: Patients with transient ischaemic attack (TIA) or minor stroke need rapid treatment of risk
factors to prevent recurrent stroke. ABCD2 score or magnetic resonance diffusion-weighted brain imaging
(MR DWI) may help assessment and treatment.
Objectives: Is MR with DWI cost-effective in stroke prevention compared with computed tomography (CT)
brain scanning in all patients, in specific subgroups or as ‘one-stop’ brain-carotid imaging? What is the
current UK availability of services for stroke prevention?
Data sources: Published literature; stroke registries, audit and randomised clinical trials; national
databases; survey of UK clinical and imaging services for stroke; expert opinion.
Review methods: Systematic reviews and meta-analyses of published/unpublished data. Decision-analytic
model of stroke prevention including on a 20-year time horizon including nine representative
imaging scenarios.
Results: The pooled recurrent stroke rate after TIA (53 studies, 30,558 patients) is 5.2% [95% confidence
interval (CI) 3.9% to 5.9%] by 7 days, and 6.7% (5.2% to 8.7%) at 90 days. ABCD2 score does not
identify patients with key stroke causes or identify mimics: 66% of specialist-diagnosed true TIAs and
35–41% of mimics had an ABCD2 score of ≥4; 20% of true TIAs with ABCD2 score of <4 had key risk
factors. MR DWI (45 studies, 9078 patients) showed an acute ischaemic lesion in 34.3% (95% CI 30.5%
to 38.4%) of TIA, 69% of minor stroke patients, i.e. two-thirds of TIA patients are DWI negative. TIA
mimics (16 studies, 14,542 patients) make up 40–45% of patients attending clinics. UK survey (45%
response) showed most secondary prevention started prior to clinic, 85% of primary brain imaging was
same-day CT; 51–54% of patients had MR, mostly additional to CT, on average 1 week later; 55%
omitted blood-sensitive MR sequences. Compared with ‘CT scan all patients’ MR was more expensive
and no more cost-effective, except for patients presenting at >1 week after symptoms to diagnose
haemorrhage; strategies that triaged patients with low ABCD2 scores for slow investigation or treated
DWI-negative patients as non-TIA/minor stroke prevented fewer strokes and increased costs. ‘One-stop’
CT/MR angiographic-plus-brain imaging was not cost-effective.v
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ABSTRACT
viLimitations: Data on sensitivity/specificity of MR in TIA/minor stroke, stroke costs, prognosis of TIA
mimics and accuracy of ABCD2 score by non-specialists are sparse or absent; all analysis had
substantial heterogeneity.
Conclusions: Magnetic resonance with DWI is not cost-effective for secondary stroke prevention. MR was
most helpful in patients presenting at >1 week after symptoms if blood-sensitive sequences were used.
ABCD2 score is unlikely to facilitate patient triage by non-stroke specialists. Rapid specialist assessment,
CT brain scanning and identification of serious underlying stroke causes is the most cost-effective stroke
prevention strategy.
Funding: The National Institute for Health Research Health Technology Assessment programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Stroke, the second commonest cause of death and the commonest cause of dependency, creates a huge
societal burden and costs billions of pounds in health and social care costs. Effective prevention would
minimise the consequences. Eighty per cent of strokes are ischaemic. A warning transient ischaemic attack
(TIA) or minor stroke may occur prior to the major disabling stroke. Rapid assessment, identification of
potential causes and appropriate treatment can prevent many disabling strokes.
The diagnosis of TIA/minor stroke is difficult, particularly by non-experts. Identification of key risk factors
includes imaging to identify carotid stenosis, cardiac investigations, etc. Brain imaging is critical to
differentiate ischaemic from haemorrhagic stroke, and from non-vascular lesions mimicking TIA/minor
stroke (e.g. tumours) to guide treatment. Until recently, this was performed with computed tomography
(CT) brain scanning. Although very sensitive to haemorrhage within the first week, CT is insensitive
to small ischaemic lesions. Magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI)
is very sensitive to small ischaemic lesions soon after TIA/minor stroke, with T2* sensitive to
haemorrhage indefinitely.
Clinical risk prediction scores, for example the ABCD2 score, may help triage patients for immediate
investigation. The Department of Health guidelines currently recommend triage on ABCD2 score of ≥4
versus <4, and suggest that about 50% of TIA patients should undergo MRI to diagnose the TIA/minor
stroke in order to reduce time to treatment. However, MRI is more expensive than CT, less widely
available, and in considerable demand for proven indications. It is unclear whether the greater sensitivity to
small ischaemic lesions is worth the additional cost, displacement of patients with other disorders for
which MRI is of definite benefit, and if it is beneficial then how best to use it.Objectives
To determine:
1. whether in most patients with TIA/minor stroke, magnetic resonance (MR) with relevant sequences is
cost-effective compared with CT brain scanning
2. the cost and cost-effectiveness of increased use of MR in patients presenting at >5 days after TIA/minor
stroke when CT will not identify haemorrhage reliably
3. whether ‘one-stop’ brain and carotid imaging is more cost-effective than separate brain/
carotid examinations
4. current availability and imaging use in stroke prevention.Methods
We performed systematic reviews/meta-analyses of published/unpublished data on prognosis after
TIA/minor stroke; prediction scoring methods for stroke recurrence after TIA/minor stroke; sensitivity and
specificity of CT and MRI; direct comparisons of CT and MR in TIA/minor stroke; TIA/minor stroke mimics;
costs of stroke care; and imaging. We surveyed UK stroke prevention clinics and imaging services for
stroke. We modelled the pathway of patients with suspected TIA/minor stroke, assessments, treatments,
early and late outcome events (recurrent stroke, death, myocardial infarction), and health economic
modelling on a 20-year time horizon, of strokes prevented per 1000 patients assessed, costs,xxiii
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xxivquality-adjusted life-years (QALYs), costs/QALYs for representative scenarios and key sensitivity analyses
and performed deterministic and probabilistic analyses.Results
Among 53 studies (30,558 patients) of recurrent stroke in patients presenting with TIA/minor stroke, the
pooled cumulative recurrent stroke rate was 5.2% [95% confidence interval (CI) 3.9% to 5.9%] by 7 days,
6.7% (95% CI 5.2% to 8.7%) by 90 days, and 11.3% (95% CI 7.5% to 16.6%) after 90 days in 30, 35
and nine cohorts, respectively, with considerable between-study heterogeneity. Most of the larger studies
reported the lower recurrence rates.
In meta-analyses of stroke after TIA/minor stroke, by ABCD2 score dichotomised at <4 or ≥4, all studies
used a time-based TIA definition and excluded TIA mimics; in most, a specialist assigned the ABCD2 score;
half of the studies determined ABCD2 score retrospectively from case note review; and no studies provided
information on handling of key risk factors (e.g. carotid stenosis) in risk prediction analyses. Sixty-six per
cent of true TIA patients had an ABCD2 score of ≥4 and 34% <4. The pooled risk of stroke by 7 and
90 days, respectively, was ABCD2 score of ≥4, 4.7% (95% CI 2.4% to 8.7%) and 8.2 (95% CI 4.7% to
14.0%); ABCD2 score of <4, 1.6% (95% CI 1.0% to 3.4%) and 2.7% (95% CI 1.5% to 4.7%). ABCD2
score did not identify key stroke risk factors or mimics: one-third of TIA patients with an ABCD2 score of
≥ 4 and one-fifth of TIA patients with an ABCD2 score of < 4 had tight carotid stenosis or atrial fibrillation
(AF); 35–41% of TIA mimics had an ABCD2 score of ≥ 4. In a typical population of 1000 patients
attending stroke prevention clinics including mimics, about 52% of clinic attendees would have an
ABCD2 score of ≥ 4.
Among 21 published studies plus individual patient data, adding either carotid stenosis and/or CT scanning
to any clinical risk prediction score improved stroke prediction over clinical scores alone. The independent
hazard ratios for recurrent stroke for relevant visible infarct on CT were 1.47 (95% CI 1.01 to 2.14) and
for carotid stenosis dichotomised at 70% was 2.15 (95% CI 1.42 to 3.23).
There were no direct comparisons of CT with MR in TIA/minor stroke. Therefore, we assessed the
frequency of positive findings on MR DWI. Among 45 studies, 9078 TIA patients (all specialist diagnosed;
excluding TIA/stroke mimics and haemorrhage; about half retrospective), a DWI ischaemic lesion was
visible in 34.3% (95% CI 30.5% to 38.4%, I2 = 89.3%) of TIA and 69% of minor stroke patient. Hence,
about two-thirds of TIA patients and one-third of minor stroke patients with no alternative diagnosis after
specialist assessment do not have a DWI ischaemic lesion. There were no accuracy, sensitivity or specificity
data. Some common stroke mimics (migraine, epilepsy, hypoglycaemia, multiple sclerosis) may produce
apparent ischaemic lesions on DWI. Patients with acute ischaemic lesions on DWI have higher ABCD2
scores. DWI or CT added to the ABCD2 score improved prediction of recurrent stroke but still did not
identify patients with key risk factors, such as carotid stenosis. The commonest TIA/minor stroke mimics
do not produce specific findings on MR or CT: scanning in these patients is to exclude tumours (2.0%),
subdural haematoma (1.9%) and subarachnoid haemorrhage (1.9%), not to diagnose positively the cause
of the mimic.
Among 16 published/unpublished studies (total 14,542 participants), 40–45% of patients with suspected
TIA/minor stroke had a mimic, with the commonest diagnoses being migraine (14.4%), cardiac disorders
(8.8%), syncope (6.6%), seizure (5.0%), psychiatric conditions (4.4%), and vertigo (4.0%), with substantial
heterogeneity and few data on the prognosis; recurrent stroke was lower for mimics than for TIA, but
not negligible.
Stroke prevention and imaging services in the UK (45% response rate for both), confirmed that 45% of
patients referred with suspected TIA/minor stroke have a mimic. Triage is by a nurse in 28% of clinics.
Most patients (60–100%) had already started medical secondary prevention treatments when seen in theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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addition to CT. Most departments (55%) did not include a blood-sensitive sequence (T2*), hence will
miss haemorrhages. Most CT was performed at clinic assessment, MR mostly about 1 week later, when
many DWI lesions will have disappeared. Most centres used ultrasound for carotid imaging on the day of
clinic assessment.
Compared with ‘CT brain scan all patients’ (base case), all strategies using MR instead of CT were more
expensive and no more effective, either by QALYs or strokes prevented. In some strategies, for example
triage into fast-track/slow-track using ABCD2 score of < 4/≥ 4, treat DWI-negative patients as non-TIA/
minor stroke, or start all patients on stroke prevention treatment prior to clinic assessment, MR was clearly
less effective. MR or CT brain-plus-carotid imaging combined also increased costs without increasing
effectiveness. MR became more effective only in patients presenting ≥ 1 week after TIA/minor stroke
(CT would not exclude a haemorrhage). The results were sensitive to the costs of imaging and giving
ischaemic stroke prevention drugs inadvertently to patients with haemorrhagic stroke. Data limitations
(heterogeneity, lack of information for MR accuracy) precluded the estimate of some distributions.Conclusions
The clinical utility of clinical risk scores, including the ABCD2, must be questioned: ABCD2 labels most
patients as high risk, including many mimics, while failing to identify true TIA/minor stroke patients with
known key causative disease needing fast-track treatment (carotid stenosis, AF). Furthermore, the system is
saturated with patients with an ABCD2 score of ≥ 4 who are destined not to have a stroke, delaying rapid
treatment for the most needy. One-fifth of TIA patients with an ABCD2 score of < 4 yet have tight carotid
stenosis or AF, so would not be fast-tracked for investigation on current guidance, leaving those with
tight carotid stenosis or AF (who require specific treatments) unprotected from recurrent stroke, and,
paradoxically, resulting in the strokes that stroke prevention aims to prevent. The benefits of MRI in many
unselected suspected TIA patients in routine clinical practice has yet to be demonstrated. Available
information only applies to patients with definite TIA/minor stroke diagnosed by a stroke specialist. All
technologies, including scoring systems, should be thoroughly evaluated, preferably in randomised trials, to
determine their impact on clinically important outcomes prior to their introduction into clinical practice.Implications for health care
1. In all patients with probable TIA/minor stroke, diagnostic efficiency and stroke prevention could be
maximised if investigations are focused to identify key risk factors and implement appropriate
treatment rapidly (e.g. of tight symptomatic carotid stenosis or AF).
2. Patients thought to have a TIA/minor stroke mimic (45%), many of which are cardiac or neurological,
require different treatment to avoid costly and potentially harmful effects of unnecessary antiplatelet,
statin and antihypertensive treatment.
3. The benefits of the ABCD2 score have not yet been demonstrated in reliable, generalisable studies.
4. Initial triage using the ABCD2 score alone risks relegating patients with key underlying causative
lesions but low ABCD2 scores to ‘slow stream’ investigation and treatment leaving them exposed to
higher early recurrent stroke risk that rapid endarterectomy or anticoagulation would have avoided.
5. The evidence suggests that caution is required when translating the results of these studies to routine
practice as there are no data on how accurately TIAs are diagnosed, how well the ABCD2 score
performs, how accurately mimics are identified or on the proportion of TIAs with positive DWI findings
when patients are assessed by non-specialists.
6. The justification for routine use of MR in most TIA/minor stroke is unclear. Exceptionally, the data
support the use of MR in patients presenting at > 1 week after TIA when MR with T2* is better than
CT for identifying haemorrhage, possibly when an unusual cause of symptoms is considered or when
there is doubt if a TIA/minor stroke is in the territory of a tight carotid stenosis. However, in mostxxv
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xxvi‘typical’ TIA/minor stroke patients presenting soon after onset, use of MR inflates costs substantially,
confers no advantage in stroke prevention, may increase risk through increasing delays to treatment,
and potentially delays patients with other non-cerebrovascular conditions for which there is evidence
of benefit.
7. The evidence indicates that patients diagnosed as true TIA/minor stroke by a stroke specialist, but
without a visible ischaemic lesion on DWI, will nonetheless benefit from secondary stroke prevention
treatment; if not treated, about two-thirds of patients with TIA and one-third of patients with minor
stroke who have no lesion on DWI would remain at high risk of recurrent stroke.
8. Failure to include T2* sequence as part of the MR examination for stroke or TIA, as in 55% of UK
services, will fail to diagnose haemorrhage, and risks recurrent haemorrhage if patients with
haemorrhage are treated with antithrombotic drugs.
9. Triage on the basis of MR DWI alone will fail to identify underlying risk factors, not correctly
differentiate stroke/TIA from mimic, not identify haemorrhage or correctly identify positively all true
TIAs or minor strokes.
10. The use of MR in addition to CT is not justified, at least not at its current frequency (50% of patients).
Using CT or MR, but not both together, would help streamline TIA/minor stroke investigations.
11. There was strong evidence to support ultrasound as the most widely used routine investigation for
carotid stenosis; CT or MR angiography are not cost-effective alternatives, even when combined into
one examination session with brain CT or MR.
12. The justification for changing the definition of TIA from time based to tissue based is unclear:
two-thirds of specialist-diagnosed TIAs and one-third of minor stroke do not have a DWI-visible lesion.
13. There are still many delays during the assessment of patients with suspected TIA/minor stroke,
including delay to endarterectomy; identifying and overcoming those delays would increase speed of
investigation and prevent more strokes.Recommendations for research
1. We identified a lack of reliable, relevant and generalisable data on use of MR in TIA/minor stroke,
specifically no direct comparisons of CT and MR.
2. There is a strong case to perform a randomised controlled trial to test a policy of ‘early CT brain scan’
compared with ‘early MR DWI and T2* brain scan’ with a primary outcome of recurrent stroke and
vascular death.
3. Use of ABCD2 score by non-specialists should be tested against stroke experts to determine the
reliability and clinical utility of the ABCD2 score in different settings.
4. The effect of changing TIA definition from time based to tissue based is required in large populations
across multiple stroke centres and scanners to determine the effect on TIA/stroke incidence, prevalence
and outcome, preferably before the definition is changed.
5. Research should examine why MR is frequently used after CT; reducing duplicate examinations and
effective triage in one examination would help to improve efficient use of staff and equipment.
6. Reliable data are required on all costs for stroke including imaging and their variation with different
health-care scenarios.
7. Research into the reasons for substantial heterogeneity between studies on all topics related to TIA is
required to improve consistency of diagnosis. The wide variation observed is unlikely to reflect true
differences in disease frequency.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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In the UK, about 150,000 people have a stroke each year. About 30% die within 6 months and another30% survive dependent on others for everyday activities, making stroke the commonest cause of
dependency in adults and the second commonest cause of death in the world.1,2 Stroke is estimated to
cost the NHS between £4.6B3 and £7B per year.4 Stroke is also one of the major causes of disability in
adults.5 Eighty per cent of strokes are ischaemic, and most (75%) ischaemic strokes are due to an artery
in the brain becoming blocked by atherothromboembolism. Treatment of ischaemic stroke is limited to
thrombolysis, which can be used only in the first few hours after the stroke,6 a minor effect of aspirin, and
co-ordinated stroke unit care, so prevention is vital.
About 20–40% of people have a warning transient ischaemic attack (TIA) or minor non-disabling
ischaemic stroke shortly before they have a major disabling stroke.7,8 In the UK, there are estimated to be
80,000–90,000 TIAs per year.9 If these people can be assessed quickly, potential stroke causes identified
and treated appropriately to reduce risk, then many of these disabling strokes can be prevented.10 Based
on these figures, the average regional hospital serving a population of around 750,000 will see about
1000 suspected TIA/minor stroke cases per year, i.e. about 20 per week. Delivering effective stroke
prevention to this number of people is challenging and requires highly organised stroke services that are
able to respond rapidly, accurately and effectively for stroke prevention, while avoiding adverse affects on
other services within finite resources. The personal, societal, public health and financial burden of stroke in
the UK is such that every effort should be made to limit the damaging effects of having a major disabling
stroke, and to determine how to make best use of our available resources.5,11–13
Transient ischaemic attack is defined as ‘a sudden loss of focal cerebral or monocular function lasting less
than 24 hours due to inadequate cerebral or ocular blood supply as a result of low blood flow, thrombosis
or embolism associated with disease of the arteries, heart or blood’.14 Although the definition of TIA purely
on the basis of clinical grounds is the subject of debate,15,16 and a tissue-based definition has been
proposed,17 for the present time we have used the clinical definition. Patients with minor stroke, which
differs from TIA only by symptoms or signs lasting more than 24 hours, are also at high risk of early
recurrent stroke and need the same assessment and treatment as for patients with TIA to prevent a further
disabling stroke or death. A small proportion of TIA/minor stroke (< 5%)18–20 is actually due to a small
haemorrhage in the brain but this can be distinguished from ischaemic stroke only by brain scanning.
The period of highest risk of disabling stroke is in the first few hours and days after a TIA/minor stroke,
thus making suspected TIA/minor stroke a medical emergency:8,14,21,22 the Oxford Vascular Study (OXVASC)
suggested that between 8.0% and 11.5% of patients will have a recurrent stroke by 1 week, and between
11.5% and 15.0% by 1 month after TIA/minor stroke unless effective secondary prevention is started.9 In the
USA, there are about 240,000 TIAs per annum, of whom 25% had experienced a further TIA, a stroke or
died by 3 months.23 Prevention of recurrent ischaemic stroke is by rapid identification of underlying risk
factors [such as ipsilateral tight carotid artery stenosis, atrial fibrillation (AF), hypercholesterolaemia,
hypertension] and implementation of optimal medical (antiplatelet agents, statins, antihypertensive drugs
or anticoagulant drugs where necessary)10,14,24 and surgical treatment (endarterectomy for symptomatic
moderate to severe carotid stenosis).25
Hence, patients with definite acute ischaemic stroke are now given standard quadruple preventative
therapy [antiplatelet agent, statin, angiotensin-converting enzyme (ACE) inhibitor and diuretic drug] and
patients who present with suspected TIA/minor stroke are started on quadruple therapy pending specialist
investigation and treatment. It is therefore important to ensure that the patients whose symptoms after
due investigation are proven not to be caused by acute ischaemic cerebrovascular (CV) disease, particularly
the small proportion (≈5%) whose symptoms are due to a small haemorrhage, then avoid inappropriate,
ineffective, expensive, unnecessary or possibly hazardous26–30 drug treatment.1
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wardlaw et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
2
INTRODUCTIONThe conventional brain scanning technique for stroke and TIA is computed tomography (CT), now widely
available in the NHS. Although CT excludes tumours and haemorrhage if performed acutely,31 it is
insensitive to small ischaemic lesions, so does not ‘positively’ diagnose TIA/minor stroke.32 CT demonstrates
an infarct in a maximum of 50% of minor acute strokes33 and 43% of mixed minor stroke and TIA,34
although the sensitivity may be lower in older patients with brain tissue loss and leukoaraiosis.
Nonetheless, the presence of an infarct on CT in patients presenting with TIA is associated with increased
short-term risk of stroke,35 CT has high specificity for ischaemia,36 visible infarction on CT is an
independent predictor of poor outcome (dependency or death) after ischaemic stroke of all severities,33,37
CT is very accurate for haemorrhage within the first 5 days of symptoms32,36 and for tumours and
other non-vascular causes of sudden neurological symptoms, giving it many advantages to balance its
two disadvantages: the low sensitivity for acute ischaemic stroke and for small haemorrhages that are
> 5 days old.31
Magnetic resonance with diffusion-weighted imaging (MR DWI) is very sensitive to ischaemia.38 Magnetic
resonance imaging (MRI) is widely used to investigate many neurological disorders, musculoskeletal
problems and in oncology. MRI is very versatile because different sequences can be used to highlight
different types of pathology relevant to stroke. For example, DWI is very sensitive to changes in the
mobility of water in the brain; one of the earliest changes in the brain at the onset of ischaemia is cell
swelling, which reduces the extracellular space and hence restricts water movement. Thus, early ischaemia
shows up well on DWI, even very early after the symptoms start and even in very small lesions causing mild
symptoms38 if the effects of the ischaemic insult are sufficient to cause enough cell swelling to change the
DWI signal. When considering how to use and interpret any brain imaging, it is important not to forget
about the pathophysiological steps in ischaemia, knowledge that has been available since the early 1970s
(Figure 1): the first step at the start of an ischaemic insult is that neurons cease their electrical activity
when blood flow drops below about 35ml/100 mg/minute (which is when the neurological symptoms
start), well above the level required to precipitate loss of ion pump activity and cell swelling (about
20 ml/100 mg/minute) or cell death (10 ml/100 mg/minute).39 It is therefore perfectly possible to have
symptoms without any visible lesion on even the most sensitive scans, such as DWI, if the ischaemic insult
is enough to drop the flow below the electrical shutdown level, but not so as to precipitate cell swelling or
even on perfusion imaging if the amount of brain affected by the loss of flow is below the resolution of
current perfusion imaging methods. If the flow recovers rapidly and never reached the level of causing
cellular oedema then the symptoms will resolve and there will never be a lesion visible on the scan. If the
flow recovers rapidly even after falling to a nadir below the cell oedema stage but not for long enough to
result in cell death then the DWI-visible lesion will resolve rapidly as the cell swelling resolves and no lesion
will be seen on the scan.40 Only if the flow reduction persists for long enough and is low enough to have
caused significant amounts of cell death will the scan show a positive lesion – the DWI lesion will last for
variable times depending on the amount of tissue damage.41 The chances of seeing an acute ischaemic
lesion on DWI increase with increasing stroke severity,42,43 but even in patients with moderate to severe


















FIGURE 1 Critical flow thresholds for development of symptoms and MR DWI imaging lesions.
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would appear on other sequences, notably T2-weighted, fluid-attenuated inversion recovery (FLAIR) or
T1-weighted magnetic resonance (MR) images or CT, but after a week or so, when any acute swelling
has disappeared, the recent lesion would be difficult to differentiate from an old prior lesion.45 This
physiological explanation is one of several valid and probably quite common reasons for having true
ischaemic disease but a negative DWI even on acute scanning. Other reasons include delays to scanning,
variation in sensitivity of sequences on individual MR machines and between MR machines of the same
field strength and of different field strengths and generation of manufacture.46
Diffusion-weighted imaging primarily displays ischaemic areas as white on a dark background, so
ischaemic lesions when present are much more obvious than they are on CT scanning, where ischaemic
lesions appear as dark on a dark background. Thus even very tiny ischaemic lesions stand out on MR DWI
(with the above caveat) soon after symptom onset in 16–67% of TIAs (mean 37%)47,48 and about 70–90%
of minor strokes overall, even if scanned weeks after the event in some minor stroke patients.36,38,45,48–50
However, in general, the chance of finding an ischaemic lesion on DWI falls rapidly with increasing time
after symptoms,45,50 and probably most rapidly for small cortical ischaemic lesions,44 meaning that delays to
scanning of even a few days will reduce the sensitivity of MR DWI to small ischaemic lesions. Currently,
with CT scanning, if the scan provides no positive evidence of an ischaemic lesion, the diagnosis of
ischaemia is often assumed if the scan has excluded haemorrhage and stroke mimics. By contrast, MR
including DWI could help make a ‘positive’ diagnosis of brain ischaemia in TIA/minor stroke if it showed
positive findings of ischaemia in a large proportion of patients, although a diagnosis of TIA/minor stroke
would still have to be assumed if the DWI were negative and no alternative diagnosis could be
made clinically.
MR, if it includes T2*-weighted imaging or equivalent, is very sensitive to haemorrhage, even years after
the event.51 Other commonly used MR sequences (T2-weighted, T1-weighted and, particularly, FLAIR
imaging) are much less sensitive.51 Very acute haemorrhage (i.e. within the first few hours after symptom
onset) is less easy to identify on MR and may be mistaken for ischaemia or a mass lesion until the
characteristic paramagnetic features of blood breakdown products have had time to form.52,53 In contrast,
CT is very sensitive to acute haemorrhage54 but cannot reliably detect haemorrhage in patients who first
present at > 5 days after a minor ischaemic stroke (Figure 2).31 The high sensitivity of MR T2* sequences
for haemorrhage is essential to diagnose haemorrhage correctly51,55,56 in patients who present late to
medical services to avoid inappropriate use of antiplatelet agents, anticoagulants and carotid
endarterectomy in patients with haemorrhagic stroke.
Magnetic resonance DWI could also help management in other ways. In some patients with carotid
stenosis it is difficult to decide if the clinical event occurred in the territory of that artery or not.57 DWI is
helpful if it can confirm that a TIA/minor ischaemic stroke was in the territory of a tight carotid stenosis, so
leading to endarterectomy.57 The presence of lesions in several territories would indicate a need to search
a more proximal source of embolism, for example in the heart.58
The ability of MR to differentiate common stroke mimics from true ischaemic events is unclear. MR DWI is
not specific to acute ischaemia: multiple sclerosis (MS), migraine, postictal changes, hypoglycaemia and
even infection can produce high signal lesions on DWI (and reduced apparent diffusion coefficient). Many
mimics do not produce any abnormality on either CT or MR brain imaging.
If MR is proven also to have high sensitivity and specificity for ischaemic events then by helping to exclude
acute ischaemic CV disease as the cause of symptoms, and if in a large enough proportion of patients, it
will potentially have a greater role in avoiding unnecessary or inappropriate treatment. However, if there is
an over-reliance on the sensitivity of MR DWI to detect minor ischaemic change such that physicians start
to think that patients presenting with suspected TIA/minor stroke without an acute ischaemic lesion on
DWI do not have a TIA/minor stroke and therefore assign alternative diagnoses and do not implement
secondary stroke prevention measures then greater use of MR could actually have a net damaging effect3
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FIGURE 2 Images from a patient presenting 8 days after developing mild left arm and leg numbness: top row,
CT; bottom row, T2* MRI. Images from a patient presenting 8 days after developing mild left arm and leg numbness.
CT is almost completely normal (a thin white circle is visible in the central image in the superior right thalamus,
indicating a small resolving haemorrhage, arrow middle top image) but MR T2* clearly shows the low signal
(black circle, arrow left bottom image) characteristic of a haemorrhage.
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INTRODUCTIONon stroke prevention. Similarly, if more MR is used – but without including all relevant sequences required
to reliably identify haemorrhage,51,56 as well as ischaemia and any structural lesions acting as a mimic as
the cause of symptoms – then it may also result in no benefit or net harm if patients with haemorrhage
are misdiagnosed and given drugs that increase bleeding risk.
Several clinical scoring systems have been devised that aim to improve identification of patients at high risk
of disabling recurrent stroke after TIA/minor stroke.59–65 These scores could help to reduce delays to
reaching medical attention and to triage patients,66 so that those needing most rapid treatment, such as
carotid endarterectomy, would reach surgery more quickly. They might also improve the accuracy of
clinical diagnosis of TIA by non-stroke physicians, thereby also making better use of resources. Not all of
these have been externally validated. All except two60,64 use only simple clinical features so are rapid and
easy to apply without needing complex technologies.59,61,62,65 For example, the ABCD2 score uses age,
blood pressure, clinical features, duration of symptoms and diabetes to derive a score from 0 to 7. The
ABCD2 score has been adopted in National Institute for Health and Care Excellence (NICE) guidelines to
aid patient triage in the UK:67 those with a score of ≥ 4 to be prioritised for assessment and treatment
within 24 hours of reaching medical attention; those with a score of < 4 within 1 week.
Many of these scores performed well in the population from which they were derived and often also in
initial testing in a different cohort68,69 but then wider use uncovered difficulties. For example, independent
testing of the ABCD and ABCD2 scores62 has not been universally positive.70,71 Although in OXVASC the
ABCD2 score was highly predictive of recurrent stroke within 7 days of TIA (p < 0.01), it did not predict
stroke at between 8 and 90 days, because in this group, patients with lower scores had a higher risk ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27stroke than those with high ABCD2 scores (p = 0.04).71 The ABCD2 score also did not predict recurrent
stroke in patients with minor stroke (as opposed to TIA). Thus TIA clinical risk prediction scores may not
usefully predict stroke risk at > 7 days after TIA and may be of limited value in patients with minor stroke.
Most scores were devised and tested in highly selected populations of patients with definite TIA/minor
stroke such as randomised multicentre trials or observational studies after screening by a stroke expert
where the patient had to have a definite TIA/minor stroke to get into the study. However, this is not the
population of suspected TIA/minor stroke that typically presents to the ‘front door’ of the hospital. In this
unselected population, up to 50% do not ultimately turn out to have had a TIA/minor stroke and
therefore should have a low risk of recurrent stroke.72 However, the net effect of applying a clinical risk
score in this mixed population was that many true TIA/minor strokes were given a low ABCD2 score and
therefore would have missed rapid access to stroke services.72 In this sense, the use of a clinical risk score
could actually lead to a net failure to prevent recurrent stroke. This reflects a general limitation of low
specificity scoring or screening systems – namely that while they may detect the small proportion of
patients with particularly high risk of recurrent stroke, many recurrent strokes actually occur in patients
deemed to be at moderate or low risk only (because there are many more of them). Widespread use of
clinical risk scores in this setting could therefore put at risk patients in a ‘slow stream’ who would then
potentially not receive treatment quickly enough to prevent stroke and has not been tested.
Part of the problem may be that (1) the clinical diagnosis of TIA/minor stroke is difficult73–75 and (2) the clinical
findings have low specificity for the likely underlying cause, but the future stroke risk is closely related to the
cause. The clinical diagnosis of TIA and minor stroke is made difficult, especially for non-experts, by the high
proportion of patients (up to 50%)5,72,76–78 who actually have common mimics of TIA/minor stroke. Common
mimics include migraine, transient global amnesia, epilepsy, simple faints, tumours, functional disorders,
etc.72,77 It is not possible to determine the cerebral pathological cause of symptoms, i.e. whether infarct,
haemorrhage or mimic (e.g. tumour), without a brain scan, although most mimics do not show specific
positive findings on imaging, meaning that accurate diagnosis still rests heavily on clinical skills.26,79
Some have questioned the usefulness of scores that do not incorporate significant carotid disease or other
potential cardioembolic sources.80,81 Two scoring systems that included carotid stenosis as part of the risk
prediction60,64 found that adding tight carotid stenosis did improve risk prediction. Carotid imaging is an
integral part of the assessment of TIA and minor stroke to identify those with ipsilateral tight carotid
stenosis who will benefit from carotid endarterectomy.82 The cost-effectiveness of carotid imaging was
assessed in a previous Health Technology Assessment (HTA)-funded project by our group.5 This work
showed that rapid access to carotid imaging to identify and measure carotid stenosis was the most
cost-effective way of using carotid imaging, and that the four non-invasive imaging methods functioned
similarly in terms of accuracy83,84 and stroke prevention, although ultrasound was the most cost-effective of
the four techniques if used early after TIA/minor stroke.85 The focus of the present application is on how to
improve stroke prevention through use of brain imaging techniques, so comparative carotid imaging will
not be considered further.
The evidence on the contribution of MR to diagnosis, stroke prediction and hence potential for patient
management and cost-effectiveness after TIA/minor stroke is uncertain – it could be very useful if used within
its limitations in a targeted way, or it could be potentially harmful if used indiscriminately and without
including all relevant sequences. No studies have considered these points or addressed the cost-effectiveness
of using MR including DWI and T2* in TIA/minor stroke. Most studies of cost-effectiveness of imaging in
stroke have either concentrated on hyperacute disabling stroke26,86 or on carotid imaging for carotid stenosis5
as part of carotid endarterectomy.86 There are no clinical trials of diagnostic accuracy or effect on prediction
of prognosis of MR including DWI, only observational studies using DWI in populations of patients with
TIA/minor stroke. Many publications come from the same few research groups meaning there is likely to be
data duplication: at the start of this project, all published studies were from single centres so lacked
generalisability; some were retrospective; many only included a modest proportion of their TIA population
(e.g. 53%)87 so were prone to various biases.88–90 An acute lesion on DWI may be associated with increased
risk of recurrent stroke and helps to confirm a positive diagnosis of stroke, but the additional prognostic value5
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INTRODUCTIONover clinical scoring, the role of carotid imaging, the effect of sample biases, etc., had not been evaluated
thoroughly and was therefore unclear.87,87,91–94 The accuracy of MR for common mimics of TIA/minor stroke
was unclear, as most publications excluded patients who turned out after further testing not to have
had a stroke.
There are barriers to the wider use of MR in stroke prevention. In addition to limitations owing to study
methodological factors, listed above, MR is more expensive than CT scanning (about £400 for MR vs. £150
for CT brain scanning)5 and less available than CT in the UK, with long waiting lists even for patients with
established indications for MR. There is limited capacity to provide rapid access to MR for people with TIA
and stroke. MR delayed even by a few days would be of little value, as the patient would miss the period of
highest recurrent stroke risk95 and the chance of finding an ischaemic lesion on DWI falls rapidly with
increasing time after symptoms.45,50 In the mid-2000s, although 75% of UK hospitals had MR on site,
< 10% were able to scan patients early after stroke.95 Similarly, across the EU, only 5% of hospitals met
criteria for stroke care, which included availability of MR for stroke (and surprisingly the UK had the highest
proportion of hospitals with MR for stroke).96 Current availability is not known. Any increase in use of MR
for stroke prevention could result in reduced availability for patients with MS, cancer and many other
conditions for which MR is of established benefit. Some patients cannot have MR because of
contraindications, for example having a pacemaker, claustrophobia or metal implant, so there would always
be a need for CT. In one recent study, 90/904 patients (10%) considered for MR had contraindications and
only 477/904 (53%) of all patients presenting with TIA actually underwent MR; of those having MR only
155/477 (33%, or 17% of the initial cohort) had a DWI-positive lesion.87 Not all TIA patients have CT at
present, so MR including DWI would partly replace, and partly be an additional investigation, if it proved to
be cost-effective in stroke prevention.
What do guidelines say?
The 2008 UK NICE Guidelines advocate use of DWI in about 50%97 of TIA/minor stroke patients
(www.dh.gov.uk/stroke).67
Specifically, what is the guidance?
The objective for brain imaging for TIA is:4 ‘To confirm the diagnosis and/or vascular territory affected in
those patients where either is unclear.’NIHRImaging for TIA (p. 8)5. About 50 per cent of suspected TIAs require MRI of the brain. The diagnosis of TIA is difficult and
doubt often remains, even after expert clinical assessment, whether or not the event was a TIA. Of
patients presenting with symptoms suggesting a TIA, about half prove to have some other cause.
For those who have had a TIA, the location of the lesion (damaged tissue) may not be known.6. Computed Tomography (CT) is not sufficiently sensitive to demonstrate the small lesions found in
TIA. MRI of the brain with diffusion-weighted imaging (DWI) is needed where the diagnosis or
location of the lesion remains in doubt. The MRI may answer the question of whether the lesion is in
vertebral (brain/brainstem) or carotid neck territory, prompting further carotid investigation where
appropriate. If multiple lesions are found, this may suggest a cardiac source of the clot(s), and prompt
investigation of the heart.8. Carotid imaging should ideally be performed at initial assessment and should not be delayed for
more than 24 hours after first clinical assessment of TIA for those at higher risk of stroke (i.e. ABCD2
score ≥ 4) or in those with non-cardioembolic carotid-territory minor stroke. Those people who are
found to have carotid stenosis will require carotid intervention within 48 hours of presentation.Journals Library www.journalslibrary.nihr.ac.uk




Park, S9. For those people at lower risk of subsequent stroke (i.e. ABCD2 score of < 4), carotid imaging
should be performed within 7 days. If they are found to have carotid stenosis, they should have
carotid intervention within two weeks of presentation.10. Expert clinical assessment coupled with appropriate imaging provides the best diagnostic pathway
for patients with TIA.Furthermore, the Executive Summary states:5. Imaging services managing TIA and stroke will need to be able to provide the following services:5.1 TIAMRI/MRA brain for those patients requiring it available 7 days a week with Contrast Enhanced MRA
(CEMRA) for first-line carotid imaging. This requires MR software for diffusion weighted and gradient
echo imaging and CEMRA, and a pump injector for CEMRA; andCarotid imaging seven days a week, which will ideally include CEMRA and duplex ultrasound, and
CT angiography.5.2 Stroke24-hour access to CT;Rapidly accessible MRI, with the features described above, for those patients who require it; andAbility to undertake more complex imaging examinations for stroke subtypes as required.This policy is summarised in the NICE flow chart (Figure 3).67 Whether or not this policy would reduce
recurrent stroke and improve quality of life after TIA, or simply flood the system with large numbers of
patients with negative MR scans while displacing others with diagnoses for which MR does have a clear
indication, is uncertain. Since the start of this project, NHS Improvement in England have introduced tariffs
to encourage the establishment of stroke prevention clinics that meet key performance criteria, and
additional tariffs for rapid assessment and treatment of patients with high ABCD2 scores and for
performing MRI in TIA patients (amount payable £450–634 per patient).98,99
Enthusiasm for a policy of more MR is expressed in many other guidelines. The American Heart Association
(AHA)100 and related organisations101 stated that ‘TIA patients should undergo neuroimaging evaluation
within 24 hours of symptom onset, preferably with magnetic resonance imaging including diffusion
sequences’.17 The revised National Clinical Guidelines for Stroke,102 Scottish Intercollegiate Guidelines
Network (SIGN) Guidelines 2008,103 and European Guidelines104 are more cautious but still advocate
immediate brain imaging and use of MR, including DWI in large proportions of patients especially those
with mild stroke. Therefore, there is a ‘mismatch’ between national and international guidance on the one
hand,17,97 and convincing evidence to support this approach,47,48 information to guide precise usage,105
details of cost-effectiveness and available technology to deliver it on the other,95,96 resulting in confusion
about what to do in routine practice. This is mirrored in the NHS Purchasing and Supply Agency 2008
report, which stated only that ‘DWI shows significant potential in the study of TIA/minor stroke’, but also
called for ‘more evidence’.105 The limited evidence has also led some reviewers to call for more data on
imaging to guide physicians treating TIA patients.106,107
In summary, MR including DWI could make a substantial impact as a positive diagnostic test for TIA/minor
stroke by improving diagnosis of the cause of stroke; efficient patient selection for medical secondary
prevention in patients with a proven diagnosis; conversely, the avoidance of unnecessary treatment in7
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FIGURE 3 Summary of current NICE guidance on investigation and management of patients with suspected TIA
and minor stroke. Contains public sector information licensed under the Open Government License v1.0. NASCET,
North American Symptomatic Carotid Endarterectomy Trial. a, Unless MRI contraindicated, in which case ct
should be used.
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27patients in whom acute ischaemic CV disease was reliably excluded; and best use of carotid
endarterectomy (especially where stroke expertise is limited). There are potential cost implications.
TIA/minor stroke is so common that MR would be in daily use in every hospital if such a strategy were
adopted wholeheartedly, but the direct costs to the NHS would be substantial – £16M per year to scan
just the 50% of TIA patients suggested in recent UK guidelines, not including the minor strokes and all of
the TIA mimics, assuming that MR were available. The opportunity cost to meet the demand by increasing
MR scanning capacity, (without which there would also be substantial disadvantage to other MR users).
It is not clear if the potential diagnostic and prognostic advantages of MR outweigh the disadvantages
of the obvious expense, limited availability, failure to make a positive diagnosis of ischaemic lesion in up to
66% of TIA patients, unquantified accuracy for other stroke-related diagnoses, and possibility that the
strokes that we are trying to prevent might occur during the wait for a scan if availability cannot be rapidly
increased. Any strategy to increase MR usage would have to factor in the effect of varying delays
introduced because of waiting for MR. We are not aware of any large or multicentre studies ongoing on
this topic, although it is likely that single centre studies are ongoing.
This study aimed to resolve this controversy by summarising all available data on MR including DWI,
diagnosis and stroke prediction, and modelling the cost-effectiveness of using MR including DWI in a
range of stroke prevention strategies.
Our primary research objective is to determine whether MR DWI as well as other relevant structural and
blood-sensitive sequences is cost-effective in the majority of patients with TIA or minor stroke to guide
diagnosis and secondary stroke prevention, compared with the current alternative of CT brain scanning.
Second, to determine the cost and cost-effectiveness of increased use of MR including DWI and
blood-sensitive sequences in patients presenting at >5 days after TIA/minor stroke when CT will not be
able to identify haemorrhage as the cause of stroke reliably.
Third, to estimate if ‘one-stop’ brain and carotid imaging is more cost-effective than individual separate
brain and carotid examinations, in what proportion of patients a ‘one-stop’ approach could be used, and
the practical and cost implications.
Fourth, to determine physicians and radiologists current attitudes to increased use of MR in TIA/minor
stroke, the availability, barriers to greater use, costs of increasing availability, and net effect on other
patient groups in whom MR is commonly used.
We planned to do this by using health economic decision-analytic modelling to assess the effectiveness,
cost-effectiveness and practical implications of using MRI in different proportions of patients with TIA or
minor stroke at different times after symptom onset, obtaining data from systematic reviews of the
relevant literature, surveys of current practice and costs, existing stroke registry and cohort data. If MR
cannot be justified in all patient then our aim was to determine in which subgroups of patients the use of
MR is cost-effective. We aimed to provide a range of options reflecting the effect of using MR in different
proportions of TIA/minor stroke patients at different times after TIA/minor stroke to guide decision-making
by health service purchasers. We anticipated that the health economic modelling would be a hybrid of
methods used in two previous HTA-funded cost-effectiveness analyses in stroke: a decision-analytic tree
model to reflect the initial diagnosis of TIA/minor stroke compared with mimic, and ischaemic stroke
compared with haemorrhagic stroke from work on the cost-effectiveness of CT scanning in acute stroke,26
followed by a probabilistic time-based model to reflect the varying risk of recurrent stroke and other
vascular events following TIA/minor stroke, over a long time horizon from the work on cost-effectiveness
of different carotid imaging methods in stroke prevention.59
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Chapter 2 General methodsIntroductionThe research involved gathering information from many sources. This chapter provides a short résumé of
the main objectives of the work and a brief general summary of the methods used. More detailed
methods specific to the question being addressed are provided in each relevant chapter or section.ObjectivesOur primary research objective was to determine whether MR DWI and additional relevant structural and
blood-sensitive sequences is cost-effective in the majority of patients with TIA or minor stroke to guide
diagnosis and secondary stroke prevention, compared with the current alternative of CT brain scanning.
Our second objective was to determine the cost and cost-effectiveness of increased use of MR including
DWI and blood-sensitive sequences in patients presenting at > 5 days after TIA/minor stroke when CT will
not be able to identify haemorrhage as the cause of stroke reliably.
Our third objective was to estimate if ‘one-stop’ brain and carotid imaging was more cost-effective than
individual separate brain and carotid examinations, in what proportion of patients a ‘one-stop’ approach
could be used, and the practical and cost implications.
Our fourth objective was to determine physicians’ and radiologists’ current use of imaging in stroke
prevention and attitudes to increased use of MRI in TIA/minor stroke, the availability, barriers to greater
use, costs of increasing availability and net effect on other patient groups in whom MR is commonly used.
We undertook this work using a range of tools. We modelleding the effectiveness, cost-effectiveness and
practical implications of using MRI in different proportions of patients with TIA or minor stroke at different
times after symptom onset, using systematic reviews of the relevant literature, surveys of current practice
and costs, and existing stroke registry and cohort data. If MRI could not be justified in all patients then we
aimed to determine in which subgroups of patients the use of MR was cost-effective. We aimed to provide
a range of options reflecting the effect of using MRI in different proportions of TIA/minor stroke patients
so as to guide decision-making by health service purchasers. The extent to which these objectives would
be fulfilled would depend on the amount of relevant evidence available in the literature on use of imaging
in patients with TIA and minor stroke and mimics.DesignThe study was an evidence synthesis of data from the literature, new surveys of current UK practice and
costs, and health economic modelling with sensitivity analyses of important variables (Figure 4). Further
details on the following are given in relevant chapters.
1. Systematic reviews We systematically reviewed the literature to:
i. summarise the risk of recurrent stroke after TIA and minor stroke by time period (see Chapter 3)
ii. summarise clinical risk scoring systems and in particular the ABCD2 score and its predictive accuracy
(see Chapter 4)11
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GENERAL METHODSiii. estimate the sensitivity/specificity of CT and MR including DWI sequences in TIA/minor stroke,
including the arterial territory; and
iv. assess their role in prediction of stroke after TIA (see Chapters 5 and 6)
v. estimate the proportion of suspected TIA/minor stroke patients who are diagnosed as a mimic
(see Chapter 7)
vi. assess previous studies of cost-effectiveness of imaging in stroke prevention (see Chapter 9)
vii. gather all of the data required to model stroke prevention after TIA, including estimating
costs of CT and MR (summarised to 2003 in Wardlaw et al.26 but requiring updating)
(see Chapters 10 and 11).
2. All aspects of these systematic reviews, including literature searching, quality assessment, data
extraction, and evidence synthesis were performed according to the Cochrane Collaboration and
Stroke Group standards, including recommendations from the Screening and Diagnostic Tests
Methods Group.5,36 Occasionally we were not able to apply Cochrane methodology, and wherever
this occurred, we give the reasons why and describe any alternative methodology used. The methods
for evidence synthesis (meta-analyses performed according to the summary receiver operating
characteristic (SROC) curve methodology or separate meta-analyses of sensitivity and specificity
estimates) were determined by the data obtained and we used the most appropriate method, as
described in each relevant chapter/section.108 We explored heterogeneity by examination of forest
plots and I2-statistics.109 However, we did not use meta-regression, i.e. meta-analyses with covariates
to explain heterogeneity, due to limited numbers of studies and a lack of information on relevant
covariates. Where possible, we used a standardised quality assessment instrument [i.e. the Quality
Assessment of Diagnostic Studies (QUADAS) tool],110 adapted to the topic in question asNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27appropriate.26,83 For chapters on prediction or prognosis, we created bespoke tools to suit the clinical
context as there are no universally accepted instruments. Details are given as required in each chapter.
As studies may be reported in multiple publications, we took care to include data from any given
cohort only once in the reviews.
3. We obtained data on demographics, risk factors, medications, recurrent stroke and death in patients
with TIA/minor stroke relevant to the UK, treatments and their effects, data on quality-adjusted
life-years (QALYs) and utility weights and in order to construct the health economic model (see
Chapters 10 and 11). We used existing data sets where possible, for example large stroke and TIA
registries,111 individual patient data sets and routinely collected anonymised national audit data, as in
previous work.5,26
4. We surveyed UK stroke physicians through the Royal College of Physicians Stroke Audit and NHS
Health Improvement,5 to ask about stroke prevention clinics including current access to and use of
MR sequences, including DWI in patients with TIA/minor stroke in the NHS, aspirations and consensus
on role of MR, and to gather additional unpublished data on MR including DWI in TIA/minor stroke
(see Chapter 8).
5. We surveyed UK radiology departments across the UK to determine current use of imaging for stroke,
types of imaging used, what capacity there is for increased throughput of TIA and minor stroke
patients, and to identify the perceived major barriers to increased or faster throughput of TIA/minor
stroke patients and what additional resources would be required to provide additional access for these
patients (see Chapter 8).
6. We obtained UK data on imaging costs from the NHS Department of Health (DOH) NHS Reference
Costs database, the literature and CT and MR from individual radiology departments,5,26 and the
health-care costs associated with management of stroke patients by literature review of relevant
electronic databases3 and by interrogation of specific sources, such as stroke registry data as in
previous work (see below for specific details).5,26 We also sought costs of stroke care by outcome and
stroke prevention treatments (see Chapter 11).
7. We obtained data on quality of life after stroke for key subgroups from the literature, from previous
work, unpublished sources and from our local stroke register data (see Chapter 11).112
8. We built a model to reflect key stages and outcomes in secondary stroke prevention after TIA/minor
stroke, including all data on assessments, medical and surgical interventions, outcomes, and timings,
populated with representative data from TIA/stroke services in the UK. The timelines in the model
were stratified by time after symptoms, key patient characteristics, use of prognostic scores (ABCD2),62
including conventional routinely available investigations (brain CT, carotid imaging), the comparator
MRI and treatment decisions, and key outcomes of non-disabling and disabling stroke and death at
various time intervals out to a lifetime time horizon (see Chapter 11).
9. We modelled the incremental cost-effectiveness of implementing MR including DWI with or without
T2* instead of usual care in the diagnosis of TIA/minor stroke and a range of different strategies
where proportions of patients would vary by key characteristics and timing of investigations, etc. in
sensitivity analyses. We estimated the effect of using MR or CT also to diagnose carotid stenosis as a
‘one-stop’ investigation using magnetic resonance angiography (MRA) or CT angiography (CTA),
respectively, instead of performing the MR or CT of the brain scan and separately performing
carotid imaging with, for example, ultrasound. We used data from our previous HTA report (see
Chapter 12).5,84
10. We summarised the effect of different investigative approaches on recurrent stroke, costs, and QALYs,
and hence the probability that the new diagnostic strategy is more cost-effective than usual care. The
results are presented for a cohort of patients presenting to stroke prevention clinics with suspected
TIA/minor stroke. Various analyses were conducted to investigate the worth of commissioning further
research on the cost-effectiveness of MR DWI imaging and inform the design of any future research.
All modelling work was performed according to recommended guidance (www.equator-network.org)
(see Chapter 12).11313
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GENERAL METHODSInclusion/exclusion criteria
We modelled a typical population of patients presenting with suspected TIA/minor stroke including mimics
based on existing data reflecting current demographic, pre-stroke medications, and stroke treatments
using information from the literature and a large national stroke audit.
These data sources included:
l the North Edinburgh Stroke Study and Lothian Stroke Register (LSR, n=2598, a hospital-based registry
of all inpatients and outpatients with TIA and stroke presenting to the hospital between 1992 and
2000 with demographic information, imaging and laboratory investigations, past medical history,
medications prior to and following the TIA/stroke, and quality-of-life data) and followed up to 4 years
for recurrent stroke, cardiac events and death and used in two previous HTA reports5,26
l the Edinburgh Stroke Study (ESS, n=1367, a hospital-based registry of all inpatients and outpatients
with TIA and stroke presenting to the hospital between 2002 and 2005 with the same information
except quality of life) and so far followed up to 4 years after the stroke111
l the Scottish Stroke Care Audit Study (SSCAS), a Scottish national routine collection of anonymised
audit data from TIA and stroke services
l data from other studies of stroke and TIA with more detailed imaging, including a study comparing CT
and MR scans in minor stroke between 1998 and 2001 (n=230) conducted as part of a previous
HTA-funded project31
l a study of patients with mild cortical and lacunar stroke between 2005 and 2007 (n=250), all with MR
DWI and T2* imaging114
l audit data of TIA and stroke mimics from stroke prevention services in Leicester (Eveson; obtained
through NHS Improvement)
l data on quality of life at 6 months after stroke by functional outcome Oxford Handicap Score from the
Clots in Legs Or sTockings after Stroke (CLOTS) trials.115Ethical arrangements
The use of existing anonymised data to populate the model and perform other analyses did not require
additional ethics approvals. All data used in the proposed modelling were anonymised.Proposed sample size
We modelled the effect of incremental change in proportions of TIA/minor stroke patients undergoing MRI
for a typical UK population of 1000 patients. The existing data sets included several thousand patients
with TIA, minor and major stroke, with initial clinical and imaging assessment, and data on functional
status, stroke recurrence and death at 6 months, 1 year and later. We provide the results in the form of
‘events per a cohort of 1000 patients presenting to hospital with suspected TIA and minor stroke’.Statistical analyses
Systematic review of diagnostic accuracy
Indices of diagnostic performance were extracted or derived from data presented in each primary study
for each imaging test. Where data were available, we constructed 2 × 2 contingency tables of test
results compared with reference standard to show the cross-classification of disease status and test
outcome. We calculated sensitivity and specificity with 95% confidence intervals (CIs) for each imaging
test for each study where possible. To describe and visualise the data, we used forest plots showing
the pairs of sensitivity and specificity estimates for each study. We also used receiver operating
characteristic (ROC) plots, random-effects SROC curves, survival curves, and various other meta-analytic
techniques as appropriate. All reviews, analysis of observational data and other types of analysis
including critical appraisal were conducted according to the established relevant recommendations
(www.equator-network.org).110,116NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The primary outcome was the incremental cost-effectiveness of MR scanning compared with CT for the
whole population. Secondary outcome measures included the number of strokes prevented per strategy,
costs and QALYs. We tested the effect of substituting MR for CT in key subgroups by time to imaging,
ABCD2 score, assuming that DWI-negative TIA patients did not have a TIA/minor stroke, and combining
carotid and brain imaging in one examination. We tested the effect of changing the proportion of patients
with TIA/minor stroke with a visible ischaemic lesion on ‘MR including DWI’ and CT brain scanning and the
association with key clinical variables; whether adding information from brain scanning to clinical risk
scoring improves prediction of future risk of stroke or death; the association between a positive or
negative brain scan and risk factors for stroke, such as carotid stenosis; delays to diagnosis, delays to
starting medical or surgical treatment if MR including DWI were to replace CT brain scanning; the number
of disabling strokes prevented at 6 months, 1 and 5 years after TIA/minor stroke if ‘MR including DWI’
were to be used in most patients for a cohort of 1000 patients. We tested the effect of QALYs stratified by
key patient groups. We will provide a range of options reflecting effect of using MR in different
proportions of TIA/minor stroke patients to guide decision-making by health service purchasers.
A brief discussion of the specific aspects of each chapter is provided at the end of each chapter and a
discussion of the whole project and main findings in Chapter 13.15
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of stroke risk after transient ischaemic attackIntroductionThe early risk of recurrent stroke after TIA has been underestimated for many years. Approximately
15–20% of ischaemic strokes are preceded by a TIA117 and the appropriate detection and urgent
diagnostic work-up for patients with TIA can avoid a further disabling stroke if the correct treatment is
indicated. A retrospective study of consecutive patients attending emergency departments (EDs) within
24 hours after TIA demonstrated that the stroke risk after the index event was higher than previously
thought; the stroke rate was 10.5% at 90 days, with half of the events (5.3%) occurring within 2 days of
symptoms onset.8 A further analysis of a population-based TIA incidence study [Oxfordshire Community
Stroke Project (OCSP)] also reported a high stroke rate after index TIA, with risks of 8.6% at 7 days and
12.0% at 30 days.21 Several studies have been published after these publications. With respect to stroke
immediately after TIA, in a prospective population-based incidence study of TIA and stroke (OXVASC), in
488 patients with a first TIA the risks of stroke at 6, 12 and 24 hours were 1.2% (95% CI 0.2% to 2.2%),
2.1% (0.8% to 3.2%) and 5.1% (3.1% to 7.1%), respectively. Furthermore, 42% of all stroke during the
30 days after a first TIA occurred within the first 24 hours.118 Different studies have reported conflicting
stroke rates after TIA, and cohorts from Oxford, UK and northern Portugal have published very high risks
of stroke at 7 days (11% to 13%) and 90 days (17% to 21%), respectively.9,119 A systematic review and
meta-analysis of 11 observational studies reporting the early risk of stroke after TIA (total n = 7238),
showed that risks of stroke ranged from 1.4–9.9% at 2 days, 3.2–17.7% at 30 days, and 3.9–17.3% at
90 days, with significant heterogeneity for all periods considered. Using a random-effects model, the
pooled estimate of risk was 3.5% (95% CI 2.1% to 5.0%) at 2 days, 8.0% (5.7% to 10.2%) at 30 days,
and 9.2% (6.8% to 11.5%) at 90 days; the risk was higher when the methodology of the studies involved
active ascertainment of stroke outcome (9.9%, 13.4% and 17.3%, respectively).120 Another systematic
review and meta-analysis of studies reporting the risk of stroke exclusively within 7 days of TIA (total
18 cohorts, n = 10,126 patients) showed pooled risk of stroke of 3.1% (95% CI 2.0% to 4.1%) at 2 days
and 5.2% (3.9% to 6.5%) at 7 days, with a substantial heterogeneity across studies for both pooled risk
estimates. The risks of stroke after TIA observed in patients treated urgently by specialist stroke services
were 0.6% (95% CI 0.0% to 1.6%) at 2 days, and 0.9% (95% CI 0.0% to 1.9%) at 7 days compared
with 3.6% (95% CI 2.4% to 4.7%) at 2 days and 6.0% (95% CI 4.7% to 7.3%) at 7 days from
other cohorts.121
Recent studies24,122 included in the systematic review by Giles and Rothwell121 have reported very low risks
of recurrent stroke for patients in whom a secondary prevention treatment [mainly antiplatelet drugs and
blood pressure (BP)-lowering drugs] was started immediately after confirmed diagnosis of TIA or minor
stroke. An early detection of medical conditions with a high risk of early stroke recurrence, such as severe
carotid stenosis or a cardiac source of embolism requiring specific treatments (i.e. carotid endarterectomy
or anticoagulant therapy) can also explain the significant reductions in stroke rates in those cohorts.Methods
Objectives
For the purpose of this HTA project we have conducted a systematic review considering all primary studies
reporting the overall rate of stroke in TIA patients. Recent published systematic reviews on stroke risk after17
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A SYSTEMATIC REVIEW AND META-ANALYSIS OF STROKE RISK AFTER TRANSIENT ISCHAEMIC ATTACKTIA (e.g. Wu and colleagues120 and Giles and Rothwell121) were used only as a source of relevant
references. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines for systematic reviews of studies that evaluate health-care interventions to conduct
this review.123 We aimed to identify all published studies reporting the risk of recurrent stroke among
patients with TIA and/or minor stroke irrespective of the clinical setting or type of study design.Identification of studies
We searched indexed records that appeared in MEDLINE (Ovid) from January 1995 to November 2011. It is
worth noting that for the purpose of this systematic review we combined the comprehensive literature
searches we developed for Chapter 6 (DWI in patients with TIA and minor stroke) and for Chapter 4
(clinical prediction score and risk of stroke after TIA and minor stroke) of this assessment. The MEDLINE
search strategy included both subject headings [medical subject headings (MeSH) terms] and text words
for the target condition (e.g. stroke, TIA, minor stroke). We adapted the MEDLINE search to search
EMBASE. In particular, we ‘translated’ the MEDLINE MeSH terms into the corresponding terms available in
the Emtree vocabulary. We did not apply any language restrictions. The searches were initially run in
November 2010 and updated in November 2011. Full details of the MEDLINE and the EMBASE search
strategies are presented in Appendix 1. We imported all citations identified by the MEDLINE and EMBASE
search strategies into the Reference Manager bibliographic database version 11 (ISI Research Software, San
Francisco, CA, USA). We hand-searched all proceedings of the International Stroke Conference (2011) and
the European Stroke Conference (2011, 2012). We also contacted experts in the field and perused the
reference lists of all relevant articles to identify further published studies for possible inclusion in the
review. Only full-text articles were deemed suitable for inclusion.124Inclusion/exclusion criteria
One review author (MB) examined the identified titles and abstracts and retrieved all potentially relevant
citations in full. Full-text articles were assessed by two reviewer authors (MB, HM) and retained if
they reported the number and proportion of patients with stroke recurrence at 7 days, 90 days, and/or
> 90 days after index TIA. We analysed all studies regardless of whether they reported recurrent stroke at
7 days, 90 days or > 90 days. We excluded non-English articles for which a full-text translation was
not available.Quality assessment and data extraction
Two review authors (MB, HM) independently conducted data extraction and review the methodological
quality of selected studies using the primary papers. Disagreements were resolved by discussion or referred
to a third author (JMW) if necessary. We recorded data on study methods (e.g. setting, study design)
characteristics of patients (first vs. recurrent TIA), and outcomes (stroke events at 7, 90 and > 90 days). We
also collected information on the following methodological aspects, which we considered more likely to
introduce potential biases: prospective compared with retrospective study design, data source for cohort
identification (e.g. registries, databases, medical notes), patients’ selection criteria, definition of TIA and
recurrent event, timing of clinical assessment, evaluating clinicians, and method of outcome ascertainment
(active vs. passive).Data synthesis
For each study we calculated the total number of patients with stroke recurrence after index event (first or
recurrent TIA). The pooled proportion of TIA patients with stroke recurrence was calculated by means of a
univariate random-effects meta-analysis with within-study variance modelled as binomial. Heterogeneity
between studies was assessed visually by inspection of the forest plots and by calculating I2-statistics.109
Data were analysed in R version 2.14.2 (The R Foundation for Statistical Computing, Vienna, Austria)
(cran.r-project.org).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Number of included/excluded studies
The literature searches identified 11,389 citations. After initial screening of titles and abstracts we
selected 248 citations for full-text retrieval. Two additional studies published in 2005 were included after
hand-searching of reference lists of relevant studies, yielding a total of 250 studies. After full-text
examination, 197 studies were excluded, leaving 53 studies that fulfilled the inclusion criteria. The main
reason for exclusion was that the number of recurrent events was not clearly reported (Figure 5).
We translated one report published in Spanish; all other included reports were originally published in
English. We observed, as have others,125 that some studies come from the same TIA cohorts (i.e. Oxford,
north Dublin, California, Massachusetts, Lleida and Paris cohorts) and we experienced difficulty in avoiding
double counting of the same patient data appearing in multiple publications. Many studies were published
from the same research groups and the same cohorts of patients were described in multiple reports – with
some reports assessing more than one patient cohort (i.e. Oxford, north Dublin, California, Massachusetts,
Lleida and Paris cohorts). Even although we attempted to exclude multiple publications we found it
challenging to identify which cohort was assessed in which study, as precise information were somehow
lacking. When a single study included separate cohorts (e.g. community-based TIA patients and patients
from specialist unit) for the purpose of the analyses we considered the separate cohorts as coming from
separate studies.Characteristics of included studies
The methodological characteristics of selected studies are shown in Table 1.
The 53 studies varied in their primary objectives. Eleven were population-based studies including cohorts
from the UK (Oxford), Ireland (Dublin), USA (Texas and Minnesota), Canada (Alberta) and northern
Portugal.9,21,61,119,126,127,132,140,144,147,151 Seventeen were ED-based studies,23,69,87,129,131,134–136,143,149,153,156–159,161,163Full-text papers assessed
(n = 250) 
Additional papers
identified through other
sources (n = 6)
Citations excluded after
assessing both titles and
abstracts (n = 11,145)
Excluded (n = 197)
Main reason for
exclusion:
number of TIA patients








FIGURE 5 Identification and selection of studies.
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A SYSTEMATIC REVIEW AND META-ANALYSIS OF STROKE RISK AFTER TRANSIENT ISCHAEMIC ATTACKthree were focused on TIA clinics (one included OXVASC participants),24,130,145 10 were hospital-based studies
(the authors of which did not describe characteristics of the hospital unit),65,81,120,133,142,148,152,155,160,162 10 recruited
patients admitted to a specialist unit [including stroke unit, neurological ward or highly-specialised
neurovascular (NV) clinics],122,137–139,141,146,150,154,164,165 one focused on patients attending ED and TIA clinics
(including OXVASC participants)62 and one128 recruited patients as part of a hospital-based clinical trial.
The 53 studies included a total of 30,558 participants. The risk of recurrent stroke at 7 days was reported in
28 studies (30 cohorts) of 12,332 participants, 34 studies (35 cohorts) of 19,769 participants reported the
stroke risk at 90 days and nine studies of 8699 participants reported the stroke risk > 90 days. For studies
reporting the stroke risk > 90 days, the length of follow-up ranged from 6 months to 14 years.
The study design was prospective in 33 studies9,21,24,61,65,69,81,119,122,126,128,129,132–134,136,138,139,141–144,148,
150–154,156,160,161,164,165 and retrospective in 19;23,87,120,127,130,135,137,140,145–147,149,155,157–159,162,163 one study62
included two cohorts recruited prospectively and retrospectively. Participants were included
consecutively in 45 studies. The diagnosis of TIA was made by a neurologist or stroke physician in
36 studies,9,21,24,61,65,69,81,87,119,122,126,128,130,132–134,137,139–142,144–148,150–152,154,156,157,160,161,164,165 by an emergency
medicine physician in 10 studies,23,127,129,131,135,136,143,149,153,159 and by both in four;62,158,162,163 in three
studies120,138,155 this information was not reported.
With respect to the timing of patient assessment after the index event, in 10 studies TIA patients
were assessed within 24 hours of symptoms onset,62,69,87,134–136,138,143,155,161 in six studies within
48 hours,137,139,141,142,150,165 in one study140 within 72 hours and in one study160 within 7 days. Another
four studies9,61,132,144 reported that ‘patients were assessed as soon as possible after the event’ but did not
give a time. One study62 (including two cohorts) assessed patients within 24 hours and ‘as soon as possible
after the event’, another study120assessed patients ‘immediately’ after the event, and in
three studies65,128,145 the timing of assessment was beyond 7 days. The remaining 27 studies did not clearly
provide this information (see Table 1). Four studies included patients with first-ever TIA, 34 included either
first-ever or recurrent TIA, and in 15 studies the authors did not report this information.
The majority of studies (n = 46) used a time-based definition of TIA (see Table 1), one study145 recruited
patients retrospectively from clinical records using the International Classification of Diseases (ICD), Ninth
Edition, definition of TIA, one study157 included just patients with transient symptoms and DWI visible
lesion, in five studies the information was not reported. One study128 included a highly selected sample of
patients with TIA and carotid stenosis, and three studies65,141,155 excluded patients with specific conditions
[i.e. cardioembolic events or blood coagulation disorders, AF and posterior circulation TIAs, respectively].
The ascertainment of stroke events after TIA was carried out by face-to-face patient assessment or
telephone interviews in 25 studies,9,21,24,61,69,81,119,122,128,132–134,137–139,144,149–152,155,156,161,164,165 by medical
records in 15 studies,23,62,87,120,126,127,129,130,130,135,136,140,143,145,157,159 by mixed methods involving
face-to-face assessment plus another method (i.e. telephone interviews, medical records, letters) in
11 studies,65,131,146–148,153,154,158,160,162,163 and was not reported in two studies.141,142NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Table 2 shows the proportion of patients with stroke recurrence reported in all studies at different time
points. The number of events was 974 out of 12,332 patients for studies reporting stroke risk at 7 days,
1567 out of 19,803 patients for risk at 90 days, and 927 out of 8699 patients for risk > 90 days. The risk
of stroke reported across studies ranged from 0.0% to 22.4% at 7 days, 0.6% to 23.7% at 90 days, and
4.7% to 27% at > 90 days. There was evidence of significant heterogeneity between studies; the
I2-statistics were 96.4%, 96.3%, and 97.8% for stroke risk at 7, 90 and > 90 days, respectively. Using
random-effects meta-analysis, the pooled risk of stroke was 5.2% (95% CI 3.9% to 5.9%) at 7 days, and
6.7% (95% CI 5.2% to 8.7%) at 90 days. For stroke risk at > 90 days the pooled estimate was 11.3%
(95% CI 7.5% to 16.6%). Figures 6–8 show the forest plots for studies reporting the proportion of
patients with stroke recurrence at 7, 90 and > 90 days after index TIA.TABLE 2 Stroke risk after TIA at 7, 90 and > 90 days
Study ID Size Setting Study design
Percentage of stroke recurrence (n)

























603 NASCET Prospective 20.1 (121)
Gladstone and
colleagues, 2004129
265 ED Prospective 3.8 (10) 6.4 (17)
Kleindorfer and
colleagues, 200523













121 TIA clinics Retrospective 5.8 (7)
Van Wijk and
colleagues, 200565













3.0 (29) 5.8 (56)
315 TIA clinic Prospective
(Oxford)
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TABLE 2 Stroke risk after TIA at 7, 90 and > 90 days (continued )
Study ID Size Setting Study design
Percentage of stroke recurrence (n)




















639 Hospital Retrospective 7.0 (45)
Atanassova and
colleagues, 2008133
89 Hospital Prospective 14.6 (13)
aCoutts and
colleagues, 2008134








221 Hospital Prospective 19.0 (42)
Sciolla and Melis,
200869



































































7.5 (92) 12.0 (139)
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TABLE 2 Stroke risk after TIA at 7, 90 and > 90 days (continued )
Study ID Size Setting Study design
Percentage of stroke recurrence (n)
7 days 90 days > 90 days
Nakajima and
colleagues, 2010148
113 Hospital Prospective 8.0 (9) 10.6 (12)
Ong and
colleagues, 2010149












3.4 (15) 7.5 (33)
Tsivgoulis and
colleagues, 2010152
148 Hospital Prospective 8.1 (12) 16.2 (24)
Wasserman and
colleagues, 2010153








490 Hospital Retrospective 16.0 (76)
Amort and
colleagues, 2011156













5.3 (25) 9.9 (47)
Meng and
colleagues, 2011160
410 Hospital Prospective 27.0 (111)
Olivot and
colleagues, 2011161
157 ED Prospective 0.6 (1) 0.6 (1)
Sanders and
colleagues, 2011162
289 Hospital Retrospective 2.4 (7)
Stead and
colleagues, 2011163












Prospective 2.6 (29) 3.9 (43)
NASCET, North American Symptomatic Carotid Endarterectomy Trial; SOS-TIA, SOS Transient Ischaemic Attack study.
a Number of events estimated from the percentage of patients with events and the total number of participants.
b Values extracted from Wu and colleagues.120
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Summary estimate 0.052 (0.039 to 0.069)
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FIGURE 6 Forest plot for studies reporting stroke recurrence at 7 days after index TIA. The Johnston paper62 reports
results for two cohorts: (a) the California clinic and (b) the Oxford clinic. The Rothwell paper61 also reports results
for two cohorts: (a) the OXVASC cohort and (b) the hospital clinic.
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Summary estimate 0.067 (0.052 to 0.087)
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FIGURE 7 Forest plot for studies reporting stroke recurrence at 90 days after index TIA. The Johnston paper62 reports
results for two cohorts: (a) the California clinic and (b) the Oxford clinic.
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FIGURE 8 Forest plot for studies reporting stroke recurrence beyond 90 days after index TIA.
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We identified 53 studies with a total of 30,558 participants, published between 2003 and 2011, providing
data on stroke risk at 7 days, 90 days or > 90 days after TIA. The rate of recurrent stroke at all time points
assessed varied widely from 0% to 22.4% at 7 days, 0.6% to 23.7% at 90 days, and 4.7% to 27.0% at
> 90 days. The random-effects meta-analysis showed the pooled risk of recurrent stroke at 7 days to be
5.2% (95% CI 3.9% to 5.9%), at 90 days to be 6.7% (95% CI 5.2% to 8.7%) and at > 90 days to be
11.3% (95% CI 7.5% to 16.6%). The heterogeneity between studies was huge. In some individual studies
the rate was up to three times higher than the median rate and up to 4–4.5 times higher than the pooled
risk rate. However, this summary of all available data indicates that the pooled risk of stroke after TIA is
one-quarter of that stated in the current NICE guidance, which states in the Guide to Implementing the
National Stroke Strategy Guide, Imaging for TIA, p. 8, that ‘Approximately 20% of TIAs will be followed
by a stroke within four weeks’.97 The upper 95% CI of our pooled risk barely passes one-quarter of that
value. The few individual studies that reported such high rates were all very small.
Two systematic reviews of the risk of stroke after TIA120,121 and one systematic review of the risk of
recurrent stroke after first-ever stroke169 have been published in 2007 and 2011, respectively. The review
by Giles and Rothwell121 focused on stroke risk within 7 days of TIA and included 18 independent cohorts
with 10,126 patients. The pooled stroke risk was 5.2% (95% CI 3.9% to 6.5%) at 7 days, ranging
from 0.0% to 12.8%, and with substantial between study heterogeneity. The heterogeneity was largely
explained by setting, with the lowest rates in emergency settings with urgent treatment and highest in
population-based studies without urgent treatment. In the same year, Wu and colleagues120 published a
systematic review focusing on stroke risk at 2, 30 and 90 days, and included 11 studies with 7238
patients. The pooled risk for all studies was 3.5%, 8.0% and 9.2% at 2, 30 and 90 days, respectively.
The pooled risk for studies with active prospective case ascertainment was 9.9%, 13.4% and 17.3% at 2,31
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A SYSTEMATIC REVIEW AND META-ANALYSIS OF STROKE RISK AFTER TRANSIENT ISCHAEMIC ATTACK30 and 90 days, respectively. Despite both addressing the same topic, 11/18 studies included in Giles and
Rothwell121 were not included in Wu and colleagues,120 and 5/11 studies in Wu and colleagues120 were not
included in the Giles and Rothwell study,121 some because stroke rates were not reported at the precisely
required time, but this did not account for all omissions. Mohan and colleagues169 published a review of
13 studies of 9115 patients published between 1961 and 2006 focusing on stroke recurrence after
first-ever stroke (not TIA) showing a pooled risk of 3.1% (95% CI 1.7% to 4.4%) at 30 days and 11.1%
(95% CI 9.0% to 13.3%) at 1 year, also with substantial heterogeneity between studies.
There has been considerable interest in the rate of stroke after TIA since the mid-2000s but this alone
cannot account for the large difference between these earlier reviews of stroke risk after TIA and our study
in the number of included studies or patients, our review including nearly treble the number of studies (53)
and patients (30,558). Twenty-eight studies alone reported stroke risk at 7 days in 12,332 patients. We
may inadvertently have included some of the same patients more than once as many of these studies
come from the same few research groups and it was difficult to disentangle some of these studies.
Substantial proportions of these studies were based in EDs (17, 32%) and, although details were a bit
short in some studies, many of the rest could be considered to be recruiting in a rapid-access fast-response
environment, and 33/53 were prospective, and 45/53 studies included consecutive patients. Our pooled
risk rate is similar to that of Giles and Rothwell121 and midway between the estimates provided by Wu and
colleagues.120 Differences in the speed of assessment may account for differences in risk rates between
studies, but many other factors are possible. For example, few studies reported on how patients were
treated and how those with tight symptomatic carotid stenosis were managed. Presumably they were
offered early endarterectomy, removing much of their stroke risk. Presumably many patients were offered
immediate medical treatment, in many cases started by their family doctor prior to arriving at the specialist
clinic or hospital ED. This practice might have increased since the publication of the Early use of eXisting
PREventive Strategies for Stroke (EXPRESS) study in 200624 and might explain why some newer studies had
lower stroke rates. With a few exceptions, these points are largely not mentioned. Regardless of that,
lower rates were also observed in many older studies and therefore the real differences between studies
are likely to be more complex than simply variation in rapidity of referral or early treatment.
Given the large variation in stroke risk between studies, and not having any good reasons to choose one
group of studies over another, and, as the calculated pooled risk at each time point had pretty tight CIs
indicating some reliability even if there is substantial heterogeneity, we will use the pooled risk rates at
7 days (28 studies, 12,332 patients), 90 days (34 studies; 19,769 patients) and > 90 days (nine studies;
8669 patients) as the most reliable base estimates of stroke risk in the present work.Weaknesses of the review
Overall, our findings are limited by the great variation between included studies, especially in terms of
study design, time of assessment from symptoms onset, type of TIA considered, and evaluating clinicians.
As there is no a validated instrument for the quality assessment of observational studies on stroke risk, we
pre-defined the methodological aspects that we considered more likely to represent potential sources of
bias. The results of the quality assessment were used in only a descriptive way and not to inform further
statistical analyses (e.g. meta-regression).
With regard to our literature searches, we focused mainly on two major electronic databases (MEDLINE and
EMBASE). We did not search additional electronic databases, such as the Bioscience Information Service
(BIOSIS), the Latin American and Caribbean Health Sciences Literature (LILACS) or the Science Citation Index
(SCI), first because the number and relevance of indexed journals in these databases is limited compared
with those indexed in MEDLINE and EMBASE, and, second, we are confident we have enhanced the overall
sensitivity of our literature searches by hand-searching all recent conference proceedings of two major
international stroke conferences, contacting experts in the field and perusing the reference lists of all
relevant selected studies. Owing to time and resources constraints, we avoid searching grey literature
sources, which are known to be time consuming and not particularly well developed.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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transient ischaemic attack and minor strokeIntroductionThe incidence of TIA has been estimated as ranging from 20,000 to 90,000 in the UK,9,173 and from
200,000 to 500,000 in the USA.169,170 The risk of recurrent stroke after TIA is high, especially during the
first week after the index event (see Chapters 1 and 3).121 The benefit of medical therapy to prevent
recurrent stroke after TIA is greatest if given as early as possible after TIA.24,122,153 Likewise, the benefit of
endarterectomy for symptomatic carotid stenosis is highest when performed within 2 weeks after the
index event and falls rapidly with increasing delay.171 A deferred intervention would be futile, or at least of
much reduced benefit, as the high-risk period without medical or surgical intervention will have passed.10
Consequently, patients with TIA need a rapid comprehensive assessment to reduce the short- and
long-term risks of recurrent stroke and other vascular conditions.
However, delays between the onset of symptoms and specialist assessment and treatment have previously
been reported in the UK172,173 and are confirmed in a survey conducted for this report (see Chapter 8). These
delays would decrease the proportion of patients started on appropriate secondary prevention treatment
soon after the index event and before disabling stroke occurs. At this point, the use of a clinical score to
predict the early risk of recurrent stroke after TIA emerges as a reasonable strategy for identifying patients
with the highest stroke risk, in whom a more urgent clinical approach is needed. Assuming that a clinical
score correctly predicts the early stroke recurrence after TIA, its use would allow efforts and resources to be
concentrated on those with a higher risk, reducing the incidence of stroke in this population.
Numerous clinical risk prediction scores have been developed all aiming to do the same thing – identify
patients at high risk of stroke to prioritise services. However, the ABCD2 and related scores have achieved
particular prominence such that the ABCD2 score is recommended for use in UK stroke prevention
services67 to triage the speed at which patients pass through clinics and access services. Hence, some detail
is worthwhile here as to how it initially developed and has evolved.
A northern California study8 demonstrated that simple clinical variables were associated with the risk of
stroke at 90 days in patients with a diagnosis of TIA who were initially admitted to an ED. Age, presence
of diabetes mellitus, duration of episode > 10 minutes, weakness and speech impairment during episode
were independently associated with the risk of stroke after TIA; the estimated risk of further stroke was
34% in patients presenting with all five predictors. In addition, a population-based study127 conducted in
Canada showed that age, and diabetes mellitus together with hypertension, were associated with a higher
risk of stroke 1 year after TIA. Subsequently, the ABCD score was created to predict the stroke risk during
the first week after TIA using those clinical variables that have been independent predictors of stroke.61
Derived from the OCSP population and validated in the OXVASC and local TIA clinic populations, the score
showed a fair accuracy in the prediction of stroke risk at 7 days in these patients. A further validation of
the ABCD and California scores showed that both had a fair accuracy in the prediction of early recurrent
stroke at 2, 7 and 90 days.62 By combining the components of these two scores, the authors generated a
unified prediction tool, the ABCD2 score, in 2007 (Table 3).62
The ABCD2 score includes age, blood pressure elevation on first assessment after TIA, unilateral weakness,
speech disturbance, duration of symptoms and diabetes mellitus as clinical variables, and predicted the early
risk of stroke in the California and Oxford cohorts at 2, 7 and 90 days. The score classifies TIA or minor stroke
patients at low, moderate or high risk using cut-off points of < 4, 4–5 and > 5. Recently, the ABCD2 risk
prediction score has been adopted by many stroke prevention services in the UK as part of NICE guidance6733
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SBP > 140 or DBP > 90 1
Clinical features
Unilateral weakness 2
Speech disturbance without weakness 1




DBP, diastolic blood pressure; SBP, systolic blood pressure.
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ABCD2 SCORE AND RISK OF STROKE AFTER TRANSIENT ISCHAEMIC ATTACK AND MINOR STROKEto prioritise patients who need urgent treatment. Stratification strategies to effectively prioritise TIA patients
have become essential because (1) it is very challenging to assess every TIA/minor stroke patient within 24
hours of symptoms onset and (2) approximately half of the patients referred to stroke prevention services
ultimately do not have a diagnosis of TIA or minor stroke (see Chapters 7 and 8). For these reasons, recent
clinical guidelines have recommended the use of the ABCD2 score as a tool to select patients for whom an
urgent management is required.67 However, the ability of ABCD2 score to distinguish between TIA and
non-TIA/mimics and to predict risk of stroke early after TIA has been questioned. Some independent
validation studies of ABCD and ABCD2 scores have shown conflicting results in their discriminatory ability
to predict stroke,69,70,151,152 and, in particular, a number of studies have suggested that high ABCD2 scores
do not reliably identify patients with high stroke risk conditions, such as the presence of severe
carotid stenosis.132,170,174
The ABCD/ABCD2 scores have spawned numerous other variants (ABCD2-I, ABCD3, ABCD3-I),147,150 which
add either more clinical or brain or carotid imaging variables, most of which have not been tested
independently. Numerous variations may be causing confusion. For example, there is no consensus on the
best ABCD2 cut-off for stratifying the risk of stroke and select patients for whom an urgent assessment is
needed. Clinical guidelines issued by the AHA, for example, advocate admission to hospital and early
assessment/treatment for patients with an ABCD2 score of ≥ 3,17 whereas national guidelines in the UK
recommended a specialist assessment and investigation within 24 hours of symptoms for patients with an
ABCD2 score of ≥ 4 and within 1 week for those patients with an ABCD2 score of < 4.67
The aim of this systematic review was to evaluate all existing evidence on the performance of the ABCD2
prediction score to predict stroke recurrence in patients at high risk (score ≥ 4) and low risk (score of < 4)
of stroke, i.e. at cut-off points used in current clinical guidelines.67Methods
Objectives
We followed the PRISMA guidelines for systematic reviews of observational studies to conduct this
review.175 We aimed to identify all published studies in which ABCD2 score was used to predict risk of
stroke among patients with TIA and/or minor stroke irrespective of the clinical setting or type of study
design and that reported on the actual rate of recurrent stroke.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Identification of studies
We searched indexed records which appeared in MEDLINE (Ovid) from January 2005 to November 2011.
The choice of this time period reflected the introduction of the ABCD prediction score into clinical practice
(even although the ABCD2 score was published for the first time in 2007, we adopted an over-inclusive
approach and searched the literature from 2005 when the ABCD clinical prediction score was originally
developed). The MEDLINE search strategy included both subject headings (MeSH terms) and text words for
the target condition (e.g. stroke, TIA, minor stroke) and the prediction score under consideration (ABCD).
We did not apply any language restrictions. We adapted the MEDLINE search to search EMBASE. In
particular, we ‘translated’ the MEDLINE MeSH terms into the corresponding terms available in the Emtree
vocabulary. The searches were initially run in November 2010, and updated in November 2011. Full details
of both the MEDLINE and the EMBASE search strategies are presented in Appendix 1. We imported all
citations identified by the MEDLINE and EMBASE search strategies into the Reference Manager
bibliographic database. We hand-searched all proceedings of the International Stroke Conference (2011)
and the European Stroke Conference (2011, 2012). We also contacted experts in the field and perused the
reference lists of all relevant articles to identify further published studies for possible inclusion in the
review. Only full-text articles were deemed suitable for inclusion.Inclusion/exclusion criteria
One review author (MB) examined the identified titles and abstracts, and retrieved all potentially relevant
citations in full. Full-text articles were retained if they studied the application of the ABCD2 score in
cohorts of TIA and minor stroke patients and reported early risk of stroke assessed at 7, 90 and > 90 days.
Studies that did not consider the incidence of further stroke in TIA/minor stroke patients; assess patients by
means of the ABCD2 score; classify patients at high and low risk according to the cut-off score of 4; or
report original data were excluded.Quality assessment and data extraction
Two review authors (MB, HM) independently conducted data extraction and review the methodological
quality of selected studies. Disagreements were resolved by discussion or referred to a third author (JMW)
if necessary. We recorded data on study methods (e.g. setting, study design) characteristics of patients
(first vs. recurrent TIA) and outcomes (stroke events at 7, 90 and > 90 days). We also collected information
on the following methodological aspects, which we considered more likely to introduce potential biases:
prospective compared with retrospective study design, data source for cohort identification (e.g. registries,
databases, medical notes), patients’ selection criteria, spectrum of disease severity, definition of TIA, timing
of clinical assessment, evaluating clinicians, and method of outcome ascertainment (active vs. passive).Data synthesis
For each study we calculated the total number of patients with an ABCD2 score of > 4 and < 4, and the
proportion of patients in each ABCD2 dichotomised category suffering a recurrent stroke at 7, 90 and
> 90 days. The pooled risks of stroke for ABCD2 score of > 4 and < 4 at 7, 90 and > 90 days were
calculated by means of univariate random-effects meta-analyses with within-study variance modelled as
binomial. The discriminative ability of the ABCD2 cut-off score of 4 for stroke risk at 7, 90 and > 90 days
was evaluated either by bivariate ROC curve random-effects meta-analyses or by random-effects univariate
meta-analyses. We analysed all studies regardless of whether they reported recurrent stroke at only 7 or
90 days, and also restricted the analysis to just those studies that reported recurrent stroke at both 7 and
90 days, the latter to reduce the impact of some methodological differences between studies. We
calculated estimates of sensitivity, specificity, positive and negative predictive values for a hypothetical
cohort of 1000 TIA patients and expressed the proportion with recurrent stroke per 1000 patients assessed
to improve the clinical relevance of the results. We used the statistical software R version 2.14.2 for
our analyses.35
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ABCD2 SCORE AND RISK OF STROKE AFTER TRANSIENT ISCHAEMIC ATTACK AND MINOR STROKEResults
Number of included/excluded studies
The electronic searches identified 3406 citations. Of these, we considered 59 reports to be potentially
relevant and retrieved the full-text articles for detailed assessment. Hand-searching of reference lists and of
recent issues of Stroke journal (not yet indexed in MEDLINE) resulted in a further two reports to be
included. We subsequently excluded 33 articles. The most common reason for exclusion was that the study
did not provide data in sufficient detail to allow calculation of the ABCD2 score for above and below 4.
Twenty-six studies published in 28 reports fulfilled our inclusions criteria (Figure 9). Thirteen were
observational prospective cohort studies and 13 were observational retrospective cohort studies. The
included studies ranged in size from 69 to 1679 patients, and the total number of TIA/minor stroke
patients assessed was 12,586.
Characteristics of included studies
The methodological characteristics of the individual studies are shown in Table 4.
All studies used a time-based definition of TIA as opposed to the recently new proposed
tissue-based definition.176
Four studies assessed population-based cohorts,132,140,144,151 three studies hospital-based cohorts,142,155,160
nine studies patients from EDs,87,134,135,143,149,153,158,162,163 and 10 studies patients from specialist stroke or
neurology units.62,137–139,145,146,150,152,164,177Full-text papers assessed
(n = 61) 
Additional papers
identified through other
sources (n = 2)
Citations excluded after
assessing both titles and
abstracts (n = 3347)
Articles included in
quantitative synthesis
(n = 26; published in 28)
Citations identified through
literature searches after
duplicates removal (n = 3406) 






FIGURE 9 Identification and selection of studies.
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ABCD2 SCORE AND RISK OF STROKE AFTER TRANSIENT ISCHAEMIC ATTACK AND MINOR STROKEIn 15 studies the ABCD2 score was derived directly by patient assessment, whereas in the remaining
11 studies it was retrospectively calculated from medical notes.
Timing of patient assessment after symptom onset varied across studies. In seven studies ,TIA patients
were assessed within 24 hours of symptoms onset, in four studies within 48 hours, in one study within
72 hours, and in two studies within 7 days. Another three studies reported that ‘patients were assessed as
soon as possible after the event’ but did not give a time, and another study stated that the median time
from symptoms onset was 15 days. Eight studies did not clearly provide this information (see Table 4).
Most of the studies included only patients with a definite or confirmed TIA by a neurologist/stroke
physician and excluded TIA mimics. TIA diagnosis was made by a neurologist in 14 studies, by an
emergency medicine physician in six studies, initially by an emergency medicine physician and subsequently
confirmed by a neurologist in two studies and by a stroke physician in another two studies; The status of
the diagnosing physician was not reported in the remaining two studies.
Little information was available on patients with carotid stenosis or use of endarterectomy. Similarly,
information on how many TIA patients received secondary prevention drugs was rarely reported in the
included studies. Only five studies stated that approximately 45–50% of TIA patients were administered
antithrombotic therapy,143,152,153,158,162 and another study that 15% of patients received aspirin.149
Ascertainment of stroke events after TIA was carried out by face-to-face patient assessment or telephone
interviews in 17 studies, by medical records in five studies, by mixed methods (i.e. both telephone
interviews and medical records) in three studies, and was not clearly reported in one study
(see Table 4). Six cohorts reported only stroke events at 7 days,87,132,138,140,142,144 seven studies
at 90 days,134,135,145,153,162,164,177 10 studies reported stroke events both at 7 and
90 days,62,137,139,143,149–152,158,163 and three studies reported stroke events at > 90 days.146,155,160Main findings
Considering all 16 studies that reported stroke events at 7 days, the total number of TIA patients with an
ABCD2 score of ≥ 4 was 4590/6920 (66%) and the total number of recurrent strokes at 7 days was 488.
In contrast, the total number of TIA patients with an ABCD2 score of < 4 was 2330/6920 (34%) and
the total number of recurrent strokes at 7 days was 76.
In the 19 studies reporting stroke events at 90 days, the total number of TIA patients with an ABCD2 score
of ≥ 4 was 6294/9849 (64%), and the total number of recurrent strokes at 90 days was 544 (Table 5). In
contrast, the total number of TIA patients with an ABCD2 score of < 4 was 3555/9849 (36%) and the
total number of recurrent strokes at 90 days was 80.
In the three studies146,155,160 reporting stroke events at > 90 days, 736/1073 (69%) patients with an ABCD2
score of ≥ 4 experienced a total of 152 recurrent strokes. In contrast, 337/1073 (31%) TIA patients with
ABCD2 score of < 4 had a total of 44 recurrent strokes.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 5 Studies results according to the ABCD dichotomised score (≥ 4 and < 4)
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as in Asimos and
colleagues, 2010143
695 39 5.6 208 2 1.0
Ay and colleagues,
200987
315 21 6.7 162 2 1.2
Bonifati and
colleagues, 2011158
357 10 2.8 145 1 0.7




204 5 2.5 139 0 0.0
9 4.4 1 0.7
Capone and
colleagues, 2012177
6 0 0.0 88 2 2.3
Chandratheva and
colleagues, 2010144




84 9 10.7 33 2 6.0
Coutts and colleagues,
2008134
166 20 12.0 14 0 0.0
Cucchiara and
colleagues, 2009,139
106 3 2.8 61 1 1.6
Cucchiara and
colleagues, 200670
4 3.8 0 0.0
Fothergill and
colleagues, 2009140
208 31 15.0 68 4 5.9
Harrison and
colleagues, 2010145
644 23 3.6 145 1 0.7
Holzer and
colleagues, 2010146
120 9 7.5a 53 0 0.0
Johnston and
colleagues, 200762
689 43 6.2 588 3 0.5
continued
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TABLE 5 Studies results according to the ABCD dichotomised score (≥ 4 and < 4) (continued )
































65 9.4 13 2.2
Josephson and
colleagues, 2008135






250 76 30.4b 160 35 21.9b
Ong and colleagues,
2010149
325 76 23.4 145 12 8.3
90 27.8 14 9.7
Purroy and colleagues,
2010,150 2007168
243 15 6.2 67 3 4.5
20 8.2 4 6
Sanders and
colleagues, 2011162
208 5 2.4 81 2 2.5
Sheehan and
colleagues, 2010151
274 10 3.6 169 5 2.9
25 9.1 8 4.7
Stead and colleagues,
2011163
444 4 0.9 187 2 1.0
11 2.5 4 2.1
Tan and colleagues,
2009142
64 14 21.9 72 1 1.4
Tsivgoulis and
colleagues, 2010152
77 10 12.9 71 2 2.8
21 27.3 3 4.2
Wasserman and
colleagues, 2010153
661 28 4.2 321 3 0.9
Yang and colleagues,
2010155
366 67 18.3c 124 9 7.3c
a Median follow-up 27 months (range 4–64 months).
b Twelve months.
c Up to 54 months.
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27The corresponding pooled risks of stroke for patients with ABCD2 score of > 4 and < 4 at 7, 90 and
> 90 days are shown in Table 6.
The pooled risks of stroke for patients with an ABCD2 score of > 4 and < 4 at 7, 90 and > 90 days for all
included studies are shown in Figures 10–12.
Many studies presented their results as accuracy of stroke risk prediction expressed as the area under
receiver operating characteristic curve (AUROC) analyses. For completeness, we summarise the published
area under the curve (AUC) values and 95% CI for stroke risk at 7 and 90 days in Table 7. We list these in
order of publication year as it might be expected that patients would have been assessed more rapidly
after TIA/minor stroke in the more recent studies (owing to greater awareness of the importance of
seeking medical attention rapidly, better organised clinics, faster services, fewer recurrent strokes missed)
and that this might have had some impact on the early stroke recurrence rate (higher rates in more recent
studies) and in turn on the performance of risk prediction scores. However, there is no obvious trend in
either the 7- or 90-day stroke risk or in the performance of the ABCD2 score in more recent years
compared with earlier years, even allowing for the republication of some earlier data sets among later
meta-analytic studies.
Figures 10–12 show considerable heterogeneity between studies and wide CIs, which may reflect variation
in study methods or different populations of patients contributing to estimates of recurrence at different
times, as outlined in the results above, rather than true differences in stroke rates at 7 and 90 days or in
times to assessment. A previous meta-analysis found that the predictive value for 7-day stroke risk was
higher in studies using in-person or clinical records to calculate the score than in studies with retrospective
calculations of the ABCD2 score from hospital records.178
To reduce the impact of any between-study heterogeneity, we considered separately the 10 studies that
provided data on stroke risk at both 7 and 90 days.62,137,139,143,149–152,158,163 The study by Asimos and
colleagues was published in two reports.136,143 Even although the same cohort of patients was studied in
both publications, data on risk of stroke at 7 days were reported in the 2010 publication, whereas
data on risk of stroke at 90 days were reported in the 2009 publication. The number of recurrent events
at 90 days was strangely low compared with that at 7 days (see Table 5). Therefore, we excluded this
study from further analyses to avoid introducing conflicting or mismatched estimates and examined the
remaining nine studies that considered risk of stroke at both 7 and 90 days in the exact same cohorts
of patients. These nine studies included a total of 4291 patients. Five of the nine studies identified
patients retrospectively from review of medical records or equivalent. These five studies included
2019 patients, 47% of the total data from studies providing information at both 7 and 90 days.TABLE 6 Pooled stroke risks for ABCD2 dichotomised score at 7, 90 and > 90 days for all included studies
ABCD2 score Percentage 95% CI
At 7 days
≥ 4 7.5 4.7 to 11.7
< 4 2.4 1.3 to 4.2
At 90 days
≥ 4 7.1 4.6 to 10.7
< 4 2.1 1.3 to 3.3
At > 90 days
≥ 4 17.2 8.8 to 30.9
< 4 5.2 1.0 to 28.9
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7 days (%) AUC (95% CI)
Stroke risk at
90 days (%) AUC (95% CI)
OCSPa 8.4 0.72 (0.60 to 0.84) 14.3 0.69 (0.60 to 0.77)
OXVASCa 10.6 0.87 (0.81 to 0.92) 17.6 0.76 (0.68 to 0.85)
Oxford Clinica 5.4 0.75 (0.68 to 0.83) 7.0 0.75 (0.67 to 0.84)
aJohnston and colleagues, 20008 6.0 0.66 (0.62 to 0.71) 10.5 0.67 (0.63 to 0.71)
Johnston and colleagues, 200762
California clinic 3.0 0.75 (0.68 to 0.83) 6.0 0.68 (0.61 to 0.75)
California ED 7.0 0.63 (0.57 to 0.69) 10 0.64 (0.58 to 0.69)
aMlynash, 2009141 1.0 0.62 (0.43 to 0.82) 1.0 0.60 (0.38 to 0.81)
SOS-TIAa 0.3 0.74 (0.57 to 0.90) 1.2 0.71 (0.60 to 0.81)
Calvet and colleagues, 2009137 1.5 0.80a (0.62 to 0.98) 2.9 0.75 (0.61 to 0.89)
aCucchiara and colleagues, 2009139 2.4 0.75 (0.45 to 1.00) 3.0 0.71 (0.45 to 0.97)
Coutts and colleagues, 2008134 3.6a 0.75a (0.56 to 0.94) 11.1 0.78 (0.68 to 0.87)
Tan and colleagues, 2009142 11.8 0.76 (NR) – –
Fothergill and colleagues, 2009140 12.7 0.65 (NR) – –
aAy and colleagues, 2009136 4.8 0.66 (0.57 to 0.76) – –
Asimos and colleagues, 2010143 22.0 0.59 (0.56 to 0.62) – –
Sheehan and colleagues, 2010151 3.4 0.49 (0.35 to 0.63) 7.5 0.55 (0.45 to 0.64)
Ong and colleagues, 2010149 18.7 0.66 (NR) 22.1 0.66 (NR)
Arsava, 2011157 6.2 0.57 (0.45 to 0.69) – –
Tsivgoulis and colleagues, 2010152 8.0 0.72 (0.57 to 0.88) 16.0 0.75 (0.65 to 0.86)
bSanders and colleagues, 2011162 1.4 0.80 (0.68 to 0.91) 2.4 0.62 (0.40 to 0.83)
Purroy and colleagues, 2012165 2.6 0.56 (0.45 to 0.66) 3.9 0.55 (0.46 to 0.64)
NR, not reported; SOS-TIA, SOS Transient Ischaemic Attack study.
a Estimates derived from Giles and Rothwell 2010.178
b Similar stroke risk at 2 and 7 days; AUC estimated for stroke prediction at 2 days.
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27In these nine studies, the total number of TIA patients with an ABCD2 score of ≥ 4 was 2719/4291 (63%),
and the total number of recurrent strokes at 7 days and 90 days was 176 and 264, respectively. In contrast,
the total number of TIA patients with an ABCD2 score of < 4 was 1572/4291 (37%), and the total number
of recurrent strokes at 7 and 90 days was 29 and 44, respectively. The pooled stroke risk at 7 and 90 days
for these nine studies is shown in Table 8 (these studies did not provide data on stroke risk after 90 days).
The pooled sensitivity and specificity estimates for the ABCD2 score of ≥ 4 for predicting risk of stroke at
7 and 90 days are shown in Table 9.
Forest plots for the proportion of TIA/minor stroke patients with recurrent stroke at 7 days and ABCD2
score of > 4 and < 4 are shown in Figures 13 and 14 respectively, whereas forest plots for the proportion
of patients with recurrent stroke at 90 days and ABCD2 score of > 4 and < 4 are shown in Figures 15
and 16, respectively. Results from the nine studies that provide stroke risk at both 7 and 90 days
(see Figures 13 and 15: ABCD2 ≥ 4 and stroke recurrences), show reduced heterogeneity compared with47
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TABLE 8 Pooled stroke risks for ABCD2 dichotomised score for the nine studies that reported data at both
7 days and 90 days
ABCD2 score Percentage 95% CI
At 7 days
≥ 4 4.7 2.4 to 8.7
< 4 1.6 1.0 to 3.4
At 90 days
≥ 4 8.2 4.7 to 14.0
< 4 2.7 1.5 to 4.7
TABLE 9 Sensitivity and specificity estimates for ABCD2 score ≥ 4 for the nine studies that provided recurrent stroke
rates at 7 and 90 days after TIA/minor stroke
ABCD2 score of ≥ 4
Accuracy (95% CI)
Sensitivity Specificity
7 days 85.8 (80.4 to 90.0) 36.1 (30.6 to 42.1)
90 days 84.6 (80.2 to 88.2) 37.0 (40.0 to 43.4)
0.0 0.2 0.4 0.6



















Summary estimate 0.047 (0.024 to 0.087)










0.03 (0.02 to 0.05)
0.02 (0.01 to 0.06)
0.03 (0.01 to 0.06)
0.06 (0.05 to 0.08)
0.23 (0.19 to 0.28)
0.06 (0.04 to 0.10)
0.04 (0.02 to 0.07)
0.01 (0.00 to 0.02)
0.13 (0.07 to 0.22)
0.8 1.0
FIGURE 13 Proportion of patients with an ABCD2 score of > 4 who have a stroke at 7 days from the subset of
nine studies that provided data at both 7 days and 90 days.
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Summary estimate 0.016 (0.001 to 0.034)










0.01 (0.00 to 0.04)
0.00 (0.00 to 0.03)
0.02 (0.00 to 0.09)
0.01 (0.00 to 0.01)
0.08 (0.05 to 0.14)
0.04 (0.02 to 0.12)
0.03 (0.01 to 0.07)
0.01 (0.00 to 0.04)
0.03 (0.01 to 0.10)
0.8 1.0
FIGURE 14 Proportion of patients with an ABCD2 score of < 4 who have a stroke at 7 days from the subset of
nine studies that provided data at both 7 days and 90 days.
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Summary estimate 0.082 (0.047 to 0.014)










0.05 (0.03 to 0.08)
0.04 (0.02 to 0.08)
0.04 (0.01 to 0.09)
0.09 (0.07 to 0.12)
0.28 (0.23 to 0.33)
0.08 (0.05 to 0.12)
0.09 (0.06 to 0.13)
0.02 (0.01 to 0.04)
0.27 (0.19 to 0.38)
0.8 1.0
FIGURE 15 Proportion of patients with an ABCD2 score of > 4 who have a stroke at 90 days from the subset of
nine studies that provided data at both 7 days and 90 days.
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Summary estimate 0.027 (0.015 to 0.047)










0.01 (0.00 to 0.04)
0.01 (0.00 to 0.04)
0.00 (0.00 to 0.06)
0.02 (0.01 to 0.04)
0.10 (0.06 to 0.16)
0.06 (0.02 to 0.14)
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0.02 (0.01 to 0.05)
0.04 (0.01 to 0.12)
0.8 1.0
FIGURE 16 Proportion of patients with an ABCD2 score of < 4 who have a stroke at 90 days from the subset of
nine studies that provided data at both 7 days and 90 days.
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ABCD2 SCORE AND RISK OF STROKE AFTER TRANSIENT ISCHAEMIC ATTACK AND MINOR STROKEthose from all identified studies (see Figures 10 and 11). This suggests that as yet undefined methods
differences between studies were the most likely sources of the considerable heterogeneity between
studies rather than true differences in rates of recurrent stroke after TIA.
ABCD2 and proportions of patients with tight carotid stenosis
We examined all of the data on associations between the proportion of patients with high or low ABCD2
scores and an ipsilateral tight carotid stenosis, a key risk factor for recurrent stroke, to determine how
many patients with tight carotid stenosis might have their investigations delayed and be at increased risk of
stroke through having a low ABCD2 score. Four studies provided some data on carotid stenosis by ABCD2
score.132,151,180,181 Ipsilateral carotid stenosis of > 50% was more frequent in patients with ABCD2 score of
≥ 4 but was not negligible in patients with ABCD2 score of < 4. In the SOS-TIA study (SOS Transient
Ischaemic Attack), which enrolled a total of 1176 TIAs, among 679 of patients with ABCD2 scores of <4,
9%, 6% and 8% of patients, respectively, had carotid stenosis of > 50%, AF or some other high-risk factor
requiring immediate attention, compared with 14%, 11% and 10% of patients, respectively, among 497
with ABCD2 score of ≥ 4.180 Basically, one-fifth of patients with an ABCD2 score of < 4 had a serious risk
factor and one-third of patients with an ABCD2 score of ≥ 4.180 In a further analysis of the SOS-TIA data,
the 90-day stroke rate was 3.4% in patients with ABCD2 score of ≥ 4, 3.9% in patients with ABCD2 score
of < 4 and carotid stenosis or other key risk factors, and 0.4% in patients with ABCD2 score of < 4 without
key risk factors.164 In another study assessing 220 TIAs, 11%, 22% and 22%, respectively, of 55 patients
with ABCD2 scores of < 4 had carotid stenosis of > 50%, AF or both, compared with 14%, 18% and 18%,
respectively, of 165 patients with an ABCD2 score of ≥ 4.132 In a cohort of 443 specialist-confirmed TIAs,
23% of 169 patients with ABCD2 scores of < 4 had carotid stenosis of > 50%, compared with 25% of
274 patients with ABCD2 score of ≥ 4.151 Another study that assessed TIA patients with an ABCD2 score
of ≥ 5, showed that the recurrent stroke rate at 90 days increased with increasing degree of carotid
stenosis.182 Similarly, in a cohort of 40 patients with specialist-confirmed carotid territory TIA, 15% of 233
patients with ABCD2 scores of < 4 had carotid stenosis of > 50%, compared with 13% of 507 patients with
an ABCD2 score of ≥ 4.181 In short, the ABCD2 score does not predict carotid stenosis.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27ABCD2 scores in transient ischaemic attack/minor stroke mimics
There was little information on ABCD and related scores in all patients presenting to stroke clinics with
suspected TIA or minor stroke (i.e. including mimics), as most of the above studies specifically excluded
non-TIA/minor stroke patients by specialist neurological examination and did not always differentiate TIA
from minor stroke. In a retrospective cohort of 3646 patients presenting to an outpatient TIA service,
of whom 1769 (48.5%) did not have TIA, a positive association was found between low ABCD2 scores
and the diagnosis of non-CV events; after dichotomisation at 0–1 or 0–2 scores, the positive predictive
values of ABCD2 score for a non-CV diagnosis were 0.81 and 0.74, respectively.72 The analysis of the AUC
for use of the score in the diagnosis of non-CV patients suggested a reasonable accuracy [0.74 (95% CI
0.73 to 0.76)].72 In a prospective cohort (north Dublin TIA study), the diagnostic usefulness of ABCD2 score
to distinguish TIA or minor stroke from non-CV events was also assessed in 594 patients.183 Mean ABCD2
score decreased across diagnostic groups [4.9, standard deviation (SD) 1.4 for minor ischaemic stroke; 3.9,
SD 1.5 for TIA and 2.9, SD 1.5 for non-CV, p < 0.00001], as well the proportion of patients with ABCD2
scores of ≥ 4 and ≥ 6, respectively. An ABCD2 score of ≥ 4 increased the likelihood of a final diagnosis of
confirmed TIA [odds ratio (OR) 2.8; 95% CI 2.0 to 3.9] and minor stroke (OR 8.4; 95% CI 3.8 to 18.9)
compared with non-CV diagnosis. Scores of ≥ 4 had 60.3% sensitivity and 64.6% specificity for
discriminating TIA from non-CV diagnosis and 82.2% sensitivity and 64.6% specificity for discriminating
minor stroke from non-CV diagnosis. However, significant proportions of patients with a CV event
(18% of minor stroke and 39% of TIA patients) had ABCD2 scores of < 4, and 35% of those with non-CV
diagnoses had an intermediate or high ABCD2 score (≥ 4).183 In a retrospective review (medical records) of
713 patients seen in 16 northern California EDs (from March 1997 to February 1998) who received an
initial diagnosis of TIA, 79 patients (10%) had a final diagnosis of TIA mimic and 29 of them (41%) had an
ABCD2 score of ≥ 4.135 This indicates that, by placing over-reliance on the ABCD2 score, many true TIAs or
minor strokes (with lower scores) would be missed while a substantial proportion of TIA mimics (35–41%)
would be rapidly investigated.ABCD2 scores and prediction of number per 1000 with recurrent stroke
Based on all available data for the ABCD2 score and predicted risk, we calculated the number of
recurrent strokes by low or high ABCD2 scores in a hypothetical cohort of 1000 patients with probable or
definite TIA attending a stroke prevention clinic. This requires that all patients initially referred to the TIA
clinic as possible TIA/minor stroke have been filtered out by clinical assessment, which would have to be
performed by a stroke physician or neurologist, as occurred in all published studies. We restricted the
analysis to data from the nine studies that provided data on stroke at both 7 and 90 days. Among the
1000 selected probable or definite TIA/minor stroke patients there would be 634 with an ABCD2 score of
≥ 4 and 366 with ABCD2 score of < 4, of whom 30 and 6, respectively would have a recurrent stroke
within 7 days, and 52 and 10, respectively, would have a recurrent stroke by 90 days. These numbers
would shift substantially downwards if the starting population were the actual unfiltered population of
patients that are referred to stroke prevention services with a suspected TIA/minor stroke, including the
large proportion (45%) of patients with a stroke mimic as documented in the literature summarised in
Chapter 7 and as found in the survey of UK stroke prevention services summarised in Chapter 8. Even a
theoretical analysis of these data is substantially hampered by lack of information on the distribution of
ABCD2 scores in all patients presenting to stroke prevention services. However, assuming that the
neurologist was still filtering the patients into those with mimics and those with probable or definite TIA,
then of the 1000 patients presenting to the TIA clinic, about 450, would have a mimic, and 550 would
have TIA or minor stroke. Among patients with TIA/minor stroke, 349/550 would have ABCD2 score of
≥ 4 and 201/550 a core of < 4, of whom 16 and 5, respectively, would have a recurrent stroke by
7 days, and 27 and 5 by 90 days. Among the 450 with a mimic, 35–41%135,183 (say 38%) or 171 would
have an ABCD2 score of ≥ 4 and 279 a score of < 4, making a total of 520/1000 (52%) clinic
attendees with an ABCD2 score of ≥ 4, and 480/1000 48% with a score of < 4.51
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ABCD2 SCORE AND RISK OF STROKE AFTER TRANSIENT ISCHAEMIC ATTACK AND MINOR STROKEDiscussionOur systematic review combined data from 26 cohorts including 12,586 patients with TIA/minor stroke,
representing all published studies to date on recurrent stroke after TIA/minor stroke in patients
dichotomised at the ABCD2 cut-off point of ‘4’ as per UK National clinical guidelines. In terms of applying
the ABCD2 score in routine practice, the review highlights several problems with the evidence that seems
to have been overlooked previously and mean that the performance of the score will not be the same in
routine practice as in these studies.
1. About half of the studies were retrospective, using patients identified through case note review and/or
an ABCD2 score calculated also retrospectively from information derived from case notes or clinical
databases, including five of the nine studies (47% of patients) that provided data on both 7- and
90-day recurrent stroke rate, rather than prospective collection of new patients presenting to
stroke prevention services with the ABCD2 score assigned immediately in ‘real time’ after clinical
assessment. Retrospective studies are known to be prone to numerous methodological biases that limit
their reliability.
2. Most studies focused on patients with a definite (neurologist-determined) diagnosis of TIA/minor stroke,
as opposed to patients with a possible diagnosis of TIA/minor stroke or even the large number of
non-TIA/minor stroke patients who are referred to stroke prevention clinics. About 45% of patients
attending TIA/minor stroke clinics do not have a TIA/minor stroke but have a mimic (see Chapters 7
and 8). Two studies that provided relevant data showed that about one-third of patients with non-CV
diagnoses (35% and 41%, respectively) had an ABCD2 score of ≥ 4. This compares with one-fifth of
minor stroke and 40% of true TIA patients who have a ABCD2 score of < 4.72,183 The immediate and
obvious implication of these findings is that the ABCD2 score should not be used in stroke prevention
clinics except after the patient has been confirmed as a definite TIA/minor stroke by the examining
stroke physician or neurologist, as it was not derived in, nor has its performance been ascertained in,
the patients in whom it is being applied ‘at the front door’ by a non-specialist before a diagnosis of
definite TIA/minor stroke has been made. It was not derived in patients with TIA/stroke mimics and
therefore should not be used in mimics or even possible TIA/minor stroke patients. The equivalent for a
drug would be testing the drug in an randomised controlled trial (RCT) in a population of patients with
the disease that the drug was designed to treat (say thrombolysis for ischaemic stroke) but then using
the drug in a different population (e.g. all stroke – including haemorrhagic and ischaemic stroke – and
stroke mimics) coming to a hospital/clinic, many of whom did not actually have the disease that the
drug was expected to treat and therefore might not only be precluded from gaining any benefit but
could indeed be harmed by the intervention. This is an extreme example but serves to make the point.
3. Even if it were not obvious that possible TIAs and TIA mimics had been excluded from the studies, the
high proportion of patients with ABCD2 scores of ≥ 4 (two-thirds or more across all studies and time
points) should immediately raise alarm bells. Predicting risk when most of the patient population are
regarded as high risk either indicates a fundamental flaw in the score (or in the choice of the cut-off
point) or that the population is biased and not representative of routine clinical practice. We suspect
that all of these three assumptions apply. These cohorts were highly filtered; the retrospective case
ascertainment and assigning of the ABCD2 score will have inflated the number with risk points. Many
people operating stroke prevention clinics would not regard the majority of patients as being at such
high risk but rather most at low or moderate risk and only a few at high risk. What is the rationale of a
score developed to identify and triage patients at high risk for rapid treatment if it suggests that most
of them are at high risk and thereby swamps the system, the exact opposite of what it was supposed
to achieve?
4. There is little evidence that the ABCD2 score picks out patients with established markers of high risk,
such as carotid stenosis,164,181 supported by evidence that adding carotid stenosis to the ABCD2 or any
other clinical prediction score (see Chapter 5) improves recurrent stroke prediction.147,184 The high risk of
early recurrent stroke after TIA or minor stroke in patients with significant carotid stenosis is well
established.66,128,182,185 Approximately 10–15% of patients with an ABCD2 score of < 4 have carotid
stenosis of > 50% or even > 70% (very similar to the rate in patients with ABCD2 scores of ≥ 4) andNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27should therefore be referred for endarterectomy.132,162,164,181 Notably, in a French cohort, patients with
TIA and ABCD2 score of < 4 had similar 90-day risk of recurrent stroke (3.9%) as those with a score of
≥ 4 (3.4%) in the presence of internal carotid or intracranial artery stenosis of ≥ 50% by North
American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria or major cardiac source of
embolism. In this cohort, one TIA patient in five with a ABCD2 score of < 4 had a major finding that
required immediate medical decision.164 The presence of symptomatic carotid stenosis in patients with
low ABCD score has also been shown in other cohorts, ranging from 9% to 23%.132,151,164,181 Under
present NICE guidance,67 patients with ABCD2 scores of < 4 would not be triaged for rapid assessment
and would not reach endarterectomy in time for it to have maximum benefit. This risks undermining
one of the strongest pieces of evidence that we have for stroke prevention, from the several
1000 patients in the carotid endarterectomy trials, which demonstrate that endarterectomy reduces
the risk of ipsilateral ischaemic stroke in patients with a tight carotid stenosis by ≥ 50%.25
5. Few studies indicated what secondary prevention measures were used in their patients (endarterectomy,
medical therapy) yet these have been established in guidelines for at least 15 (endarterectomy) or more
(aspirin, statins, BP-lowering drugs) years. It is unlikely that patients in these studies would have been
denied such treatments and presumably they were not, but the application of endarterectomy and drugs
may have reduced the risk of stroke that they were attempting to observe.
Other limitations with the literature are that there was significant heterogeneity between included studies,
which could be explained by clinical and methodological factors. Clinical setting, time of assessment from
symptom onset, diagnosis of TIAs, and evaluating clinicians varied considerably across studies. Our crude
assessment of variation in recurrent stroke rates after TIA with year of study publication did not suggest
that simple changes in referral rates would explain the heterogeneity. Many studies did not differentiate
recurrent disabling stroke from any recurrent stroke and some studies may have counted a recurrent TIA as
a stroke recurrence. Furthermore, in some studies the authors could not establish with certainty whether
early strokes were due to progression of initial symptoms or a new event.
Various attempts have been made to improve the yield of clinical prediction scores in the stratification of
stroke risk after TIA by including the use of brain and carotid imaging findings,69,147 and resulted in a
confusing plethora of ABCD2 clones with limited validation or evidence of truly improved performance.
The effect of adding brain imaging to the ABCD2 score is summarised in Chapters 5 and 6.
A recent systematic review and meta-analysis of ABCD2 scores and stroke risk125 in 33 studies, 16,070
patients, published shortly before submission of this report, is entirely consistent with our results.
Differences between their work and ours are that they did not dichotomise on ABCD2 score of 4; they
included information only published in abstract; and they did not identify the issues regarding case
ascertainment, assignment of ABCD2 score, population distribution of scores, uncertainty over risk factor
identification or treatment of these, or filtering by experts that we have highlighted. However, they did
observe that many studies come from the same few research groups and, like us, experienced difficulty in
avoiding double-counting of the same patient data appearing in multiple publications. Their pooled
sensitivity and specificity for stroke risk at 7 days were nearly identical to ours. They concluded that ‘the
ABCD2 score leads to only small revisions of baseline stroke risk particularly in settings of very low baseline
risk and when used by non-specialists’, although most of the data in their review came from specialists.
A systematic review and pooled analysis of validation studies of ABCD and ABCD2 scores showed pooled
AUCs for the prediction of stroke at 7 days of 0.72 (95% CI 0.67 to 0.77) and 0.72 (95% CI 0.63 to 0.80)
for studies using the ABCD and ABCD2 score, respectively; the pooled AUCs for studies using both scores
were 0.72 (95% CI 0.66 to 0.78) and 0.72 (95% CI 0.63 to 0.82) respectively, with significant
heterogeneity for all given estimates.178 The pooled AUCs for the ABCD2 score assessed in the Oxford or
California cohorts and independent studies were 0.77 (95% CI 0.63 to 0.91) and 0.69 (95% CI 0.64 to
0.74) respectively; the predictive value for 7-day stroke risk was higher for studies using in person or
clinical records calculations of the score than studies with retrospective calculations from ED records.53
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ABCD2 SCORE AND RISK OF STROKE AFTER TRANSIENT ISCHAEMIC ATTACK AND MINOR STROKESince the publication of this systematic review, a number of further studies evaluating the ABCD2 score
have been published, with conflicting results.19,20,37,39,46,67 A more recent meta-analysis of 16 ABCD2 score
validation studies assessed the predictive value of the score in stroke risk at 7 and 90 days after TIA using
three strata of risk: low, moderate and high (0–3, 4–5 and 6–7 points, respectively). The score correctly
predicted the occurrence of stroke at 7 days after TIA in all strata of risk but tended to overpredict the
occurrence of stroke at 90 days.166 There is an indication that ABCD scores work differently in stroke and
TIA patients, with some publications suggesting that ABCD scores may predict stroke recurrence with any
accuracy only within the first 7 days of TIA. In the OXVASC population cohort the risk of recurrent stroke
at 90 days in patients presenting with a first minor stroke was 11.7%; the ABCD2 score was poorly
predictive of stroke recurrence within 7 and 90 days in this group of patients – AUCs 0.57 (95% CI 0.47
to 0.68) and 0.60 (95% CI 0.53 to 0.67), respectively.186 Other scores have been used to predict the
long-term risk of stroke. An external validation of several prediction models for long-term risk of major
vascular events after TIA or minor stroke showed that the discrimination was poor for all prediction models
for risk at 2 years. After adjustment for baseline risk and prevalence of risk factors, clinical usefulness may
be best for the ABCD2 model, with a reasonable c-statistic (0.64). Notably, patients with AF, significant
symptomatic carotid stenosis, mechanical heart valve and a proven dissection were excluded.187 Another
prospective assessment of prognostic scores in patients with TIA or non-disabling stroke [including Essen
Stroke Risk Score (ESRS), Stroke Prognosis Instrument II (SPI-II), Life Long After Cerebral ischaemia (LiLAC)
score and Hankey score, discussed in Chapter 5] showed that the discrimination for annual risk of stroke
was similar across each score, with a marginal superiority of SPI-II score (AUC 0.65; 95% CI 0.6 to 0.7).154
Current clinical guidelines67 recommend urgent treatment only for patients with high ABCD2 scores,
whereas patients with low scores should be triaged for further clinical assessment within 1 week.67,97
This would risk missing patients with carotid stenosis requiring endarterectomy. On the other hand, not
everyone may be using these scores in real life, as indicated in the survey of stroke prevention services in
the UK, which indicates that only 13% of the respondents described the use of ABCD2 score to stratify
the promptitude of assessment of TIA patients (see Chapter 8).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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after transient ischaemic attack and the effect of
adding information from plain computerised
tomography or carotid imagingIntroductionPatients who have recently experienced a TIA or minor stroke are at a higher risk of major disabling stroke
and other vascular events.188 Prediction of who will suffer recurrent disabling stroke may help triage those
patients at highest risk to effective stroke prevention treatment faster. It may also help determine the
intensity and type of treatment that is offered.
Numerous risk prediction scores have been developed over the last 20 years, which aim to improve
identification of patients at high risk of disabling recurrent stroke after TIA/minor stroke: a score developed
in 469 patients with TIA seen in the 1980s based on clinical variables;9 a score developed in the European
Carotid Surgery Trial (ECST) (1980s to mid-1990s) data;11 the ABCD score developed using data from a
population-based stroke and TIA registry conducted in the 1980s (OCSP) and tested in a repeat study in
the same population in the early 2000s (OXVASC);61 an updated version of this derived in the OCSP TIA
patients and patients attending a private health provider in the USA and tested in OXVASC and more USA
patients – the ABCD2 score;62 the ESRS, which was derived from a subset of ischaemic stroke patients in
the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial and validated in two
observational studies and in data from another stroke prevention trial;63 Stroke Prognosis Instrument I (SPI-I)
and SPI-II were developed in medical stroke prevention trials and validated in three independent cohorts;64
and the LiLAC score, which was based on data from the Dutch TIA trial (1986–9) and has not been
externally validated.65
All except two60,64 of these scores use only simple clinical features and so they are rapid and easy to apply
without needing complex technologies.59,61,62,65 For example, the ABCD2 score uses age, blood pressure,
clinical features, duration of symptoms and diabetes to derive a score from 0 to 7. These scores could
help to reduce delays to reaching medical attention and to triage patients,66 so that those needing most
rapid treatment, such as carotid endarterectomy, would reach surgery more quickly. They might also
improve the accuracy of clinical diagnosis of TIA by non-stroke physicians, thereby also making better
use of resources.
Development of risk prediction scores involves collecting a range of variables that are potentially associated
with outcome (in this case recurrent stroke), performing statistical modelling to determine which of these
are the most powerful predictors then turning these into a score and performing validation in external
data sets that reflect the circumstances in which the score will be used in clinical practice. Proposed
prediction scores include numerous ABCD and derivative scores, the Californian score, the ESRS score,
SPI-II, and the clinical and imaging-based predictive (CIP) model.61,63,64,189 These prediction scores aim to
estimate the risk of recurrent stroke for a given patient in a specified timeframe, at the bedside. Although
these scores are used in clinical practice, there are benefits from studying their accuracy and practicality
when in wider use as validation is rarely extensive or adequate in the primary publication.166,189,19055
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56Stroke patients routinely undergo imaging of the brain and carotid arteries. It is reasonable to ask whether
the addition of routinely available imaging of the brain and carotid arteries to models based on clinical
variables alone improves prediction. To investigate this question, we systematically reviewed the literature.
It was necessary to modify the methodology used for systematic reviews of RCTs to allow for the various
study designs used by the original studies. We specifically examined the addition of CT brain imaging and
carotid imaging by any modality to prediction rules or models of recurrent stroke using clinical predictors in
patients with recent TIAs or minor strokes.Methods
Identification of studies
Application of systematic review methodology to reviews of prognostic factors or prediction rules is not
straightforward. Current methodology focuses on the retrieval and appraisal of particular kinds of study,
particularly RCTs,191 yet most prediction rules are not developed in the context of RCTs. RCTs are carefully
indexed as such in online medical databases. However, studies investigating the predictors of recurrent
stroke are not restricted to any particular study design, especially not to RCTs, making it difficult to limit
the number of hits found by a systematic literature search in medical databases, such as MEDLINE, by a
study design filter. A simple, non-exhaustive, search strategy (see Appendix 1) in MEDLINE to find studies
about recurrent stroke yielded 16,556 hits – an unworkably large number, given the resources available.
Even for formal clinical prediction rules it is far more challenging to create an efficient yet exhaustive
search strategy than for RCTs.192
We therefore used a citation search method. Starting with a routinely collected reasonably comprehensive
series of papers collected by one of the authors (JMW) over the last 20 years and several key papers,61,147,166,184
one reviewer (FMC) checked their references for relevant articles and also used Web of Knowledge ISI
(http://wokinfo.com) to find articles that had cited the key papers. If a new study met our inclusion criteria,
we also checked its references and found the studies that had cited it. This process was carried on iteratively
until no new papers were found. This method has the advantages of transparency, repeatability and
practicality. It can identify relevant literature without requiring the resources needed to administer thousands
of abstracts and hundreds of full-text articles that would be identified by an exhaustive literature search but
that would ultimately be irrelevant.Inclusion/exclusion criteria
Each study had to contain data that could be used to ascertain recurrent stroke risk using either specified
clinical prediction rules (ABCD, ABCD2, SP-II, the ESRS and the Californian rule; the CIP rule was not
included as it is the ABCD rule plus DWI) or a described but un-named statistical model linking clinical
predictors with recurrent stroke, with CT brain imaging or carotid imaging by any modality in adult
patients who had had a recent TIA or minor stroke. Studies that did not use brain CT/carotid imaging, or
used only imaging to predict stroke, were not included. Studies using a highly selected subset, for example
young patients only, were noted but not included in the review. Studies were also excluded unless the
predicted outcome was recurrent stroke. Studies published prior to 1990 were also excluded owing to
developments in imaging technology since that time.Quality assessment and data extraction
We derived a critical appraisal tool using a framework suggested for prognosis studies (see Appendix 2).193
We particularly wished to examine patient recruitment into studies and patient selection for imaging as
potential sources of bias. A brief inspection of the literature showed that patients may have had probable,
possible or definite TIAs, imaging may have been reported for the entire or a subset of the sample, and
recurrent stroke outcome events reported for 7, 30 or 90 days. Two other important issues were theNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27definition of outcome and any stroke prevention treatment the patients may have received. Outcome was
often simply defined as recurrent stroke without any indication of the severity. Also any treatment given
will have an effect on stroke outcomes.
The data extracted from each article included the following:
l number of patients
l setting [e.g. hospital specialist clinic vs. community-based or accident and emergency (A+E)
department]
l percentage male
l percentage TIA and minor stroke (possible, probable, definite)
l recruitment procedure (e.g. consecutive recruitment)
l age (mean/median age plus range)
l length of follow-up
l if patients at high risk of stroke were treated and the treatment given
l timing of baseline imaging from symptom onset or presentation
l clinical prediction rule or details of the statistical model
l type of additional imaging
l definition of recurrent event
l definition of positive imaging
l method of ascertaining effect of adding imaging to the clinical prediction rule/statistical model
l the added value of imaging to the clinical prediction rule/statistical model (this last may be expressed in
a number of ways, most simply as the changes in the numbers of patients correctly predicted to have
or not have a recurrent stroke).
One reviewer (FMC) performed the critical appraisal and extracted the data; ambiguous papers were
discussed with a second reviewer (JMW) to minimise appraisal or data extraction errors.Data synthesis
We planned to conduct two meta-analyses of the CT and carotid stenosis data. Studies were grouped
according to their outcome measure [AUC, hazard ratio (HR), relative risk (RR)] for separate analysis as
different outcome measures generally cannot be combined. We used forest plots and calculated
I2-statistics109 to assess heterogeneity. All analyses were done in R using the generic inverse variance
method in the meta-package.Additional individual patient data from Lothian cohort
We also had access to data from a large prospective observational study – the LSR – conducted between
October 1991 and 1999 in the stroke service at the Western General Hospital (WGH), Edinburgh, the
methods of which have been published previously.37 For the stroke prediction analysis, we used data on all
patients referred with TIA, amaurosis fugax (AFx), retinal artery occlusion (RAO) or stroke, outpatients and
inpatients between October 1994 and December 1999. Patients were excluded if they had a primary
intracerebral haemorrhage (PICH) on CT/MRI scanning or were diagnosed with major stroke (abnormal
verbal score on Glasgow Coma Scale, could not walk, could not lift both arms at examination). All patients
were seen by a stroke physician mostly as outpatients in a rapid access stroke prevention clinic that
operated twice per week in addition to patients being seen in A+E and on the wards. The details of the
current and past history, and examination (with particular emphasis on vascular risk factors), blood tests,
chest radiography, electrocardiography (ECG), CT brain and carotid artery imaging were entered into a
database, of the LSR. The diagnosis of definite, probable or possible stroke/TIA/retinal ischaemia and not
stroke/TIA/retinal ischaemia were determined by a consultant stroke physician in discussion with a panel of
expert stroke physicians, prospectively, held weekly and blind to all follow-up events. The stroke physician
also assigned an OCSP stroke subtype total anterior circulation cortical stroke (TACS), partial anterior57
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58circulation cortical stroke (PACS), lacunar stroke (LACS) or posterior circulation stroke (POCS).194 The CT
scans were coded by an expert neuroradiologist for the presence of any visible, recent and ‘likely to be
relevant to the recent symptoms’ infarct for any old stroke lesions and non-stroke lesions using a
structured validated scoring method.195 The rater was not blind to the clinical presenting symptoms and
signs so as to determine if any visible lesion were likely to be relevant or not, but was blind to any
recurrent stroke or other outcomes and to the presence of other risk factors including carotid stenosis.
Carotid stenosis was measured by ultrasound, the imaging being performed by one of two trained
operators (a radiographer or neuroradiologist) who recorded velocities in the internal, external and
common carotid and vertebral arteries [internal carotid artery (ICA), external carotid artery, common
carotid artery (CCA), vertebral artery, respectively] on both sides of the neck.196 In addition, any visible
stenosis was noted, including its location, the degree of luminal narrowing by calliper measurement of the
residual and original lumen at the point of maximum stenosis, the CCA lumen, and the ICA lumen distal
to the stenosis by calliper measurements on the ultrasound console.197 The degree of stenosis was
assigned according to the ECST measurement method,82 using the velocity readings and calliper
measurements, a method that has been validated against intra-arterial angiography (IAA).197 The
appearance of the stenosing plaque (smooth surface and of uniform echoity indicating ‘quiescent plaque’
or irregular surface and mixed echoity indicating ‘active plaque’) was also recorded.198 The ECST velocity
and calliper measurements were also converted to stenosis, expressed using the NASCET method for
comparison with other studies.199 Patients with >50% NASCET (>70% ECST) stenosis in the symptomatic
ICA underwent confirmatory imaging with IAA prior to 1998 and MRA or repeat Doppler ultrasound (DUS)
by a blinded operator thereafter.
Patients were followed up at 6 months, 1 year and 2 years by a trained researcher using a postal/
telephone questionnaire, blinded to initial presenting symptoms and imaging features, using validated
methods, to identify whether they had had a further stroke, myocardial infarction (MI) or died (and if so
from what), and to determine their functional status. Therefore, the data were representative of practice in
a rapid-access, same-day investigation NV clinic that accepted unscreened referrals from general
practitioners (GPs) and other hospitals in the geographical area of north Edinburgh.
In all patients with mild stroke [defined as non-disabling and usually equivalent to a PACS, LACS, or POCS
syndrome according to the OCSP classification,194 or TIA, or eye ischaemic symptoms (AFx or RAO),
including those who would be candidates for endarterectomy] we performed multivariate survival analyses
(Cox proportional hazards). The final predictive model included:
l residual neurological signs (yes/no)
l carotid stenosis (deciles, ECST criteria)
l age (years)
l previous stroke (yes/no)
l ocular not cerebral symptoms (yes/no)
l coronary illness (yes/no)
l visible infarct (yes/no).
Coronary illness was defined as the presence of one or more of the following: angina, previous MI, ECG
showing acute or old MI. Predicted outcome was non-fatal disabling or fatal stroke. The model was rerun
with and without carotid stenosis and CT visible infarct:
l Model A included all of the above except carotid and brain imaging (clinical only).
l Model B included all of the above except brain imaging (clinical plus carotid).
l Model C included all of the above except carotid imaging (clinical plus CT).
l Model D included all of the above (clinical plus carotid plus CT).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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expressed as a probability from 0 to 1. A cut-off of 0.045 was applied to these risks to divide the patients
into those predicted to have a stroke and those not predicted to have a stroke. The figure of 0.0045 was
the cut-off chosen in the original LSR analyses for outcomes at 1 year.
The variables tested included age (years), residual neurological signs (yes/no), previous stroke, ocular as
opposed to brain symptoms, coronary disease, the degree of ipsilateral carotid stenosis, atheroma plaque
appearance or visible (likely to be relevant) infarct on CT. We tested the association between these variables
and fatal or non-fatal disabling stroke during follow-up. Data were analysed with SAS version 9.1.3
(SAS Institute Inc., Cary, NC, USA; www.sas.com).Results
Number of included/excluded studies
The citation search method produced 1116 papers after removing duplicates and papers published prior
to 1990; among this were 117 potentially relevant studies that were considered for inclusion. Ninety-six
studies were rejected for the following reasons: 36 did not use brain CT or carotid imaging to predict
recurrent stroke, 15 did not have recurrent stroke as an outcome, the relevant data were not reported in
13 studies, and a further 32 were rejected for a variety of reasons. This left 21 studies. The study designs
ranged from population-based epidemiological studies to RCTs.
One of these 21 studies was an individual patient data (IPD) meta-analysis, which provided estimates of
accuracy of prediction of the ABCD2 and brain CT individually for seven of the included studies.178 We
extracted CT results for each of the seven studies, but did not use the meta-analysis further, for example it
was not included in the critical appraisal process. One of these seven studies also provided CT results in
the primary publication.69 A further 11 studies provided CT data, i.e. there were 18 studies providing data
on CT brain imaging in total. There were 10 studies with carotid imaging data, and another 12 studies
that used large artery atherosclerosis (LAA) where carotid stenosis was a component as a predictor.
We recorded the results of the LAA studies for interest, but, owing to the heterogeneous definitions
of LAA, did not formally include them in the review. Six studies had data on both CT and carotid
imaging (Table 10).
We were careful to avoid duplicate publication of the same patient data, as some studies produced several
publications. Only one reference per study was listed in the included studies, where that reference gave
the required CT or carotid results. Secondary publications of included studies are given in Table 11, and
were used for extra information in the critical appraisal and data extraction stages, with the exception of
the studies used in the IPD meta-analysis,184 where the studies contributing to the IPD meta-analysis and
which provided additional information on imaging findings, are listed as included studies, even if their own
original publications did not provide CT brain or carotid imaging results.59
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TABLE 10 Data available from primary studies, comprising 18 CT studies and 10 carotid studies used in the analyses,




aAsimos and colleagues, 2010143 Yes No No
Bonifati and colleagues, 2011158 Yes Yes No
Calvet and colleagues, 2009137 No No Yes
Cancelli and colleagues, 2011200 No Yes No
Coutts and colleagues, 2008134 Yes No Yes
Coutts and colleagues, 2011201 No Yes No
aCucchiara and colleagues, 2009139 Yes No No
aDouglas and colleagues, 200335 Yes No No
The Dutch TIA Trial Study Group 1993202 Yes No No
Eliasziw and colleagues, 1995203 Yes Yes No
Giles and colleagues, 2010184 Yes No No
Hankey and colleagues, 1992204 Yes Yes No
Hier and colleagues, 1991205 Yes No No
Holzer and colleagues, 2010146 No No Yes
Kernan and colleagues, 1991206 No No Yes
Kernan and colleagues, 200064 Yes Yes No
Lavallée and colleagues, 2007122 Yes No No
Lovett and colleagues, 2004207 No No Yes
Marnane and colleagues, 2011208 No Yes Yes
Merwick and colleagues, 2010147 No No Yes
Ois and colleagues, 200881 No No Yes
Purroy and colleagues, 2007182 No Yes Yes
Purroy and colleagues, 2010150 Yes No Yes
Purroy and colleagues, 2012165 Yes No Yes
Purroy and colleagues, 2011209 No No Yes
Rothwell and Warlow, 199960 Yes Yes No
aRothwell and colleagues, 200561 Yes No No
Sciolla and Melis, 200869 Yes No No
aSheehan and colleagues, 2010151 Yes Yes No
a Computed tomography results available from Giles and colleagues,186 IPD meta-analysis only.
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TABLE 11 Secondary publications
Primary publication listed in included studies Secondary publications
Douglas VC, Johnston CM, Elkins J, Sidney S, Gress DR,
Johnston SC. Head computed tomography findings
predict short-term stroke risk after transient ischemic
attack. Stroke 2003;34:2894–835
Johnston SC, Gress DR, Bronwer WS, Sidney S. Short-term
prognosis after emergency department diagnosis of TIA.
JAMA 2000;284:2901–68
The Dutch TIA Trial Study Group. Predictors of major
vascular events in patients with a transient ischemic
attack or nondisabling stroke. Stroke 1993;24:527–31202
Van Swieten JC, Kappelle LJ, Algra A, van Latum JC,
Koudstaal PJ, van Gijn J, for the Dutch TIA Trial Study Group.
Hypodensity of the cerebral white matter in patients with
transient ischemic attack or minor stroke: influence on the
rate of subsequent stroke. Ann Neurol 1992;32:177–83211
Van Wijk I, Kappelle LJ, van Gijn J, Koudstaal PJ, Franke CL,
Vermeulen M, et al. A. Long-term survival and vascular event
risk after transient ischaemic attack or minor ischaemic
stroke: a cohort study. Lancet 2005;365:2098–10465
Eliasziw M, Streifler JY, Spence JD, Fox AJ, Hachinski VC,
Barnett HJM. Prognosis for patients following a transient
ischaemic attack with and without a cerebral infarction
on brain CT. Neurology 1995;45:428–31203
Steifler JY, Eliasziw M, Benavente OR, Harbison JW,
Hachinski VC, Barnett HJM, et al. The risk of stroke in
patients with first-ever retinal vs. hemispheric transient
ischemic attacks and high-grade carotid stenosis. Arch
Neurol 1995;52:246–9212
North American Symptomatic Carotid Endarterectomy Trial
Collaborators. Beneficial effect of carotid endarterectomy in
symptomatic patients with high-grade carotid stenosis.
N Engl J Med 1991;325:445–53213
Giles MF, Albers GW, Amarenco P, Arsava MM,
Asimos A, Ay H, et al. Addition of brain infarction to
the ABCD2 Score (ABCD2I): a collaborative analysis
of unpublished data on 4574 patients. Stroke
2010;41:1907–13184
Giles MF, Albers GW, Amarenco P, Arsava EM, Ay H,
Calvet D, et al. Early stroke risk and ABCD2 score
performance in tissue- vs. time-defined TIA: a multicenter
study. Neurology 2011;77:1222–8210
Giles MF, Rothwell PM. Systematic review and pooled
analysis of published and unpublished validations of the
ABCD and ABCD2 transient ischemic attack risk scores.
Stroke 2010;41:667–73178
Giles MF, Rothwell PM. Risk of stroke early after transient
ischaemic attack: a systematic review and meta-analysis.
Lancet Neurol 2007;6:1063–72121
Hankey GJ, Slattery JM, Warlow CP. Transient
ischaemic attacks: which patients are at high (and low)
risk of serious vascular events? J Neurol Neurosurg
Psychiatr 1992;55:640–52204
Hankey GJ, Slattery JM, Warlow CP. The prognosis of
hospital-referred transient ischemic attacks. J Neurol
Neurosurg Psychiatr 1991;54:793–802214
Purroy F, Montaner J, Molina CA, Delgado P, Ribo M,
Álvarez-Sabín J. Patterns and predictors of early risk of
recurrence after transient ischemic attack with respect
to etiologic subtypes. Stroke 2007;38:3225–9168
Purroy García F, Molina Cateriano CA, Montaner Villalonga
J, Delgado Martínez P, Santmarina Pérez E, Toledo M, et al.
Lack of usefulness of ABCD score in the early risk of
recurrent stroke in transient ischemic attack patients.
Med Clin 2007;128:201–3190
Purroy F, Montaner J, Rovira A, Delgado P, Quintana M,
Álvarez-Sabín J. Higher risk of further vascular events among
transient ischaemic attack patients with diffusion-weighted
imaging acute ischemic lesions. Stroke 2004;35:2313–1993
Rothwell PM, Warlow CP. Prediction of benefit
from carotid endarterectomy in individual patients:
a risk-modelling study. Lancet 1999;353:2105–1060
European Carotid Surgery Trialists’ Collaborative Group.
Randomised controlled trial of endarterectomy for recently
symptomatic carotid stenosis: final results of the MRC
European Carotid Surgery Trial (ECST). Lancet
1998;351:1379–8782
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The papers were broadly similar in their critical appraisal results (Figures 17 and 18). However, it was
notable that the carotid stenosis papers mostly did define carotid stenosis adequately, whereas more than
half of the CT papers did not give a description of a positive CT scan.
Many papers lacked details on exactly how the patients were recruited and, in particular, whether or not
they were a consecutive sample, although the studies by Bonifati and colleagues,158 Cancelli and
colleagues,200 and Sheehan and colleagues151 stressed the efforts made by the authors to identify all
possible patients, and Sciolla and Melis69 and Purroy and colleagues150 explicitly stated that their sample was
consecutively recruited. In addition, a few references had obtained data from RCTs (Table 12).60,64,202,203
A more important point may be the various eligibility criteria used by the individual studies with regard to TIA
status – some studies recruited patients if the emergency doctor suspected a TIA, whereas others recruited
only patients with ischaemic stroke confirmed by a neurologist. The difference between these patient groups
is likely to be a key factor in the rates of and prediction of recurrent stroke. However, the definitions of a TIA
from study to study were generally very similar; a TIA was often defined as focal neurological symptoms
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FIGURE 18 Results of critical appraisal of studies contributing carotid stenosis data. Each item on the checklist
was coded ‘Yes’, ‘No’ or ‘Unclear’, with ‘Yes’ indicating better reporting or methodology (see Appendix 2).
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FIGURE 17 Results of critical appraisal of studies contributing CT data. Each item on the checklist was coded ‘Yes’,
‘No’ or ‘Unclear’, with ‘Yes’ indicating better reporting or methodology (see Appendix 2). Note: item 5 is
not included as it refers to carotid stenosis imaging.
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TABLE 12 Patient recruitment (item 1 from the critical appraisal checklist)a






Non-consecutive sample Exclusion criteria: history of stroke, unknown












Prospective review of patient
records, including admission
registers, and referrals to
neurology and neuroradiology
departments
Exclusion criteria: non-resident of the Udine
area, non-consent, history of stroke, presenting
at time of recurrent stroke rather than initial





Prospective cohort study Inclusion criteria: examination by study
neurologist within 12 hours of onset, aged
≥ 18 years, consent given, CT and MRI imaging








Prospective cohort study Exclusion criteria: evaluation more than 48
hours after symptom onset, severe or terminal
illness, on warfarin with an international
normalised ratio of ≥ 1.5
Inclusion criteria: diagnostic testing for NV





Prospective cohort study Exclusion criteria: patients with missing records
or who were not members of the specified
health plan, who had ED diagnoses other than






Patients recruited to a RCT
of aspirin
Exclusion criteria: final non-CV diagnosis, or ‘. . .
cerebral ischemia from causes other than
artery-to-artery embolism, such as
haematological disorders, vasculitis,








Non-surgical arm of a RCT
(NASCET) for carotid
endarterectomy. All patients
with 70–99% carotid stenosis
with a TIA presenting event
Exclusion criteria: stroke or any history of
stroke, ischaemic event attributed to a cardiac
source, presenting event occurring at ≥ 120
days prior to randomisation, aged > 80 years,
significant intracranial vascular disease,





Various methods used in the
primary studies
Various inclusion/exclusion criteria used in the
primary studies; the IPD meta-analysis did not






Prospective cohort study Inclusion criteria: ‘. . . presenting TIA was







Prospective cohort study All patients presented with an ischaemic stroke.
Exclusion criteria included cerebral oedema,
hypoperfusion, metabolic disturbance,
toxaemia, fever, epilepsy, stroke related to
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TABLE 12 Patient recruitment (item 1 from the critical appraisal checklist)a (continued )






Relevant results derived from
patients recruited into a RCT
(Women’s Oestrogen for
Stroke Trial, WEST)
Inclusion criteria: postmenopausal women
presenting with TIA or non-disabling stroke at
< 90 days prior to randomisation
Ischaemic
strokes
(n = 403) and




Prospective cohort of patients
recruited to a TIA clinic
Patients thought to have non-neurological
transient symptoms, or persistent ischaemic
symptoms consistent with evolving stroke were
excluded. Although this study did recruit and
present results for patients with minor stroke,







Exclusion criteria: presenting with a TIA or
haemorrhagic stroke, stroke associated with







Prospective study of patients
presenting at A+E






Prospective study of consecutive





Prospective study of patients
referred to stroke units
Exclusion criteria: non-TIA diagnosis or a mRS





Non-surgical arm of a
RCT (ECST) for carotid
endarterectomy
Inclusion criteria: ‘. . . carotid distribution
transient ischaemic attack, minor ischaemic
stroke, non-disabling major stroke, or a retinal
infarction in the previous 6 months, and had















Inclusion criteria: TIA diagnosis confirmed by
neurologist within 24 hours of onset
Exclusion criteria: presentation more than







cohort study with ‘hot’ and
‘cold’ pursuit in the first year
Exclusion criteria: non-CV diagnosis TIA only
mRS, modified Rankin Scale; NR, not reported.
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TABLE 13 Results of critical appraisal: TIA status (items 2 and 3 from the critical appraisal checklist)a




Sudden focal loss of neurologic function
involving the brain or retina, supplied by a
specific vascular territory, with complete
recovery in 24 hours
Emergency physicians or other admitting
physicians identified . . . admitted





According to the World Health
Organisation (WHO), TIA was defined as
an episode of focal neurological symptoms
with abrupt onset and rapid resolution
lasting < 24 hours and thought to be due
to altered circulation to a limited region of
the brain
Retrospective analysis of ED discharge diagnosis
The discharge diagnosis was not always
coded as TIA but all patients discharged
with neurological symptoms were
evaluated. Clinical charts of all patients with
a focal neurological deficit were further




. . . an acute loss of focal cerebral or ocular
function lasting < 24 hours presumed,
after adequate investigation, to be
attributable to embolic or thrombotic
vascular disease
Patients were assessed as soon as possible
by a study neurologist in the hospital or at
home . . . Hospital and outpatients records
were reviewed to obtain a confirmation of
the self-reported diagnosis . . .
Only definite TIA patients were included in the





TIA patients needed to have motor or
speech symptoms (or both) lasting at least
five minutes . . .
. . . examined by a Stroke Neurologist within




. . . acute onset of focal cerebral or
monocular symptoms lasting less than
24 hours and thought possibly to have a
vascular cause in the opinion of the
neurologist evaluating the patient




. . . based on the World Health
Organisation criteria as rapidly developed
clinical signs of focal or global disturbance
of cerebral function lasting fewer than 24
hours, with no apparent nonvascular cause





A TIA was defined as a focal neurological
deficit with abrupt or relatively rapid
onset, persisting less than 24 hours; and a
minor stroke, as a similarly focal
neurological deficit persisting more than
24 hours




. . . transient focal neurologic dysfunction
of ischemic origin that resolved within
24 hours, leaving no deficit. Retinal events
were defined as transient monocular
visual loss
TIA diagnosis confirmed as part of recruitment




Patients were eligible if they had a
diagnosis of TIA made according to the
World Health Organisation time-based
definition
Presumably various as the primary studies may
have recruited patients with presumed TIA
or definite TIA. The methods do not





. . . an acute loss of focal cerebral or
monocular function with symptoms lasting
less than 24 hours and which after
adequate investigation was presumed
to be due to embolic or thrombotic
vascular disease
TIA diagnosis was confirmed by a neurologist
continued
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TABLE 13 Results of critical appraisal: TIA status (items 2 and 3 from the critical appraisal checklist)a (continued )




Stroke was defined as a sudden,
nonconvulsive, focal neurological deficit
persisting for > 24 hours




Our case definitions for both a transient
ischemic attack and a minor stroke in the
carotid distribution included the sudden
onset of dysphasia, unilateral motor
weakness, or monocular blindness. For a
transient ischemic attack, the case
definition required the complete resolution
of all neurologic signs and symptoms
within 24 hours of symptom onset. The
case definition for minor stroke required
the persistence of neurologic signs beyond





TIA was defined as an acute loss of focal
cerebral or ocular function with symptoms
that lasted less than 24 hours and that
were attributed to inadequate
blood supply
Patients who had transient focal
neurological features but whose clinical and
radiological features were not sufficiently
clear to affirm or exclude the diagnosis of
TIA were judged to have a possible TIA.
Patients with incomplete recovery were




Ischaemic stroke identified by an
appropriate clinical syndrome (according to
WHO definition) in whom brain imaging or





TIA was defined as a reversible episode of
neurologic deficit of ischemic origin that
resolved completely within 24 hours




TIA was defined as a focal cerebral or ocular
dysfunction with symptoms lasting less than
24 hours caused by vascular insufficiency or an
arterial thromboembolism




A TIA was defined as a reversible episode
of neurological deficit of ischemic origin
that resolved completely with 24 hours
TIA was diagnosed by a neurologist
Rothwell and
Warlow, 199960
Not defined TIA diagnosis confirmed as patients were
assessed by neurologist and surgeon for





‘. . . the standard definition.’ The reference
gives, ‘rapidly developing clinical signs of
focal (at times global) disturbance of
cerebral function . . . with no apparent
cause other than that of vascular origin’
Results are given for suspected vs. probable and
definite TIA diagnosis. However, the TIA status
used by the IPD meta-analysis is not known
Sciolla and
Melis, 200869




TIA was defined clinically as an acute loss
of focal cerebral or ocular function lasting
< 24 hours, presumed, after investigation,
to be due to embolic or thrombotic
vascular disease . . .
TIA diagnosis was confirmed by a stroke
specialist physician
NR, not reported; WHO, World Health Organization.
a Where appropriate, direct quotes from the papers are given.
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Most studies recruited patients from hospital settings, although three studies described themselves as population
based.61,151,208 The proportion of male patients ranged from 40.4% to 67.6%, but one study reported results
for women only.64 The reported average ages and age ranges were also broadly similar (Table 14).
The reporting of secondary prevention therapy offered to patients generally listed the medical therapies
without information on the proportion of patients receiving them, or speed of administration.
Some studies gave the numbers of patients undergoing carotid surgery, but none indicated how the
removal of what is known to be a major source of stroke risk was accounted for in the prediction
modelling (Table 15).
Many studies used the same definition of stroke, which was often the World Health Organization (WHO)
definition of stroke or very similar (Table 16, and see Figures 17 and 18). Only one study specified that the
recurrent stroke had to have a certain severity,143 two studies defined recurrent stroke as worsening or
new symptoms201,202 and one study collected information on whether or not the recurrent stroke was
disabling, but did not use this information in the analyses.204
The definition of carotid stenosis varied from study to study. Three studies stated that the stenosis was
dichotomised at 50%, but did not say whether this meant 50% by the NASCET or ECST criteria,200,201,208
and others also categorised their data, for example into 0–49%, 50–69% and 70–99% by the NASCET
criteria.151 Carotid stenosis was most often measured by ultrasound.
The definition of a positive CT scan also varied from study to study. Some specified that the infarct had to
be new or consistent with the patient’s symptoms.122,143,203 Two studies said that, owing to the difficulty
of distinguishing between old and new lesions, the appearance of any lesion meant that the scan was
deemed positive.69,165 All of the other studies either did not report or inadequately reported their definition
of a positive CT scan (see Table 16). The time of imaging from either symptom onset or presentation was
recorded because the ability of CT to detect stroke lesions is heavily time dependent, particularly so in the
first few hours after symptom onset. The timing varied from within 24 hours to within 1 month of
symptom onset.67
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182 72.4 ± 14.4 40.4 A+E departments
Bonifati and colleagues,
2011158
502 68.7 ± 17.1 46.4 Primary care hospital
Cancelli and colleagues,
2011200














322 NR 52.8 16 US A+E departments
The Dutch TIA Trial
Study Group, 1993202
3127 NR, but 1489 were









469 Average not reported







1273 Average not reported








525 Average not reported,




204 64.7 ± 14.8 51.0 Hospital-based TIA clinic
Marnane and colleagues,
2011208
314 70.3 51.6 Population based
Purroy and colleagues,
2007182
















227 73.7 ± 12.5 42.0 Population based
Sciolla and Melis, 200869 274 71.5 ± 10.5 61.7 Hospital A+E departments
Sheehan and colleagues,
2010151
88 68.0 ± 13.0 44.7 Population based
NR, not reported.
a Note that this table does not include data from the IPD meta-analysis, as results from the IPD patients are given in the
primary studies contributing IPD.
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TABLE 15 Disease status, treatments and outcomea
Study
TIA/minor







Probable TIA NR 0.042
Bonifati and
colleagues, 2011158
Probable TIA Antiplatelet therapy for nearly all patients, also
anticoagulation and statins if indicated; nine

















Probable TIA NR 0.109











Definite TIA Antiplatelet treatment (1300mg of aspirin per
day, antihypertensive, antilipid, and antidiabetic
therapy, no carotid endarterectomy as this was














Some patients had been randomised to received




Probable TIA Aspirin, blood pressure and lipid-lowering




Definite stroke Five patients underwent carotid endarterectomy
and three patients underwent carotid stenting.
The majority of patients also received antiplatelet




Definite TIA Aspirin, clopidogrel, triflusal, anticoagulation,





Definite TIA Nine patients received carotid endarterectomy,
80.9% of patients received antiplatelet therapy,
19.0% received anticoagulant therapy, 36.8% began





Definite TIA Aspirin, clopidogrel, triflusal, anticoagulation,
statins, renin–angiotensin system blockers, carotid
endarterectomy, and carotid angioplasty
0.038
continued
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TABLE 15 Disease status, treatments and outcomea (continued )
Study
TIA/minor







Definite TIA Smoking advice, antihypertensive treatment,
antiplatelet drugs, no carotid endarterectomy as




Probable TIA NR 0.053
Sciolla and Melis,
200869
Definite TIA Carotid endarterectomy (n = 7), intracranial stenting





Definite TIA Thirty-eight patients with endarterectomy, and
carotid stenting in six
0.114
NR, not reported.
a Patients are described as ‘probable’ if the diagnosis was considered likely by a non-stroke specialist (e.g. A&E doctor)
who referred the patients for further testing, patients are described as ‘definite’ if the diagnosis was confirmed by a
neurologist or stroke specialist.
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Prediction of recurrent stroke
Seven of the CT studies’ results were provided by the IPD meta-analysis,184 expressed as the AUC of logistic
regression models for the ABCD2 and ABCD2I clinical prediction scores. The total number of patients
contributing CT data was 1368. The increase in the AUC for both 7- and 90-day recurrent stroke outcome
was often modest, with a large overlap of CI between the AUCs of the two scores. The IPD study reported
a summary 7-day AUC increase from 0.64 (95% CI 0.49 to 0.79) to 0.71 (95% CI 0.57 to 0.84), and a
summary 90-day AUC increase from 0.69 (95% CI 0.65 to 0.74) to 0.75 (95% CI 0.70 to 0.80).184
Unfortunately, only three studies,60,202,203 with a total of 4499 patients, provided data suitable for a
meta-analysis of HRs. Each of the three studies used a statistical model rather than a simple score, with
predictors not found in the other two studies. There was also evidence of significant heterogeneity
demonstrated by both the forest plot (Figure 19) and a high I2-statistic of 78.5%. The summary HR was
1.74 (95% CI 0.82 to 3.70, p = 0.15); however, this is difficult to interpret beyond there being a positive
though non-significant relationship between having a lesion found by CT and recurrent stroke. The
difficulties derive from different patients groups (probable TIA202 vs. definite TIA)60,203 different definitions
of lesion positive and outcome, and timing of imaging (Table 17) and different statistical models (Table 18).
The possibility of bias must also be considered, given how small a subset of studies contributed to
the meta-analysis.
Considering all CT studies, whether used in a meta-analysis or not, some found CT to be not significantly
associated with recurrent stroke when adjusted for other predictors60,201,203–205 in survival analyses.
Three studies also found CT to be non-significant with other analytic methods.64,150,165 Only two studies
found a significant relationship: one study that reported only p-values158 but another that gave fuller
results202 (see Table 17).
The results for carotid stenosis provide stronger evidence of a relationship with recurrent stroke, with 6 out
of 10 studies60,151,158,182,201,208 finding a significant relationship (see Table 18). One of the studies had not
excluded patients with < 70% stenosis by the NASCET criteria,203 so could not provide an estimate of the
risk of stroke between patients with lower degrees of stenosis compared with higher degrees.0.5 1.0 1.5 5.0
Dutch TIA Trial 1993202
3.5 (95% Cl 2.0 to 6.0)
Eliasziw 1995203
0.97 (95% Cl 0.35 to 2.68)
Rothwell 199960
1.32 (95% Cl 0.88 to 1.96)
Random-effects summary
1.74 (95% Cl 0.82 to 3.70)
I 2 78.5%
Hazard ratio
FIGURE 19 Forest plot of HRs of having a lesion found by brain CT in a multivariate model in the prediction of
recurrent stroke. Summary HR is 1.74 (95% CI 0.82 to 3.70) from a random-effects meta-analysis of data from
4499 patients.
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TABLE 17 Primary study results for the addition of CT imaging to clinical variables for the prediction of
recurrent stroke




ABCD2 vs. ABCD2I (patients given an additional
point for a positive CT scan)
AUC for logistic regression model increased from
0.68 (95% CI 0.54 to 0.83) to 0.86 (95% CI 0.76
to 0.95) for recurrent stroke at 7 days; results




ABCD2 with both CT and carotid stenosis added Survival analysis (Cox proportional hazards) was
used. CT (and carotid stenosis) remained





Results for CT are available from a univariate
analysis only
Survival analysis (Cox proportional hazards);




ABCD2 vs. ABCD2I (patients given an additional
point for a positive CT scan)
AUC for logistic regression model increased from
0.62 (95% CI 0.24 to 0.99) to 0.64 (0.23 to
1.00) for recurrent stroke at 7 days
AUC for logistic regression model increased from
0.57 (95% 0.27 to 0.87) to 0.64 (0.32 to 0.95)




ABCD2 vs. ABCD2I (patients given an additional
point for a positive CT scan)
AUC for logistic regression model increased from
0.64 (95% CI 0.55 to 0.73) to 0.67 (95% CI 0.57
to 0.77) for recurrent stroke at 7 days
AUC for logistic regression model increased from
0.70 (95% CI 0.62 to 0.78) to 0.72 (0.64 to





Male sex, age > 65 years, dysarthria, multiple
attacks, persisting > 6 weeks [minor strokes
were also recruited], diabetes, intermittent
claudication, haematocrit > 0.45 l/l, anteroseptal
infarct, increased terminal P-wave
Survival analysis model (Cox proportional odds).
Border zone infarct on CT, HR 3.5 (95% CI 2.0 to
6.0), any other infarct 1.6 (95% CI 1.2 to 2.0),




Age, TIA duration, ipsilateral stenosis, most
recent event and history of TIA, hypertension,
coronary artery disease, ipsilateral ulcerated
plaque, occluded contralateral artery
Survival analysis (Cox proportional hazards);
presence of infarct on CT was significant in
univariate analysis (HR 2.31; 95% CI 1.04 to
5.16) but not in a multivariate model (HR 0.97;




Sex, age, left ventricular hypertrophy, peripheral
vascular disease, diabetes, carotid bruit, arcus
senilis, cardiomegaly, ischaemic heart disease, AF,
migraine, SBP, body mass index, number of
cigarettes per day, alcohol units per day, carotid/
vertebrobasilar presentation, AFx, residual
neurological signs, low haematocrit, high
haematocrit, infarct on CT on symptomatic side,
infarct on CT for asymptomatic side, carotid
stenosis on symptomatic side
Survival analysis (Cox proportional hazards). No
numerical results reported. ‘. . . non-significant
factors were . . . cranial CT evidence of infarction




Diabetes, diastolic hypertension (≥ 100mmHg),
prior stroke, infarct of unknown cause
Survival analysis (Kaplan–Meier); although an
abnormal baseline CT scan was significant in
univariate analysis (risk of stroke within 2 years,
p = 0.03), it was not included in the
multivariate model
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TABLE 17 Primary study results for the addition of CT imaging to clinical variables for the prediction of
recurrent stroke (continued )




Age, physical functioning, cognitive skills, > 80%
carotid stenosis, prior TIAs or strokes,
hypertension, coronary artery disease, myocardial
dysfunction, AF, left ventricular hypotrophy,
diabetes peripheral vascular disease
RR for stroke or death within 2 years of infarct on
CT imaging adjusted for all other variables was




ABCD2 vs. ABCD2I (patients given an
additional point for a positive CT scan)
AUC for logistic regression model increased from
0.77 (95% CI 0.58 to 0.95) to 0.85 (95% CI 0.72
to 0.98) for recurrent stroke at 7 days
AUC for logistic regression model increased from
0.60 (95% CI 0.36 to 0.84) to 0.65 (95% CI 0.39




ABCD, ABCD2, ABCDI, ABCD2I (patients given
an additional point for a positive CT scan)
None of the models was found to be statistically
significant predictors of ischaemic stroke at either
7 or 90 days. AUCs are 0.55 (95% 0.43 to 0.67)
for ABCD, 0.57 (95% CI 0.45 to 0.69) for
ABCD2, 0.53 (95% CI 0.41 to 0.65) for ABCDI,
and 0.55 (95% CI 0.43 to 0.67) for ABCD2I. It is
not clear from the text whether these figures refer
to outcome at 7 or 90 days. Other analyses by the
authors (not reported here) clearly demonstrate
no statistically significant relationship between




ABCD, ABCD2, ABCDI, ABCD2I, ABCD3 (patients
given an additional point for a positive CT scan,
ABCD3 includes a point for prior TIA within
1 week of presenting event)
Method of analysis is described as ‘Cox
regression analysis’, i.e. survival analysis;
however, results are reported for specific time
points, i.e. as if the method of analysis was
logistic regression. Only ABCD3 was a significant
predictor of recurrent stroke at either
7 or 90 days
AUCs for stroke at 7 days: ABCD 0.57 (95% CI
0.46 to 0.68), ABCD2 0.56 (95% CI 0.45 to
0.66), ABCDI 0.56 (95% CI 0.44 to 0.67),
ABCD2I 0.56 (95 % CI 0.45 to 0.67) and ABCD3
0.66 (95% CI 0.57 to 0.81)
AUCs for stroke at 90 days: ABCD 0.55 (95% CI
0.46 to 0.64), ABCD2 0.55 (95% CI 0.46 to
0.64), ABCDI 0.56 (95% CI 0.45 to 0.67),
ABCD2I 0.55 (95% CI 0.44 to 0.65) and ABCD3




Cerebral vs. ocular events, residual neurological
signs after 7 days, diabetes, any ischaemic event
in previous 2 months, number of events in
previous 3 years, previous MI, degree of carotid
stenosis, plaque surface irregularity, poststenotic
collapse of the ICA, age, male sex, SBP, DBP,
peripheral vascular disease, angina, left
ventricular hypertrophy, occlusion of contralateral
carotid artery
Survival analysis (Cox proportional hazards).
Cerebral infarction on symptomatic side by CT
was not found to be significant in a multivariate




ABCD2 vs. ABCD2I (patients given an additional
point for a positive CT scan)
AUC for logistic regression model increased from
0.78 (95% CI 0.69 to 0.86) to 0.79 (95% CI 0.71
to 0.87) for recurrent stroke at 7 days
AUC for logistic regression model increased from
0.67 (95% CI 0.58 to 0.76) to 0.71 (95% CI 0.63
to 0.8) for recurrent stroke at 90 days
continued
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TABLE 17 Primary study results for the addition of CT imaging to clinical variables for the prediction of
recurrent stroke (continued )
Study Model Effect of addition of CT
Sciolla and
Melis, 200869
ABCD2 vs. ABCD2I (patients given an additional
point for a positive CT scan)
AUC for logistic regression model increased from
0.75 (95% CI 0.63 to 0.88) to 0.78 (95% CI 0.64
to 0.92) for recurrent stroke at 7 days
AUC for logistic regression model changed from
0.76 (95% CI 0.66 to 0.86) to 0.76 (95% CI 0.65




ABCD2 vs. ABCD2I (patients given an additional
point for a positive CT scan)
AUC for logistic regression model increased from
0.24 (95% CI 0.11 to 0.36) to 0.31 (95% CI 0.17
to 0.45) for recurrent stroke at 7 days
AUC for logistic regression model increased from
0.61 (95% CI 0.38 to 0.85) to 0.70 (95% CI 0.50
to 0.90) for recurrent stroke at 90 days
DBP, diastolic blood pressure; SBP, systolic blood pressure.
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ABCD2 with both CT and carotid stenosis added Survival analysis (Cox proportional hazards) was
used. Carotid stenosis (and CT) remained





It is not clear whether or not carotid stenosis was
included in a multivariate model
Survival analysis (Kaplan–Meier) was used.
Symptomatic internal carotid stenosis > 50% was





Final model for stroke recurrence included blood
glucose >8mmol/l and symptomatic internal
carotid stenosis ≥50%
Survival analysis (Cox proportional hazards) in
patients with an NIHSS score of ≤ 5, HR for carotid




Age, TIA duration, ipsilateral stenosis, most
recent event and history of TIA, hypertension,
coronary artery disease, ipsilateral ulcerated
plaque, occluded contralateral artery
Survival analysis (Cox proportional hazards).
Carotid stenosis was categorised to the nearest
decile and was not found to be significant, HR
1.30 (95% CI 0.78 to 2.14), although this study




Sex, age, left ventricular hypertrophy, peripheral
vascular disease, diabetes, carotid bruit, arcus
senilis, cardiomegaly, ischaemic heart disease,
AF, migraine, SBP, body mass index, number of
cigarettes per day, alcohol units per day, carotid/
vertebrobasilar presentation, AFx, residual
neurological signs, low haematocrit, high
haematocrit, infarct on CT on symptomatic side,
infarct on CT for asymptomatic side, carotid
stenosis on symptomatic side
Survival analysis (Cox proportional hazards).
No numerical results reported, although results




Age, physical functioning, cognitive skills, >80%
carotid stenosis, prior TIAs or strokes,
hypertension, coronary artery disease, myocardial
dysfunction, AF, left ventricular hypotrophy,
diabetes peripheral vascular disease
RR for stroke or death within 2 years for carotid
stenosis >80% in univariate analysis was 1.0; no




Age, sex, hypertension, diabetes, smoking, AF,
acute antiplatelet and statin treatment
Survival analysis (Cox proportional hazards).
Carotid stenosis was the only independent
predictor of stroke at 72 hours (HR 36.1; 95% CI
1.6 to 837.5); results also available for 7 days
(HR 9.1; 95% CI 1.1 to 79.2) and 14 days (HR 4.6;




Results available for a univariate analysis only See Table 16 for definitions. Carotid stenosis
absent, 5% risk of stroke, mild 25% risk of stroke,
moderate, 11% risk of stroke, and severe 35%




Cerebral vs. ocular events, residual neurological
signs after 7 days, diabetes, any ischaemic event
in previous 2 months, number of events in
previous 3 years, previous MI, degree of carotid
stenosis, plaque surface irregularity, poststenotic
collapse of the ICA, age, male sex, SBP, DBP,
peripheral vascular disease, angina, left
ventricular hypertrophy, occlusion of contralateral
carotid artery
Survival analysis (Cox proportional hazards).
Adjusted HR for carotid stenosis 1.25 (95% CI
1.18 to 1.40) in medically treated patients; carotid





Age and sex Survival analysis (Cox proportional hazards); results
available for ≥50% stenosis (HR 2.65; 95% CI
1.28 to 5.20) and ≥70% (HR 3.23; 95% CI 1.45
to 7.21)
DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure.
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80Four of the studies provided data from 1944 patients suitable for a meta-analysis of HRs.60,151,201,208 There
was evidence of significant heterogeneity from both the forest plot (Figure 20) and the I2-statistic (81.9%),
and the summary HR for carotid stenosis was 3.02 (95% CI 1.18 to 7.75, p = 0.02). Again, the
interpretation of these summary statistics is challenging owing to different definitions of carotid stenosis
and patient populations, and different statistical models used by the primary studies, but it does provide
evidence of a link between carotid stenosis and recurrent stroke.
Perhaps the strongest evidence comes from an analysis of data from the ECST, in which carotid stenosis
was a significant predictor of recurrent stroke in patients receiving medical treatment only, but not in
those who underwent carotid endarterectomy.60 When studies looked at the presence/absence of large
artery atherosclerosis, which included carotid stenosis as a component, it was found to be a predictor of
recurrent stroke at 90 days.81,134,137,146,147,165,182,204–209
The LSR registered 2940 patients with definite, probable or possible stroke, TIA, AFx or RAO, but 929 were
excluded from the present analysis because of severe stroke or only possible cerebral or ocular ischaemic
symptoms, leaving 2011 patients for inclusion in the analysis [1093 (54%) minor stroke, 828 (41%) TIA
and the remainder had RAO]. Ninety-seven per cent of patients were followed up to 6 months, 90% to
12 months, and 62% to 24 months. The numbers suffering a stroke were 65, 85 and 82 by 6, 12 and
24 months, respectively. Of the recurrent strokes, 93% were ischaemic, and 48% were small cortical
(PACS), 28% large cortical (TACS) and 9% were lacunar (LACS). Overall, 189/2011 (9%) patients had a
tight (70–99%) symptomatic carotid stenosis and 86 (4%) patients had a carotid endarterectomy at a
mean of 3 months after the presenting event (range 6 days to 1.5 years).
The analysis of the data from the LSR found both carotid stenosis and visible infarct on CT to be
significantly associated with recurrent disabling or fatal stroke (Table 19). Unadjusted HRs for carotid
stenosis by the NASCET criteria and visible infarct on CT were 1.006 (95% CI 1.003 to 1.008) and 2.45
(95% CI 1.73 to 3.46), respectively. The HR for carotid stenosis is small because it represents the change in
risk for an increase of just one degree of stenosis. If carotid stenosis is dichotomised at 70% then the HR
for patients above compared with below this cut-off is 2.42 (95% CI 1.63 to 3.61). When adjusted for
residual neurological signs, age, previous stroke, brain compared with ocular symptoms, and coronaryCoutts 2011201
5.6 (95% Cl 2.0 to 15.6)
Marnane 2011208
9.1 (95% Cl 1.1 to 79.2)
Rothwell 199960
1.25 (95% Cl 1.18 to 1.40)
Sheehan 2010151
3.23 (95% Cl 1.45 to 7.21)
Random-effects summary
3.02 (95% Cl 1.18 to 7.75)
I 2 81.9%
0.5 1.0 1.5 5.0 10.0
Hazard ratio
FIGURE 20 Forest plot of HRs of carotid stenosis in a multivariate model in the prediction of recurrent stroke.
Summary HR is 3.02 (95% CI 1.18 to 7.75) from a random-effects meta-analysis of data from 1944 patients.
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TABLE 19 Results of survival analyses of the 2011 patients from the LSR cohort
Model Predictor HR 95% CI p-value
Model A Residual neurological signs 1.818 1.238 to 2.668 0.0023
Age 1.031 1.014 to 1.048 0.0004
Previous stroke 1.938 1.307 to 2.873 0.0010
Ocular symptoms 0.449 0.195 to 1.036 0.0606
Coronary disease 1.619 1.139 to 2.301 0.0072
Model B Residual neurological signs 1.834 1.249 to 2.693 0.0020
Carotid stenosis 1.009 1.005 to 1.013 < 0.0001
Age 1.029 1.011 to 1.047 0.0013
Previous stroke 1.824 1.228 to 2.711 0.0029
Ocular symptoms 0.379 0.164 to 0.879 0.0238
Coronary disease 1.524 1.072 to 2.168 0.0190
Model C Residual neurological signs 1.577 1.050 to 2.368 0.0282
Age 1.030 1.013 to 1.048 0.0006
Previous stroke 1.999 1.348 to 2.967 0.0006
Ocular symptoms 0.509 0.218 to 1.188 0.1184
Coronary disease 1.648 1.159 to 2.343 0.0054
Visible infarct 1.518 1.043 to 2.210 0.0293
Model D Residual neurological signs 1.612 1.074 to 2.419 0.0211
Carotid stenosis 1.009 1.004 to 1.013 < 0.0001
Age 1.028 1.011 to 1.046 0.0016
Previous stroke 1.898 1.276 to 2.823 0.0016
Ocular symptoms 0.428 0.182 to 1.003 0.0509
Coronary disease 1.552 1.091 to 2.209 0.0146
Visible infarct 1.471 1.011 to 2.140 0.0437
Age, per year increase; carotid stenosis, per degree increase in stenosis; all other variables, yes/no.
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27disease, the HRs for carotid stenosis and visible infarct on CT are 1.009 (95% CI 1.004 to 1.013) and 1.47
(95% CI 1.01 to 2.14), respectively. If carotid stenosis is dichotomised at the 70% cut-off, its adjusted HR
is 2.15 (95% CI 1.42 to 3.23). The carotid stenosis HRs are also adjusted for CT and vice versa.
None of the models A, B, C or D predicted that any patient would have a fatal or non-fatal but disabling
stroke by 7 days. However, three patients did go on to have a non-fatal disabling stroke, another had a
fatal stroke and there were also three other deaths within 7 days. All of these patients presented with
minor stroke rather than TIA or RAO.
The results for 90 days and 2 years are given in Table 20. All of the models were better at correctly
predicting a stroke outcome (fatal or non-fatal disabling stroke) at 2 years rather than 90 days. Conversely,
all were better at predicting being alive and well at 90 days than 2 years.
At 90 days there were 27 fatal and non-fatal disabling strokes, 20 patients with another non-stroke event
(MI, vascular or non-vascular death) and 1963 patients with no further events. At 2 years there were81
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TABLE 20 Predicted and actual outcomes at 90 days and 2 years for the four predictive modelsa
Outcome and time point Model A Model B Model C Model D
At 90 days
No. of correctly predicted fatal or disabling strokes 2 7 4 7
No. of stroke outcomes that were not predicted 26 21 24 21
No. alive and well, and predicted no recurrent strokes 1814 1798 1822 1800
At 2 years
No. of correctly predicted fatal or disabling strokes 84 80 82 81
No. of stroke outcomes that were not predicted 10 14 12 13
No. alive and well, and predicted no recurrent strokes 647 724 687 764
a Results for 7 days are not included, as no patients were predicted to have a stroke outcome at 7 days.
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8294 fatal and non-fatal disabling strokes, 103 patients with another non-stroke event and 1814 patients
with no further events.
For all models, 91–92% of patients had a correctly predicted outcome at 90 days. This fell to 41–47% of
patients when considering outcomes at 2 years. Model D (clinical variables, plus carotid and brain CT
imaging) had the highest proportion of correctly predicted outcomes at 2 years (47%). It is obvious that
the time after presenting event at which the outcome is predicted is crucial in the prediction of stroke.DiscussionIn general, the performance of clinical prediction rules and statistical models are highly dependent on the
characteristics of the patient sample used to test them. The studies found in this review used very different
recruitment criteria, notably with regard to confirmation of TIA or ischaemic stroke diagnosis. A given
model is likely to give different results depending on whether the patients are those with suspected TIA
only, or confirmed ischaemic strokes only; this is particularly important given the high proportion of
non-CV patients who present at TIA clinics (see Chapters 7 and 8). It must also be noted that the
prognostic value of an infarct found by CT may be especially influenced by the patient sample, as the
proportion of lesions is likely to increase with increasing severity of presenting symptoms. The studies
were dissimilar in terms of the patients who they recruited.
The most common definition of outcome was simply recurrent stroke without any distinction made
between disabling and non-disabling strokes. It may be that some factors are predictive of more severe
outcomes, but any evidence of a relationship has been lost.
It is also difficult to draw any firm conclusions about any association that there may be between a positive
CT scan and recurrent stroke. There are problems due to the timing of imaging – if a scan is done very
soon after symptom onset, lesions are hard to detect. A further challenge to investigating the relationship
is that some studies deliberately combined old and new lesions. The evidence found by this review on CT
imaging is not robust enough to make a convincing case either way.
The case for carotid stenosis is stronger, with the majority of the studies and the multivariate survival
analysis of the 2011 patients in the LSR finding a significant relationship with recurrent stroke. Perhaps the
most convincing evidence comes from the endarterectomy trial data,60 where carotid stenosis was a
predictor in medically treated patients, but not in those who had undergone carotid endarterectomy.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27It would be very hard to explain the efficacy of carotid endarterectomy if carotid stenosis were not a risk
factor for recurrent stroke.
All of the studies contributing to the CT meta-analysis used data from RCTs. The studies contributing to
the carotid stenosis meta-analysis used data from a RCT, two population-based studies and one
prospective cohort study. Systematic review methodology is most developed in the area of interventions,
where restriction to a particular study design, such as RCT, is sensible on both methodological (using the
best available evidence) and pragmatic (limiting the number of studies to be assessed) grounds. Most
systematic reviews use some kind of study design filter but our results suggest that it is important to
consider using all study designs in a review of predictors so as to retrieve all of the available evidence. It is
also worth noting that RCTs are often larger than observational studies – the three studies contributing to
our CT meta-analysis had over three times as many patients as the seven observational studies contributing
to the CT IPD meta-analysis.
Prediction of stroke is hard, and ascertainment of outcome is heavily dependent on the length of
follow-up. The trade-off that must be made when using a clinical prediction score to designate patients
into high- and low-risk categories, i.e. between not aggressively treating patients likely to have a recurrent
stroke and asking patients to undergo stroke prevention treatment that is unlikely to be to their benefit,
needs to consider the length of follow-up used when developing the original prediction score.Weaknesses of the review
Owing to the nature of the underlying studies, our methodology had to be adapted from the ‘gold
standard’ methodology used for RCTs. In particular, the citation search method and the critical appraisal
checklist are unvalidated, although both were extremely thorough and produced in as methodologically
sound way as possible.
The results of the meta-analyses are based on a small subset of the available studies due to factors beyond
our control. However, we include a larger sample than were included in recent meta-analyses on stroke
risk prediction, for example, 1368 patients with CT184,210 compared with our 4499. The results are difficult
to interpret given the differences between the primary studies, and there is also a possibility of bias, not
least because the studies with non-significant results could not be included owing to a lack of data.Weaknesses of the Lothian Stroke Register analysis
The data were collected in the 1990s and so represent older CT technologies than those that are in use
today (DUS with colour has changed relatively little in practical terms). For diagnosis of carotid stenosis, the
same velocity criteria and image measurement have been in use since the 1990s so the stenosis measures
are relevant and valid. The CT technology has moved to thinner scan sections, which may increase
detection of small lesions, but the contrast has not improved. The presence of a visible infarct on 1990s
technology is as relevant as on scanners today, although lesions may have been missed that would have
been visible on current technology. On the other hand, many of the literature reports concern patients
recruited in a similar time period on similar technology therefore the LSR data are still highly relevant.
There would have been more delay between symptom onset and patient assessment in the 1990s owing
to greater awareness now of the need to seek medical attention quickly after TIA/minor stroke. Although
the LSR took place in a rapid access clinic that ran several times weekly with same day CT and US and
direct access from GPs, patients may not have contacted their GP quickly, thereby incurring delays prior to
reaching medical attention. Similarly, this problem will have affected all of the studies that use data from
the 1990s but should not make a material difference in terms of identifying the factors which most
strongly predict recurrent vascular events.83
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84ConclusionsCarotid stenosis predicts recurrent stroke. However, investigating the link between carotid stenosis and
disabling or fatal recurrent stroke compared with non-fatal non-disabling recurrent stroke would be of
benefit. Carotid analyses that do not dichotomise the stenosis into severe and non-severe categories would
increase the information available from the data. The evidence on brain CT imaging is inconclusive, as the
studies were inconsistent in the timing of imaging and definition of a positive CT scan.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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with transient ischaemic attack or minor strokeIntroductionPatients with TIA are at high risk of early recurrent stroke. Accurate diagnosis and recognition of ischaemic
causes of neurological symptoms are essential for effective management and stroke prevention. The
observer agreement for diagnosis of TIA among physicians is poor, even with rating scales.73,74 The territory
affected by a TIA/minor stroke may be difficult to ascertain clinically.57 A retrospective study75 used clinical
records of 55 patients with suspected TIA to assess the diagnostic agreement between stroke neurologists.
Using three scales with different rates of likelihood for the diagnosis of TIA, the study showed that the
agreement for TIA was poor, regardless of the scale used. Scales with more points had fewer patients
classed as unlikely TIA (suggesting that scale format influences diagnostic certainty); these results support
that the interpretation of TIA likelihood is subjective and argue for use of other technologies to make
diagnosis, as clinical diagnosis is so poor.
Magnetic resonance DWI is very sensitive to small ischaemic lesions.38 Demonstration of an ischaemic
lesion on MR DWI has been associated with an increased risk of stroke in TIA patients. The 29 studies of
MR DWI in patients with TIA or TIA and minor stroke published between 1999 and the start of this project
(in two systematic reviews and three additional primary studies) included 2881 patients imaged between a
few hours of onset of symptoms and up to nearly 3 weeks after the event. DWI was positive for ischaemic
change in 37% (mean ± 12% SD, range 16–67%).47,48,87,137,215 Having an acute ischaemic lesion on DWI
(compared with not having a lesion) may predict increased risk of subsequent stroke,87,92,93 but the effect
of a DWI ischaemic lesion on stroke prediction independent of clinical scoring47,94 was unclear.87,92–94
Clinical features and carotid stenosis may be a stronger predictor of recurrent stroke risk.93,137 Given the
uncertainty around the accuracy of the widely publicised ABCD and ABCD2 clinical scores62 in predicting
stroke risk,71,144,168 DWI could add prognostic as well as diagnostic value. The amount of publication bias in
this literature has not been assessed. Several other studies and meta-analyses of rates of positive DWI in
patients with TIA/minor stroke and of DWI added to ABCD or related score in risk prediction have been
published since the award of this project.
We aimed to assess the sensitivity and specificity of MR compared with CT in patients with minor stroke or
TIA, but it became clear that there were no such comparisons. We had previously performed a systematic
review and meta-analysis of studies comparing CT with MR in the diagnosis of acute ischaemic and
haemorrhagic stroke.36,216 These data were very limited. Most papers included few patients, included only
hospital-admitted patients with moderate to severe stroke, so were not relevant to the present topic,
suffered from lack of blinding and incorporation bias. One study that included patients with mild stroke
and TIA as well as more severe stroke32 did not present data for these subgroups separately, had
substantial incorporation bias (all TIAs with a DWI-positive lesion were reclassified as stroke), and was
pseudo-retrospective because the diagnosis of TIA/stroke was made from the hospital records. Having
initially attempted to update this review, but being unable to find any other more recent or more relevant
literature, we therefore focused on assessing the frequency of DWI visible lesions in TIA or minor stroke
patients. We also summarised the available data on the effect of adding MR DWI or CT to ABCD2 scores
in predicting recurrent stroke.85
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DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKEMethods
Objectives
We performed this analysis according to the PRISMA guidelines for systematic reviews of observational
studies.175 Following an initial search for papers comparing MR with CT in the same TIA/minor stroke
patients, we focused on identifying all published studies in which TIA and/or minor stroke patients were
assessed by DWI irrespective of aims, type of study design, and clinical setting.Identification of studies
We searched indexed records that appeared in MEDLINE (Ovid) from January 1995 to November 2011. The
choice of this time period reflected the introduction in the mid-1990s of DW MR sequences into clinical
practice. The MEDLINE search strategy included both subject headings (MeSH terms) and text words for
the target condition (e.g. stroke, TIA, minor stroke) and the imaging modality under investigation (MRI,
DWI). We did not apply any language restrictions. We adapted the MEDLINE search to search EMBASE. In
particular, we ‘translated’ the MEDLINE MeSH terms into the corresponding terms available in the Emtree
vocabulary. The searches were initially run in November 2010 and updated in November 2011. Full details
of both the MEDLINE and the EMBASE search strategies are presented in Appendix 1. We imported
all citations identified by the MEDLINE and EMBASE search strategies into the Reference Manager
bibliographic database. We hand-searched all proceedings of the International Stroke Conference (2011)
and the European Stroke Conference (2011, 2012). We also contacted experts in the field and perused
the reference lists of all relevant articles, as well as the most recent issues of Stroke and Cerebrovascular
Diseases (not yet indexed in MEDLINE or EMBASE) to identify further published studies for possible
inclusion in the review.Inclusion/exclusion criteria
One review author (MB) examined the titles and abstracts identified by the literature search and retrieved
all potentially relevant citations in full. Full-text articles were retained if they focused on primary studies
of TIA or minor stroke patients who had DWI as brain imaging in the acute and subacute phase. Studies
that did not assess patients by means of DWI, did not report the proportion of patients with positive DWI
lesions, or did not report original data, were excluded. In cases of multiple or subsequent publications
from the same patient cohort, the most recent or more complete report was chosen.
Two review authors (MB, HM) independently conducted data extraction and reviewed the methodological
quality of selected studies. Disagreements were resolved by discussion or referred to a third author (JW).
We recorded data on study methods (e.g. setting, study design), characteristics of patients (TIA vs. minor
stroke) and imaging findings (DWI-positive brain lesions) as the proportion of patients with an ischaemic
lesion on DWI. We also recorded any analyses comparing the prediction of recurrent stroke using the
ABCD2 score without and with DWI findings. We also collected information on the following
methodological aspects: prospective compared with retrospective study design, definition of TIA,
timing of imaging assessment and evaluating clinicians.Data synthesis
For each study we calculated the total number of patients with a visible DWI lesion. The pooled proportion
of TIA patients with a positive DWI lesion was calculated by means of a univariate random-effects
meta-analysis with within-study variance modelled as binomial. Heterogeneity between studies was
assessed visually by inspection of forest plots and by calculating I2-statistics.109 We used the statistical
software R for our analyses.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Number of included/excluded studiesDiffusion-weighted imaging in patients with transient ischaemic
attack/minor stroke
The electronic searches identified 7983 citations. Of these, we considered 185 reports potentially relevant
and retrieved the full-text articles for detailed assessment. For two citations, full-text was not easily
available and we examined the information contained in the abstracts. Hand-searching of reference lists
and of recent issues of relevant medical journal (e.g. European Neurology), not yet indexed in MEDLINE or
EMBASE, resulted in a further four reports to be included. We subsequently excluded 127 reports. The
most common reason for exclusion was that the study did not provide the number of patients with
positive DWI lesions. A total of 45 full-text studies published in 58 reports, and two abstracts, fulfilled our
inclusions criteria (Figure 21).Characteristics of included studies
The methodological characteristics of the included studies are shown in Table 21. Eighteen were
observational prospective cohort studies, 17 were observational retrospective cohort studies and 12 studies
did not clearly state the type of study design (see Table 21).
All studies used a time-based definition of TIA as opposed to the recently new proposed
tissue-based definition.176
Two studies assessed population-based cohorts, seven studies assessed hospital-based cohorts, eight
studies assessed patients from EDs, 27 studies assessed patients from specialist stroke or neurology units
and three studies did not clearly provide this information. TIA diagnosis was made by a neurologist in
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FIGURE 21 Study identification and selection.
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based
definition
23.0 ± 9.2 hours
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based
definition
4.7 ± 2.6 days
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based
definition
Within 7 days Neurologist
Restrepo and
colleagues, 2004231
Retrospective Specialist unit 22 Time-
based
definition
Within 24 hours NR
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Within 24 hours Stroke specialist
Nakajima and
colleagues, 2010148

















NR NR 36 Time-
based
definition
Within 24 hours NR
Meng and
colleagues, 2011160
Prospective Specialist unit 410 Time-
based
definition
Within 7 days Neurologist
Olivot and
colleagues, 2011161









Retrospective Specialist unit 215 Time-
based
definition
Within 24 hours NR
IQR, interquartile range; NR, not reported; R-TIA, recurrent transient ischaemic attack; S-TIA, single transient
ischaemic attack.
a Median.
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27initially by an emergency medicine physician and subsequently confirmed by a stroke specialist in another
study; the status of the diagnosing physician was not reported in the remaining 20 studies. Timing of DWI
assessment after symptom onset varied across studies (see Table 21). In 18 studies, TIA patients were
assessed within 24 hours of symptom onset, in six studies within 48 hours, in 12 studies within 7 days, in
three studies within 2 weeks and in the remaining two studies within 3 weeks. Six studies did not clearly
provide this information.Main findings
The total number of TIA/minor stroke patients assessed in the included studies was 9078 (range 18 to
1693 patients). All studies except eight57,72,134,224,225,232,233,248 restricted inclusion to TIA patients. The
frequency of positive DWI findings ranged from 9% to 67% across studies (Table 22). Overall, 3048/9078
TIA patients had a visible lesion on DWI. Using a univariate random-effects meta-analysis, the pooled
proportion of TIA patients with a positive DWI lesion was 34.3% (95.0% CI 30.5% to 38.4%), with
heterogeneity between studies demonstrated by both the forest plot and a high I2-statistic of 89.3%.
The forest plot of all included studies is shown in Figure 22.91
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Two studies also reported findings on CT:138,251 Chatzikonstantinou and colleagues138 found that 2/122
patients had a relevant visible ischaemic lesion on CT (1.6%), compared with 21/122 (17.0%) on DWI;
Förster and colleagues251 found that 7/161 (4%) of patients had a visible ischaemic lesion on CT,
compared with 71/215 (33%) on DWI. A further study reported only old lesions on CT,93 and one study
used CT to exclude non-stroke lesions.226
Studies varied considerably in terms of sample size, time interval between symptom onset and DWI,
symptom duration, aetiology, selection criteria, and setting. We explored potential reasons for
heterogeneity of DWI-positive rates between studies including time and inclusion of minor stroke as well
as TIA. Four studies provided data separately for TIA and minor stroke patients.224,225,232,233 The proportion
of minor stroke patients with visible ischaemic lesions on DWI was 47% in one study,227 70% in another
study,232 and reached 100% in two studies.224,233 It is worth noting that the two studies in which all minor
stroke patients showed a positive DWI lesion were of small sample size and enrolled patients with a
definite diagnosis of TIA or minor stroke as opposed to a possible diagnosis of TIA or minor stroke – for
example Kastrup and colleagues224 included only patients with high-grade symptomatic carotid stenosis.
Similarly, the study by Schulz and colleagues,232 in which 70% of minor stroke patients had a positive DWI
lesion, focused on patients with a definite TIA or stroke and scanned patients 3 days after symptom onset
or later. In another four studies that included patients with minor stroke as well as TIA but did not report
the results separately, the proportion of patients with visible ischaemic lesions on DWI was not noticeably
higher than in the studies reporting TIA alone: 53.0%,134 28.0%,57 39.3%72 and 39.0% respectively.248
We examined the DWI-positive rate by time between symptom onset and scanning (Figure 23)
using aggregate data from the primary studies, which showed no obvious time trend although most
studies scanned patients within 8 days. Within those 8 days, the proportion with a DWI lesion ranged
from 0.09 to 0.68.
There is also no readily apparent difference between studies that reported average times and those that
reported maximum times to imaging. Attempts to investigate the relationship between proportion DWI












































FIGURE 23 Scatterplot of time to imaging vs. proportion of patients with a positive DWI scan. Average time may
indicate either a mean or median time.
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DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKEDiffusion-weighted imaging in patients with minor stroke
From the results of our literature search we identified a further four studies that provided data on patients
with minor stroke alone, i.e. not TIA.45,252–254 Three of these studies were performed in the same centre in
a regional NV clinic over a total of 12 years (1998–2011)252–254 and included a total of 627 patients (mean
209, range 153–246 patients). The patients were all assessed by expert stroke physicians and neurologists
and were discussed at a weekly multidisciplinary meeting, and patients with non-vascular causes of minor
stroke (i.e. mimics) were carefully excluded. The patients were scanned on two different MR scanners,
about one-third on one scanner and the other two-thirds on the other scanner, but both used the same
sequences. The time to scanning varied from within 24 hours to several weeks, but all were scanned on
the day of presentation to the clinic. The average proportion of patients with a visible ischaemic lesion on
DWI was 69%. Schulz and colleagues50 studied 51 patients with minor stroke and found that 29 patients
had an ischaemic lesion on DWI at an average of 3 weeks after the stroke (57%), this lower proportion
probably reflecting the greater delay to scanning. Chalela and colleagues32 included some patients with
minor stroke [median National Institutes of Health Stroke Scale (NIHSS) score 3] in their prospective
comparison of CT and MR DWI, but their assessment of sensitivity and specificity is confounded by
switching the diagnosis from TIA to stroke in TIA patients with an ischaemic lesion on DWI.ABCD2 score and diffusion-weighted imaging or computed
tomography finding
Several publications assessed the use of MR DWI findings added to the ABCD2 score (Table 23). We have
not re-meta-analysed these studies independently but present a summary of all studies providing
information on ABCD2 and DWI findings here. In general, the addition of DWI findings to the ABCD2
score improved the risk prediction (higher AUC values in Table 23). A multicentre study184 assessed the
early risk of recurrent stroke after TIA, and performance of ABCD2 score subcategorised as tissue positive
or negative on either DWI or CT imaging. Among 3206 patients with DWI, 27.6% (884 patients) had an
acute brain infarction. In 1368 patients imaged with CT, 23.9% (327 patients) had an acute or old
infarction. For patients with DWI imaging, pooled rates of recurrent stroke at 7 days were 7.1% (95% CI
5.5% to 9.1%) in those with tissue-positive events compared with 0.4% (95% CI 0.2% to 0.7%) in those
with tissue-negative events (p < 0.0001). For patients imaged with CT, rates were 12.8% (95% CI 9.3% to
17.4%) and 3.0% (95% CI 2.0% to 4.2%), respectively (p < 0.0001).
There was no information on DWI in TIA/minor stroke mimics, as these patients were excluded from
all studies.
Patients with infarction on brain imaging had higher ABCD2 scores than those without any lesion.
Tables 24–26 show the risk of recurrent stroke stratified by the presence of brain infarction on imaging
and dichotomised ABCD2 score (above and below 4). Data were derived from the systematic review
conducted by Giles and colleagues in 2011,210 who reported published and unpublished TIA data from
12 independent centres. Patients with ABCD2 score ≥ 4 and visible lesion on CT or DWI had a 7-day risk
of stroke of 10.7%, compared with 1.9% in those without visible lesion; for patients with ABCD2 score of
< 4 the risk of stroke was 2.3% and 0.2%, respectively. For patients with visible infarction on DWI and
ABCD2 score ≥ 4, the 7-day risk of stroke was 8.9% compared with 0.6% in those without visible lesion;
in patients with an ABCD2 score of < 4 these risks were 1.8% and 0.1%, respectively. For patients with
visible infarction on CT and ABCD2 score ≥ 4, the 7-day risk of stroke was 15.5%, compared with 4.2% in
those without visible lesion, and 3.9% and 0.9% in patients with ABCD2 score of < 4, respectively. The
presence of infarction on DWI or CT imaging was the main determinant of early recurrent stroke; however,
ABCD2 score had predictive value in the acute phase in both tissue-positive and tissue-negative patients,
including both MRI and CT imaging, with an AUC for the prediction of stroke at 7 days of 0.68 (95% CI
0.63 to 0.73) and 0.73 (95% CI 0.67 to 0.80), respectively (p < 0.0001 for both results); AUCs for
prediction of recurrent stroke at 90 days were 0.66 (95% CI 0.61 to 0.71) and 0.69 (95% CI 0.62 to
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TABLE 24 Presence of visible lesion on CT and DWI and risk of recurrent stroke, stratified by ABCD2 scorea
ABCD2 score
Visible lesion on
CT-DWI 7 days risk (%) n/total patients 90 days risk (%) n/total patients
≥ 4 (+) 10.7 98/912 14.6 106/728
(–) 1.9 37/1997 3.1 49/1602
< 4 (+) 2.3 7/299 3.9 9/230
(–) 0.2 3/1366 1.1 12/1140
Total 3.2 145/4574 4.8 176/3700
a Estimates derived from Giles and colleagues.210
TABLE 26 Presence of visible lesion on CT and risk of recurrent stroke, stratified by ABCD2 scorea
ABCD2 score Visible lesion on CT 7 days risk (%) n/total patients
≥ 4 (+) 15.5 39/251
(–) 4.2 29/698
< 4 (+) 3.9 3/76
(–) 0.9 3/343
Total 5.4 74/1368
a Estimates derived from Giles and colleagues.210
TABLE 25 Presence of visible lesion on DWI and risk of recurrent stroke, stratified by ABCD2 scorea
ABCD2 score
Visible lesion on
DWI 7 days risk (%) n/total patients 90 days risk (%) n/total patients
≥ 4 (+) 8.9 59/661 10.0 52/520
(–) 0.6 8/1299 1.2 13/1059
< 4 (+) 1.8 4/223 0.6 1/164
(–) 0.1 1/1023 0.7 6/863
Total 2.2 72/3206 2.8 72/2606
a Estimates derived from Giles and colleagues, 2011.210
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This summary includes all available literature on DWI in patients with TIA and the effect of ABCD2 scores
and DWI or CT in combination. In clinical practice, DWI shows a definite acute ischaemic lesion in
one-third of TIA patients, but in most (two-thirds) patients with definite TIA DWI is negative. In 26 out of
47 studies, the diagnosis of definite TIA was made by a stroke physician or neurologist, and in most
studies (25/47) the patients were scanned within 48 hours of their TIA. Therefore, the low proportion with
a visible ischaemic lesion cannot be attributed either to dilution of the samples with non-TIA patients or to
excessive delays to scanning. We conclude that absence of an ischaemic lesion on DWI is the commonest
finding in patients with definite TIA and should not preclude effective secondary prevention, as these
patients are at risk of recurrent stroke.215 We also conclude that absence of an ischaemic lesion on DWI
occurs in about one-third of patients with minor stroke alone who have been screened by a specialist
neurologist or stroke physician and for whom no alternative cause of symptoms has been found.
Therefore, absence of a lesion on DWI in patients with expert/physician-confirmed minor stroke should
also not preclude use of effective secondary prevention treatment for stroke. It remains to be
demonstrated whether an ischaemic DWI lesion is an independent risk factor for stroke in the population
in whom it is currently being used in stroke prevention clinics and in what proportion the DWI is positive.
We found no apparent link between proportion of patients with a DWI lesion and time to imaging within the
first 8 days in the studies. At least time to imaging did not explain the huge (sevenfold) variation in the
proportion with a DWI lesion within the first 8 days. However, as we had to use summary data from the primary
studies, our analysis does not provide strong evidence against there being an association. It may well be that the
use of summary data results in a loss of information great enough to hide any relationship – an average time
does not indicate the range of times to imaging – which would ideally be investigation with IPD, i.e. where the
scan results and time to imaging for each patient are available.
We did not find any data from studies comparing DWI with CT directly in the same patients with TIA. The
literature that does compare DWI with CT focuses on major disabling stroke requiring hospital admission,
so is not relevant to the present analysis.36,216 The paper by Chalela and colleagues32 comparing CT and
DWI suffered from substantial incorporation bias by changing the diagnosis from TIA to stroke in patients
with a DWI-positive lesion, among numerous other problems. In most studies it was difficult to disentangle
the patients with minor stroke from those with TIA and the few studies that provided data separately
included a small selected group of stroke patients, with, in some cases, a high proportion of other major
risk factors. There were few studies on patients with minor stroke specifically. There is a larger literature on
DWI in patients with mild stroke or specific subtypes such as lacunar stroke, but most of these focus on
patients with a DWI lesion and some other specific characteristic so provide no information on proportions
of patients with/without ischaemic lesions, i.e. the information needed for the present analysis.38 The rate
of ischaemic lesions in patients with minor stroke on DWI appears consistent however at around 69%,
meaning that about one-third of physician-confirmed minor stroke patients do not have a DWI lesion and
should not be denied secondary prevention treatment for stroke.215
The studies assessing the addition of CT brain scan findings to ABCD2 suffer from lack of clarity whether
the visible ischaemic lesion was thought to be recent, relevant to the presenting symptoms, or old and not
relevant, or just areas of prominent leukoaraiosis. It was beyond the scope of this project to obtain
additional data from the study investigators. It may be that having a visible infarct on CT simply indicates
that patients who have had one infarct in the past are more likely to have another one, or that patients
with visible lesions have more vulnerability to ischaemic brain damage. Thus, CT visible infarct may be
acting differently to DWI visible infarct in terms of stroke prediction.
There is no information on which to calculate sensitivity or specificity of DWI or CT in TIA/minor stroke as
all patients with mimics or haemorrhage were excluded and the reference standard for determining the
diagnosis of stroke or TIA was varied and frequently uncertain. Many studies relied on retrospective case
note identification of patients and for ascertainment of the ABCD2 score. These approaches will have103
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DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKEbiased the results. The proportion of TIA and minor stroke patients without a visible ischaemic lesion on
DWI (66% and 31%, respectively) would be much higher if the denominator were all patients attending
the clinic, including mimics, rather than just those with a definite TIA/minor stroke determined on expert
neurology assessment. Assuming that the 45% of patients attending stroke prevention clinics with a final
diagnosis of mimic (see Chapter 7) did not have DWI-visible lesions (which is incorrect as some with
migraine, postictal states or hypoglycaemia would have DWI-positive lesions) and were included in the
denominator then there would be much larger proportions of DWI-negative scans undertaken. As an
approximation, DWI would be positive in only 19% of patients with suspected TIA and 38% of suspected
minor stroke, leaving a large proportion of negative, non-contributory scans (see Chapter 4, Discussion,
which provides an estimate of proportions with stroke, TIA or mimic by ABCD2 score).
What might happen if the DWI-negative patients in whom no alternative diagnosis apart from an
ischaemic CV event can be found do not receive stroke secondary prevention? One-third of minor stroke
and two-thirds of TIA patients might be denied effective stroke secondary prevention. Although these
patients might be at lower risk by virtue of not having a DWI lesion, they still have some risk,215 particularly
the 20% with a tight ipsilateral carotid stenosis (see Chapters 4 and 5). Failure to use routine and
established investigations to identify established risk factors such as ipsilateral tight carotid stenosis
through belief that a negative DWI excluded TIA/minor stroke would mean that patients with carotid
stenosis would be denied an effective and established treatment (endarterectomy); others would be denied
medical therapies, also evidence based and highly effective in combination. If patients with suspected
TIA/minor stroke are to be given these therapies anyway then what is the point of placing so much
emphasis on MR DWI? If effective stroke prevention can be achieved with a neurological assessment to
differentiate definite or probable TIA/minor stroke from mimics, carotid ultrasound to identify those with
tight ipsilateral carotid stenosis who require endarterectomy, cardiac investigation to identify AF or other
key risk factors and a CT brain scan to exclude haemorrhage and structural mimics, it is unclear what the
ABCD2 score or MR examinations are likely to add.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Chapter 7 Diagnosis of transient ischaemic attack,
minor stroke and mimics: systematic review and
meta-analysis of frequency, differential diagnosis,
and prognosis of non-cardiovascular eventsIntroductionThe short-term risk of stroke after TIA or minor stroke is high, especially in the first few days after the
event. In light of the early stroke risk, clinical guidelines advocate urgent diagnostic work-up and treatment
of these patients.15,103,255,256 However, after expert clinical assessment, an important number of patients
referred with the diagnosis of suspected TIA have a final diagnosis of a non-CV event or mimic.73,257
Accurate diagnosis of CV compared with non-CV causes of symptoms is essential to ensure appropriate
management. However, the diagnosis is often difficult and disagreement on whether a patient has had a
TIA is frequent in clinical practice.258 Because of the lack of a universally accepted diagnostic criteria or
objective confirmatory tests to identify TIA from other transient neurological symptoms, the final diagnosis
relies mainly on clinical history alone and recollections of the patient who, by definition, was neurologically
impaired.168,259–261 Brain imaging is useful in identifying an acute ischaemic lesion or some non-vascular
conditions (e.g. brain tumour, MS); however, a normal CT or MRI is still compatible with the diagnosis of
both TIA (66% of TIAs do not have a visible lesion on imaging – see Chapter 5) and non-CV (many
common non-vascular causes of TIA/minor stroke-like symptoms do not show any abnormality on
brain imaging).
Less is known about the prognosis of patients with a non-CV event, although these are generally
considered to be benign in most cases and given less attention. Several medical conditions can imitate a
TIA or minor stroke, and require different therapeutic approaches from CV events.26 Furthermore, previous
publications reported a considerable proportion of patients with unclassifiable or miscellaneous events,
probably including entities with different pathophysiology and unknown prognosis.168,262,263
In order to determine the proportion of patients attending stroke prevention clinics with a final diagnosis
of non-CV event, and the most frequent non-vascular diagnoses and their risk of recurrent neurological
symptoms and functional outcome, we conducted a systematic review of studies reporting the frequency,
main alternative diagnoses and outcomes in these patients.Methods
Objectives
We performed this systematic review in accordance with Meta-analysis Of Observational Studies in
Epidemiology (MOOSE)116 and PRISMA264 statements. We aimed to identify all studies reporting:
l the proportion of patients with transient or mild non-disabling neurological symptoms with a final
diagnosis of a non-vascular cause of their symptoms, irrespective of the study design or setting
l the main causes (i.e. differential diagnosis) of non-CV events
l the short and long-term prognosis of non-CV events.105
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106Identification of studies
We identified potential relevant studies by searching Ovid MEDLINE and EMBASE from 1980 to December
2011 (see Appendix 1). We included the following search terms: transient ischaemic attack, TIA, atypical
TIA, non-focal TIA, TIA mimics, transient neurological attack or non-CV. Considering that the number of
studies assessing the prognosis of patients with non-CV events could be small, first we used a search
strategy with broad definitions of TIA, minor stroke and non-CV events in order to retrieve the highest
number of articles, and subsequently we included specific search terms for prognosis in these patients. We
also screened the reference lists of all relevant studies and review articles. We excluded non-English articles
for which a full-text translation was not available.
In the expectation that the literature might be biased towards highly specialist practice that was not
relevant to routine clinics, we also identified several sources of unpublished data from operational clinics.
These included a prospective data set of patients referred to a local stroke prevention clinic (WGH,
Edinburgh, UK) from July 2009 to June 2011, who received a final diagnosis of TIA or minor stroke.173 This
data set is a subset of the SSCAS initiative that has collected anonymised information to monitor stroke
care from all hospitals managing acute stroke in Scotland since 2002. We also identified data from an
audit undertaken in Leicester.Inclusion/exclusion criteria
One reviewer (HM) screened the identified titles and retrieved all potentially relevant citations in full-text.
Articles were included in this systematic review if they provided any data on proportions of patients
diagnosed as non-CV, TIA/minor stroke and also if those studies included a control group of healthy
subjects or patients with an alternative condition as long as these subject categories could be clearly
distinguished. Studies that did not include patients with non-CV events, did not report the proportion
of patients with this condition, or published in abstract form were excluded. In cases when multiple
publications were available for the same patient cohort, the most complete report was selected. Duplicates
were removed using Reference Manager.Quality assessment and data extraction
From the selected studies, one reviewer (HM) sought and extracted data on the following variables:
l sample size of study
l study design
l setting of diagnosis
l whether the final diagnosis had been made by a neurologist, geriatrician, stroke physician,
GP or nurse
l use of predefined diagnostic criteria for TIA or stroke and method of final diagnosis (i.e. clinical
records, in person)
l proportion of patients with a final diagnosis of a non-CV event
l most frequent differential diagnoses in patients with non-CV events
l prognosis of patients with non-CV events, in particular risk of further stroke, MI, and vascular death
l method of follow-up (i.e. telephone, records, in person).
We contacted authors of one study for further information about the person making diagnosis of TIA or
non-CV event. For the purpose of this review, patients with diagnosis of ‘possible TIA’ were included in the
TIA group, as, in our experience, these patients are treated as TIA in clinical practice. Series including either
TIA or minor stroke patients were considered for this review, in light of the frequent description of both
conditions in studies reporting the risk of vascular events (i.e. recurrent stroke) after TIA, especially in the
context of outpatient clinics.Data synthesis
We aimed to investigate whether risk of outcome (stroke or vascular death at 7, 90 and > 90 days after
presentation) varied between TIA, non-CV and asymptomatic/control patients. Specifically, we comparedNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27outcomes between TIA and non-CV patients, and also between non-CV and asymptomatic/control patients
on which data on the above outcomes were available. We used simple logistic regression, as the outcomes
were binary and the data were not amenable to more complex analyses, to allow for within-study
clustering. We also assessed heterogeneity between studies owing to different settings (TIA clinics, hospital
clinics and population-based studies) visually with forest plots and calculated I2-statistics.109 Data were
analysed in SAS and R.Results
Number of included/excluded studies
The literature searches identified 1775 citations. After initial screening of titles and abstracts we selected
53 citations for full-text retrieval. An additional six studies were included after hand-searching of reference
lists of relevant studies, yielding a total of 59 studies. After full-text examination, 43 studies were excluded,
leaving 16 studies that fulfilled the inclusion criteria. The reasons for exclusion were: not relevant (n = 10),
non-CV events excluded (n=13), review articles (n=5), conference abstracts (n=13), risk of duplicated
data (n=1) and no description of the person making diagnosis of non-CV event (n=1) (Figure 24). None
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FIGURE 24 Study selection and reasons for exclusion.
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108Characteristics of included studies
The 16 included studies7,73,122,156,161,173,257,263,265–271 varied in terms of their primary objectives. Three were
population-based studies assessing the incidence of TIA in the general population in UK, the Netherlands
and Spain (OCSP, Rotterdam Study and a community-based register in Segovia, respectively).7,263,265
Eight studies focused on patients attending TIA clinics,122,173,257,266–270 and one study183 enrolled patients
from multiple settings as part of a population-based study, even although the final diagnosis was made in
a TIA clinic (North Dublin TIA Study). Two were ED-based studies,156,161 one included patients from ED and
TIA clinics and reported the results for each setting separately and so contributed two independent data
points,73 and one recruited patients as part of a hospital-based clinical trial.271
The 16 studies included a total of 14,542 participants, and all provided data on frequency of mimics
compared with true TIA/minor stroke;7,73,122,156,161,173,183,257,263,265–271 11 studies with a total of
3786 participants reported the main causes of non-CV events7,122,156,161,173,263,266–270 and five studies
with a total of 8596 participants reported prognosis data.122,156,265,270,271 One study deliberately excluded
patients with some specific diagnoses other than TIA (i.e. migraine, epilepsy or vertigo). However, other
non-specific transient neurological symptoms were incorporated (e.g. positive visual phenomena, dizziness
or amnesia) and, consequently, the study was included in this review.265 The same study used the term
‘mixed TIA’ for patients with focal and non-focal brain symptoms. For the statistical analysis, these patients
were included in the group with focal brain symptoms (n = 38, 0.6% of the study sample). Forty-one per
cent of the data related to frequency and 66% of the data related to differential diagnosis came from two
studies,173,270 and 41% of the data for prognosis came from one study.271 Follow-up was at least 1 year in
all but one study assessing prognosis.
The study design was prospective in 13 studies and retrospective in three (Table 27). The final diagnosis of
TIA or non-CV event was made by a neurologist, geriatrician or stroke physician in 15 studies, and one
study reported the results of an anterior circulation TIA clinic led by a specialist NV nurse.268 The final
diagnosis of true compared with non-CV event was done in person in 14 studies (from consecutive
referrals in eight studies); in two of them a predefined symptoms checklist was used [derived from the
Face Arm Speech Test (FAST) in one study]. In two cohorts the final diagnosis was made using clinical
records. Thirteen studies used time-based criteria of TIA, whereas three studies did not report which
criteria were used. Subjects with minor stroke were included in 13 studies; 10 described the proportion of










































































































































































































































































































































































































































































































































































































































































































© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wardlaw et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.




























































































































































































































































































































































































































































































































































































































DIAGNOSIS OF TIA, MINOR STROKE AND MIMICS
110TA C S B S
h W A O H C a b
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Main findingsFrequency of non-cardiovascular events
Figure 25 shows the proportion of patients with a non-CV event in 17 cohorts reported in 16 studies
(range 18% to 55%). The summary estimate for proportion of non-CV events was 34% (95% CI 28% to
42%); however, there was evidence of substantial heterogeneity across all selected studies – the I2-statistic
was very high, 98.4%. The lowest proportion of non-CV events (14%) was described in a TIA clinic led
by a specialist nurse and the highest (55%) in an ED-based study. The proportion of non-CV events was
40% (95% CI 23% to 60%) for TIA clinics, 40% (95% CI 23% to 60%) for population-based studies and
32% (95% CI 10% to 66%) for hospital-/ED-based studies, but with evidence of significant heterogeneity
between studies in each setting (Figures 26–28 and Table 28) – the I2-statistics were 97.8%, 95.2%,
and 97.9%, respectively, for hospital-/ED-based studies, population-based studies and TIA clinics.0.0 0.2 0.4 0.6



































Summary estimate 0.349 (0.284 to 0.42)
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FIGURE 25 Proportion of patients with a non-CV diagnosis reported in the literature. NA, not applicable.
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Summary estimate 0.317 (0.104 to 0.663)
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FIGURE 26 Hospital/ED-based studies and proportion of non-CV events.
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Summary estimate 0.404 (0.233 to 0.60)
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FIGURE 27 Population-based studies and proportion of non-CV events.
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Summary estimate 0.341 (0.241 to 0.456)
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FIGURE 28 Transient ischaemic attack clinic studies and proportion of non-CV events. NA, not applicable.
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The main causes of non-CV events were detailed in 11 studies.7,122,156,161,173,263,266–270 The most frequent
alternative diagnoses and the proportion of all non-CV diagnoses were migraine (10 studies, mean
14.4%7,122,156,161,173,266–270), syncope (seven studies, 6.6%7,161,173,262,267–269), seizure/epilepsy (11 studies,
5.0%7,122,156,161,173,266–268,270), psychiatric (seven studies, 4.4%122,156,173,266–268,270) and vertigo (nine studies,
4.0%7,122,156,161,173,263,266,267,269). Only one study reported a proportion of 8.8% of patients with cardiac
disorders (144 out of 1643 participants).266 Other less frequent diagnoses were peripheral nerve
conditions, postural hypotension, transient global amnesia, toxic or metabolic causes (e.g. drugs,
hypoglycaemia) and brain tumour (Table 29).Outcomes for transient ischaemic attack compared with
non-cardiovascular events
The risks of stroke and other vascular events after TIA and non-CV event were described in five
studies.122,156,265,270,271 One retrospective study enrolled 3533 participants with TIA and non-CV events
and 3915 control subjects without any neurological symptoms. A prospective population-based study
enrolled 548 patients with transient neurological attacks and 5514 control subjects; however, the definite
diagnosis of each event was derived retrospectively from medical records. Another three prospective
studies included data for TIA and non-CV, but without asymptomatic control subjects.
The reported stroke risk up to 90 days was lower for non-CV events than for TIA (three studies,122,265,271
zero events vs. 1.5–5.2%, respectively). Owing to the absence of events in the first group, any further113
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TABLE 28 Proportion of non-CV events in different settings




Koudstaal and colleagues, 1992271 572 3127 0.18 (0.17 to 0.19)
Ferro and colleagues, 199673 17 31 0.55 (0.38 to 0.71)
Amort and colleagues, 2011156 55 303 0.18 (0.14 to 0.23)
Olivot and colleagues, 2011161 108 224 0.48 (0.42 to 0.55)
Summary 0.32 (0.10 to 0.66)
Population based
Dennis and colleagues, 19897 271 512 0.53 (0.49 to 0.57)
Sempere and colleagues, 1996263 78 313 0.25 (0.21 to 0.30)
Bos and colleagues, 2007262 228 548 0.42 (0.38 to 0.46)
Sheehan and colleagues, 2009183 257 594 0.43 (0.39 to 0.47)
Summary 0.40 (0.23 to 0.60)
TIA clinics
Ferro and colleagues, 199673 16 52 0.31 (0.20 to 0.45)
Martin and colleagues, 1997257 135 508 0.27 (0.23 to 0.31)
Karunaratne and colleagues, 1999266 64 128 0.50 (0.41 to 0.59)
Murray and colleagues, 2007267 395 811 0.49 (0.46 to 0.52)
Lavallée and colleagues, 2007122 240 1085 0.22 (0.20 to 0.25)
Banerjee and colleagues, 2009268 40 282 0.14 (0.10 to 0.19)
WGH 2011 841 2368 0.36 (0.34 to 0.38)
Hörer 2011269 54 123 0.44 (0.36 to 0.53)
Cameron and colleagues, 2011270 1643 3533 0.47 (0.45 to 0.49)
Summary 0.40 (0.23 to 0.60)
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114analysis proved unfeasible. With respect to stroke risk of > 90 days, two studies were considered.265,271
We excluded one study because of the absence of events in the non-CV group.122 The risk of stroke at
> 90 days was significantly higher for TIA than for non-CV events (OR 1.63; 95% CI 1.21 to 2.20,
p = 0.0013). However, some differences between the studies undermined the reliability of the data on
stroke risk at > 90 days.
A combined outcome of stroke, MI or vascular death was specified in four studies.122,156,270,271 The risk of
this combined outcome was significantly higher for patients with TIA than for non-CV events (OR 1.597;
95% CI 1.400 to 1.810, p < 0.001); the OR remained unaffected after excluding from analysis a cohort
without events for the non-CV group.122 The risk of vascular death was described in three studies and
tended to be lower in the group with non-CV events than in patients with TIA, without a significant
difference (OR 0.86; 95% CI 0.71 to 1.05, p = 0.1614).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 29 Alternative diagnoses of non-CV events, proportion of non-CV events and their ranges
Final diagnosis
Proportion of total non-CV
events (%) Mean Study reference
Migraine 4–33 14.4 7, 122, 156, 161, 173, 262–266
Cardiac disorders 8.8 8.8 266
Syncope 2–18 6.6 7, 161, 173, 257, 263–265
Seizure/epilepsy 3–44 5.0 7, 122, 156, 161, 173, 259, 262–266
Psychiatric 3–10 4.4 122, 156, 173, 262–264, 266
Vertigo 1–19 4.0 7, 122, 156, 161, 173, 259, 262, 263, 265
Peripheral nerve 1–15 3.1 156, 161, 173, 259, 262, 263–265
Postural hypotension 1–11 2.9 173, 262, 263
Transient global
amnesia
2–7 2.7 7, 156, 161, 173, 259, 262, 263, 265, 266
Toxic/metabolic 0.3–8.0 2.3 156, 161, 263, 265
Brain tumour 0.7–6.0 2.0 7, 156, 161, 259, 262, 264, 265
Subdural haemorrhage 1.9 1.9 265
Subarachnoid
haemorrhage
1.8–1.9 1.9 156, 265
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Outcomes for non-cardiovascular events compared with asymptomatic
control subjects
There were limited data comparing prognosis in patients with non-CV events and asymptomatic control
subjects. Only one study compared the risks of stroke at > 90 days in these groups, and found no
significant difference between groups (OR 1.23; 95% CI 0.82 to 1.86, p = 0.3).265 Two studies reported
the risk of vascular death for these groups.265,270 Again, there was no difference between asymptomatic
control subjects and patients with non-CV events (OR 0.93; 95% CI 0.75 to 1.14, p = 0.46).Non-vascular events in transient ischaemic attack and
non- non-cardiovascular events
There is a lack of published data regarding fatal and non-fatal non-vascular events in patients with TIA
and non-CV events. One study reported a HR of 1.59 (95% CI 1.11 to 2.26) for dementia in patients with
non-CV compared with asymptomatic control subjects,265 and one recently published cohort reported that
the risk of neurological events excluding vascular conditions was significantly higher in patients with
non-CV events than in those with TIA (HR 1.37; 95% CI 1.10 to 1.69, p = 0.003).270Discussion
The complexity of the diagnosis of transient ischaemic attack
An accurate diagnosis of TIA is key to preventing a major CV event in patients with transient neurological
symptoms of vascular origin and avoiding committing non-CV patients to taking antiplatelet drugs, statins
and antihypertensive drugs for the rest of their lives and to stopping driving for a year, with its attendant
inconveniences, which may include loss of employment. The correct diagnosis of TIA is frequently difficult
and usually depends on the skill with which the clinical history is taken as objective findings on clinical
examination as well as positive diagnostic findings are scarce.180,272 Some atypical symptoms could mislead
clinicians into diagnosing a non-CV event; this is particularly relevant in the diagnosis of posterior115
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116circulation TIA, considering they are often more difficult to identify with certainty. On the other hand,
when the diagnosis of TIA is still not clear to different observers, they usually agree to diagnose TIA
instead of a non-CV event.74,260 Delays in time from onset of symptoms to assessment can cause patients
to forget some important clinical features, making the diagnosis even more difficult. Patients with transient
or mild neurological symptoms are evaluated in different settings, including emergency services, in-hospital
consultations, ophthalmological clinics, primary health care centres and NV clinics. The diversity of settings
could indicate differences in the clinical features of each event, making the diagnosis of TIA even more
challenging. In view of the lack of universally accepted diagnostic criteria for TIA and non-CV events, the
best standard is still the clinical experience or judgement of the physician.259Frequency of non-cardiovascular event in different settings
This systematic review shows a high frequency of non-CV events in TIA clinics (40%) higher than hospital/
ED studies (32%); however, there was a substantial heterogeneity between studies in each setting, with
both the forest plots and the I2-statistics confirming the impression given by reading the primary studies
that there is significant variation between the primary studies, leading to difficulties with interpreting the
summary estimates, the so-called ‘apples and oranges’ problem.273 The differences between studies are
attributable to several factors. The lowest proportion of non-CV events was described in a TIA clinic led by
a specialist nurse. This clinical service was focused on anterior circulation TIAs, and the identification of
anterior circulation events was done using a referral protocol based on the FAST instrument.274 Patients
identified by this method were eligible for further investigation in the nurse-led clinic, included in the
study, and followed up in a weekly neurologist-led clinic, where the diagnosis was reviewed; referrals
excluded by the protocol (e.g. possible posterior circulation events or other non-neurological diagnoses)
were seen directly in a NV clinic led by neurologist. The use of predefined referral protocol and the
exclusion of posterior circulation TIAs or other diagnoses could have improved the selection of true
vascular events in this cohort. Likewise, different criteria for referral between the included studies could
explain the observed heterogeneity in frequencies of non-CV events.
Differences could also be accounted for by the study design. A hospital-based RCT reported a proportion
of 18% of ‘atypical TIA’. Subjects were included using a predefined checklist about symptoms and time
course of the event; here the use of rigorous inclusion criteria may explain the lower frequency of
those events.
Another cause can be found in the severity of the neurological symptoms and their probable true vascular
origin; patients with a more severe condition are more likely to attend to emergency services and those
with less severe or subtle symptoms (e.g. mild hypoaesthesia) are more likely to attend primary health care
centres. Other plausible explanation could lie in who makes the diagnosis in each setting. Ferro and
colleagues73 reported that, in patients referred for neurological evaluation by ED physicians with a
suspected TIA, the final diagnosis was a non-CV event in 55%, with 32% having a definite stroke.
However, other hospital/ED-based studies have reported a lower proportion of non-CV events, even when
the final diagnosis was assessed by neurologists.156,271
The availability of specialist assessment could be another important factor; services with more access to
neurological consultation can have a higher proportion of patients referred with an uncertain diagnosis
and consequently a higher probability of non-CV events.73 Certainly, all of these proportions can be
affected by the number of patients who decline to attend TIA clinics after the first assessment in primary
health care centres or ED, patients with evident non-CV events who were identified in a first evaluation
and the effect of multiple interviews on the ability to remember some symptoms. Considering that the
final diagnosis of TIA or non-CV was made by neurologists or physicians with an interest in stroke in all
but one included study, we could not estimate differences in proportions of each diagnosis between
different observers (i.e. with less experience in stroke).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The most frequent conditions mimicking TIA were consistently reported across the included studies. It is
well recognised that migraine and seizures can cause transient neurological symptoms as part of their
manifestations. Migraine can present reversible focal neurological symptoms with gradual onset over a
few minutes (i.e. aura), but typical aura can also occur without headache and last longer than a few
minutes.275 Generalised seizures can present with sudden loss of consciousness and involuntary jerking of
limbs; postictal neurological findings (i.e. Todd paralysis) are frequent and can be confused with a CV
event. Simple and complex partial seizures have less evident manifestations and also can cause a postictal
deficit.276 Psychiatric conditions (e.g. somatoform disorders) resemble transient or permanent neurological
symptoms and the diagnosis can be demanding in some settings. Other diagnoses, such as vertigo,
transient global amnesia or peripheral nerve diseases, can require an expert assessment or further
exploration to exclude a CV event. Other rare causes of mimics include cerebral tumours (primary and
secondary), subdural haematomas (SDHs), subarachnoid haemorrhage and MS. All of these are rare but
require specific investigation, management and treatment and it is important to differentiate them from
true TIA/minor ischaemic stroke. Tumours require sensitive investigation and treatment to make the best of
remaining quality of life if aggressive malignant. SDHs probably do not benefit from antiplatelet agents
and may require surgical evaluation. Similarly, subarachnoid haemorrhage and MS are important diagnoses
not to overlook.
Whereas these conditions share clinical features with TIA, others are simply misdiagnosed as CV. Syncope
and postural hypotension were present in 6.6% and 2.9% of patients with non-CV events, respectively;
these entities usually have different clinical features from TIA, and diagnosis is usually straightforward.
In a previous systematic review of patients with suspected stroke of all severities (not including TIA), the
proportion of non-CV events ranged from 1% to 37% (mean 12.5%; 95% CI 6.7% to 18.3%) and the
most common events were primary and secondary cerebral neoplasm, seizures, systemic infections and
SDHs.26 In a more recent systematic review of patients with suspected stroke (again generally excluding
TIA), including 20 studies of 7221 patients, the proportion of patients with a final diagnosis of a true CV
event was 73% (95% CI 62% to 84%); the most frequent non-CV diagnoses in order of frequency were
seizures, syncope, sepsis, functional disorders, migraine and brain tumours, among others.277 Compared
with patients with stroke-like symptoms, our systematic review showed that in patients with transient
neurological symptoms of non-vascular origin, migraine was the most frequent alternative diagnosis.
Whereas seizures and syncope were also frequent in these patients, the presence of brain neoplasm or
systemic infections were less important than its relative frequency as ‘stroke mimic’.26 Differences could be
partially explained by the presence of a permanent more than transient neurological deficit in patients with
brain neoplasm or infections.
Awareness of the main differential diagnosis of transient neurological events can lead to improvements in
the diagnosis of true compared with non-CV events; a more accurate identification and treatment of each
condition can improve the prognosis of each condition and quality of life, especially in those with TIA.Prognosis of non-cardiovascular events
There is a paucity of good-quality data comparing the prognosis of patients with non-CV events with TIA
or general population. We identified five studies with data for prognosis of non-CV events; only two of
them included a control group without any neurological symptom. Owing to the retrospective design, in
two studies the event ascertainment relied on clinical records and would be less accurate than prospective
studies. Despite these shortcomings, the findings deserve our attention. It is not surprising that patients
with TIA can have a higher stroke risk compared with non-CV patients provided that the diagnosis of TIA
was correct; the risk of a combined cardiovascular outcome was also higher for TIA patients. There was a
trend towards a higher risk of stroke and vascular death for non-CV events than control subjects but
without a significant difference.
Considering these results, the prognosis for any transient neurological event other than TIA has not yet
been fully delineated. Diagnoses of atypical TIA, TIA mimic, non-focal transient neurological attack or117
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118non-CV event combine a wide array of conditions with distinct pathophysiologies and probably different
cardiovascular risks;258 the assumed benign prognosis of these entities seems to be an oversimplification of
their outcomes. Some conditions, such as syncope, can have different causes in elderly and young patients.
In elderly persons, cardiac or orthostatic syncope can occur more often, and the prognosis is relatively poor
in these patients.278 Additionally, some TIA can be misdiagnosed as non-CV increasing the risk of stroke
and other CV events in this group if the correct treatment is not indicated.
In view of the absence of a standard classification or clinical guidelines for the management of non-CV
events, methodical research looking for a better classification and long-term follow-up of these patients is
required. This large sector of TIA clinic patients have largely been ignored and further studies should
determine the true risk of vascular or other non-vascular events in these patients, as well as identify
conditions with a worse prognosis in which a more urgent approach is needed.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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services for stroke prevention after suspected
transient ischaemic attack or minor stroke in the UKIntroductionTransient ischaemic attack and minor stroke are medical emergencies, with up to 90,000 cases every year
in the UK.9,170 Delivering effective stroke prevention requires highly organised services. We surveyed UK
clinical and imaging secondary stroke prevention services to see if they met recent guidelines.MethodsWe devised two electronic survey questionnaires for clinical and imaging services for stroke prevention
in the UK using the online survey software SurveyMonkey (www.surveymonkey.com). The survey
questionnaires were initially developed by a neuroradiologist (JW) and a methodologist (MB). They were
adapted from several previous questionnaires of imaging services for stroke in the UK which achieved high
response rates.26,95,279 They were then sent for comments and suggestions to three neurologists (MD, PS
and Keith Muir), two health economists (PMcN and ZQ), a neuroradiologist (Donald Hadley) and a medical
physicist (Janet De Wilde) within the project team. We phrased each question in a sensitive manner,
avoiding ambiguous and complex terminology, and we made an effort to limit relevant questions to a
manageable number. We used a ‘closed’, ‘structured’ response format for the majority of questions.
Questions were numbered and organised in a series of linked pages, with a progress indicator on each
page. The two first pages of both questionnaires provided information on the rationale and purpose of
the study, including details of the research team, and addressed best research practice issues, such as
confidentiality and informed consent.
When agreement was reached on the format and content of the two questionnaires, they were piloted
among the members of the project team who were not involved in their original development. They were
also sent for comment to the NHS Improvement team and the Royal College of Physicians of London
Stroke Audit lead (see below). The purpose of the piloting phase was to evaluate both questionnaires
in terms of their relevance, flow, acceptability and ease of use, and identification of redundant and/or
poorly formulated questions. Following pilot testing, the agreed versions of the survey questionnaires
(see Appendices 3 and 4) contained detailed questions regarding current provision of stroke prevention
services and imaging services in the UK, with particular regard to volume of work, capacity, professionals
involved, and type and timing of investigations, number and type of scanners, timing of both brain and
carotid imaging, and endarterectomy rates. Specific questions were also included on the access of brain
scanning for TIA and minor stroke patients during normal working hours and out of hours on weekdays
and on weekends.
We considered eligible participants to be all clinical leads of UK stroke services and radiology departments.
We used multiple overlapping methods to identify and contact leads of stroke services and imaging
services in England, Wales and Scotland. Since the late 1990s and devolution, the organisation of these
services has become increasingly regionalised to the respective devolved nations, necessitating different
approaches in each country.119
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We contacted all leads of the 27 stroke networks’ clinical stroke services (with three to nine clinical sites
within each network) in England through NHS Improvement (Ian Golton, Director, Stroke Improvement
Programme, following contact with Dr Damian Jenkinson, Stroke Advisor, Department of Health) and to
Stroke Leads in Trust hospitals through the Royal College of Physicians of London Sentinel Stroke Audit
database of stroke services in England (Alex Hoffman, Professor Tony Rudd). The survey was also posted
on the Royal College of Physicians of London Stroke Audit website and circulated in the NHS Improvement
Stroke Bulletin (Barbara Zutshi). In Scotland, we contacted 15 stroke clinical leads through the SSCAS
(Professor Martin Dennis).Imaging services
In England, we contacted Radiology Directorate leads through the NHS Improvement database
(Gail Powell) and information about the survey was also circulated in the bi-weekly Radiology Bulletin.
We also contacted all known MRI services in England through the MAGNeT database (Dr Janet DeWilde).
In Scotland, we contacted all 12 Directors of Imaging Services through the Diagnostic Imaging Clinical
Network (Professor Ian Robertson, Mr James Cannon).
In Wales, we also contacted stroke services and imaging services through the Stroke Collaborative
(Michelle Price).
Covering letters explaining the objectives of the two surveys and providing the links to access the
questionnaires online were prepared for the clinical leads of both stroke prevention services and imaging
services (see Appendices 3 and 4). Participants were assured that the information they provided would be
treated in strictest confidence and with anonymity, and were informed about the amount of time required
to complete the questionnaires. No incentives were offered to take part in the surveys. The covering letters
were sent by e-mail or post to all UK stroke clinical leads and Radiology Directorates in April 2011 via
multiple routes as above. In particular, they were sent to stroke leads of all 15 NHS Boards in Scotland, to
all 40 network clinical leads covering the 27 stroke networks in the UK, to all 12 Scottish Clinical Directors
of Radiology through the Diagnostic Imaging Clinical Network [Managed Diagnostic Imaging Clinical
Network (MDICN)], to 171 Acute Trusts, 129 Foundation Trusts, and seven Welsh Trusts in the UK.
Furthermore, details of the surveys, together with the associated online links, were disseminated through
the Royal College of Physicians website and advertised through the NHS Improvement – Stroke newsletter
and Radiology newsletter. Reminder messages were sent to non-respondents in June 2011.
The results of both internet surveys were reported according to the CHEcklist for Reporting Results of
Internet E-Surveys (CHERRIES) statement.280Data management and analysisSurveys results were generated using SurveyMonkey software and subsequently entered into a Microsoft
Excel (version 11) spreadsheet (Microsoft Corporation, Redmond, WA, USA). We used descriptive statistics
to examine clinical leads’ answers. Results were expressed as proportions, medians, or means where
appropriate. Percentages reported were based on actual numbers of respondents. Not all respondents
answered all of the questionnaires’ questions.ResultsA total of 114 stroke services surveys and 146 imaging facilities surveys were partially or fully completed.
Response rate was 45% for both surveys. To calculate the response rate we divided the number of clinical
leads to whom we initially sent the invitation to take part in the surveys by the number of participants who
actually completed the online questionnaires. However, as both surveys were also disseminated andNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27advertised through professional body websites and newsletters, it proved unfeasible to calculate the exact
number of all of the potential respondents actually contacted.
As respondents were clinical leads in hospitals or specialist centres for the description of the surveys’
findings, we will use the terms ‘respondents’, ‘participants’ or ‘centres’ interchangeably.Stroke services survey findings
In total, 97% of respondents (107 out of 110 who answered this question) indicated that a specialist
stroke prevention service for TIA/minor stroke patients was available in their hospital/centre. In 99% of
centres the TIA prevention service was run at least once per week; in 47% of centres every weekday; and
in 31% of centres 7 days per week (Figure 29). The majority of centres (86%, 88 out of 102 respondents)
indicated that one to five new patients attended the stroke service each time it was run, and only 13% of
centres (13 out of 102 respondents) indicated that six to 10 new patients attended the stroke service each
time it was run (Figure 30). In half of the centres (50%, 51 out of 102 respondents), the proportion of
patients attending the stroke service who had a final diagnosis of TIA or minor stroke was between 41%
and 60%, in 31% of centres between 21% and 40% and in 15% of centres between 61% and 80%.
Only 3% of centres reported that the proportion of patients ultimately diagnosed as having TIA/minor
stroke was ≤ 20%, and only 1% of centres reported that it was between 81% and 100% (Figure 31).47%
31%
8% 10%
































































































































Number of patients attending the stroke service
FIGURE 30 Number of new patients suspected of TIA/minor stroke attending the specialist stroke service each time it
runs. Note: 109 out of 114 respondents answered this question.
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Proportion of patients with a diagnosis of TIA or minor stroke
IGURE 31 Proportion of patients attending the stroke service who are ultimately diagnosed as having TIA or minor
troke. Note: 102 out of 114 respondents answered this question.
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The proportion of patients who were already taking secondary prevention treatment, prescribed by their
GP/referring doctor after the index event, when seen at the TIA clinic was between 41% and 60% in
20%, 61–80% in 24% and 81–100% in 29% of the responses. Thus, an overall average of 75% of
patients had already been started on secondary prevention by the referring GP/ED before being seen at the
secondary prevention clinic and before any investigations. In other words, in approximately 50% of the
surveyed centres, the majority of patients (60–100%) seen at the specialist stroke prevention service had
already been prescribed secondary prevention drugs (e.g. aspirin, statin) by their GP or referring doctor in
response to their CV event.
The majority of stroke prevention services were run by consultants (stroke physicians, neurologists,
geriatricians). However, 6% of the centres indicated that a nurse or stroke nurse specialist the service
(Figure 32) and 19% of centres pointed out that a nurse was among the professionals who actually saw
the patients in the stroke service (Figure 33). The main medical assessment or triaging of TIA/minor stroke
patients was indeed undertaken by a nurse or nurse specialist in 28% of centres (Figure 34). The final
diagnosis was established either with input from or by a consultant in 71% of centres (Figure 35). In most
centres, the patient’s clinical assessment was performed by one or two doctors (one doctor in 57% of the
centres and two doctors in 35% of the centres). Only in a few centres (Figure 36) did the patient’s






































Specialists running the stroke service
FIGURE 32 Proportion of specialists running the stroke prevention service. Note: 101 out of 114 participants
answered this question.









































Specialists who actually see the TIA/minor stroke patients
FIGURE 33 Proportion of specialists who actually see the TIA/minor stroke patient in the prevention service. Note: 98





































How is the diagnosis established?































IGURE 34 Proportion of centres in which nurses or nurse specialists undertake the main medical assessment or
riaging of TIA/minor stroke patients. Note: 99 out of 114 participants answered this question.
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Number of doctors who perform patient assessment
IGURE 36 Number of doctors involved in the patient’s clinical assessment in the prevention service. Note: 98 out of
14 participants answered this question.
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All centres responding indicated that TIA/minor stroke patients were referred primarily from GPs and other
doctors within the same hospital/centre. Thirty per cent of centres also stated that patients were referred from
other hospitals, 27% of centres accepted referrals from nurses and 17% of centres from other paramedics
(e.g. paramedics in ambulance service). Self-referral was reported only by 4% of the centres (Figure 37).
On average, about one-third of the TIA/minor stroke patients referred to the specialist stroke service were seen
within 24 hours (35% same day or next day); one-quarter between 2 and 3 days (25%), and about 20%
within 1 week. Thirteen per cent of the centres indicated also that patients considered at high risk according to
the ABCD2 risk prediction score were seen within 24 hours from referral, whereas low-risk patients were seen
within 7 days (Figure 38). It worth noting that we did not ask explicitly about assessment of patients according
to the ABCD2 score but that respondents spontaneously provided this information.
More frequently (in approximately 39% of the centres), imaging of the brain or neck arteries took place
the same day of the patient’s appointment, at the same hospital visit, after clinical assessment (Figure 39).
It took place the same day of the patient’s appointment but before clinical assessment in approximately
17% of centres and the next day in approximately 15% of centres. Seven per cent of centres indicated
that patients did not undergo imaging of the brain or neck arteries.
Computed tomography was routinely used as brain imaging modality in 84% of centres, whereas MRI in
51% (98/114 respondents answered this question). Moreover, CT was more often used as initial brain








































Who refers TIA/minor stroke patients to the stroke service?
FIGURE 37 Referrals of patients suspected of TIA/minor stroke to the prevention service. Note: 101 out of
114 participants answered this question.























































Time to appointment after referral
























































Time to brain or neck arteries imaging
Neck arteries imaging
Brain imaging
IGURE 39 Time to brain or neck arteries imaging. Note: 100 out of 114 participants answered this question.













0 – 19 20 – 29 30 – 39 40 – 49 50 – 59 60 – 69 70 – 79 80 – 89 90 –100 Do not
know





















FIGURE 40 Proportion of patients attending the stroke prevention service who receive CT or MRI as initial
brain imaging investigation. Note: 101 out of 114 participants answered this question.
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126indicated that results of brain imaging were fed back to the stroke service the same day of the scanning;
for 12% of the centres; however, it took 2–7 days to feed back the imaging results, and for 11% of
centres it took > 7 days (Figure 41). In the majority of centres (76%), positive brain imaging results
(e.g. haemorrhage) were fed back to the stroke prevention service immediately. The proportion of
TIA/minor stroke patients for whom a subsequent MRI was requested after an initial CT varied considerably
among centres (range 0% to 60%), with the majority of centres (33 centres), indicating that approximately
10% of patients were subsequently scanned with MRI (Figure 42). In approximately half of the centres
(47%) the waiting time for MRI to be performed after the initial CT and the results sent back to the stroke
service was 1 month; in 35% of the centres it was 1 week or less; in 7% of the centres MRI was
performed one day after CT; and in 8% of the centres, the same day (Figure 43).
Doppler ultrasound was the first-line carotid/vertebral imaging in the majority of centres (95%).
A few centres (14/100) provided information on other imaging tests used to scan the neck arteries. These
included CTA (in 11 centres), MRA with contrast (in five centres), and MRA without contrast (in two
centres). No centre indicated IAA as a first-line carotid/vertebral investigation (Figure 44).
The majority of centres (80%) indicated that the results of neck imaging were fed back to the stroke
service the same day (Figure 45). The majority of centres (86%; 85/99 centres that answered this question)
indicated that important positive neck arteries results were fed back immediately to the stroke prevention




































Time for brain imaging results to reach the stroke service
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FIGURE 42 Proportion of TIA/minor stroke patients who undergo MRI after an initial CT. Note: 86 out of
114 participants answered this question.

















































































Time for neck arteries results to reach the stroke service





































Time to MRI after initial CT
FIGURE 43 Time to MRI after an initial CT. Note: 96 out of 114 participants answered this question.
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128for endarterectomy, CTA and contrast MRA were among the choices more often indicated (Figure 46).
However, in 19% of centres a second DUS was usually requested. The waiting time for further neck
imaging tests to be performed and results fed back to the stroke service is shown in Figure 47. The DUS
was the only test to be read and interpreted by a radiographer or vascular technician. All of the other neck
arteries tests were interpreted by a radiologist or a neuroradiologist (Figure 48). The time between the
decision to perform a carotid endarterectomy and the actual surgical procedure was reported to be
< 1 week in 59% of centres and < 1 month in approximately 37% of the centres (Figure 49).
Forty-three per cent of the centres indicated that they had spare capacity to see more patients in the
specialist stroke service, whereas 57% of centres did not. With regard to possible extra facilities to expand
the current stroke service, different choices were indicated by different centres (Figure 50). When ‘more
brain imaging’ was chosen as possible answer, all respondents opted for more MRI facilities (38/38 centres
that answered this question) rather than CT (14/38). Similarly, when ‘more imaging of the neck arteries’
was chosen, the majority of centres indicated DUS as relevant neck imaging investigation (34/43 centres
that answered this question), followed by MRA (16/43) and CTA (13/43 centres).
Among all respondent stroke services the mean catchment population was 400,000 people (median
300,000 people). Ninety-four clinical leads out of 114 respondents indicated the geographical location of





































Tests used to confirm initial DUS or neck imaging results
FIGURE 46 Further tests used to confirm the initial DUS or neck imaging results prior to referral for endarterectomy.
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Time for further tests to be performed
FIGURE 47 Time for further neck arteries tests to be performed. Note: 92 out of 114 participants answered
this question.






































IGURE 48 Specialists who perform and interpret neck arteries tests. Note: 95 out of 114 participants answered










































Delay between endarterectomy and surgery
FIGURE 49 Delay between the decision to perform endarterectomy and the actual surgical procedure. Note: 99 out of

















































IGURE 50 Resources needed to expand capacity in fully saturated stroke prevention services. Note: 77 out of
14 participants answered this question.F
1
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FIGURE 51 Geographical location of 94 out of 114 stroke prevention services that provided this information.
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130Imaging services survey findingsComputed tomography and magnetic resonance imaging availability for
transient ischaemic attack/minor stroke patients
Computed tomography and magnetic resonance imaging facilities were available in the majority of
imaging departments. The number of CT scanners ranged from one to seven across departments, with
most of the departments having one scanner (30% of departments) or two scanners (37%). Similarly, MRI
scanners ranged from one to six across departments, with most of the departments having one scanner
(44%) or two scanners (28%) (Figures 52 and 53).
Ninety-four per cent of departments (136 out of 145 respondents who answered this question) indicated
that CT was available to scan TIA and minor stroke patients. CT scanning was reported to be available out
of hours in 82% of departments. In about 10% of imaging departments, TIA/minor stroke patients were
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IGURE 53 Number of MR scanners in radiology departments. Note: 133 out of 146 participants answered
his question.
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Magnetic resonance imaging facilities were reported to be available in 99% (133/134 respondents who
answered this question), including MR diffusion imaging (96%), and were utilised to scan TIA/minor stroke
patients in 88% of departments. Most departments routinely scanned patients using MR T1/T2, DWI and
FLAIR sequences, but only half of the departments performed gradient echo (GRE) or GRE/T2* sequences
(Figure 54). In 9% of imaging departments, TIA/minor stroke patients were referred to another hospital for
MR scanning.
Thirty-nine per cent of surveyed radiology departments (57/146) provided information on which imaging
modalities were commonly used to scan patients with TIA/minor stroke. Figure 55 shows that CT was the
main modality in the majority of departments (49/57, 86%), followed by DWI/T1/T2/FLAIR sequences in
54% (31/57); DWI/T2/T1/FLAIR/GRE/T2* sequences in 46% (27/57), and DWI/T2 sequences in 18% (10/57).
Thirty-eight per cent of departments (55/146) provided information on the proportion of TIA/minor stroke
patients who received, at any time, CT or MRI as first-line brain imaging investigation. Most TIA/minor
stroke patients were initially scanned with CT rather than MRI in many departments (Figure 56).
Volume of computed tomography and magnetic resonance brain scanning
Forty-two per cent of surveyed departments provided information on volume of CT brain scanning. During
2010, an average of 4905 CT brain scans were performed per radiology department (range 20–48, 346;
median 2500). On average, 18% of brain scans were conducted out of hours. However, this varied greatly
across departments, as some departments did not perform any CT brain scanning out of hours and other131
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Imaging modalities for TIA and minor stroke
FIGURE 55 Imaging modalities commonly used to assess patients suspected of TIA/minor stroke in the surveyed

































IGURE 56 Proportion of patients suspected of TIA/minor stroke, presenting at any time, who received CT or MRI as

































FIGURE 54 Magnetic resonance sequences used to assess patients suspected of TIA/minor stroke in the surveyed
radiology departments. Note: 128 out of 146 participants answered this question.
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27departments scanned up to 77% of patients (range 0% to 77%). Of the total CT brain scans, on average
686 were conducted on patients suspected of TIA/minor stroke (range 0–5000 scans; median 200 scans).
On average, 9% of the TIA/minor stroke CT scans were performed out of hours (range 0–60% scans;
median 2% scans).
Similarly, 38% of surveyed departments provided information on volume of MR brain scanning. During
2010, an average of 2888 brain MR images were performed per radiology department (range 20–24, 391
scans; median 1530 scans). On average, only 3% of MR scans were conducted out of hours and most of
the departments did not perform any MR brain imaging out of hours (range 0–30%; median 0% scans).
Of the total MR brain image scans, on average 258 were conducted on patients suspected of TIA/minor
stroke (range 0–1200 scans; median 100 scans). On average, 3% of the TIA/minor stroke MR images were
performed out of hours (range 0–50% scans; median 0% scans).
It is worth noting that data related to the number of brain scans were not routinely recorded in many surveyed
departments, and therefore the estimates provided by the respondents should be interpreted with caution, as
they are just a ballpark figure of the volume of brain scanning for TIA/minor stroke patients in clinical practice.Access to computed tomography and magnetic resonance brain scanning
About one-third of centres provided information on access to CT scanning. In most radiology departments that
provided this information (49/56, 87%), inpatients suspected of TIA/minor stroke presenting on weekdays,
during normal working hours, were scanned with CT immediately or the same day and imaging results were
fed back immediately or the same day in 22% and 72% of centres, respectively (Figures 57 and 58).
Outpatients presenting on weekdays, during normal working hours, were scanned with CT immediately or the
same day in 59% of departments that provided this information (29/51), and within 1–2 weeks in 32%.
Imaging results were fed back the same day of the scanning (30/55, 54%) in the majority of centres (see
Figures 57 and 58). CT scanning for TIA/minor stroke patients outside normal working hours or on weekends
was available in 67% of centres that replied to this question (42/63); it could be performed but with difficulty
in about 19% of centres (12/63) and was not available in 14% of centres (9/63). The proportion of inpatients
suspected of TIA/minor stroke presenting out of hours or on weekends and scanned with CT is shown in
Figure 59. The majority of centres indicated that scanning of inpatients presenting out of hours was performed
with CT the same day of the patient assessment (48%, 25 out of 52 centres who answered this question) or
the next day (33% of centres, 17/52), and results were fed back immediately (47% of centres, 25/43) or the
same day (51% of centres, 27/53) (Figure 60). CT scanning for outpatients suspected of TIA/minor stroke
presenting out of hours or on weekends was reported to be delayed for up to 2 weeks in some centres
(see Figure 58). Outpatient imaging results were given back immediately after scanning or the same day in
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IGURE 57 Time of CT scanning for inpatients and outpatients suspected of TIA/minor stroke presenting on
eekdays, during normal working hours.F
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FIGURE 59 Time of CT scanning for inpatients and outpatients suspected of TIA/minor stroke presenting on
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FIGURE 58 Time for CT results to be received (when inpatients and outpatients are scanned on weekdays,
during normal working hours).
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scanning for TIA/minor stroke on weekdays, during normal working hours, without difficulty, whereas
31% of centres (19/62) could provide MR scanning but with some difficulty, and 8% of centres (5/62)
indicated that they could not provide MR scanning. The proportion of both inpatients and outpatients
scanned with MRI during weekdays, during normal working hours, is illustrated in Figure 61. For inpatients
suspected of TIA/minor stroke presenting on weekdays, during normal working hours, MRI was performed
on the same day in 35% of centres (in 19 out of 54 centres for which this information was supplied), the
next day in 37% of centres (20/54) or within 7 days in 26% of centres (14/54). For outpatients suspected
of TIA/minor stroke presenting on weekdays, during normal working hours, MRI was performed on the
same day in 21% of centres (10 out of 47 centres who answered this question), the next day in 11% of
centres (5/47), within 7 days in 30% of centres (14/47), within 2 weeks in 26% of centres (12/47) and
within 1 month in 10% of centres (5/47). For inpatients, MR results were given back the same day of
scanning in 83% of centres, whereas for outpatients it could take up to 7 days (27% of centres) to get
results back (Figure 62). In the majority of centres, MR scanning was not available for TIA/minor stroke
patients out of hours or on weekends (34/58, 59% of centres); could be performed with difficulty in about
24% of centres (14/58), and could be performed without any difficulty in only 17% of centres (10/58)
(Figure 63). For inpatients suspected of TIA/minor stroke presenting on weekends or out of hours, MRI was
performed on the same day in 14% of centres (6/42), the next day in 50% of centres (21/42), or within











































IGURE 61 Time of MR scanning for inpatients and outpatients suspected of TIA/minor stroke presenting on
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FIGURE 62 Time for MR results to be received (when inpatients and outpatients are scanned on weekdays,
during normal working hours).
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FIGURE 63 Magnetic resonance scanning availability for patients suspected of TIA/minor stroke presenting on
weekends or outside normal working hours. Note: 58 out of 146 participants answered this question.
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136out of hours were scanned with MRI on the same day of clinical assessment in 9% of centres (3/35); the
next day in 23% of centres (8/35); within 7 days in 40% of centres (14/35); within 2 weeks in 14% of
centres (5/35) and within 1 month in the remaining centres (5/35, 14%; Figure 64). In 77% of centres
(31/40), inpatient imaging results were returned the same day, whereas outpatient imaging results were
given back on the same day in 43% of centres (15/35), returned within the same week in 43% centres
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FIGURE 64 Time of MR scanning for inpatients and outpatients suspected of TIA/minor stroke presenting on
weekends or outside normal working hours.
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The surveys were targeted to clinical leads of stroke prevention services and radiology departments in
the UK. Response rate for both surveys was 45% which we considered overall satisfactory for surveys of
clinical services.
The findings of the surveys indicate that prevention services for TIA/minor stroke are widely available in the
UK, but their structure and organisation vary considerably across centres. In the majority of centres (78%)
specialist stroke prevention services operate every day and on average 1–5 new patients attending the
services each time. Even although the majority of specialist stroke services are run by consultants, nurses or
nurse specialists undertake the main medical assessment or triaging of TIA/minor stroke patients in a
considerable number of centres (28%). Approximately, 40–60% of patients attending the stroke services
are ultimately diagnosed as having TIA or minor stroke. This means that approximately half of the
presenting patients are non-TIA/minor stroke cases, consistent with the literature review in Chapter 7, with
important implications in terms of workload and use of resources. CT and MRI facilities are available in the
majority of centres for TIA and minor stroke patients. CT is the most common imaging investigation for
inpatients and outpatients suspected of TIA/minor stroke. The consistency between the clinical services’
and imaging departments’ responses to the question about first-line imaging method was striking (see
Figures 40 and 56, respectively). In most centres CT is performed immediately or the same day for patients
presenting on weekdays during normal working hours. Access to CT during weekends or out of hours is
available in many centres (approximately 70% of centres). In contast, MRI is available in many centres from
9 am to 5 pm on weekdays, but delays of many days or even weeks are usual, especially for outpatients.
MR facilities for TIA/minor stroke during weekends or out of hours are available, without difficulty, in only
a limited number of centres (17%). In approximately half of the centres, the important and only
evidence-based MR sequence to diagnose or exclude haemorrhage (i.e. GRE/T2*) is omitted, reducing the
potential benefit of MRI in stroke prevention. The surveys also confirmed the common use of DUS as the
first-line carotid imaging for TIA patients (95%) rather than MRA or CTA. In just over half of the stroke
services (57%) endarterectomy was performed within 1 week of the decision to operate and in 37% of
centres within 1 month. No stroke service performed endarterectomy at > 6 months after the decision
to operate.
Both questionnaires provided useful data to populate the cost-effectiveness model, especially with regard
to the type and timing of clinical assessments, and imaging investigations and volume of non-CV diagnosis
patients. Timing of imaging is a crucial factor in the model and the questionnaires provided up-to date
information on the range of times taken to scan TIA/minor stroke patients in different UK stroke
prevention services.
Although both internet surveys provided invaluable data for the economic model, we need to
acknowledge some limitations. Some data were not routinely collected in all centres involved in the
surveys, and respondents provided rough estimates to some of the survey questions. Furthermore,
not all respondents answered all questions (especially for the survey of imaging services), limiting the
generalisability of the surveys findings.
There are no other current data on activity in stroke prevention clinics or imaging departments in the UK
or relevant data on service delivery in other countries. It is difficult to know what is happening across the
UK as a whole or whether the non-responders to the present survey are undertaking more or less MR in
TIA/minor stroke, seeing patients faster or slower, or making greater use of MRA or CTA for carotid
imaging. The key points are that:
l Nurses perform a primary role in patient diagnosis and assessment in nearly one-third of clinics.
l In total, 34% of patients are seen the day after referral and 26% at between 2 and 3 days (not after
TIA – these data are not available). In total 60% of patients are seen within 1 week of referral.
l In total, 50% of patients attending these clinics do not have TIA/minor stroke but a mimic.137
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138l About 75% of patients have been started on secondary prevention treatment by their GP before
attending the clinic.
l CT is widely available and is the first-line test in the vast majority of centres, and is routinely used in
81% of centres.
l MR is used in 51% of centres but in about half of those it is after an initial CT scan and there are
greater delays to MRI.
l The stroke clinical and imaging services provided remarkably consistent responses regarding the
proportion of patients having CT or MR as the primary brain imaging investigation.
l Imaging departments have more CT scanners than MR scanners.
l The key MR sequence needed to diagnose haemorrhage is omitted in more than half (54%) of centres,
making the diagnosis of haemorrhagic stroke unreliable with MRI.
l Ultrasound is the primary carotid imaging test in 95% of centres.
l 60% of carotid endarterectomies are being performed within a week of taking the decision to operate
l There is limited capacity to undertake more imaging, although about 40% of stroke services indicated
that they had capacity to see more patients; however, the main barrier to seeing more patients was
the limited availability of MRI.
The current Tariff for England and Wales98,99 incentivises services to deliver stroke prevention more rapidly
by providing increased payment for patients who are correctly diagnosed, assessed and treated quickly
through Integrated Performance Measures. A base tariff (£450) applies to patients who are treated in
a dedicated stroke prevention clinic meeting minimum best practice criteria. Additional tariffs are paid for
high-risk patients who are assessed and treated within 24 hours (£92) and for use of MRI (£92) in any
suspected TIA patients. It uses the ABCD2 score to define high-risk patients (score ≥ 4) and the score
is completed by the healthcare professional referring the patient – in most cases this would be the GP.
In none of the studies in the literature as reviewed in Chapter 4 was the ABCD2 score assigned by GPs or
nurses. There is little published information on agreement between ABCD2 scores assigned by GPs
(or nurses) and by stroke specialists, but there are many examples of the large number of patients with
a TIA/minor stroke mimic who are referred to stroke prevention clinics87,183 – in one population-based
study set in north-eastern Italy, of 1150 patients referred by their GPs or presenting to hospital with
suspected TIA, only 175 were confirmed as definite TIA by the stroke specialists (10%).200 The investigation
of high-risk patients, to be completed within 24 hours, includes brain imaging, preferably with DWI MRI,
and carotid imaging. MR DWI is also encouraged in all other patients. Thus, a total of £634 could be paid
for a high-risk patient (ABCD2 score of ≥ 4) investigated with MR DWI and started on treatment within
24 hours of first contact with health services.Weaknesses of the clinical surveys
Even although we consider satisfactory a response rate of 45% for both surveys, we cannot be sure to
have captured the full variance of current clinical practice. We were not able to compare characteristics of
responders with those of non-responders, as only a very limited number of responders provided details and
demographic characteristics of their hospitals/centres. Therefore, our findings may not be applicable to the
entire stroke prevention community. However, considering the high consistency between the findings of
the stroke services survey and those of the imaging services survey, it is likely that we have been successful
in highlighting the most important clinical issues related to secondary stroke prevention and use of current
stroke services.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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cost-effectiveness analyses of imaging in stroke
treatment and preventionIntroductionStroke is a major illness in the UK and uses substantial amounts of health-care resources. About 150,000 people
have a stroke in the UK each year, with about 30% dying within 6 months. A further 30% survive but
become dependent on others for everyday activities. Treatment options for stroke are limited, so prevention is
vital, particularly among those who have early warning TIA or minor non-disabling stroke, early assessment and
management of whom can help to avoid future, more disabling strokes, thereby providing health gains to
patients, cost savings to the health-care system and economic gains to society. The aim of this chapter is to review
previous studies of the cost-effectiveness of MR including DWI compared with the current alternative of CT.
The specific objectives are to:
(a) determine, by undertaking a systematic review of the literature, current knowledge regarding the
cost-effectiveness of using MRI compared with CT, to identify and manage TIA and minor stroke
(b) use this knowledge to inform development of an economic model to compare the cost-effectiveness
of using MRI relative to CT for the purpose of identifying and managing cases of TIA and minor stroke.Methods
Objectives
We assessed the literature that has compared the cost-effectiveness of CT and/or MRI strategies. We
focused on UK studies and those from other countries in Europe; costs information from other countries
is likely to be less relevant for NHS decision-making. The review also gathers information on costs of
treatment for stroke patients in different health states. The review acts as an evidence base for the
development of parameters for economic modelling.Identification of studies
A comprehensive search was undertaken to identify studies that assessed the cost-effectiveness of CT
and/or MRI in the management of stroke after TIA or minor stroke. The search strategy is in Appendix 1.
For costs data, studies were relevant if they reported the costs of CT and/or MRI, or the costs of treatment
averted (i.e. health-care resource use costs associated with management of TIA and minor stroke, as well as
management of future stroke events after TIA or minor stroke, associated with provision of either imaging
technique). For cost-effectiveness, studies were relevant if the costs and outcomes of two or more diagnostic
strategies were compared. The databases that were searched were MEDLINE, MEDLINE in Process and Other
Non-Indexed Citations, EMBASE Science Citation Index, NHS Economic Evaluations Database, the HTA
database. Only studies that were published in English were considered. Also, only studies published in the
year 2000 and beyond were included, as reviews of earlier studies published prior to 2000 were identified and
appraised in previous HTA programme-commissioned research.5,26 However, to inform the model
development, the reference lists of all identified studies were checked for additional potentially relevant
studies if it appeared from the title that they provided information on costs of imaging, costs of stroke care or
health state outcomes/health state utilities. These include cost analyses or cost-effectiveness of different
strategies for treating or managing stroke. The full texts of all potentially relevant reports were obtained
and assessed in terms of their relevance to the stated objectives outlined earlier in the chapter.139
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140Inclusion/exclusion criteria
In selecting studies for the cost-effectiveness review, studies had to be a cost-effectiveness analysis or a
cost–utility analysis of alternative imaging techniques, specifically MRI and/or CT, to identify and manage
TIA, minor stroke or stroke. Non-English language studies were excluded. Only studies published in the
year 2000 and beyond were included.Quality assessment and data extraction
Information and relevant data were extracted by an economist according to the guidelines produced by
the Centre for Reviews and Dissemination for the critical appraisal of economic evaluations.281 Where an
economic evaluation had been based on a modelling exercise, additional data extraction criteria developed
by Philips and colleagues282 and NICE283 were applied. A data extraction form was applied to the studies
that met the inclusion criteria.ResultsOut of a total of 12 full cost-effectiveness studies that were identified as potentially relevant, four studies
were deemed suitable for inclusion in the review: Wardlaw and colleagues,5,26 Buskens and colleagues,284
and Tholen and colleagues.285 Among the eight not considered relevant, one study by the Centre for
Evidence-based Purchasing published in 2008105 concluded that there was no information on which to
base a cost-effectiveness assessment of DWI in TIA/minor stroke, and was not considered further. Four
other studies,286–289 although relevant to stroke prevention in the UK, focused on organisation of stroke
prevention clinics in general including factors such as whether TIA patients should be admitted to hospital
or managed as outpatients,289 but did not address the cost-effectiveness of any contribution of imaging
specifically, and one of them was > 10 years old. The three potentially relevant studies on imaging in
stroke that were excluded (and the reasons) were (1) a study of cost-effectiveness of MR perfusion imaging
for patient assessment prior to thrombolytic therapy for acute ischaemic stroke treatment290 (not relevant
to stroke prevention); (2) a study of the cost-effectiveness of multimodal CT (i.e. plain CT, CTA, CT
perfusion) for patient assessment prior to thrombolytic therapy for acute stroke treatment291 (not relevant
to stroke prevention); and (3) a study of carotid imaging strategies in patients with carotid stenosis prior to
carotid endarterectomy for stroke prevention292 (only considered patients with carotid stenosis).
All four included studies were model-based studies. The study by Wardlaw and colleagues26 determined
the cost-effectiveness of different CT scan strategies for patients with suspected ischaemic or
haemorrhagic stroke or stroke mimics. Using a decision-tree model, the aim was to compare standard
care, defined as CT scanning for all within 48 hours of admission to hospital, with 12 alternative strategies:
1. Scan all patients immediately upon admission.
2. Scan patients on anticoagulants or in life-threatening conditions immediately and scan all remaining
patients within 24 hours of admissions to hospital.
3. Scan patients on anticoagulants or in life-threatening conditions immediately and scan all remaining
patients within 48 hours of admissions to hospital.
4. Scan patients on anticoagulants or in life-threatening conditions immediately and scan all remaining
patients within 7 days of admissions to hospital.
5. Scan patients on anticoagulants or in life-threatening conditions immediately and scan all remaining
patients within 14 days of admissions to hospital.
6. Scan patients on anticoagulants, those with life-threatening conditions or are candidates for hyperacute
treatment immediately, and scan all remaining patients within 24 hours of admission to hospital.
7. Scan patients on anticoagulants, those with life-threatening conditions or are candidates for hyperacute
treatment immediately, and scan all remaining patients within 48 hours of admission to hospital.
8. Scan patients on anticoagulants, those with life-threatening conditions or are candidates for
hyperacute treatment immediately, and scan all remaining patients within 7 days of admission
to hospital.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 279. Scan patients on anticoagulants, those with life-threatening conditions or are candidates for
hyperacute treatment immediately, and scan all remaining patients within 14 days of admission
to hospital.
10. Scan only patients in arterial fibrillation, on anticoagulants or an antiplatelet drugs within 7 days of
admission to hospital.
11. Scan only patients with life-threatening stroke or on anticoagulants within 7 days of admission
to hospital.
12. Do not scan.
The study by Buskens and colleagues284 examined the cost-effectiveness of non-invasive strategies in
patients with TIA or minor stroke suspected of having carotid artery stenosis (CAS). The non-invasive
strategies in this study included DUS, MRA and the two examinations combined; all were compared
against intra-arterial digital subtraction angiography (DSA), which was the reference standard. Both
Buskens and colleagues284 and Tholen and colleagues285 used the ECST trial cohort to develop the
model-based analysis. However, studies selected different cohorts for their analysis. Buskens and
colleagues284 included only male patients, recruited during 1997 through 2000, and the average age
was 55 years. Their economic evaluation was reported in 1998 US dollars.
The second study by Wardlaw and colleagues5 examined the cost-effectiveness of replacing a widely used
method of diagnosis of carotid disease, IAA, with less invasive methods among patients with symptomatic
carotid disease for patients who had suffered a TIA or minor stroke. IAA was compared against ultrasound,
CTA, MRA and contrast-enhanced magnetic resonance angiography (CEMRA). The cost-effectiveness of a
baseline strategy for which IAA was performed on all patients with an ultrasound reading of between 49%
and 99% stenosis was compared with 21 alternative strategies, where test methods were varied and surgery
was offered for different levels of stenosis. Expected costs and benefits were modelled over a 20-year time
horizon for a cohort of 100 patients with TIA or minor stroke.
The study by Tholen and colleagues285 considered the cost-effectiveness of non-invasive diagnostic imaging
strategies in patients with a TIA or minor stroke suspected of having carotid stenosis. The strategies that
were compared included DUS, CTA, CEMRA and a combination of these strategies. In this study the main
emphasis was on the time window between the first ischaemic symptoms and carotid endarterectomy,
for different cut-off values as indications for surgery (i.e. 70–99% vs. 50–99% stenosis). Tholen and
colleagues285 used data from 351 patients (both male and female) with TIA or minor stroke admitted
between January 2002 and January 2005 to the Erasmus University Medical Centre, Rotterdam, The
Netherlands. The age range of the population was 19–90 years, with an average age of 62 years.
The economic evaluation was reported in 2007 euros. The alternatives that were compared with the
base case included the following:
1. CTA for 70–99% stenosis
2. DUS and CTA for 50–99% stenosis
3. DUS for 50–90% stenosis and CTA for 70–90%
4. CTA for 50%–90% stenosis
5. DUS and CEMRA for 70–99%
6. DUS and CEMRA for 50–99%
7. DUS for 50–99% and CEMRA for 70–99%
8. CEMRA for 50–99% stenosis
9. CEMRA for 70–99% stenosis
10. DUS for 70–99% stenosis
11. DUS for 50–99% stenosis.
Table 30 summarises the economic evaluation of the strategies compared in the studies included in
the review.141
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EVPI, expected value of perfect information; ICER, incremental cost-effectiveness ratio.
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142Data source on costs and outcomes of the economic evaluation
studies reviewed
Further information relating to the data sources used in the above studies is shown in Tables 31 and 32.
Wardlaw and colleagues26 conducted a detailed costing exercise based on three hospitals in Scotland and
calculated the direct costs of equipment (CT scanner, laser printer and maintenance) in three different
categories of hospitals (teaching, rural, and urban, during normal and out of hours) using a ‘bottom-up’
microcosting approach. These estimates were also used by Wardlaw and colleagues.5 Further, Wardlaw
and colleagues26 estimated the cost of treatment for stroke based on length of stay (LOS) data obtained
from general acute inpatient and day-case discharge data sets from Information and Statistics Division
(ISD), Scotland. These data were used to derive the mean duration of stay by type and severity of stroke.
The data suggest that there are significant differences in LOS between patients who are alive and
independent at 6 months and those who are dependent at 6 months. These data and the cost per
in-patient bed-day were combined to derive average total acute care cost estimates. Similar approaches
were undertaken in Wardlaw and colleagues.5 Both studies by Wardlaw and colleagues5,26 used the
EuroQol five-dimension (EQ-5D) instrument to derive quality-of-life weights, with weights taken from
the study by Dorman and colleagues,112 who conducted a trial that included EQ-5D data from
867 UK patients.
Buskens and colleagues284 costed the imaging procedures using expenditures incurred for personnel,
equipment, materials, maintenance, housing, cleaning, administration and overheads at one university
hospital (University Medical Centre, Utrecht, The Netherlands) and one general hospital (Enschede Medical
Centre, Enschede, The Netherlands). Estimates of costs associated with hospital stays and longer-term
costs were obtained from individual patient-based data from previously published studies undertaken
in the Netherlands. No information was reported on how health state utilities were calculated.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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although figures were taken from a different local hospital (Erasmus Medical Centre, Rotterdam,
The Netherlands). Estimates of costs associated with hospital stays and longer-term costs were obtained
from Buskens and colleagues.284 Disutilities for quality of life after TIA (0.0017 decrement), or after a minor
stroke (0.0524 decrement), were estimated from Buskens and colleagues284 and Sullivan and colleagues.293
A utility of 0.31 was estimated for major stroke, taken from Wardlaw and colleagues.5
Wardlaw and colleagues26 found that a strategy of immediate CT scans for all patients upon
admission dominated all other strategies; it was not only the least costly strategy, but also it produced the
greatest number of QALYs. The total expected QALYs for this strategy was estimated at 1982.2 for cohort of
1000 patients aged between 70 and 74 years, with total expected costs of £9994. Sensitivity analyses varied
the cost of scanning, the cost-effectiveness of strategies for different age groups, the proportions of different
types of strokes, the accuracy of CT, utility weights and lengths of hospital stays. The model was most sensitive
to reductions in the costs of inpatient care; a cost per bed-day that differed by > 5% from the base-case
assumption in a downwards direction led to the ‘scan all immediately’ strategy being less cost-effective
(equally effective but more costly) than the main comparator strategy of scanning all within 48 hours.
Buskens and colleagues284 suggested that DUS was both less expensive and more effective than all other
strategies included. The study suggested that, with the use of low stenosis-degree threshold as an
indication for surgery, DUS as a single examination strategy would on average yield 11.4 QALYs at a cost
of US$20,400.284 The results were robust to a series of deterministic sensitivity analyses; changes to the
likelihood of complications resulting from DSA or surgery, and the cost estimates, in general, revealed that
the rank of the strategies in terms of incremental cost-effectiveness was largely unaffected.143
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on the speed with which patients could be investigated and treated, and also test accuracy. The study
noted that the current stroke prevention approaches were too slow to prevent many strokes.5 The clinical
outcome in terms of time to endarterectomy did not differ much in those strategies that compared the
first 24 hours of presentation of the patients. In strategies in which only one diagnostic test was used to
determine CAS, the time to endarterectomy was on average 41 days. Two strategies (both using only one
ultrasound) reduced it to 31 days, and eight strategies reduced it to 35 days.
The number of strokes suffered within the first year varied across the different strategies that were
compared. The better strategies in terms of stroke prevention were those that enabled the endarterectomy
to be undertaken expediently, i.e. those where the ultrasound show the stenosis level of 70–90% and
the patient is subsequently provided with surgery. In this case 18.14 strokes occurred per 100 patients
treated or investigated. If the patients were found to have stenosis level of > 49% and were offered
endarterectomy, 17.94 strokes occurred per 100 patients investigated or treated. The number of QALYs
gained from the different strategies examined in the analysis were related to the clinical results and ranged
from 567.1 to 569.1 for 100 patients. The strategies where all patients with ultrasound reading of > 49%
receive endarterectomy were found to be better in terms of QALY gains. Higher level of QALY gains were
also observed where endarterectomy was offered to all patients with stenosis of > 69%.
The sensitivity of the model was examined by changes to assumptions regarding the assumed sensitivity
of the tests, the time taken to reach surgery following the diagnostic tests, the costs of diagnostic tests, and
the costs of endarterectomy. The results were moderately sensitive to changes in costs for endarterectomy
and changes in accuracy of less invasive diagnostic tests. For example, the net monetary benefit changed
from just over £10,000 to just over £50,000 by moving from a high to a low endarterectomy cost. Further,
taking the extreme ends of the 95% CIs, for strategy 1 (surgery for stenosis of 70–99% following
ultrasound), the low sensitivity showed a net monetary benefit of £13,000, whereas the high sensitivity
showed a net monetary benefit of £35,000. However, the conclusion that less-invasive tests were preferred
to DSA on cost-effectiveness grounds did not change, and the rank ordering of the less-invasive test
strategies did not change.
Finally, Tholen and colleagues285 found that those strategies that used CTA or CEMRA, either as an
independent strategy or in combination with an initial DUS, showed similar cost and effectiveness, where it
is assumed that there is 2- to 4-week delay in surgery. For men, the combination strategy of DUS, followed
by CTA with a cut off of 70–90% stenosis, was found to be the most cost-effective and dominated all
other strategies except for the strategy of CTA with cut-off of 70–99% stenosis. The cost and QALY for
the base case for men was estimated at €39,826, with QALY of 14.3832. The solo CTA strategy with a
cut-off of 70–99% yielded slightly more QALYs (14.3841), giving a value of €71,419 per QALY gained. For
the women-only cohort, likewise, the DUS–CTA combination strategy with a cut-off 70–90% dominated
all other strategies. The costs for such a strategy were found to be 45,911 with QALYs of 16.4605.
Probabilistic sensitivity analysis (PSA) showed that the combination strategy of DUS and CTA with a cut-off
of 70–99% stenosis had the highest probability of cost-effectiveness (33–48%).
The main recommendation of the study was that the patient with a TIA or minor stroke should undergo
DUS as initial diagnostic test, followed by CTA if the DUS results are positive, with surgery for 70–99%
stenosis, whereas in patients with higher-risk profiles, with high prior probability of carotid stenosis,
or who can undergo surgery without delay, immediate CTA and surgery for 50–99% stenosis are
indicated.285 Value-of-information analysis suggested an expected value of perfect information (EVPI) for
further research of €318 per male patient, which implies a population EVPI of €1.5B for the European
Union, and for females the EVPI was €40 per patient, implying a population EVPI of €193M for the
European Union.147
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148DiscussionThis review found that no previous studies have assessed the cost-effectiveness of MRI compared with CT
for minor stroke and TIA. One study attempted to perform a cost-effectiveness analysis of DWI in stroke
prevention in 2008 but gave up through lack of data on accuracy of DWI or impact on management or
other parameters required.105 This is in contrast with the rapidly rising use of MR in stroke prevention,
mostly performed in addition to CT rather than instead of, identified both in our UK survey of stroke
services (see Chapter 8) and in a study performed using centralised health usage data in the USA.298 In the
USA between 1999 and 2008, the absolute utilisation of MRI for stroke increased by 38% but the relative
use increased by 235%, from 28% of strokes in 1999 to 66% in 2008.298 CT usage did not change over
the same period.
The closest study on cost-effectiveness of imaging in stroke that we identified was that of Wardlaw and
colleagues,26 who examined the role of CT. Three studies5,284,285 were identified that had addressed the
question of diagnostic techniques for the management of carotid stenosis. Among these, Tholen and
colleagues285 found very small differences in QALYs across the strategies, and larger differences in costs.
These results were very different to those reported by Buskens and colleagues,284 which showed that
Doppler ultrasound was the most effective and least costly strategy. Buskens and colleagues,284 however,
compared Doppler ultrasound with non-enhanced rather than contrast-enhanced MR angiography, and
did not consider CT angiography. Similarly, Wardlaw and colleagues5 concluded that Doppler ultrasound
is the most cost-effective strategy.
As highlighted by Tholen and colleagues,285 a finding of large difference in costs but very small differences
in QALYs is common in diagnostic test evaluation; model estimates may well be dominated by treatment
costs and effects, which are common across different diagnostic strategies, with the only difference
between strategies relating to any extra costs associated with capital and running expenditures of the
imaging test itself. The importance of cost differences depends heavily on the local context. Where there
is greater demand on MRI scanners for stroke as well as other conditions, revealed through waiting times
that are unacceptable to clinicians and patients, it may be that the opportunity costs – i.e. the health
benefits foregone as a result of delayed diagnosis and treatment – are so large that CT is indicated. For
outcome differences, even where these are small on average on a per-patient basis, they are nevertheless
important, as they apply to a large patient population, and therefore have a large effect once account is
taken of total health benefit at a population level.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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of stroke preventionIntroductionThis chapter describes the data sources and summarises the data chosen for use in the model of stroke
prevention clinics for components that have not been covered already in detail in the preceding chapters.
It also presents some additional analyses of unpublished data where relevant. We have assumed that stroke
prevention treatment (medical or surgical as appropriate) would be offered to patients with TIA or minor stroke
due to ischaemic causes and not to patients with haemorrhagic stroke/TIA and non-vascular causes of their
symptoms – the patients with haemorrhage would avoid ischaemic stroke prevention drugs/surgery and those
with non-vascular diagnoses would be offered correct treatment for their true medical diagnosis. The effect of
false-positive and negative diagnosis of stroke/TIA compared with not stroke/TIA and of ischaemic compared
with haemorrhagic stroke/TIA and the use of imaging to differentiate these will be tested in the model. The
supplementary table (at end of this chapter, see Table 61) lists full details of all values and ranges; ‘box’ refers
to the relevant section identified by number in the left-hand column of this table.Proportion of patients with non-vascular compared with
vascular causes of symptoms (see Table 61, boxes 1–7)Approximately half of the patients who attend NV clinics in the UK with transient or mild neurological
symptoms do not have a final diagnosis of a CV event; less is know about the prognosis of these patients,
although non-CV events are usually considered a benign condition.266,267 These high proportions of TIA/minor
stroke mimics among patients attending stroke prevention clinics in the UK are a common finding;
in a recent survey of stroke prevention clinics in 2011, half of the centres indicated that the proportion of
patients with a final diagnosis of TIA or minor stroke was between 11% and 60% (see Chapter 8). The final
diagnosis of all patients (non-overlapping samples) referred to several different stroke prevention clinics in
Scotland and Leicester, including the proportions of TIA, minor stroke and non-CV events, which are shown
in Tables 33–35. In a large cohort of patients referred to a TIA clinic in Scotland with suspected TIA, 46% of
the patients did not have a CV explanation for their symptoms (i.e. did not have a TIA or minor stroke).271
The systematic review of studies of the frequency, main alternative diagnoses and outcomes in patients
with a final non-CV diagnosis are reported in Chapter 7 and specific causes in the supplementary table
(see Table 61, boxes 27–37). The summary estimate of the proportion for non-CV events reported across
all selected studies was 34% (95% CI 28% to 42%), and ranged from 18% to 55%. However, there was
evidence of substantial heterogeneity between studies; the summary estimates of proportions for non-CV
events in TIA clinics, population-based and hospital/ED-based studies were 40% (95% CI 23% to 60%),
40% (95% CI 23% to 60%) and 32% (95% CI 10% to 66%), respectively, with evidence of significant
heterogeneity between studies in each setting.Prognosis among patients with suspected transient ischaemic
attack and minor strokeAs regards prognosis of mimics, the HR for cardiovascular death in patients with both TIA and non-CV events
was higher than in a control population without any neurological symptom (HR 3.61; 95% CI 3.06 to 4.25;
HR 2.37/95% CI, 1.97 to 2.86, respectively) with a median follow-up of 87 months.270 In a prospective
population-based study of patients with transient neurological symptoms, the risks of stroke and dementia were149
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TABLE 33 Scottish Stroke Care Audit baseline characteristics and diagnosis dataa
Variable Before hotline After hotline p-value
No. of patients seen in clinic 1625 2523
No. seen per month 63 81
Demographics
Mean age, years (SD) 68.5 (13) 67.5 (13) 0.02
Male, n (%) 802 (49) 1259 (50) 0.75
Diagnoses, n (%)
Stroke definite 458 (28) 650 (26) 0.09
Stroke possible 28 (2) 91 (4) < 0.01
TIA definite 427 (26) 670 (27) 0.87
TIA possible 57 (4) 121 (5) 0.05
RAO 50 (3) 93 (4) 0.34
Transient monocular blindness 95 (6) 142 (6) 0.82
Definite non-CV 399 (25) 785 (31) < 0.01
Source of referral
Referred by GP, n (%) 1298 (80) 2048 (81) 0.32
Risk factors for those with CV disease 1009 1547
History of diabetes, n (%) 131 (13) 199 (13) 0.98
Previous stroke, n (%) 145 (14) 240 (16) 0.54
a From Kerr and colleagues,173 with additional unpublished data.
ABLE 34 University Hospital Leicester TIA Clinic Database Project diagnosis data, Leicester (Eveson, extracted
eptember 2011, unpublished data)
Final diagnosis Patients (n) Percentage
TIA 1137 29
Minor ischaemic stroke 650 17
Retinal ischaemia 155 4
Primary haemorrhagic stroke 17 0.4
Subdural haemorrhage 9 0.2





Peripheral nerve 89 2
Vestibular 86 2
Transient global amnesia 77 2
Seizure 54 1
150
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 35 GH Stroke/TIA Clinic Diagnosis Audit data (from July 2009 to June 2011, unpublished data)
Final diagnosis Patients (n) Percentage
TIA 668 28
Stroke 631 27







Anxiety or panic 24 1
Seizure 23 1
Syncope 18 1
Transient global amnesia 18 1
Bell’s palsy 14 1
Vertigo 12 1
Postural hypotension 11 0.5
Other 380 16
Total non-CV 841 35.5
Total patients 2368 100
TABLE 34 University Hospital Leicester TIA Clinic Database Project diagnosis data, Leicester (Eveson, extracted
September 2011, unpublished data) (continued )




Parkinson’s disease 5 0
Others 955 25
Total non-CV 1892 49
Total patients 3862 100
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONalso higher for patients with transient diffuse non-localising events than control subjects without any
symptoms.266 In the systematic review of all studies of mimics, a non-significant tendency for a higher risk of
stroke and vascular death was found in patients with non-CV events compared with asymptomatic control
subjects. Considering the few studies included with data for prognosis of non-CV compared with control
subjects, the prognosis for any transient neurological event other than TIA is poorly documented. It would seem
that from the perspective of stroke prevention clinics, that these non-CV patients are largely ignored.
Details on prognosis after definite TIA or minor stroke by underlying pathology and carotid stenosis are provided
in Population of the model, below, and in the supplementary table (see Table 61, boxes 10–26 and 38–49).Prognosis scoring systems in patients with transient ischaemic
attack/minor stroke (see Table 61, box 54)Several risk prediction scores based mainly on easy-to-elicit clinical features have been developed in the
last 20 years to try to identify patients at higher stroke risk who could be fast tracked to secondary
prevention. These are described in Chapters 4 and 6, and have largely coalesced into the ABCD2 score
and its many variants in the last 5 years.152,167,177,186,209
For the purpose of the present HTA project, we systematically reviewed studies that assessed ABCD score of
≥ 4 or < 4 in TIA patients (see Chapter 4). Among 26 cohorts, 15 cohorts reported the risk of recurrent
stroke at 7 days; 18 cohorts at 90 days, and three cohorts at > 90 days, and nine studies63,139,141,151–154,160,165
provided stroke risk data at both 7 and 90 days. Among these nine studies63,139,141,151–154,160,165 the pooled
estimates for stroke risk at 7 days were 4.76% (95% CI 2.40% to 8.70%) in patients with an ABCD2 score
of ≥ 4 and 1.6% (95% CI 1.0% to 3.4%) in patients with score of < 4; at 90 days the risk was 8.2%
(95% CI 4.7% to 14.0%) and 2.7% (95% CI 1.5% to 4.7%), respectively. The estimates for the risk of
stroke at > 90 days were 17.2% (95% CI 8.8% to 30.9%) in patients with an ABCD2 score of ≥ 4 and 5.2%
(95% CI 1 to 28.9%) in those with score of < 4.
The predictive value for CT visible ischaemic lesions and carotid stenosis for recurrent stroke is given in the
supplementary table (see Table 61, boxes 55–58).Proportion of ischaemic stroke/transient ischaemic attack with
a relevant lesion on computed tomography, diffusion-weighted
imaging (see Table 61, boxes 50–53)Several studies have reported the proportion of patients with TIA and relevant visible lesion on CT; these
values ranged from 0.0% to 11.5% (ESS data111).35,69,81,122,138,150,158,249,251 A recent multicentre study
showed that the proportion of patients with final diagnosis of TIA and visible lesion on CT was 23.9%;
however, it is unclear if this was just the relevant lesion and in many cases it was an old and irrelevant
lesion.211 In patients with diagnosis of minor stroke, the proportion of patients with a visible relevant lesion
on CT ranged from 42% to 52% (ESS data111).33,252 With respect to minor stroke and visible lesion on
DWI, few studies have shown that approximately two-thirds of patients have a relevant lesion during the
first days after the event, ranging from 60% to 71%.92,252,254
For the purpose of this HTA project we conducted a systematic review of DWI studies in TIA patients
(see Chapter 6). We identified 47 studies with 9078 participants evaluating the proportion of TIA patients with
positive DWI lesions. Sample size ranged from 14 to 1693 patients (mean 190 patients; median 85 patients).
The proportion of patients with positive DWI lesions ranged from 9% to 67%. After random-effects
meta-analysis, the proportion of TIA patients with a DWI abnormality was 34.3% (95% CI 31.0% to 38.4%).
Studies varied in terms of time interval between symptoms onset and DWI, symptoms duration, aetiology,
selection criteria and setting. The proportion of patients with minor stroke and a lesion on DWI was 69%.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Accuracy of computed tomography and magnetic resonance
(diffusion-weighted imaging, gradient echo, T2/fluid-attenuated
inversion recovery) for non-vascular compared with
ischaemic stroke/transient ischaemic attack compared with
haemorrhagic stroke/transient ischaemic attack by time after
index event (see Table 61, boxes 59–64)A recent systematic review aimed to estimate the accuracy of MR DWI compared with CT for the diagnosis
of acute ischaemic stroke and to assess the accuracy of MRI (all feasible sequences) for the early detection
of haemorrhagic stroke.36 Most studies focused on acute hospital-admitted stroke patients who were being
considered for acute primary treatment rather than for secondary prevention. Hence they are of limited
relevance to the present topic. We found no studies that directly compared MR DWI and other appropriate
sequences with CT in patients with TIA and minor stroke. For studies that assessed patients with ischaemic
stroke (seven studies) in the systematic review of hospital-admitted patients,36 the pooled estimates for DWI
sensitivity and specificity were 0.99 (95% CI 0.23 to 1.00) and 0.92 (95% CI 0.83 to 0.97) respectively,
whereas the pooled estimates for CT sensitivity and specificity were 0.39 (95% CI 0.16 to 0.69) and
1.00 (95% CI 0.94 to 1.00), respectively. The one study that did include minor stroke suffered from
incorporation bias because they changed the diagnosis of TIA to stroke in patients with a relevant
lesion on DWI. They also excluded all mimics and haemorrhagic strokes.32
Assessment of TIA/minor stroke patients may be delayed if the patient presents late or there are delays to
investigations. We therefore estimated the likely sensitivity and specificity of MR DWI for ischaemic lesions, by
time periods after symptom onset, for 100 patients presenting with suspected minor stroke for standard MR
sequences required for diagnosis of ischaemic stroke (DWI, FLAIR, T2, T1) (Table 36). These estimates were
based on the limited data available from observational studies of MR in patients with TIA/minor stroke. There
are no reliable serial MRI studies of patients with minor stroke or TIA, or comparisons with CT. The estimatesTABLE 36 Estimated sensitivity and specificity of MR DWI for ischaemic stroke by time after symptom onset
MR DWI/FLAIR/T2/T1 ischaemic stroke
TotalPositive Negative
< 7 days
Ischaemic stroke + 35 20 55
– 5 40 45
Total 40 60 100
Sensitivity = 63%, specificity = 88%
7–21 days
Ischaemic stroke + 15 40 55
– 10 35 45
Total 25 75 100
Sensitivity = 27%, specificity = 77%
> 21 days
Ischaemic stroke + 5 50 55
– 15 30 45
Total 20 80 100
Sensitivity = 10%, specificity = 66%
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONtake account of the estimated loss of DWI hyperintensity with time after stroke and include the 45% with
non-vascular diagnosis, assume that 66% of minor stroke would have DWI-positive lesion, and that without the
DWI-positive lesion the other sequences T2, FLAIR and T1 are no better than CT, or actually worse because they
show more white matter lesions, which are then mistaken for a recent infarct, thereby inflating the false-positive
rate. DWI is also positive in migraine, epilepsy, MS, transient global amnesia, etc., hence the early false-positive
rate. Between 7 and 21 days, fewer patients have a DWI-positive lesion (33%) and the rest may have a lesion
visible on FLAIR/T2, etc., but this would be difficult to identify as the acute lesion – there would be other white
matter lesions and old lesions that would be mistaken for the recent lesion, as they cannot be distinguished
except with DWI, so the false-positive rate increases whereas the true-positive rate goes down. By 21 days or
later, the DWI positives have almost vanished, the false positives have gone up a bit, etc. This estimation was
necessary in the absence of other data. The effect of changing sensitivity and specificity would be the same for
TIA patients except that the true-positive rate would be lower, as DWI shows a positive lesion in only one-third
of TIA patients scanned within the first couple of days, and the lesion probably disappears even faster than for
minor stroke and is less likely to leave any sign of permanent damage on T2, FLAIR or T1 than in minor stroke.
For CT scanning, we calculated the proportion of patients with minor stroke with a visible relevant infarct
by time of scanning within 7 days and after 7 days, using data on 892 relevant patients from the ESS
(ESS data111). A visible infarct was seen within 7 days in 246/383 (64%) of patients and after 7 days in
277/507 (55%) of patients.
For sensitivity and specificity of MR in haemorrhagic stroke (two publications), one showed a sensitivity of 0.83
(95% CI 0.52 to 0.98) and a specificity of 1.00 (95% CI 0.95 to 1.00) for gradient-echo and diffusion-weighted
MRI in patients assessed within 3 hours of stroke; compared with CT and clinical assessment, however,
sensitivity was estimated from 13% of the 90 patients included in the study. The second study reported 1.00
(95% CI 0.91 to 1.00) for both sensitivity and specificity of diffusion-weighted MRI and 1.00 (95% CI 0.91 to
1.00) sensitivity and 0.98 (95% CI 0.87 to 1.00) specificity for GRE MRI performed within 6 hours of symptoms,
but with no CT comparator in most of the patients.36 Fifty per cent of patients in this study had haemorrhagic
stroke compared with the 10–15% proportion of haemorrhagic stroke in the general population and about
5% among patients with minor stroke. This indicated the presence of highly selected patient sample that
was likely to have increased sensitivity and influenced specificity, and is virtually irrelevant to the present work
and the situation in daily practice.36 MR detection of haemorrhage varies with sequence, T2* (GRE) or
susceptibility-weighted sequences being the most sensitive, and T2 and FLAIR sequences being relatively
insensitive.51,299 We set the sensitivity and specificity of MR for haemorrhage as 0.83 and 1.00 if T2* was used
and 0.50 if T2* was not used, respectively (see Table 61, boxes 62 and 64).
The signs of acute haemorrhage on CT have been well described and were discussed extensively in the
HTA report on cost-effectiveness of CT scanning in acute stroke.26 The characteristic CT features of acute
haemorrhage (increased attenuation lesion – white – with respect to normal brain) appear virtually
immediately on CT300 and last for between 5 days and perhaps 3 weeks,31 depending on the amount of
initial blood.301 Small amounts of blood are broken down more rapidly and can lose their characteristic
whiteness by as early as 1 week after the stroke20,31 becoming isoattenuated and then hypoattenuated
(dark) with respect to normal brain.302 Eventually, a small slit-like cavity may remain, or the lesion may
leave no trace, or it may leave a cavity with a white (haemosiderin-containing) rim. The latter is highly
specific for old haemorrhage. There are almost no long-term systematic studies where patients with
haemorrhage were scanned repeatedly to determine the rapidity with which haematomas resolve and
what proportion remain visible or not as a cavity with or without a white rim for obvious reasons due to
radiation dose.302 However, for the purpose of the present analysis, the loss of characteristic whiteness in
minor stroke and TIA patients with small haematomas is the important factor. We assumed that within the
first week after stroke or TIA, the sensitivity and specificity of CT would be 0.99 and thereafter would fall
to much lower levels (see Table 61, box 60).NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27There are few data on the sensitivity or specificity of CT or MR in the many potential mimics of TIA and
minor stroke, with relevant few new studies since the publication of the HTA report on cost-effectiveness
of CT scanning in acute stroke26 for which this topic was extensively reviewed. Unfortunately, most
studies in which the data could have been collected excluded the mimics. Both CT and MR detect and
misinterpret tumours and arteriovenous malformations, SDHs with equal sensitivity and specificity. MR may
identify more patients with MS, but, on the other hand, MR also shows more incidental lesions, particularly
white matter hyperintensities, which may be completely irrelevant to the presenting symptoms but be
mistaken for vascular or non-vascular lesions. Neither technique will show much of relevance in migraine
or epilepsy or other common mimics, although the former two pathologies may be associated with
transient hyperintensities on DWI that would be mistaken for ischaemic events. Therefore, we used data
from the HTA report on CT in acute stroke,26 and informed professional opinion and set the sensitivity and









Migraine 14 –ve –ve Need antimigraine
drugs
Unlikely to die from
migraine but does
need to be correctly
identified and
treated – death rate
as for general
population
Vertigo 4 –ve/NC –ve/NC Need symptom
control – usually
self-resolvingb
Unlikely to die from
vertigo but does
need to be correctly
identified and
treated – death rate
as for general
population
Psychiatric 4 –ve/NC –ve/NC Need relevant
psychiatric
consultation
Unlikely to die from
psychiatric conditions
but does need to be
correctly identified
and treated – death
rate as for general
population












Seizure 5 –ve –ve Need relevant
antiepileptic
treatment – failure
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from tumour – bad
practice not to
manage correctly
even if tumour is
ultimately not curable













of bang on head,
may be on warfarin
already – set risk of













to identify if has
aneurysm and
treatment of it –


















Syncope 7 –ve/NC –ve/NC Identify cause (if any)
of syncope on clinical/
other tests (not
scanning) and rectify
to avoid falls, etc. and
resulting damageb
Main problem ‘falls in
elderly’ or over-
treated hypertension
resulting in drops in
BP, falls, banged
head, trauma, SDH,
etc. So need to be
correctly diagnosed
and managed – risk
of death/dependency
30%/30% (estimate)
–ve, expect no positive scan finding – scan done simply to exclude other causes of headaches (e.g. in case of migraine);
NC, scan non-contributory [e.g. disorder does not require scanning to diagnose, probable non-contributory resource use or
worse, exposes patient to radiation (CT)] – disorder should be diagnosed on basis of competent history and examination,
but, where patients are not seen by an experienced stroke doctor, scanning may be requested.
a Of mimics.
b Very rare causes of vertigo or syncope include brain tumours or developmental abnormalities but these present with
headache with or without syncope and are classed under tumours – they are exceptional and have unusual symptoms
different to ‘routine’ vertigo or syncope.
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Population of the modelEpidemiological data: profile of the patients who have suffered a transient
ischaemic attack
Only patients aged ≥ 55 years and who were non-disabled were considered in the model. Table 38 shows
the distribution of age at first event against sex and type of TIA/stroke of all severities from the ESS.111
The proportions of patients with haemorrhagic stroke in patients with a final diagnosis of TIA and minor
stroke were taken from the ESS (ESS data111), previous population studies summarised in26 the SSCAS and
other unpublished audit data (see Table 61, boxes 4 and 5).
The incidence of TIA per annum was taken from OXVASC,303 as were the data for minor stroke, assuming
that one-third of ischaemic strokes would be minor. The rates of minor stroke and TIA per age and sex
band were applied to a hypothetical population of 500,000 with an age and sex mixture equal to that of
England and Wales,304 which resulted in an estimated 490 minor strokes and TIAs per annum. This
resulted in estimated number of TIAs and minor strokes per annum as given in Table 39.
Figures in parentheses indicate the percentage of the total number of TIAs or minor strokes. Figures may
not tally exactly because of rounding.ABLE 38 Age (years) at time of first event against sex and type of stroke, including TIA/stroke of all
everities (ESS data111)
Frequency < 55 years 55–64 years 65–74 years 75–84 years ≥ 85 years Total
Female 86 157 285 366 150 1044
Male 124 229 353 336 80 1122
Haemorrhagic 6 12 24 39 14 95
Ischaemic 180 329 541 611 200 1861
Other 22 44 59 43 10 178
Uncertain 2 1 14 9 6 32
Total, n (%) 210 (10) 386 (18) 638 (29) 702 (32) 230 (11) 2166




55–64 65–74 75–84 ≥ 85 Total
Male, n (%) 22.5 (5) 66.3 (14) 63.4 (13) 25.7 (5) 177.9 (36)
Female, n (%) 30.1 (6) 65.3 (13) 130.7 (27) 86.0 (18) 312.1 (64)
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONThe OXVASC study303 was a population-based incidence study of stroke and TIA in 2002–4. During the
study period, 476 individuals had at least one TIA or stroke. Of these, 262 were first-ever incident strokes
(223 ischaemic strokes), 76 were recurrent strokes and 138 individuals experienced at least one TIA (93
with incident TIA, 20 with previous TIA, 17 with previous stroke and eight with both). The crude incidence
per 1000 population in OXVASC303 was 1.87 (95% CI 1.67 to 2.08) for any stroke, 1.45 (95% CI 1.28 to
1.63) for first-ever stroke and 0.42 (95% CI 0.33 to 0.53) for recurrent stroke. Table 40 shows the overall
incidence of TIA adjusted to the 2001 Census population on England and Wales303 and Table 41 shows
the age-specific incidence of TIA in men and woman in the OXVASC population.305
The Greater Cincinnati/Northern Kentucky Stroke Study23 was a large USA population-based metropolitan
study (biracial population of 1.3 million) of incidence rates of TIA and short-term outcomes after TIA.
During the study (1 year), a total of 1023 TIA events occurred among 927 patients (first ever or recurrent),
with an overall annual age- and sex-adjusted incidence rate, for a single TIA, of 83 per 100,000 (95% CI
78 to 88) (Table 42). Black people and men had higher rates of TIA than white people and women. The
risk of TIA and stroke after TIA was 8.6% and 14.6% at 3 months, respectively.23 This indicates that the
incidence of TIA is similar in western countries.
A systematic review of the incidence of all stroke in the UK showed a incidence among men of all ages
ranging from 124 per 100,000 in south London to 185 per 100,000 in the Scottish Borders region, and
from 88 to 146 per 100,000 among women in the same studies.306Carotid stenosis and risk of stroke
Owing to the significant correlation between stenosis level and the risk of stroke,307 the TIAs and minor
strokes were subdivided into those occurring in patients with an ipsilateral internal carotid stenosis level of
70–99%, those occurring in patients with a stenosis level of 50–69% and those in patients where stenosis
was < 50% or where the carotid artery had occluded. The percentages of patients suffering a TIA or minor
stroke who fall into these stenoses bands are given in Tables 42–44 and the patients were assumed to be
the same as those in the LSR5 and ESS111 data report. It was also assumed that the stenosis distribution in
patients with a minor stroke was identical to that of patients with a TIA (see Tables 43 and 44). Details of
key risk factors (carotid stenosis and AF) in patients with TIA and minor stroke were also obtained from
multiple sources (see Table 61, boxes 8 and 9).118,132,164,185TABLE 40 Overall incidence of TIA in OXVASC by sex and age303
Incidence Annual TIA incidence per 1000 (95% CI)
Crude incidence
Men 0.35 (0.24 to 0.49)
Women 0.69 (0.53 to 0.89)
All 0.51 (0.41 to 0.63)
Standardised incidence
Men 0.37 (0.24 to 0.50)
Women 0.77 (0.57 to 0.96)
All 0.58 (0.46 to 0.69)
Standardised incidence by age
≥ 85 years 6.41 (3.45 to 9.38)
< 85 years 0.46 (0.35 to 0.56)
< 75 years 0.24 (0.17 to 0.32)
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TABLE 42 Age-specific incidence rates of TIA per 100,000 by race and gender in the Greater Cincinnati/Northern
Kentucky Stroke Study23
Age (years)
Incidence rate (95% CI)
White Black
Male Female Male Female
< 35 1.0 (0.0 to 2.2) 1.8 (0.2 to 3.3) 1.7 (0.0 to 5.2) 3.2 (0.0 to 7.8)
35–44 4.6 (0.1 to 9.0) 12.3 (5.0 to 19.6) 16.0 (0.0 to 38.3) 12.7 (0.0 to 30.2)
45–54 82.2 (59.2 to 105.2) 73.3 (52.3 to 94.2) 129.8 (49.4 to 210.3) 30.2 (0.0 to 64.3)
55–64 155.4 (118.0 to 192.1) 96.3 (69.0 to 123.5) 205.7 (89.3 to 322.1) 249.0 (139.9 to 358.2)
65–74 468.5 (395.7 to 541.3) 246.6 (201.1 to 292.1) 338.2 (172.5 to 503.9) 330.2 (192.2 to 468.3)
75–84 750.4 (620.9 to 879.9) 521.1 (441.8 to 600.4) 612.8 (279.7 to 945.9) 647.9 (393.9 to 901.9)




100.6 (91.1 to 110.1) 67.6 (861.4 to 73.9) 107.2 (79.8 to 134.7) 92.6 (72.9 to 112.4)
TABLE 43 Distribution of patients with TIA and minor stroke between stenosis bands (ESS data report111)
Carotid stenosis band by NASCET
Minor stroke TIA
% n % n
0–49% and occluded 90.3 901 90.9 421
50–69% 3.5 35 2.8 13
70–99% 6.2 62 6.3 29
ABLE 44 Distribution of patients with TIA and minor stroke between stenosis bands (LSR, Wardlaw
nd colleagues5)
Stenosis level Percentage of all TIAs
70–99% 6
50–69% 4
< 50% or occluded 90
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a
These groups were further subdivided into patients who were currently taking aspirin and those who were
not, as this could affect the magnitude of benefit of initiating medical therapy at an earlier stage, when a
diagnostic algorithm would result in treatment being initiated more rapidly. It was assumed that 51% of
patients would be on aspirin at the time of experiencing TIA or minor stroke.9,303 In the SOS-TIA and
EXPRESS studies, 22% and 45% of patients respectively, with a diagnosis of TIA or minor stroke, were on
antiplatelet drugs at baseline. In ED assessment of TIA, nearly 30% of patients were already on aspirin.8,153
Audit data from Lothians 2010–11 show that 50–52% of patients were already on aspirin or other
antithrombotic treatment at the time of their TIA/minor stroke (Table 45).NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 45 Drug therapy at first assessment in Lothian stroke clinics (SJH and WGH 2010–11)
Drugs at first assessment
2010 2011 so far
WGH SJH Lothian WGH SJH Lothian
Aspirin, n (%) 453 153 606 (48) 127 58 185 (38.7)
Other antiplatelet, n (%) 38 14 52 (4.1) 50 4 54 (11.3)
Anticoagulant, n (%) 30 16 46 (3.6) 8 4 12 (2.5)
Total patients 1261 477
SJH, St John’s Hospital.
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We have assumed that these distributions are independent of age and sex, as there were no reliable
population-based data on the age and sex distribution of patients with TIA or minor stroke who also
gave information on the degree of carotid stenosis. The risks of stroke and MI for patients within the
same carotid stenosis band were assumed to be homogeneous; however, death from all other causes
would vary within stenosis bands dependent on the age and sex of the patient.
Risks of recurrent stroke after transient ischaemic attack and minor stroke
The proportions of patients experiencing a recurrent stroke by time after and severity of index stroke or
TIA, including the risk of recurrent haemorrhage in patients with haemorrhagic stroke, were derived in
the systematic reviews in Chapter 3 for ischaemic stroke and from multiple data sources for haemorrhagic
stroke (see Table 61, boxes 38–41).5,26,28,308
The systematic review of all published studies resulted in a pooled estimate of recurrent stroke after TIA
of 5.2% (95% CI 3.9% to 5.9%) at 7 days, 6.7% (95% CI 5.2% to 8.7%) at 90 days and 11.3%
(95% CI 7.5% to 16.6%) at > 90 days (see Chapter 3).
Data on recurrent haemorrhage in patients on antithrombotic drugs were taken from the HTA report on
CT in acute stroke and a recent systematic review (see Table 61, box 49).27,30
We obtained data on non-fatal and fatal stroke, MI and other causes of death at 7 and 90 days and
2 years after TIA and minor stroke from the LSR (Table 46).ABLE 46 Outcomes at 7 days, 90 days and 2 years after TIA or minor stroke in the LSR
Outcomea
TIA Minor stroke
7 days 90 days 2 years 7 days 90 days 2 years
Non-fatal stroke 0 3 17 3 13 38
Fatal stroke 0 4 12 1 7 25
Non-fatal MI 0 0 7 0 1 10
Fatal MI 0 1 1 0 1 9
Other vascular death 0 4 16 1 4 22
Non-vascular death 0 3 18 2 5 19
Alive, no events 828 813 757 1086 1062 970
Total (n) 828 828 828 1093 1093 1093
a Values shown in absolute numbers.T
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONRisks of stroke in relation to the degree of stenosis
The longer-term risks of stroke following a TIA have been well described.9,21,22,127 Chapter 5 details the
effect of adding carotid stenosis to clinical risk prediction scores. As determined in the carotid
endarterectomy trials, carotid stenosis is a key risk factor for recurrent ipsilateral ischaemic stroke. However,
although data were available on the longer-term risk stratified by stenosis level,25 the short-term data were
not.9 We have therefore assumed that the ratio of risks between stenosis bands observed in the initial
year in the carotid surgery trials25 were also applicable to the initial 3-month period. The assumed risks
associated with the patients within these trials are presented in Table 47. See Tables 48 and 49 for risks of
stroke and MI by time and stenosis band from ESS data report (ESS data111). Table 48 shows the frequency
of recurrent stroke by time and carotid stenosis bands, including six patients with endarterectomy. In these
patients, there were five strokes, all at ≤ 6 months’ follow-up (one in a patient with 50–69% ipsilateral
carotid stenosis and four in patients with 70–99% ipsilateral carotid stenosis) (ESS data111). However, this is
under-reported, as ESS did not collect routinely the information on carotid endarterectomy.111
The early risk of ipsilateral ischaemic stroke after first TIA in medically treated patients with symptomatic ICA
disease was obtained from multiple sources. In the medical arm of the NASCET trial, the 2- and 90-day risks
of ipsilateral stroke were 5.5 and 20% for patients with hemispheric TIA and 0.0 and 2.3% respectively for
hemispheric stroke. The risks were higher in the presence of infarct visible in brain imaging (adjusted HR
2.1; 95% CI 1.5 to 3.0) and intracranial major-artery disease (adjusted HR 1.9; 95% CI 1.3 to 2.7) but
similar in patients with severe carotid stenosis (≥ 70%) compared with lower degrees of stenosis.128ABLE 47 Risk of stroke in medically treated patients by time after TIA or minor stroke and stenosis band
ardlaw and colleagues5)
Time
Cumulative risk (%) of stroke in medically treated patients
Stenosis level
< 50% and occluded 50–69% 70–99%
1 week 7 8 13
1 month 9 12 19
3 months 14 18 29
15 months 20 25 39
27 months 23 30 45
39 months 26 33 48
ABLE 48 Frequency (n, %) of recurrent (any) stroke by time and carotid stenosis bands (ESS data report111)
Time to recurrent stroke Unknown 0–49% and occluded
Stenosis band
50–69% 70–99% All
≤ 6 months 20 (4.2) 63 (4.2) 1 (1.7) 9 (8.0) 93
> 6 months to 1 year 8 (1.7) 30 (2) 0 2 (1.7) 40
13–24 months 7 (1.4) 29 (2) 5 (8.7) 2 (1.7) 43
25–36 months 3 (0.6) 19 (1.3) 0 3 (2.6) 25
37 months to 5 years 1 (0.2) 2 (0.13) 1 (1.7) 0 4
No second stroke 440 (91) 1,375 (91) 50 (88.0) 96 (86.0) 1961
All 479 1518 57 112 2166T
(W
T
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Unknown 2 5 4 1 3 1 463 479
0–49% and
occluded
– 11 7 7 5 1 1487 1518
50–69% – – – 1 1 – 55 57
70–99% – 1 1 1 1 1 107 112
All 2 17 12 10 10 3 2112 2166
Cumulative
risk, n (%)a
2 (0) 17 (0.8) 2 (1.3) 39 (1.8) 49 (2.3) 52 (2.4) 2112 (97.5) 2166
a Excluding number of MI prior to first event.
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The consequences of the delays of carotid imaging and surgery for the effectiveness of stroke prevention
have been assessed in the OXVASC study population. The median times from event to referral and event
to imaging in this cohort were 7 and 28 days, respectively. The risk of recurrent stroke in patients with
≥ 50% stenosis censored before any surgery was 21% at 14 days and 32% at 12 weeks.66 These values
could reflect the delayed prescription of appropriate secondary prevention treatment soon after the index
event and before surgery. More recent data from a prospective single-centre study described the recurrence
rate at 2 weeks in 163 patients with symptomatic carotid stenosis of ≥ 50% and first-ever non-disabling
stroke or TIA. Recurrence was defined as new neurological clinical event: TIA or stroke in patients with TIA,
or worsening ≥ 4 points from the initial NIHSS or new symptoms suggesting a new neurological event in
patients with mild stroke. During the first 2 weeks, 45 patients (27.6%) had recurrence, 26 (16.0%) patients
in the first 24 hours after admission, 11 (6.7%) between 72 hours and 7 days, and 6 (3.7%) between 7 days
and 2 weeks. When new TIAs were excluded, the risk of new stroke was 22.7% (37 patients) and increased
with the degree of stenosis.185 All of these rates seem a high estimate, perhaps because they admitted the
patients and watched them very closely and maybe they were counting subtle neurological changes as
recurrences during their strict follow-up. For the purpose of this project we applied the recurrence rates by
per cent stenosis used in the 2006 HTA report (Wardlaw and colleagues5) derived from combined carotid
endarterectomy trial data,25 because they are more consistent with local audit data and with the recurrence
rates described in the literature reviews (see Table 47).The risk of stroke in relation to medical treatment
The carotid surgery trials reported the risks of stroke following medical treatment. Antiplatelet treatment
and BP-lowering drugs were prescribed in the NASCET, ECST and Veterans Administration carotid
endarterectomy trials.25 Lipid-lowering drugs are now in widespread use, and in the recent OXVASC
epidemiology study 32% of patients with TIA and 24% of those with minor stroke were on lipid-lowering
agents at the time of their stroke.9
To calculate the risks of stroke in patients who remained untreated for a period after their TIA or minor
stroke, we have assumed that the efficacy of medication seen in RCTs would apply (see Efficacy of medical
treatment, below).309–314 In fact, the survey of UK stroke prevention clinics shows that as in 2011, < 25%
of patients were unmedicated for any length of time after their TIA/minor stroke. There are no other new
data from clinical trials to change any assumptions regarding effects of medical treatment.163
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONLong-term risks of stroke after transient ischaemic attack in the
presence of carotid stenosis
We assumed that 39 months after a TIA or minor stroke (i.e. by just over 3 years) the risks of stroke were
equal regardless of stenosis level. The risk of stroke in treated patients after 3 years has been set as 2.3%
per annum and is the weighted average of data presented by Clark and colleagues,315 Cunningham and
colleagues316 and Barnett and colleagues.317 Therefore, immediately following successful endarterectomy
in the model, we set the risk of stroke to 2.3% per annum, assuming it to be the same as in patients who
had survived 3 years or more since a TIA or minor stroke.Long-term outcomes after stroke
The proportion of patients dying as a result of index stroke or TIA by various time periods, by stroke type,
by cause of death, were taken from multiple sources including data amassed in the two previous HTA
reports of imaging in stroke5,26 the ESS (ESS data111), analysis of the LSR, and published data (see Table 61,
boxes 10–26).8,153,164,308,315,318–325
Data on the proportion of patients who would be alive and independent after stroke by severity and time after
index stroke were obtained from multiple sources (see Table 61, boxes 42–49).320,326 The proportion of patients
dying, surviving in a dependent or independent state after stroke according to the Rankin score, by age of
patient, was taken from the LSR327,328 and the ESS.111 A Rankin score of ‘0–2’ indicates independent survival,
‘3–5’ indicates survival in a dependent state, and ‘6’ is dead. The LSR is a hospital-based register of all patients
with TIA or stroke, attending the WGH in Edinburgh, collected between 1990 and 1999. The WGH has a
catchment population of 500,000 and serves north Edinburgh. These data are not truly community based, as
patients who die prior to hospital assessment are not included in the Registry, but there are only limited data on
long-term outcome after stroke from other sources (see below). The outcome values derived from the LSR are
provided in Table 50. These values are broadly similar to those presented in the study of Bond and colleagues,329
in which for all patients the fatality rate was 13%. The rates of disabling stroke and non-disabling stroke were
30% and 57%, respectively. Outcome at 6 months after stroke by age of the patient from ESS data report111 on
a similar population of patients seen in Lothian with stroke between 2002 and 2005 are shown in Table 51.
Long-term follow-up of 2447 patients recruited in the Dutch TIA Trial (excluding patients with cardiac source
of embolism or a clotting disorder) over 10 years, showed that 1489 (60%) had died and 1336 (54%) had
experienced at least one other vascular event.65 Ten-year risk of death was 42% (95% CI 41% to 45%)
and of a first vascular event was 44% (95% CI 42% to 46%) and similar factors predicted vascular event as
vascular death (non-fatal stroke 480/1741 total events, non-fatal MI 185/1741, fatal stroke 139/1741, fatal
MI 138/1741).65 The Perth Community Stroke Study (PCSS)318,319 was a population-based study in Western
Australia and also reported long-term survival after first-ever stroke. The 10-year cumulative risk of death was
79% (95% CI 74% to 84%). Case fatality was greatest in the first year after stroke (36%; 95% CI 30% to
41%), and particularly in the first 30 days after stroke 22% (95% CI 17% to 28%).
Among 1-year survivors of stroke, the average annual case fatality over the next 9 years was 4.8%,
6.0% between years 1 and 5, and 4.0% between years 6 and 10.319TABLE 50 The outcome at 6 months after stroke by age of the patient (LSR data)
Age (years) Rankin score 0–2 Rankin score 3–5 Fatality 30-day fatality in OXVASC300
55 to 64 76% 22% 2% 12%
65 to 74 79% 17% 4% 10%
75 to 84 73% 21% 6% 15%
≥ 85 52% 39% 10% 31%
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 51 Outcome at 6 months after stroke by age of the patient (ESS data report111)
Age (years) Unknown (n, %)
mRS
Dead (n, %) AllRankin score 0–2 (n, %) Rankin score 3–5 (n, %)
< 55 37 (36) 56 (54) 10 (10) 1 (1) 104
55 to 64 53 (27) 114 (59) 18 (9) 9 (5) 194
65 to 74 106 (29) 181 (49) 52 (14) 29 (8) 368
75 to 84 128 (29) 192 (43) 60 (14) 62 (14) 442
≥ 85 55 (34) 30 (19) 22 (14) 55 (34) 162
Total 379 (30) 573 (45) 162 (13) 156 (12) 1270
mRS, modified Rankin Scale.
Age defined at first clinical assessment; figures may not tally exactly due to rounding; there are 896 patients not included
owing to lack of data.
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27The increased risk of all cause mortality following a stroke
Following stroke, the risk of death is increased 2.5-fold compared with patients of the same age and sex
without stroke, as reported in the PCSS,330 with this effect persisting until death. The 10-year follow-up of
this study showed that all patients with a first-ever stroke had an approximately three times greater risk of
dying compared with individuals of the same age and sex in the general population of Western Australia,
with a ninefold (95% CI 7.1 to 10.8) greater risk of death in the first year after stroke and then a twofold
increase in risk in each of the subsequent years.319
The longer-term outcome of patients alive at 6 months after stroke is related to Rankin status at 6 months:
patients who were independent at 6 months had a median survival of 9.7 (95% CI 8.9 to 10.6) years, and
in those who were dependent it was 6.0 (5.7 to 6.4) years; median survival of those with a modified Rankin
Scale (mRS) score of 0–1 was 12.9 (10.0–15.9) years, reducing to 2.5 (1.4–3.5) years in those with a mRS of
5 (combined OCSP, LSR and [International Stroke Trial (IST) data] (Tables 52 and 53).320 The patients who
are dependent at 6 months after stroke onset had an overall RR of dying from a stroke-related cause of
1.68 (95% CI 1.49 to 1.91) (including OCSP, LSR and IST cohorts). The RR of dying from stroke-relatedABLE 52 Combined analysis estimating association between functional status at 6 months and subsequent median
urvival (combined OCSP, LSR and IST data)320
Functional status Median survival, years (95% CI)
Rankin score in OCSP and Lothians cohorts (no. of patients)
0 (311) > 15.0a
1 (540) 11.7 (8.4 to 14.9)
2 (576) 8.4 (7.6 to 9.3)
3 (433) 6.0 (5.2 to 6.8)
4 (189) 3.7 (2.9 to 4.6)
5 (136) 2.5 (1.4 to 3.5)
All three cohorts (no. of patients)
Independent (2525) 9.7 (8.9 to 10.6)
Dependent (3436) 6.0 (5.7 to 6.4)
a Data range not available for mRS = 0.T
s
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ABLE 53 Survival categorised by functional outcome at 6 months after ischaemic stroke in three different cohorts





























6 months 285 (100) 154 (100) 1142 (100) 604 (100) 1098 (100) 2678 (100)
1 year 280 (98) 138 (90) 1101 (96) 543 (90) 1067 (97) 2478 (93)
5 years 209 (73) 69 (45) 325 (28) 147 (24) 696 (63) 1321 (49)
9 years 149 (52) 42 (27) 1 (0.08) 0 28 (2.5) 19 (0.7)
10 years 132 (46) 39 (25) – – – –
15 years 68 (24) 25 (16) – – – –
mRS, modified Rankin Scale.
a Functional outcome defined by ‘two simple questions’ method.
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(ccauses increased with an increasing mRS score (OCSP and LSR cohorts) (Table 54).321 Table 55 shows
Kaplan–Meier estimates of the risk of death within defined time intervals after first-ever stroke.319
The risks of myocardial infarction
Data on MI after TIA or stroke were obtained from the LSR and a population study and a systematic review
(see Table 61, box 44).331,332 The risk of MI or cardiovascular death following a TIA or non-haemorrhagic
minor stroke has been published by Clark and colleagues315 and was 27.8% at 10 years, which equates to
3.2% per annum. An updated systematic review and meta-analysis of risk of MI and vascular death after
TIA and ischaemic stroke found an annual risk of 2.1% (95% CI 1.9% to 2.4%) for non-stroke vascular
death, 2.2% (95% CI 1.7% to 2.7%) for total MI, 0.9% (95% CI 0.7% to 1.2%) for non-fatal MI, and
1.1% (95% CI 0.8% to 1.5%) for fatal MI; the time course of risk was linear.332 In a cohort of patients of
≥ 65 years with first ischaemic stroke, the rates for recurrent stroke and coronary heart disease (CHD) were
105.4/1000 and 59.3/1000, respectively, during the first year of follow-up. After the first year, the stroke
rate was 52/1000 and the CHD rate was 46.5/1000.333 In the Rochester TIA study,331 the average annual
incidence of MI after TIA was 1%, double that of the normal population and with higher rates in younger
(< 60 years) than older patients. The risk remained constant over time and was an independent predictor
of death after TIA (HR 3.11; 95% CI 2.11 to 4.57). Increasing age (HR 1.51 per 10 years; 95% CI 1.14 to
2.01), male sex (HR, 2.19; 95% CI 1.18 to 4.06) and the use of lipid-lowering therapy at the time of TIA
(HR 3.10; 95%, 1.20 to 8.00) were independent risk factors for MI after TIA.ABLE 54 Relative risk of dying from stroke-related cause by mRS at 6 months after stroke onset (OCSP and
SR cohorts combined)320
mRS RR (95% CI)
0–1 1.00 (baseline)
2 1.12 (0.82 to 1.56)
3 1.66 (1.24 to 2.23)
4 1.92 (1.41 to 2.61)
5 2.57 (1.92 to 3.43)T
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONWe assumed that these patients were taking antiplatelet therapy and BP-lowering medication. The risk
for patients not on antiplatelet or antihypertensive treatment was calculated assuming the efficacy of
treatment as seen in RCTs (see Efficacy of medical treatment, below).309–314 We assumed that the fatality
rates associated with MI were, for men, 35% for ages 55–64 years, and 48%, 69% and 82% for age
bands 65–74 years, 75–84 years and ≥ 85 years, respectively; for women, the corresponding rates were
31%, 55%, 77% and 90%, respectively. These values were calculated by the authors from data reported
by Volmink and colleagues.334 Table 56 shows the time to MI from event by age, extracted from the ESS
data report.111
Effect of treatment
The beneficial effects of medical intervention were incorporated by reducing the risks of stroke and MI
in accordance with efficacy values from RCTs and systematic reviews of these treatments (see below and
Table 61, boxes 65–70).309–314
The beneficial effects of surgery on reducing stroke risk in patients with symptomatic carotid stenosis
and the possibility of surgical complications were incorporated using the values from RCTs (details given
below).25,329,335–339 For both medical therapy and surgery it was assumed that any effect would begin in
the time period in which the intervention was initiated.
Carotid endarterectomy would be offered to most patients with 70–99% symptomatic carotid stenosis
(on NASCET criteria)25 and some patients with 50–69% NASCET stenosis. Patients with stenoses of
< 50% (NASCET) or patients in whom the carotid artery had occluded would be offered best medical
therapy only.
The survey of services for patients with suspected TIA or minor stroke in the UK in 2011 showed that the
proportion of patients under secondary prevention treatment, prescribed by their GP/referring doctor after
the index event, was between 41% and 60% in 20% of the responses, between 61% and 80% in 24%,
and between 81% and 100% in 29% (see Table 61, box 71). That is, an overall average of 75% of
patients had already been started on secondary prevention by the referring GP/ED before being seen at
the secondary prevention clinic and before any investigations. We tested the effect of initiating secondary
prevention treatment by the GP prior to hospital referral compared with at stroke clinic assessment in

















< 55 1 1 208 210
55–64 1 1 1 1 1 1 380 386
65–74 1 5 3 3 2 624 638
75–84 6 6 3 4 1 682 702
≥ 85 5 2 2 3 218 230
All 2 (0.09%) 17 (0.78) 12 (0.55) 10 (0.46) 10 (0.46) 3 (0.14) 2112 (97) 2166
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The risks associated with carotid endarterectomy were taken from a systematic review and meta-analyses
of symptomatic patients undergoing a carotid endarterectomy.25 The estimated risk of death was 1.1%
and the risk of non-fatal stroke was 6.0%. This review also showed that the risk of surgery was the same
for patients with TIA and stroke. This work also showed no increase in mortality or complications with
surgery performed early after stable stroke or TIA compared with surgery performed after a time lapse,
although the benefit of surgery was greatest when surgery was performed quickly after TIA or stroke
(in patients with evolving stroke symptoms the risk of surgery was higher).171 A more recent meta-analysis
showed that the pooled absolute risks of stroke and death after urgent surgery were high in patients with
stroke-in-evolution (20.2%, 95% CI 12.0% to 28.4%) and in patients with crescendo TIA (11.4%; 95% CI
6.1% to 16.7%), but without significant difference between early and later surgery in neurologically stable
patients with recent TIA or non-disabling stroke (< 1 week compared with ≥ 1 week, OR 1.2, 0.9 to 1.7,
p = 0.17; < 2 weeks vs. ≥ 2 weeks, OR 1.2, 0.9 to 1.6, p = 0.13).340 We assumed that the risk of a
non-fatal MI following carotid endarterectomy was 0.6%, using data from Barnett and colleagues335
and Bond and colleagues.329 The last UK carotid endarterectomy audit (June 2011) found a rate of
complication at 30 days of 3% for stroke and death, 0.8% for MI, 4% for bleeding postoperatively and
4% for cranial nerve injury (CNI) (Table 57).341
Risks of death through other causes
The risks of death through other causes were taken from UK life tables.342 These values were adjusted to
avoid double counting of deaths through stroke, MI or unsuccessful carotid endarterectomy.Efficacy of medical treatment
We assumed that following a TIA a patient will be prescribed aspirin and dipyridamole, a BP-lowering drug
and a lipid-lowering drug, respectively (see Table 61, boxes 65–70).Assumed efficacy of aspirin
It was assumed that in the initial 3-month period following a TIA, aspirin produced a 23% RR reduction
for stroke (95% CI 13% to 31%).309 After this period it was assumed that efficacy fell to a 15% RR
reduction (95% CI 6% to 33%).310 Patients already taking aspirin at the time of the TIA were assumed to
have a constant 15% risk reduction of stroke throughout the duration of the model. The impact of aspirinABLE 57 Reported complications for endarterectomy in the UK Carotid Endarterectomy Audit Rounds 2 and 3
une 2011)341
Complication Stage complication was experienced
National n (%)
Round 2 Round 3
MI Inpatient 48/6983 (0.7) 40/4971 (0.8)
Bleeding Inpatient 192/6983 (2.7) 177/4971 (4)
CNI Inpatient CNI 136/6983 (1.9) 96/4971 (2)
Overall CNI (inpatient/follow-up) 135/5503 (2.5) 184/4971 (4)
TIA Inpatient 28/5274 (0.5) 26/4971 (0.5)
Stroke Inpatient stroke 75/6983 (1.1) 104/4971 (2)
Stroke at any point by follow-up 109/6151 (1.8) 134/4749 (3)
Stroke within 30 days of operation 83/6135 (1.4) 124/4749 (3)
Death Inpatient death 38/6983 (0.5) 37/4954 (0.8)
Death within 30 days of operation 50/6151 (0.8) 39/4742 (0.8)
Stroke/death Death and/or stroke within 30 days 112/6135 (1.8) 139/4749 (3)
MI/stroke/death Inpatient 128/6983 (1.8) 150/4954 (3)T
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONon MI was assumed to be constant at 27% (95% CI 12% to 39%) calculated using data for combined
antiplatelet therapy from the Antithrombotic Trialists’ (ATT) collaboration.311 A recent systematic review
of antiplatelet therapy for acute ischaemic stroke showed a significant decrease in death or dependency in
patients treated with aspirin 160–300mg daily and started within 48 hours of onset with a maximum
follow-up of 6 months (OR 0.95; 95% CI 0.91 to 0.99). For every 1000 patients treated, 13 patients would
avoid death or dependency [number needed to treat to benefit (NNTB) 79]. The use of antiplatelet therapy
(chiefly aspirin) was associated with a reduction in recurrent ischaemic strokes (OR 0.77; 95% CI 0.68 to
0.86, p < 0.00001, NNTB 140) and increased symptomatic intracranial haemorrhages [OR 1.33; 95% CI
1.1 to 1.62, number needed to treat to harm (NNTH) 574].343 In long-term secondary prevention trials, for
patients with previous MI or TIA/stroke aspirin provided an absolute risk reduction of serious vascular
events (stroke, MI or vascular death) of 1.5% per year (6.69% in aspirin vs. 8.19% in placebo, RR 0.81;
95% CI 0.75 to 0.87, p < 0.00001) and reductions of about one-fifth in total stroke (2.08% vs. 2.54% per
year, p = 0.002). For patients with previous TIA/stroke, aspirin provided an absolute risk reduction (ARR) of
serious vascular events of 1.28% per year (6.78% in aspirin vs. 8.06% in placebo, RR 0.83; 0.75 to 0.93,
p = 0.001) and 0.78% per year in total stroke (3.9% vs. 4.68% per year, RR 0.83; 0.72–0.96, p = 0.01).344Assumed efficacy of dipyridamole
It was assumed that the additional use of dipyridamole added a further 10% RR reduction for stroke
compared with aspirin alone.312 A meta-analysis of dipyridamole plus aspirin versus aspirin alone showed
a HR of 0.82 (95% CI 0.72 to 0.92) for the composite event of vascular death, non-fatal MI and non-fatal
stroke. A proportion of 12.5% of patients in the combined aspirin-plus-dipyridamole group had a primary
outcome event compared with 15.2% in the aspirin group, with a mean length of follow-up of 2.6 years.345
In patients with non-cardioembolic ischaemic stroke or TIA, the use of antiplatelet agents is recommended by
the European Stroke Organisation (ESO) and AHA/American Stroke Association (ASA) guidelines100 to reduce
the risk of recurrent stroke and other CV events. Combined aspirin and dipyridamole or clopidogrel have
been suggested by ESO and SIGN guidelines, as well as aspirin or triflusal (ESO255 and SIGN guidelines103).The assumed efficacy of blood pressure-lowering drugs
Data on the efficacy of BP-lowering drugs were taken from the Perindopril pROtection aGainst Recurrent
Stroke Study (PROGRESS; 2001).313 The relative reduction in non-fatal stroke was 42% (95% CI 29% to
53%) and the relative reduction in non-fatal MI 42% (95% CI 11% to 62%). Analysing the graphs
presented in the PROGRESS trial,313 we assumed that the effects of BP-lowering drugs would not be
seen for 6 months (although clearly the drugs would be pharmacologically active as soon as started).
A systematic review and meta-regression of RCTs showed that lowering BP or treating hypertension
reduced stroke (OR 0.76; 95% CI 0.63 to 0.92), non-fatal stroke (OR 0.79; 0.65 to 0.95), MI (OR 0.79; 0.63
to 0.98) and total vascular events (OR 0.79; 0.66 to 0.95) in patients with prior ischaemic or haemorrhagic
stroke or TIA.346 BP reduction is recommended for both prevention of recurrent stroke and prevention of
other vascular events in persons who have had an ischaemic stroke or TIA and are beyond the first 24 hours
(AHA/ASA100 and ESO guidelines255), and this benefit extends to patients with or without hypertension.
The use of ACE inhibitors and thiazides has been recommended by USA and local clinical guidelines.
(AHA/ASA guidelines 2011,100 SIGN guidelines 2008103).
Adverse effects of giving aspirin, dipyridamole and clopidogrel to patients with haemorrhagic stroke were
estimated from literature data. In a systematic review assessing the effect of antithrombotic or anticoagulant
treatment given to patients with definite intracranial haemorrhage on outcome, for those with any acute
intracranial haemorrhage (1997 patients) or just intraparenchymal cerebral haemorrhage (773 patients), the
OR for death for those allocated to antiplatelet treatment compared with control was 0.85 (95% CI 0.63 to
1.15) and 0.96 (95% CI 0.62 to 1.50), respectively. For recurrent intracranial haemorrhage, in patients with
any acute intracranial haemorrhage or just intraparenchymal cerebral haemorrhage, the OR was 1.00
(95% CI 0.73 to 1.37) and 1.02 (95% CI 0.58 to 1.80) respectively.26,27 The effect of antiplatelet drugs on
death and recurrent intracranial haemorrhage are neutral or favourable for patients with any intracranial
haemorrhage, and less favourable for patients with intraparenchymal cerebral haemorrhage; however, theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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few days. A systematic review of recurrent brain haemorrhage after intracranial haemorrhage showed an
aggregate rate of recurrent haemorrhagic stroke of 2.4% and 8.8% of death per year.28 If aspirin was given
this would result in a 3.7% (95% CI 2.7% to 3.8%) increase in haemorrhagic stroke and a 12.3% (95% CI
7.3% to 15.4%) increase in death.26 An observational study of 417 patients who survived to discharge for an
intracerebral haemorrhage (ICH) described the level of antiplatelet drugs prescribing after haemorrhagic
stroke and the risk of subsequent events.29 There were 14 recurrent ICHs, two of those were on antiplatelet
treatment and all in patients with an initial lobar haemorrhage. HRs associated with antiplatelet exposure
were 1.07 (95% CI 0.24 to 4.84) for recurrent ICH and 0.23 (95% CI 0.03 to 1.68) for ischaemic stroke.The assumed efficacy of lipid-lowering drugs
The efficacy of lipid-lowering drugs has been published by Kaste.314 The relative reduction in stroke was
assumed to be 25% (95% CI 15% to 34%), whereas the reduction in MI was 38% (95% CI 29% to 45%).
Data from the Heart Protection Study347 imply that lipid-lowering drugs have a slow onset of effect.
Accordingly we have assumed that the effects of lipid-lowering drugs were not realised for 12 months from
the commencement of therapy. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels
(SPARCL) study included patients who had had stroke or TIA (including 2% of haemorrhagic stroke) within
1–6 months before study entry, and had no known CHD; those patients were assigned to atorvastatin
80mg (2365 patients) or placebo (2366 patients), with a 5-year absolute reduction in risk of fatal or
non-fatal stroke of 2.2% in patients receiving atorvastatin (HR 0.84; 95% CI 0.71 to 0.99, p = 0.03, number
needed to treat (NNT) 46) and a 5-year absolute reduction in risk of major cardiovascular events of 3.5%
(HR 0.80; 95% CI 0.69 to 0.92, p = 0.002, NNT 29) compared with placebo.348 There was a small increase
in the incidence of haemorrhagic stroke in patients taking atorvastatin (HR 1.68; 95% CI 1.09 to 2.59,
p = 0.02); multivariable regression showed that risk was higher in those patients with haemorrhagic stroke
as the entry event (HR 5.65; 95% CI 2.82 to 11.30, p < 0.001), in men (HR 1.79; 95% CI 1.13 to 2.84,
p = 0.01), with age (10-year increments, HR 1.42; 95% CI 1.16 to 1.74, p = 0.001) and Stage 2 [Seventh
Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC-7)] hypertension at the last study visit before a haemorrhagic stroke (HR 6.19; 95% CI 1.47 to
26.11, p = 0.01).349 A systematic review (including SPARCL study349) showed that statin therapy had a
marginal benefit in reducing subsequent CV events in patients with a previous history of stroke or TIA
(OR 0.88; 95% CI 0.77 to 1.00), with a protective effect for ischaemic stroke (OR 0.78; 95% CI 0.67 to
0.92) and an increased risk of haemorrhagic stroke (OR 1.72; 95% CI 1.20 to 2.46).350 Statin therapy with
intensive lipid-lowering effects now is recommended to reduce the risk of stroke and other cardiovascular
events after TIA or stroke by USA and local guidelines (AHA/ASA guidelines 2011,100 SIGN 2008103).Estimating the combined efficacy of aspirin, dipyridamole, blood
pressure-lowering drugs and lipid-lowering drugs
Few data are available on the combined efficacy of different classes of drugs. It has been hypothesised
that the drugs work independently additively and that a reduction in stroke of 75% can be obtained
(Professor R Collins, University of Oxford, 2005, personal communication).351 Two studies (SOS-TIA122 and
EXPRESS24) have reported very low risks of recurrent stroke for patients in whom a secondary prevention
treatment (mainly antiplatelet and BP-lowering drugs) was started immediately after confirmed diagnosis
of TIA or minor stroke. The EXPRESS study24 assessed the risk of stroke at 90 days before and after
implementing a fast-access stroke prevention clinic at which secondary prevention treatment was started
immediately after the diagnosis was confirmed. The before-and-after study found that, of 1278 patients
presenting with TIA or minor stroke, the 90-day risk of recurrent stroke was 10.3% in phase I [slow:
median time to tablets 20 days, interquartile range (IQR) 8–53 days] and 2.1% in phase II (fast: early
medical intervention, median time to tablets 1 day). The adjusted HR was 0.20 (95% CI 0.08 to 0.49),
independent of age and sex and without any increased hazard of early intervention.24 The SOS-TIA clinic
study assessed the effects of a NV clinic with 24-hour access for patients with symptoms of TIA, with a
short standardised clinical assessment followed by initiation of a comprehensive stroke prevention
programme.122 The programme recommended starting therapy at the time of discharge from clinic or
to family doctors with a loading dose of 300–500mg aspirin, therapy to lower BP and blood lipids171
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONconcentrations with predefined objectives. The recorded 90-day risk of stroke was 1.24% (95% CI 0.72%
to 2.12%), whereas the expected risk from the ABCD2 scores was 5.96%. The risk of all stroke and the
combined outcome of all stroke, MI and vascular death at 1 year as 1.95 (95% CI 1.26 to 3.00) and 2.54
(95% CI 1.74 to 3.72), respectively.122 Thus, the 90-day risks of stroke were 1.24% and 2.10%,
respectively, in these two before-and-after studies.24,122
The cumulative benefit that could be obtained by combining multiple approaches for secondary prevention
of TIA and stroke has been estimated using data from meta-analyses in secondary prevention trials. The
calculated cumulative risk reduction for implementing diet, exercise, aspirin, statins and antihypertensive
therapy was estimated in 80%. Using a 5-year major vascular event rate of 24.4% as seen in LiLAC (Dutch
TIA trial cohort65), the ARR conferred by combination therapy was 20% (NNT 5) and the residual 5-year of
major cardiovascular events after treatment was 5%. At 10 years the ARR, NNT and residual risk for
treatment applied for a decade were 35%, 3 and 9%, respectively.352 An exploratory analysis of the
SPARCL study showed that the patients in whom the 1-month reduction in low-density lipoprotein (LDL)
levels was higher the median (16%) experienced greater reductions in stroke and major cardiovascular
events than those with smaller LDL reductions.353 At each level of LDL reduction, patients with a 1-month
high-density lipoprotein (HDL) above the median (47 mg/dl) had a reduction in the risk of stroke and major
cardiovascular events, as did patients with a systolic blood pressure below the median (138mmHg)
compared with those above the median. An optimal control of LDL, triglycerides, BP and HDL had a
cumulative effect on reducing stroke and major cardiovascular events, with HRs decreasing as optimal
levels of one, two, three or four of these factors were achieved.
We have assumed that the different classes of drugs are independent, and we have used the mean
efficacy estimate for aspirin and dipyridamole. In view of the controversy and lack of new direct data from
clinical trials comparing effect of multiple treatments but those mentioned above, we have conservatively
used the lower 95% CIs for BP- and lipid-lowering drugs. The reduction in stroke and MI assumed for a
patient receiving all drugs are given in Table 58. Note that patients already taking aspirin at the time of
their TIA or minor stroke are assumed to have less risk reduction from continuing to take aspirin than
would a patient starting aspirin de novo – therefore we will apply the data on risk reduction between
3 and 6 months (see Table 58).
As mentioned above, the use of antiplatelet therapy (chiefly aspirin) for acute ischaemic stroke was
associated with increased symptomatic intracranial haemorrhages (OR 1.33; 95% CI 1.10 to 1.62, NNTH
574).343 In long-term secondary prevention trials, the risk of haemorrhagic stroke was increased with aspirin
use in patients with previous TIA/stroke (0.32% for aspirin vs. 0.14% for placebo per year: RR 1.90; 95% CI
1.06 to 3.44, p = 0.03).344 The combination of aspirin plus clopidogrel for long-term secondary prevention of
stroke or other vascular events for 18 months is associated with an increase in life-threatening bleeding with
respect to aspirin alone (2.6% vs. 1.3%).354 Recently, the data safety monitoring board of the SecondaryABLE 58 The assumed efficacy of combinations of medical therapy






Drugs assumed to be affecting
risks
< 3 monthsa 33 27 Aspirin and dipyridamole
3–6 months 25 27 Aspirin and dipyridamole
6 months to 1 year 47 35 Aspirin, dipyridamole and
BP-lowering drugs
≥ 1 year 55 54 Aspirin, dipyridamole, BP- and
lipid-lowering drugs
a Patients already taking aspirin at the time of their TIA are assumed to have less risk reduction than a patient starting
aspirin de novo – we will apply the data from the ‘3–6 months’ row.T
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the study owing to an excess of overall and major non-central nervous system haemorrhagic side effects and
total deaths in the patients receiving aspirin plus clopidogrel compared with aspirin.355Typical structure of neurovascular (stroke prevention)
clinics in the UKWe considered that it was important to base the model on realistic times to first seeing patients after a
TIA or minor stroke, investigation, obtaining results, making decisions about treatment and implementing
those decisions. There was little reliable information on how long these stages took, or the typical
structure of stroke prevention clinics in the UK172,173 and there have been many changes to speed up
assessment of patients with TIA/minor stroke in the last 5 years. In a Scottish National Audit (SSCAS) the
average delay from last TIA or stroke to assessment in the TIA clinic as 3 days, and 94% of the patients
were seen by a specialist within 96 hours of the hotline call in the last Scottish Stroke Care Audit.173
Therefore, we surveyed stroke prevention clinics and imaging services for stroke in the UK using multiple
overlapping ascertainment methods (see Chapter 8).Data from clinical services
Most (97%) centres in the UK had services for patients with suspected TIA or minor stroke, working at least
once a week in 99% of the centres offering this service. On average, patients referred to clinics get an
appointment on the same day in 3% of the responses, on the next day in 32%, after 2–3 days in 25%,
and between 3 and 7 days later in about 20% of the responses. In about 29% of centres, the patient
assessment was nurse led. In approximately 39% of the centres, imaging of the brain or neck arteries took
place on the same day as the patient’s appointment, and at the same hospital, after clinical assessment; in
17% it took place on the same day but before clinical assessment, and in 15% imaging was performed the
next day. CT was routinely used as brain imaging in 84% of centres, with MRI used in 51%; CT was more
often used as initial brain imaging. The majority of centres indicated that results were fed back to the stroke
service on the day of the scanning, and positive results (i.e. haemorrhages) were fed back immediately.Data from imaging services
Patients with suspected TIA/minor stroke usually undergo imaging of the brain and neck arteries before
a doctor’s assessment but on the same day in 16% and 19% of responses, on the same day but after
assessment in 31% and 47%, after assessment but not more than 1 day later in 17% and 13%, and a mixture
in 28% and 20% of responses, respectively. Brain CT was routinely used in 84% of response and brain MR in
51%. When important positive brain imaging results are found, these are fed back immediately to the clinic in
76% of the services. If MRI is required after initial CT, then in 8% of the services the test is performed the
same day, in 7% the next day, in 34% within 1 week, in 47% within 1 month and in 3% in > 1 month. DUS is
used as the first-line carotid and vertebral imaging investigation in 95% of the services; if DUS is not used as
the first-line investigation, CTA is used in 79% of the services, MRA with contrast in 36%, and MRA without
contrast in 14%. Important positive results of imaging neck arteries are fed back immediately to the clinic in
86% of the services. Ninety-four per cent of the centres have facilities for CT scanning in their department or
directorate for patients with suspected TIA or minor stroke and 82% of them have CT scanning available out
of hours. With respect to MRI, 88% of the services have facilities for MRI scanning for patients with suspected
TIA/minor stroke and 19% have facilities for MRI scanning available out of hours. The MR sequences usually
used are T1/T2 in 95% of the services, DWI in 97%, FLAIR in 89% and GRE susceptibility-weighted imaging in
near 50%. For outpatients suspected of TIA/minor stroke during normal working hours, CT is usually
performed immediately in 6% of the services, same day in 53%, next day in 8%, within 7 days in 18%, and
within 2 weeks in 14%. For these presenting out of hours, CT is usually performed immediately in 12% of
centres, 26% the same day, 28% the next day and 23% within 7 days. With respect to MRI, for outpatients
with TIA/minor stroke during normal working hours, the test is usually performed immediately in 2% of
the centres, same day in 21%, next day in 11%, within 7 days in 30%, within 2 weeks in 26% and within
1 month in 11%. For these patients during outside normal working hours, 9% usually perform the test the
same day and 59% of the centres could not perform MRI.173
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DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTIONDevising diagnostic algorithmsWe considered that individual hospitals might have access to different types of brain imaging tests. In some
hospitals only one modality might be available, whereas in others there might be a choice of several.
Furthermore, there might be differences in the availability of some tests, so that the choice of which test to
use might depend on the balance of time of day, day of the week, accuracy, availability and cost. There are
also specific instructions given about timing and use of imaging in NICE and other national guidelines and
incentive tariffs offered in parts of the UK which some centres have already adopted. For these reasons, we
felt it important to model a number of different usages (algorithms) compared with the reference standard.
This would allow individual hospitals to identify the algorithm which most closely resembled their availability
of tests, and see how changing to another algorithm might affect their stroke prevention, costs, or QALYs.
We therefore devised several algorithms to reflect the commonest patterns of practice and also the
investigative pathway suggested in guidelines. These strategies are discussed further in Chapter 11.Four key scanning strategies for testing1. Base-case scenario. Scan all patients presenting to NV clinics with CT for brain imaging immediately;
ultrasound for carotid imaging. (This includes mimics, but excludes retinal events.)
2. Scan all of those who are MR compatible with MR for brain imaging, immediately (CT for non-MR
compatible patients); ultrasound for carotid. (This includes mimics, but excludes retinal events.)
3. Scan all those with ABCD2 score of ≥ 4 (and who are MR compatible) immediately with MR, and the
rest within the first week of symptoms with MR (CT for non-MR compatible patients). (This is the DOH
National Stroke Strategy Guidance; it does not distinguish and therefore includes mimics, but excludes
retinal events.)
4. Exclude probable mimics on clinical grounds (with appropriate use of CT and MR for suspected
diagnosis), scan those presenting at > 5 days after symptoms or on warfarin or with uncertain territory
or with unusual symptoms (and who are MR compatible) with MR, and the rest with CT. [This is the
pragmatic established clinic approach used in stroke prevention clinics led by experienced
senior clinicians.]Sensitivity analysesl Assume that all patients without a visible ischaemic lesion on DWI do not have a TIA/minor stroke
and withhold stroke prevention treatment.
l Use MRA instead of ultrasound in patients undergoing MR.
l Varying the proportion of mimics.Effect of delays occurring before each diagnostic testThe availability of each diagnostic procedure was estimated from the results of the Stroke Clinic and
Imaging Centres Questionnaires (see Chapter 8). We collated the responses and calculated the modal
results. Where the distribution was bimodal we selected the earlier time period. We then translated the
modal range into a time duration, assuming that the mid-point of the modal range was the true delay.
For example, if the mean answer from the Questionnaire was the range between 1 day and 1 week, we
have assumed that the delay would equate to an average of 4 days; if the modal range was between
1 week and 1 month, we have assumed that the delay would be 19 days. Given this methodology, the
estimated times to each event are given in Table 59.NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 59 The times to events as calculated from the responses from the questionnaire (see Appendices 3 and 4)
Time to (from index TIA or minor stroke) Estimated duration since the incident (days)
Appointment 4
Time to initial ultrasound 4
Time to receiving ultrasound results 4
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The last UK carotid endarterectomy audit (June 2011) showed the median number of days from symptom
to operation was 21 (IQR 9–54), with a median number of days from symptom to referral and from
referral to operation of six (IQR 2–20) and 12 (IQR 5–31), respectively. The reasons for delays of > 2 weeks
between index symptom and surgery were delay in referral (41%), delay in patient presenting at GP or
hospital (25%), operation cancellation as unfit or patient choice (18%) and delay in carotid imaging
(13%).341 The survey (see Chapter 8) showed that 60% of patients underwent carotid endarterectomy
within a week of deciding to operate. Table 60 shows the delays between symptoms, referral to clinic and
surgery in the Scottish Stroke Care Audit.173
Further details of the model development and values used are provided in Chapter 11.
Table 61 shows parameters for the model.TABLE 60 Scottish Stroke Care Audit carotid surgery data (from Kerr and colleagues177)
Carotid surgery Before hotline After hotline p-value
No. patients 53 75
Median (range) delay from last TIA/stroke to clinic (days) 19.0 (1–101) 5.5 (1–54) < 0.01
Median (range) delay from clinic to surgery (days) 33.0 (5–101) 13.0 (2–50)
Median (range) delay from last TIA/stroke to surgery (days) 58.0 (6–135) 21.5 (5–82)
175
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Assumptions/sourceBaseline % (n) 95% CI Range
Stroke and associated risk
1. Proportion of actual CV
event in a population with
stroke-like symptoms
60 Chapter 7 (systematic review of
non-CV diagnosis; proportion for
patients who attend TIA clinics)
50 41–60 Chapter 8. UK stroke services survey
(50% of the services)
55 Suggested for the model
2. Proportion of patients with
final diagnostic of minor
stroke among all patients
presenting to NV clinics
(including mimics)
30 (1227/4066) Data from diagnosis in stroke clinics,
SSCAS
17 (650/3862) UHL TIA clinic database
25 Suggested for the model
3. Proportion of patients with
final diagnostic of TIA
among all patients
presenting to NV clinics
(including mimics)
31.3 (1275/4066) Data from diagnosis in stroke clinics,
SSCAS
29 (1137/3862) UHL TIA clinic database
30 Suggested for the model
4. Proportion of haemorrhagic
stroke in patients with final
diagnosis of minor stroke
3.7 (75/2018) ESS data report111
5.0 Expert opinion
1.76 (11/622) Data from diagnosis in stroke clinics
(WGH-SJH)
5. Proportion of haemorrhagic
stroke in patients with final
diagnosis of TIA
0.86 (17/1970) UHL TIA clinics (including TIA and
minor stroke)
0.5 Suggested for the model
6. Proportion of minor
ischaemic stroke among all
patients with final
diagnosis of definite CV
event (i.e. mimics excluded)
42.5 (1227/2882) Data from diagnosis in stroke clinics,
SSCAS
33.0 (650/1970) UHL TIA clinic database
37.8 Suggested for the model
7. Proportion of TIA among
all patients with final
diagnosis of definite CV
event (i.e. mimics excluded)
44.2 (1275/2882) Data from diagnosis in stroke clinics,
SSCAS
57.7 (1137/1970) UHL TIA clinic database
51 Suggested for the model
8. Proportion of patients with
first carotid territory TIA/
minor stroke and
50–99% carotid stenosis
TIA 13.2 (29/220) Koton and Rothwell, 2007132
(OXVASC)
11.5 (41/357) Marquardt and colleagues, 2009356
(OXVASC)
9.2 (157/1713) Amarenco and colleagues, 2012164
10.0 (42/421) ESS data report111 (not clear if just
carotid territory TIAs)
14.1 (163/1151) Ois and colleagues, 2009185
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Assumptions/sourceBaseline % (n) 95% CI Range
TIA or minor stroke 9.5 (139/1461) ESS data report111 (not clear if just
for carotid territory symptoms)
10 HTA report 2006 (LSR data)
9. Proportions of patients
with first TIA/minor stroke
and AF:
TIA 14.7 (42/285) Koton and Rothwell, 2007132
(OXVASC)
14.9 (37/248) Amort and colleagues, 2011156
25.7 (112/435) Sheehan and colleagues, 2010151
TIA or minor stroke 17.6 (121/689) Ois and colleagues, 200881
10.1 (72/711) Selvarajah and colleagues, 2008322
Death after stroke or TIA
10. Proportion of patients
dying of any cause by
30 days after stroke of
all severities
22 (56/251) 17 to 28 Hardie and colleagues, 2005319
(PCSS)
17 (45/262) Coull and colleagues, 20049
20 Suggested for the model
11. Proportion of patients
dying of any cause by:
30 days after TIA 3.2 (n = 927) Kleindorfer 200523
1.34 (n = 612) Lisabeth and colleagues, 2004126
(Texas, USA)
2 Suggested for the model
90 days 0.4 (3/709) Selvarajah and colleagues, 2008322
0.9 (4/443) Sheehan and colleagues, 2010151
1.9 (11/591) Rothwell and colleagues, 200724
2.6 (45/1707) Johnston and colleagues, 20008
3.9 (n = 612) Lisabeth and colleagues, 2004126
5.2 (n = 927) Kleindorfer and colleagues, 200523
Summary estimate 2.68 (134/4989)
12. Proportion of patients
dying of any cause by
6 months after stroke of
all severities (pro_dth)
12.2 (156/1270) ESS data report111
22.6 (1749/7710) OCSP-LSR-IST1 (Slot and
colleagues, 2008320)
32 (79/251) Hardie and colleagues, 2003319
(PCSS)
19.6 (510/2603) Bravata and colleagues, 2003357
13. Proportion of patients
dying of any cause by
6 months after TIA
(pro_dth)
8.3 (n = 927) Kleindorfer and colleagues, 200523
8.1 (87/1079) Bravata and colleagues, 2003357
8.2 Suggested for the model
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Assumptions/sourceBaseline % (n) 95% CI Range
14. Proportion of patients
dying of any cause by
1 year after stroke of all
severities (pro_dth)
17.6 (224/1270) ESS data report111
36.0 (89/251) 30 to 41 Hardie and colleagues, 2003319
(PCSS)
26.4 (688/2603) Bravata and colleagues, 2003357
27.2 (2103/7710) OCSP-LSR-IST1 (Slot and
colleagues, 2008320)
15. Proportion of patients
dying of any cause by
1 year after TIA (pro_dth)
12.3 (n = 927) Kleindorfer and colleagues, 200523
14.8 (160/1079) Bravata and colleagues, 2003357
8.1 (15/184) Dennis and colleagues, 1990358
(OCSP)
9.77 (n = 612) 7.5 to 12.7 Lisabeth and colleagues, 2004126
(Texas, USA)
3.4 (n = 2473) 2.7 to 4.1 Van Wijk and colleagues, 200565
(Dutch TIA trial)
16. Proportion of patients
dying of any cause by
5 years after stroke of all
severities (pro_dth)
27.8 (354/1270) ESS data report111
59 (149/251) 52 to 65 Hardie and colleagues, 2005318
(PCSS)
60 (1561/2603) Bravata and colleagues, 2003357
64.1 (4943/7710) OCSP-LSR-IST1 (Slot and
colleagues, 2008320)
17. Proportion of patients
dying of any cause by
5 years after TIA (pro_dth)
19.4 (n = 2473) 17.9 to 21.0 Van Wijk and colleagues, 200565
(Dutch TIA trial)
31.3 (n = 184) 23.3 to 39.3 Dennis and colleagues, 1990358
(OCSP)
49.6 (535/1079) Bravata and colleagues, 2003357
(TIA)
18. Proportion of patients
dying of any cause by
10 years after stroke of all
severities (pro_dth)
79.0 (197/251) Hardie and colleagues, 2005318
(PCSS)
68.3 (368/539) OCSP cohort (Slot and
colleagues, 2008320)
19. Proportion of patients
dying of any cause by
10 years after TIA
(pro_dth)
42.7 (n = 2473) 41 to 45 Van Wijk and colleagues, 200565
(Dutch TIA trial)
20. Proportion of patients
dying of any cause after
minor stroke:
7 days 0.36 (4/1093) LSR
90 days 1.55 (17/1093)
2 years 6.86 (75/1093)
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Assumptions/sourceBaseline % (n) 95% CI Range
21. Proportion of vascular
death in patients with
stroke of all severities by:
30 days 3.3 (72/2166) ESS data report111
6 months 6.0 (131/2166)
1 year 7.8 (168/2166)
5 years 11.2 (244/2166)
22. Proportion of vascular
death in patients with
minor stroke
7 days 0.18 (2/1093) LSR
90 days 1.1 (12/1093)
2 years 5.1 (56/1093)
23. Proportion of vascular
death in patients with
TIA by:
7 days 0.0 (0/828) LSR
3 months 0.3 (2/711) Selvarajah and colleagues, 2008322
1.08 (9/828) LSR
1.7 (29/1707) Johnston and colleagues, 20008
2 years 3.5 (29/828) LSR
3 years 19.2 (15/78) Falke and colleagues, 1989323
10 years 30.0 (87/290) Clark and colleagues, 2003315
24. Proportion of recurrent
fatal stroke in patients
with initial stroke of all
severities by:
30 days 0.3 (n = 655) 0.0 to 0.7 Dhamoon and colleagues, 2006324
1 year 1.1 (n = 655) 0.3 to 2.0
5 years 2.8 (385/13599) Lee and colleagues, 2011325 (UK
General Practice Research Database)
3.7 (n = 655) 2.1 to 5.4 Dhamoon and colleagues, 2006324
25. Proportion of recurrent
fatal stroke in patients
with initial minor strokea
7 days 0.1 (1/1093) LSR
90 days 0.64 (7/1093)
2 years 2.3 (25/1093)
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Assumptions/sourceBaseline % (n) 95% CI Range
26. Proportion of recurrent
fatal stroke in patients
with initial TIA by:a
7 days 0.0 (0/828) LSR
30 days 0.17 (3/1679) Amarenco and colleagues, 2012164
3 months 0.3 (3/982) Wasserman and colleagues, 2010153
0.48 (4/828) LSR
2.2 38/1707) Johnston and colleagues, 20008
2 years 1.44 (12/808) LSR
10 years 6.8 (20/290) Clark and colleagues, 2003315
Non-stroke
27. Proportion of
non-stroke (all causes) in
population with stroke-
like symptoms (prevNst)
40.0 23–60 Chapter 7 (patients who attend TIA
clinics)
50.0 41–60 Chapter 8. UK stroke services survey
(50% of the services)
45.0 Suggested for the model
28. Proportion of migraine in
population with non-
stroke diagnosis
14.4 4–33 Chapter 7




4.0 1–19 Chapter 7




4.0 3–10 Chapter 7




8.8 Chapter 7 (West Glasgow Stroke
Registry)
32. Proportion of post seizure
in population with non-
stroke diagnosis after
stroke-like symptoms
5.0 3–44 Chapter 7





2.0 1–6 Chapter 7, data from UHL TIA clinics
and diagnosis in WGH stroke clinics











0.05 (2/3862) UHL TIA clinics
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Assumptions/sourceBaseline % (n) 95% CI Range




6.6 2–18 Chapter 7
37. Proportion of all deaths in
patients with non-stroke
diagnosis after stroke-like
symptoms (by 24 months)
6.2 (103/1643) Cameron and colleagues, 2011271
Post scanning and treatment
38. Risk of recurrent stroke in
patients with stroke of all
severities by:
7 days 1.8 (30/1709) Lovett and colleagues, 2004207
30 days 3.1 (n = 9115) 1.7 to 4.4 Mohan and colleagues, 2011168
4.2 (72/1709) Lovett and colleagues, 2004207
90 days 6.6 (113/1709) Lovett and colleagues, 2004207
1 year 11.1 (n = 9115) 9.0 to 13.3 Mohan and colleagues, 2011168
6.1 (133/2166) ESS data report111
5 years 26.4 (n = 9115) 20.1 to 32.8 Mohan and colleagues, 2011168
9.46 (205/2166) ESS data report111
10 years 39.2 (n = 9115) 27.2 to 51.2 Mohan and colleagues, 2011168
39A. Risk of recurrent stroke
in patients with minor
ischaemic stroke by:
7 days 0.36 (4/1093) LSR
4.2 (22/514) 2.4 to 6.0 Chandratheva and colleagues,
2011186
90 days 1.83 (20/1093) LSR
6.3 (50/793) Rothwell and colleagues, 200724
(EXPRESS study)
2 years 5.76 (63/1093) LSR






Bailey and colleagues, 200128 (59%
are recurrent haemorrhages, 15%
uncertain and 26% ischaemic
strokes)4% p.a. –
hospital based
40. Risk of recurrent stroke in
patients with TIA by:
2 days 3.1 (290/9433) Giles and Rothwell, 2007121
7 days 5.2 (406/7830)
30 days 11.2 (n = 927) Kleindorfer 200523
3.17 (n = 612) Lisabeth and colleagues, 2004126
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TABLE 61 Parameters for the model and relative assumptions (‘box’ refers to the number of the left-hand




Assumptions/sourceBaseline % (n) 95% CI Range
2.6 (26/982) Wasserman and colleagues, 2010153
(Ottawa ED)
4.4 (n = 184) 1.5 to 7.3 Dennis and colleagues, 1990358
(OCSP)
6.7 (n = 2285) 5.7 to 7.7 Hill and colleagues, 2004127 (Alberta
ED, Canada)
3 months 3.2 (31/982) Wasserman and colleagues, 2010153
(Ottawa ED)
1.24 (13/1052) Lavallée and colleagues, 2007122
(SOS-TIA study)
8.2 (40/485) Rothwell and colleagues, 200724
(EXPRESS study)
10.5 (180/1707) Johnston and colleagues, 20008
4.05 (n = 612) 2.7 to 5.9 Lisabeth and colleagues, 2004126
9.5 (n = 2285) 8.3 to 10.7 Hill and colleagues, 2004127 (Alberta
ED, Canada)
1 year 4.7 (n = 2473) 3.8 to 5.5 Van Wijk and colleagues, 200565
(Dutch TIA trial cohort)
11.6 (n = 184) 6.9 to 16.3 Dennis and colleagues, 1990358
(OCSP)
14.5 (n = 2285) 12.8 to 16.2 Hill and colleagues, 2004127
(Alberta ED, Canada)
6.62 (n = 612) 4.8 to 9.1 Lisabeth and colleagues, 2004126
5 years 12.0 (n = 2473) 10.7 to 14.7 Van Wijk and colleagues, 200565
(Dutch TIA trial)
29.3 (n = 184) 21.3 to 37.3 Dennis and colleagues, 1990358
(OCSP)
10 years 18.4 (n = 2473) 16.7 to 20.1 Van Wijk and colleagues, 200565
(Dutch TIA trial)
See Chapter 3 with all studies with
risk of recurrent stroke
41. Risk of stroke after TIA
(pooled estimate):a
At 7 days 5.2 (974/12332) 3.9 to 5.9 Chapter 3 (systematic review of risk
of stroke after TIA, random-effects
meta-analysis)At 90 days 6.7 (1567/19769) 5.2 to 8.7
> 90 days 11.3 (927/8699) 7.5 to 16.6
42. Proportion of patients




At 6 months 18.7 (141/754) ESS data report111 (including PACS,
POCS and LACS)
1 year 23.4 (241/1029)
2 years 21.3 (230/1049)
5 years 19.8 (207/1046)
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Assumptions/sourceBaseline % (n) 95% CI Range
b. Stroke of all severities
At 6 months 12.7 (162/1270) ESS data report111
45.0 (3436/7710) Slot and colleagues, 2008320
1 year 22.0 (280/1270) ESS data report111
2 years 21.3 (271/1270)
5 years 19.4 (253/1270)





At 6 months 70.5 (532/754) ESS data report (including PACS,
POCS and LACS)
1 year 63.2 (651/1029)
2 years 59.6 (625/1049)
5 years 56.0 (591/1046)
b. Stroke of all severities
At 6 months 45.0 (573/1270) ESS data report111
33.0 (2525/7710) Slot and colleagues, 2008320
1 year 55.8 (709/1270) ESS data report111
2 years 53.3 (678/1270)
5 years 50.4 (641/1270)
44. Proportion of patients
with stroke or TIA who
suffered MI after the
stroke or TIA (pro_MI)a
Annual risk 0.95 Burns and colleagues, 2011331
(Rochester, just TIA patients)
Annual risk total MI 2.2 1.7 to 2.7 Touze and colleagues, 2005332
(including TIA and ischaemic stroke)
Annual risk for fatal MI 1.1 0.8 to 1.5
Cumulative risk for fatal MI
7 days:
TIA 0.0 (0/828) LSR
Minor stroke 0.0 (0/1093)
90 days:
TIA 0.12 (1/828) LSR
Minor stroke 0.1 (1/1093)
First year 1.3 (29/2166) ESS data report111
5 years 2.5 (52/2166)
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Assumptions/sourceBaseline % (n) 95% CI Range
45. Long-term survival after
any stroke starting with
independent status at
6 months:
Slot and colleagues, 2008320
Independent at 6 months 53 (285) OCSP cohort (n = 539)
56 (1142) LSR cohort (n = 2054)
21 (1098) IST cohort (n = 5117)
Alive at:
1 year 52 (280) OCSP cohort (n = 539)
54 (1101) LSR cohort (n = 2054)
21 (1067) IST cohort (n = 5117)
5 years 39 (209) OCSP cohort (n = 539)
16 (325) LSR cohort (n = 2054)
14 (696) IST cohort (n = 5117)
9 years 28 (149) OCSP cohort (n = 539)
0.04 (1) LSR cohort (n = 2054)
0.5 (28) IST cohort (n = 5117)
10 years 24 (132) OCSP cohort (n = 539)
15 years 13 (68) OCSP cohort (n = 539)
46. Long-term survival after
any stroke starting with
dependent status at
6 months:
Dependent at 6 months 29 (154) OCSP cohort (n = 539)
29 (604) LSR cohort (n = 2054)
52 (2678) IST cohort (n = 5117)
Alive at:
1 year 26 (138) OCSP cohort (n = 539)
26 (543) LSR cohort (n = 2054)
48 (2478) IST cohort (n = 5117)
5 years 13 (69) OCSP cohort (n = 539)
7 (147) LSR cohort (n = 2054)
26 (1321) IST cohort (n = 5117)
9 years 8 (42) OCSP cohort (n = 539)
0 (0) LSR cohort (n = 2054)
0.3 (19) IST cohort (n = 5117)
10 years 7 (39) OCSP cohort (n = 539)
15 years 5 (25) OCSP cohort (n = 539)
184
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DATA REQUIRED TO POPULATE THE MODEL OF STROKE PREVENTION
ABLE 61 Parameters for the model and relative assumptions (‘box’ refers to the number of the left-hand




Assumptions/sourceBaseline % (n) 95% CI Range




Alive and independent 26 (162/629) Rost and colleagues, 2008327
(the FUNC score)
Alive and dependent 29 (183/629)
Death 45 (284/629)
48. Proportion of patients
with a stroke or TIA who
died from all non-stroke
vascular causes
Annual risk 2.1 1.9 to 2.4 Touze and colleagues, 2005332
5 years 6.4 (n = 655) 4.1 to 8.6 Dhamoon and colleagues, 2006324
(just stroke, but > 50% were mild)










Antiplatelet drugs 11.3 (45/398) Wardlaw and colleagues, 200426
HTA report; Keir and colleagues,
200227Control 11.7 (44/375)
OR for death 0.96 0.62 to 1.50
Recurrent intracranial
haemorrhage:
Antiplatelet drugs 6.8 (27/398) Wardlaw and colleagues, 200426
HTA report; Keir and colleagues,
200227Control 6.6 (25/375)
OR for recurrence just in
patients with
intraparenchymal ICH
1.02 0.58 to 1.80 Keir and colleagues, 200227
OR for any recurrent ICH after
any spontaneous ICH
1.0 0.73 to 1.37 Keir and colleagues, 200227
OR for death or dependency 0.68 0.46 to 1.02 Keir and colleagues, 200227
Patients who have a
haemorrhagic stroke and who
were taking aspirin prior to
the haemorrhagic stroke:
Death (OR) 1.27 1.10 to 1.47 Thompson and colleagues, 201030
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Assumptions/sourceBaseline % (n) 95% CI Range
Poor functional outcome
(death or dependent, mRS
score of 4–6) multivariable
adjusted
1.10 0.93 to 1.29 Thompson and colleagues, 201030
Sensitivity and Specificity for Imaging
50. Proportion of patients
with final diagnosis of
minor stroke and lesion
on DWI
67 (165/246) Doubal and colleagues, 2011254
(median time from onset to MR
scan: 12 days)
71 (109/153) Makin and colleagues, 2011253
(abstract UK stroke forum 2011)
76 (39/51) Coutts and colleagues, 200592
60 (137/228) Keir and colleagues, 2004252
69 Suggested for the model
51. Proportion of patients
with final diagnosis of TIA
and lesion on DWI
34.3 (3048/9078) 31.0 to 38.4 9–67 Chapter 6. Systematic review on
DWI-positive lesions in TIAs
(random-effects meta-analysis)
52. Proportion of patients
with final diagnosis of
minor stroke and relevant
ischaemic lesion on CT
53.5 (122/228) Keir and colleagues, 2004252
48.2 (527/1093) Estimates from LSR data set
53. Proportion of patients
with final diagnosis of TIA
and lesion on CT:
Acute lesion 0.0 (0/438) Bonifati and colleagues, 2011158
0.0 (0/274) Sciolla and Melis, 200869
1.2 (8/643) Lavallée and colleagues, 2007122
1.8 (2/109) Chatzikonstantinou and colleagues,
2009138 (lesion compatible with TIA
symptoms)
4.3 (7/161) Förster and colleagues, 2012251
4.0 (13/322) Douglas and colleagues, 200335
7.4 (23/310) Purroy and colleagues, 2010150
8.0 (55/689) Ois and colleagues, 200881
10.0 (16/160) Totaro and colleagues, 2010249
11.5 (95/828) LSR data
Suggested 4 Suggested for the model
Acute and old lesions 27 8–42 Giles and colleagues, 2011210
54. ABCD2 score of < 4
versus ≥ 4 and risk of
stroke in TIA patients:
At 7 days: Chapter 4. For nine studies that
provided stroke risk data at both 7
and 90 days≥ 4 4.7 2.4 to 8.7
< 4 1.6 1.0 to 3.4
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Assumptions/sourceBaseline % (n) 95% CI Range
At 90 days:
≥ 4 8.2 4.7 to 14.0
< 4 2.7 1.5 to 4.7
> 90 days:
≥ 4 17.2 8.8 to 30.9
< 4 5.2 1 to 28.9
55. Predictive value of
ipsilateral lesion on CT for
the prediction of
ipsilateral major ischaemic
stroke (HR + 95% CI)
1.32 0.88 to 1.96 Rothwell and Warlow, 199960
(patients in the medical arm of the
ECST study with 0–99% carotid
stenosis)
56. Visible lesion on brain
imaging and risk of
recurrent stroke:
a. Predictive value of new
lesion visible on CT for the
prediction of ischaemic
stroke (HR + 95% CI)
2.45 1.73 to 3.46 Chapter 5. LSR data analysis
b. Visible lesion on DWI and
risk of recurrent stroke at
7 days after TIA
DWI (+) 7.1 5.5 to 9.1 Giles and colleagues, 2011212
DWI (–) 0.4 0.2 to 0.7
OR for recurrent stroke at
7 days in DWI (+) patients
19.7 9.8 to 39.8
57. Predictive value of carotid
stenosis in the prediction
of ischaemic stroke
(HR + 95% CI)
2.423 1.63 to 3.61 LSR (unadjusted HR, carotid
stenosis dichotomised at 70%)
58. Predictive model for non-
fatal disabling or fatal
stroke up to 2 years (HR)
Chapter 5. Model derived from the
LSR analysis
Model A: Clinical predictors:
Residual neurological signs 1.818 1.2 to 2.6 p = 0.0023
Age 1.031 1.0 to 1.04 p = 0.0004
Previous stroke 1.938 1.3 to 2.8 p = 0.001
Ocular symptoms 0.449 0.1 to 1.0 p = 0.0606
Coronary disease 1.619 1.1 to 2.3 p = 0.0072
continued
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Assumptions/sourceBaseline % (n) 95% CI Range
Model B: Clinical predictors
plus carotid imaging:
Residual neurological signs 1.834 1.2 to 2.6 p = 0.002
Carotid stenosis 1.009 1.0 to 1.01 p < 0.0001
Age 1.029 1.0 to 1.04 p = 0.001
Previous stroke 1.824 1.2 to 2.7 p = 0.002
Ocular symptoms 0.379 0.1 to 0.8 p = 0.023
Coronary disease 1.524 1.0 to 2.1 p = 0.019
Model C: Clinical predictors
plus visible infarct:
Residual neurological signs 1.577 1.0 to 2.3 p = 0.0282
Age 1.030 1.0 to 1.04 p = 0.0006
Previous stroke 1.999 1.3 to 2.9 p = 0.0006
Ocular symptoms 0.509 0.2 to 1.1 p = 0.1184
Coronary disease 1.648 1.1 to 2.3 p = 0.0054
Visible infarct 1.518 1.0 to 2.2 p = 0.0293
Model D: Clinical predictors
plus carotid imaging plus
visible infarct:
Residual neurological signs 1.612 1.0 to 2.4 p = 0.0211
Carotid stenosis 1.009 1.0 to 1.01 p < 0.0001
Age 1.028 1.0 to 1.04 p = 0.0016
Previous stroke 1.898 1.2 to 2.8 p = 0.0016
Ocular symptoms 0.428 0.1 to 1.0 p = 0.0509
Coronary disease 1.552 1.0 to 2.2 p = 0.0146
Visible infarct 1.471 1.0 to 2.1 p = 0.0437
59. Sensitivity and specificity
CT in identifying the
relevant symptomatic
ischaemic lesion:
a. Before 7 days
Sensitivity 0.39 0.16 to 0.69 Brazzelli and colleagues, 200936
(Studies in acute stroke until
12 hours) but hospital admitted
and not minor stroke so of
limited relevance to our population
of interest
Specificity 1.0 0.94 to 1.0
0.98 Suggested for the model
b. After 7 days
Sensitivity 0.39
Specificity 0.30 Suggested for the model
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Assumptions/sourceBaseline % (n) 95% CI Range





Sensitivity 0.99 Suggested for the model
Specificity 0.99
b. Between 7 and 21 days:
Proportion of patients with
minor haemorrhagic stroke
and visible haemorrhage on
CT
25 (2/8) Wardlaw and colleagues, 200426
HTA report (compared with MRI)
Sensitivity 0.40 Suggested for the model
Specificity 0.99
c. After 21 days
Sensitivity 0.19 Suggested for the model
Specificity 0.55
61. Sensitivity and specificity
of MRI scan in minor
ischaemic stroke
(sen_MRhm):
≤ 7 days: Expert opinion: Assumes 67%
minor stroke are DWI positive
< 7 days, drops to 33% at
7–21 days and positive ID of infarct
> 21 days of 20% – for further









62. Sensitivity of MRI scan in
haemorrhagic stroke of all
severities:
a. All sequences performed
correctly
0.83 0.52 to 0.98 Chalela and colleagues, 2007:32 this
information is of limited reliability –
there are no good studies of MR
detection of haemorrhage in minor
stroke, in which there was a
reference standard. Only if include a
T2*/GRE sequence
b. T2* missing 0.50 Suggested for the model
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Assumptions/sourceBaseline % (n) 95% CI Range
63. Sensitivity and specificity
of MR scan in ischaemic
stroke of all severities:
Sensitivity 0.99 0.23 to 1.00 Brazzelli and colleagues, 200936
there are no studies on accuracy of
MR in stroke clinic population so
this estimate is of limited reliability
and it was not used in the model
Specificity 0.92 0.83 to 0.97
64. Specificity of MR scan in
haemorrhagic stroke of all
severities:
1.00 0.95 to 1.00 Chalela and colleagues, 200732
there are no studies on accuracy of
MR in stroke clinic population so
this estimate is of very limited
reliability, particularly because the
Chalela paper32 excluded all non-
strokes. Only if include a T2*/GRE
sequence and then there are some
mimics – suggest reduce specificity
slightly as no good data
Suggested 0.99 Suggested for the model
Risk with or without treatment (medical-surgical)
65. Risk of cardiovascular or





Aspirin and dipyridamole Wardlaw and colleagues, 2006 HTA
carotid imaging report5
RR reduction of risk of stroke (%)
< 3 months 33
3–6 months 25
RR reduction in MI risk (%)




Wardlaw and colleagues, 2006 HTA
carotid imaging report5
6–12 months:
RR reduction in stroke risk (%) 47
RR reduction in MI risk (%) 35
Aspirin, dipyridamole,
BP-lowering drugs and
lipid-lowering drugs: 1 year
and beyond
Wardlaw and colleagues, 2006 HTA
carotid imaging report5
RR reduction in stroke risk (%) 55
RR reduction in MI risk (%) 54
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ABLE 61 Parameters for the model and relative assumptions (‘box’ refers to the number of the left-hand




Assumptions/sourceBaseline % (n) 95% CI Range
66. Risk of death or
dependency (mRS 3–6)








HR for patients treated with
aspirin
0.95 0.91 to 0.99
67. Risk of recurrent
ischaemic/unknown stroke
after acute stroke (up to
6 months):
Aspirin 2.4 (496/20427) Sandercock and colleagues, 2008343
(Cochrane systematic review)
Control 3.1 (636/20423)
HR for patients treated with
aspirin
0.77 0.69 to 0.87
68. Risk of cardiovascular or
CV events after TIA/stroke –
effect of aspirin:
Events per year:
Stroke, MI, vascular death
Aspirin 6.78 (698 events) Baigent and colleagues, 2009344
ATT collaboration
Adjusted control 8.06 (814 events)
Rate ratio 0.83 0.75 to 0.93
Any stroke
Aspirin 3.90 (408 events) Baigent and colleagues, 2009344
ATT collaboration
Adjusted control 4.68 (485 events)
Rate ratio 0.83 0.72 to 0.96
Definitely ischaemic stroke
Aspirin 1.32 (138 events) Baigent and colleagues, 2009344
ATT collaboration
Adjusted control 1.66 (172 events)
Rate ratio 0.79 0.62 to 1.00
Probably ischaemic stroke
Aspirin 3.58 (375 events) Baigent and colleagues, 2009344
ATT collaboration
Adjusted control 4.53 (470 events)
Rate ratio 0.78 0.68 to 0.91
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TABLE 61 Parameters for the model and relative assumptions (‘box’ refers to the number of the left-hand




Assumptions/sourceBaseline % (n) 95% CI Range
69. Risk of cardiovascular or
CV events after TIA/
stroke: effect of BP and
lipid-lowering drugs
Stroke recurrence
BP-lowering drugs 8.9 (689/7779) Rashid and colleagues, 2003346
Controls 11.5 (888/7748)
OR 0.76 0.63 to 0.92
Statins 12.1 (553/4579) Manktelow and Potter, 2009350
Controls 10.8 (501/4645)
OR 0.88 0.77 to 1.00
MI
BP-lowering drugs 3.2 (244/7729) Rashid and colleagues, 2003346
Controls 4.0 (311/7699)
OR 0.79 0.63 to 0.98
Major cardiovascular event
(stroke, MI, vascular death)
BP-lowering drugs 12.8 (993/7729) Rashid and colleagues, 2003346
Controls 16.0 (1232/7699)
OR 0.79 0.66 to 0.95
Statins 22.7 (959/4209) Manktelow and Potter, 2009350
Controls 28.4 (1192/4194)
OR 0.74 0.67 to 0.82
70. Risk of ipsilateral stroke
after TIA/minor stroke in
presence of carotid
stenosis, under medical
treatment in patients who
did not undergo carotid
endarterectomy:
7-day risk, previous TIA/minor
stroke:
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TABLE 61 Parameters for the model and relative assumptions (‘box’ refers to the number of the left-hand




Assumptions/sourceBaseline % (n) 95% CI Range
90-day risk, previous
TIA/minor stroke:




15 months’ risk, previous
TIA/minor stroke:




27 months’ risk, previous TIA/
minor stroke:




39 months’ risk, previous
TIA/minor stroke:








Antiplatelet drugs 37 (1981/5334) Rothwell and colleagues, 200724
EXPRESS; Lavallée and colleagues,
2007122 SOS-TIA study; Wasserman
and colleagues, 2010;153 Hannon and
colleagues, 2010;359 Johnston and
colleagues, 2000;8 Karunarante
and colleagues, 1999266
BP-lowering drugs 45 (641/1440) Rothwell and colleagues, 200724
EXPRESS; Hannon and colleagues,
2010;359 Wasserman and
colleagues, 2010153
Statins 25 (674/2718) Hannon and colleagues, 2010;359
Wasserman and colleagues, 2010153
72. Summary table with values for different outcomes after TIA/minor ischaemic strokeb
Values for different outcomes after TIA-minor ischaemic stroke [%/(n)]:
7 days 90 days 1 year
Recurrence free 94.65 92.35 81.80
Alive and independent 3.35 4.00 5.90
Alive and dependent 1.80 2.10 3.20
MI: alive 0.00 0.05 0.90
continued
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TABLE 61 Parameters for the model and relative assumptions (‘box’ refers to the number of the left-hand




Assumptions/sourceBaseline % (n) 95% CI Range
Death:
a. Recurrent stroke that is
fatal
0.05 (1/1921) 0.57 (11/1921) 2.3
b. Recurrent MI that is fatal 0 (0/1921) 0.1 (2/1921) 1.0
c. Other fatal events 0.15 (3/1921) 0.83 (16/1921) 4.9
All deaths (a + b + c) 0.2 (4/1921) 1.5 (29/1921) 8.2
Total 100 100 100.0
ID, identification; p.a., per annum; SJH, St John’s Hospital; UHL, University Hospital Leicester.
a See summary table (box 72) for outcomes after TIA/minor ischaemic stroke.
b Table includes values for different outcomes extracted from boxes 25 and 26 for the proportion of recurrent stroke that
is fatal after TIA or minor stroke (from LSR for patients with TIA or minor stroke); box 41 for the risk of stroke after TIA
at 7 days, 90 days and 1 year; boxes 42 and 43 for the proportion of patients alive and independent or dependent
after stroke; and box 44 for the risk of MI at 7 and 90 days (LSR) and 1 year (Touze and colleagues, 2005332).
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Chapter 11 Development of the economic modelIntroductionOur review of cost-effectiveness studies (see Chapter 9) demonstrates that no previous research has been
conducted to estimate the cost-effectiveness of MR including DWI and other relevant sequences in
TIA/minor stroke. Most studies of cost-effectiveness of imaging in stroke have either concentrated on
hyper acute disabling stroke or on carotid imaging for carotid stenosis as part of carotid endarterectomy.
There are no clinical trials of diagnostic accuracy or effect on prediction of prognosis of MR including
DWI and other relevant sequences.
Cost-effectiveness is an important criterion to address as TIA and minor stroke are so common that routine use
of MR including DWI and other relevant sequences for diagnosis could be associated with additional resources
and have a high impact on NHS budgets. Taking into account only the direct costs to the NHS associated with
each scan, the budget impact could total £16M per year to scan only the 50% of TIA patients suggested in
recent UK guidelines (i.e. not including the minor strokes and all of the TIA mimics).360 However, if MR is more
accurate in diagnosing TIA and minor stroke than CT, then it is possible that such levels of expenditure would
lead to fewer strokes in future years, thereby generating some cost savings. An estimate at 2001–2 prices
suggested that, for every patient who has a stroke, the cost to the NHS is £15,206 over a 5-year period (at
2009–10 prices, this would equate to £17,850). The estimates also suggest that, with informal care added,
costs would total £29,405 (£34,292 at 2009–10 prices).361
The current lack of a good evidence base means that there is considerable uncertainty over whether the
potential diagnostic and prognostic advantages of MR outweigh any disadvantages. The potential benefits of
MR, including DWI and other relevant sequences, include possible improvement in knowledge regarding the
cause of stroke and therefore changes in treatment, more efficient patient selection for medical secondary
prevention in patients with a proven diagnosis, the avoidance of unnecessary treatment in patients in whom
acute ischaemic TIA/minor stroke was more reliably excluded, and better use of carotid endarterectomy.
The disadvantages include the additional expenditure, the current limited availability of the equipment and
the resulting possibility that additional strokes might occur during the wait for a scan, the failure to make
a positive diagnosis of an ischaemic lesion in up to 66% of TIA patients, and uncertain accuracy for other
stroke-related diagnoses. Further, any strategy that recommends MR over CT would probably have to take
into account subsequent increased MR usage, and such increased use would most likely lead to greater
waiting time and delays to access MR, if no additional resources were allocated to hospitals.
It is clear then that there is a need to examine – using the best available evidence – the cost-effectiveness of
MR including DWI and other relevant sequence usage, relative to existing stroke prevention strategies
currently in use, for example CT. This is considered here through the development of an economic model that
incorporates current knowledge regarding effectiveness and costs of the competing diagnostic strategies.MethodsThe research methods used are guided by the research questions that were previously outlined in the
original study protocol, shown below:
l Is MR including DWI, as well as other relevant structural and blood-sensitive sequences, cost-effective
for the diagnosis and secondary prevention in the majority of patients with TIA or minor stroke
compared with the current alternative of CT brain scanning?195
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DEVELOPMENT OF THE ECONOMIC MODELl What is the cost and cost-effectiveness of increased use of MR including DWI and blood-sensitive
sequences in patients presenting at > 5 days after TIA/minor stroke when CT will not be able to
identify haemorrhage as the cause of stroke reliably?
l If ‘one-stop’ brain and carotid imaging is more cost-effective than individual separate brain and carotid
examinations, in what proportion of patients could a ‘one-stop’ approach be used, and what are the
practical and cost implications?Economic modellingA decision-analytic model was constructed to examine the cost-effectiveness of imaging using MRI
compared with CT for the diagnosis and secondary prevention of stroke in patients with suspected TIA or
minor stroke. The initial diagnostic pathways were modelled using a decision tree, whereas Markov models
at the decision tree end nodes were used to simulate ongoing treatment costs and risks of recurrent
ischaemic stroke, MI and haemorrhagic stroke or death over time. Risk of recurrent stroke was determined
by a number of factors including type of initial event, ABCD score, degree of carotid stenosis, and
appropriate diagnosis and treatment. The model incorporated costs associated with diagnosis and
subsequent implementation of secondary prevention, as well as costs associated with recurrent stroke
and MI. Health state utilities were assigned to the health states used to model recurrent stroke and MI,
allowing both cumulative costs and QALYs to be estimated for a cohort of men and women aged 70 years
(approximating the median age of patients presenting at stroke clinics). The model was initially run over
a time horizon of 20 years (at which point ≈80% of the modelled cohort were dead) owing to limited
availability of data to inform longer-term stroke risks and survival. However, we also carried out sensitivity
analysis to assess the impact of running the model for 30 years in scenarios in which cost-effectiveness
was potentially sensitive to the time horizon.
Important features of the economic model relate to the tree structure used to represent the care pathways
for patients that follow from use of the alternative diagnostic and management strategies, the resulting
health states that develop from these pathways, the probabilities associated with entering and exiting
different states of health from these pathways, and the assumptions that govern patient transitions
between different health states over time.Diagnostic pathways
An outline schematic of the first part of the model is shown in Figure 66. The population cohort enters the
model following arrival at the stroke clinic with a suspected minor stroke or TIA. Patients are initially
triaged based on clinical assessment into those with a probable TIA, those with a probable minor stroke
and probable mimics. At the next stage, using data from the evidence synthesis and expert opinion, the
groups are further categorised according to the proportion of patients with a high ABCD score (ABCD
> 4) and low ABCD score. Following this, the groups are subdivided again into true minor stroke, true TIA
or true mimic, based on the combined findings of clinical assessment and subsequent diagnostic findings.
The combined proportions to this point act as the reference standard for the model, and define the overall
prevalence of different types of event by initial clinical assessment and ABCD score. These proportions do
not vary between the diagnostic arms.
As shown in the model (see Figure 66), a small proportion (5%) of patients initially assessed as probable
minor strokes turn out to be true mimics, and a small proportion of probable mimics (5%) turn out to be
stroke or TIA. For the minor stroke and TIA groups, we also know from epidemiological prevalence data
that a certain proportion of patients in fact turn out to have had a minor haemorrhagic stroke rather than
an ischaemic stroke or TIA.
Following determination of the proportions of different types of stroke event, estimated diagnostic
accuracy parameters of CT and MR are applied to determine the diagnostic outcome by type of event and
time of presentation in the alternative arms of the model. For true mimics, the specificity of CT or MR isNIHR Journals Library www.journalslibrary.nihr.ac.uk




















































































































































































































































































































































































































© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wardlaw et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27
198
DEVELOPMENT OF THE ECONOMIC MODELapplied in the corresponding arms of the model to determine the proportion of patients correctly excluded
as not having had a TIA or minor stroke. Based on consideration of the evidence and clinical opinion,
it was felt reasonable to assume that these proportions would not differ significantly between the CT and
MR arms. Thus a simplifying assumption was made that mimics would not affect the incremental
comparison between MR and CT for diagnosing stroke, over and above their initial impact on scanning
costs. As a result, downstream costs and subsequent events were not explicitly modelled for mimics.
Instead, this group was subsequently modelled to cycle in a simple Markov model, exposed to the
age-specific risk of all-cause mortality obtained from UK life tables.361
For those patients with a true minor ischaemic stroke or TIA, a proportion of each of these groups were
modelled to have an ischaemic lesion identified on MRI or CT, based on best available estimates for these
parameters (see Table 61, boxes 59–62).26,32,36 It was also assumed that ultrasound would be used in
conjunction with both CT and MRI to pick up patients with moderate to high levels of carotid stenosis.
For those patients with a haemorrhagic stroke, estimates of the sensitivity of CT or MR for haemorrhagic
stroke were applied to determine the proportions of patients that would be correctly identified using
the alternative imaging modalities.
In the CT arm, patients identified as having a visible ischaemic lesion (on CT) were confirmed as true-positive
ischaemic strokes and treated appropriately. Those patients considered by the clinician to have a true TIA or
minor ischaemic stroke, but no visible lesion detected by CT, were also modelled to receive secondary
prevention for ischaemic stroke (antiplatelet drugs, statins, antihypertensive medication) based on the
findings of clinical assessment and the assumption that CT findings would not rule out an ischaemic stroke in
this group of patients. In the MR arm of the model, we also assumed that treatment decisions would follow
the same pattern as described above for CT in the first instance. However, we also modelled scenarios in
which treatment for ischaemic stroke in the MR arm was implemented only for those patients identified as
having a visible ischaemic lesion on DWI.
Under the above initial specification, any patients with an undetected haemorrhagic stroke were also
modelled to receive antiplatelet medication, putting them at a slightly elevated risk of suffering a recurrent
haemorrhagic stroke (see Chapter 10).
In the initial base-case analysis, we compared a strategy of immediate CT plus ultrasound compared with
immediate MR plus ultrasound in an immediate presenting cohort. In subsequent analyses we also
assessed the impact of modelling the cost-effectiveness of immediate CT plus ultrasound compared with
immediate MR plus ultrasound in later-presenting cohorts, and considered various delayed MR/ultrasound
imaging strategies for selected groups of patients compared with immediate CT plus ultrasound for all.
This was done to ascertain the potential impact of a MRI policy on waiting times to diagnosis and
treatment. The probability parameters used in the diagnostic component of the model are presented
in Table 62, along with their data sources.
Modelling longer-term outcomes
After their movement through the diagnostic branches of the decision tree, the long-term outcomes for
simulated patients were modelled using one of three Markov models: one for ischaemic stroke that accounted
for level of carotid stenosis, one for haemorrhagic stroke and one for mimics. In all three it was assumed that all
patients would start in a recurrence-free state. The models then cycled on a variable cycle length to simulate
stroke recurrence over time, accounting for time since the initial event, ABCD score and level of carotid stenosis.Group with no stenosis
For patients with a TIA or minor ischaemic stroke (without carotid stenosis), longer-term outcomes were
modelled using four basic health states: ‘recurrence free’, ‘alive following a MI’, ‘alive and independent’
(following a recurrent stroke), ‘alive and dependent’ (following a recurrent stroke) and death (Figure 67).
Within each cycle of the model, patients in the recurrence-free state could either have a recurrent stroke
(with an associated risk of death), have a MI (again with an associated risk of death), or die from otherNIHR Journals Library www.journalslibrary.nihr.ac.uk





Proportion of patients classified as
probable minor stroke, based on
clinical assessment
0.250 0.170 to 0.300 Scottish stroke care audit; UHL TIA clinic
database (see Table 61, box 2)
Proportion of patients classified as
probable TIA, based on clinical
assessment
0.300 0.290 to 0.320 Scottish stroke care audit; UHL TIA clinic
database (see Table 61, box 3)
Proportion of patients classified as
probable mimics, based on clinical
assessment
0.450 0.400 to 0.600 Systematic review of non-CV diagnosis; UK
stroke services survey (see Table 61, box 27)
Proportion of suspected minor
stroke and TIA patients with low
ABCD2 score
0.580 0.550 to 0.650 Amarenco and colleagues, 2009180 and other
literature, Chapter 4
Proportion of probable mimics with
low ABCD score
0.650 0.600 to 0.700 Josephson and colleagues, 2008;135 Sheehan
and colleagues, 2009,183 see Chapter 4
Proportion of patients with probable
minor stroke ultimately identified as
true minor stroke
0.950 0.400 to 0.980 Clinic audit data, literature review – see
Chapter 7; expert opinion
Proportion of patients with probable
TIA ultimately identified as true
minor TIA
0.950 0.400 to 0.980 As for minor stroke
Proportion of patients with a true
minor stroke with final diagnosis of
haemorrhagic stroke
0.037 0.018 to 0.050 ESS111 (see Table 61, box 4); previous HTA
reports
Proportion of patients with final
diagnosis of TIA with minor
haemorrhagic stroke
0.0050 0.0050 to 0.0086 UHL TIA clinic database (see Table 61, box 5),
literature
Specificity of CT (for excluding
mimics)
0.98 Brazzelli and colleagues, 2009;36 Wardlaw and
colleagues, 2004;26 Chapter 10, (see Table 61,
boxes 59 and 60)
Specificity of MR (for excluding
mimics)
0.99 0.95 to 1.00 Chalela and colleagues, 2007;32 Chapter 10
(see Table 61, boxes 61 and 64) (assumed
clinical assessment would prevent treatment
of false-positive lesions)
Sensitivity of CT for ischaemic stroke 0.39 0.16 to 0.69 Brazzelli and colleagues, 2009;36 Chapter 10
(see Table 61, box 59)
Sensitivity of MR for ischaemic stroke: Chapters 6 and 10, literature, expert opinion
(see Table 61, box 61)
< 7 days 0.63
7–21 days 0.27
> 21 days 0.10
Sensitivity of CT for haemorrhagic
stroke:
Wardlaw and colleagues, 200426 (see Table 61,
box 60)
< 7 days 0.99
7–21 days 0.40
> 21 days 0.19
Sensitivity of MR for haemorrhagic
stroke
0.83 0.52 to 0.98 Chalela and colleagues, 2007;32 Chapter 10 (see
Table 61, box 62); assumes T2*/GRE sequences
UHL, University Hospital Leicester.
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FIGURE 67 Markov model for ischaemic stroke.
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27causes (based on UK life table data). The risk of stroke was based on data derived from the systematic
review meta-analysis and other available literature (see Table 61), and was estimated by ABCD score
(< 4; ≥ 4) and time since initial TIA or minor stroke (see Chapter 4). Upon correct diagnosis, cycle risk
estimates were adjusted downwards by converting them to average rates and then applying RR estimates
associated with the implementation of appropriate secondary prevention5 before converting them back to
risks. In estimating the cycle risks of stroke for patients with normal stenosis, the cumulative risks by ABCD
score were adjusted downwards from those reported in Table 63, to account for the fact that proportions of
the cohorts, upon which these estimates were based, had tight stenosis incurring higher risks (see below).
A proportion of recurrent strokes were modelled to be fatal (within 30 days), whereas the remainder were
modelled to progress to one of the survivor states (‘alive and independent’ or ‘alive and dependent’). The
proportions moving to each of these states were determined from the estimated relative proportions of
patients experiencing each of these outcomes at 1 year after an initial TIA or minor stroke, obtained from
the systematic review (see Table 61, boxes 10 and 72).9,318 Alternatively, patients in the recurrence-free
state could experience a MI following their TIA or minor stroke (see Table 61, box 44),331,332 and again
a proportion of these events were modelled to be fatal, with the remainder transiting to the ‘alive
following a MI’ state for the next cycle of the model.
The Markov model was constructed to work on a variable cycle length: on a weekly basis for the first four
cycles then on a monthly basis thereafter. This was done to enable modelling of the elevated risk of stroke
immediately after TIA of MR, which then attenuates over time. A simplifying assumption of the model was
that for those patients experiencing a stroke (fatal or otherwise) the expected costs associated with acute
phase were all incurred in the model cycle in which the event occurred. Further, for fatal strokes, it was
assumed that these patients would receive zero QALYs from the time of event until actual time of death.
Patients transiting to the ‘alive following a MI’ state, were modelled to remain at risk of stroke based on the
same risk factors described above, and they were also exposed to an inflated risk of non-stroke related
mortality, based on UK life tables362,363 with stroke deaths removed364 and a standardised mortality ratio of
2.68 associated with previous MI.365 Patients in the ‘alive and independent’ and ‘alive and dependent’ states
following a recurrent stroke were modelled to be at an inflated risk of death from all causes, based on UK
life tables and the standardised mortality ratio of 2.72 associated with previous stroke.366 Although further
stroke deaths were not explicitly modelled for these patients, we applied the risk of recurrent stroke for
patients in the ‘alive and independent’ state, based on risk factors and time since previous event, and used
this to model the expected transitions form ‘alive and independent’ to ‘alive and dependent’ over time.TABLE 63 Risk of recurrent stroke by time since initial event in (assumed untreated) patient groups
Time from initial event
ABCD score Stenosis level
70–99%< 4 ≥ 4 50–69%
7 days 0.016 0.047 0.08 0.13
1 month – – 0.12 0.19
3 months 0.027 0.082 0.18 0.29
1 year 0.052 0.172 – –
1.25 years – – 0.25 0.39
2.25 years – – 0.3 0.45
3.25 years – – 0.33 0.48
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DEVELOPMENT OF THE ECONOMIC MODELGroup with tight stenosis
A proportion of the cohort presenting with a TIA or minor ischaemic stroke were also modelled to have
moderate (50–69%) or high (70–99%) levels of carotid stenosis. Overall, 10% of patients with a low
ABCD score and TIA or minor ischaemic stroke were modelled to fall into one of these categories,
compared with 14% of patients with a TIA/minor stroke and high ABCD score.132,180 These patients were
assumed to be split between the high and moderate stenosis states in a ratio of 6 : 4.5
The recurrent stroke risk for this group of patients was modelled to be significantly higher (pre-endarterectomy)
as compared with patients with normal stenosis (see Table 63).5 Separate model states (see Figure 67) mirroring
the states for patients with normal levels of stenosis were used for this purpose. Within the model patients
with tight stenosis were modelled to receive an endarterectomy upon stage of diagnosis, which, if successful,
reduced their risk of subsequent stroke to 2.3% per year.5 However, the procedure itself was modelled to bring
with it 1.1% mortality risk and a 6.0% risk of non-fatal stroke.5 The cumulative risks of recurrent stroke – by
time, ABCD score and level of stenosis – that were used to derive transition probabilities to populate the
Markov model for patients with a TIA or minor ischaemic stroke, are presented in Table 63. Note that the
estimated risks for patients with low and high ABCD scores but normal stenosis were adjusted downwards to
reflect the impact of removing the modelled 10% and 14% (respectively) of patients with moderate/high levels
of stenosis within these groups.
Group with haemorrhagic stroke
Figure 68 shows the structure of the model for the group classified as having ‘true haemorrhagic stroke’.
These patients again start the model in the recurrence-free state, and face the risk of a recurrent stroke
(haemorrhagic or ischaemic) or death due to other causes. Those who experience a recurrent haemorrhagic
stroke can move to one of three health states: ‘alive and independent’, ‘alive and dependent’ or dead as a
result of fatal haemorrhagic stroke. The risks here were again based on data from the systematic review
(see Chapter 10, Table 61, boxes 39 and 47).28,21 Modelling here accounts for the possibility of MRI or CT
missing some true cases of haemorrhagic stroke. In this situation patients are modelled to receive secondary
prevention for ischaemic stroke, including with antiplatelet drugs, which slightly increases their risk of a
recurrent haemorrhagic stroke. In the base-case analysis the RR was assumed, based on available data,
to be 1.15, and this estimate was subjected to sensitivity analysis.
Group with a stroke mimic
Figure 69 describes the pathways for those individuals identified as having had a stroke mimic. As
mentioned previously, the evidence review identified no clear evidence suggesting that the sensitivity
and specificity of CT and MRI for detecting different types of mimic would vary significantly. Thus, no
additional direct health benefit, associated with the use of one diagnostic technique over the other,
was modelled in this subgroup of the patient population. Modelling for this group was restricted to the
application of all-cause mortality, although the direct costs associated with imaging were included.
Strategies to be compared
Nine key scanning strategies were assessed in the modelling exercise. In the base-case analysis we
compared a strategy of MRI plus ultrasound for all versus CT plus ultrasound for all in a cohort of patients
presenting within a few hours of the initial event. Further scenarios assess were devised to assess the
cost-effectiveness of various delayed MRI imaging strategies and immediate imaging strategies in later
presenting cohorts:
1. Base-case scenario: Immediate MR for brain imaging plus immediate ultrasound for carotid imaging
compared with immediate CT for brain imaging plus immediate ultrasound for carotid imaging in an
immediate presenting cohort (within the first few hours of the event).
2. Delayed MRI and delayed ultrasound for those with ABCD score of < 4 (otherwise immediate MRI plus
immediate ultrasound) compared with immediate CT plus immediate ultrasound for an immediate
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FIGURE 69 Markov model for stroke mimics.
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DEVELOPMENT OF THE ECONOMIC MODEL3. Immediate ultrasound for all, but delayed MRI for those with an ABCD score of < 4 and immediate MRI
for those with an ABCD score of ≥ 4 compared with immediate CT plus immediate ultrasound for an
immediate presenting cohort.
4. Immediate MR for brain imaging plus immediate ultrasound for carotid imaging compared with
immediate MR for brain imaging plus immediate MRA for carotid imaging compared with immediate
CT for brain imaging plus immediate ultrasound for carotid imaging compared with immediate CT for
brain imaging plus CTA for carotid imaging (in immediate presenting cohort).
5. Repeat of scenario 1 but with secondary prevention for ischaemic stroke implemented in only the MRI
arm for those with a visible lesion on MR brain imaging (immediate presenting cohort).
6. Secondary prevention implemented for all but MRI and ultrasound delayed for those with a low ABCD
score (immediate presenting cohort).
7. Scenario 1 repeated for a cohort of patients presenting 7 days after the initial event.
8. Scenario 1 repeated for a cohort of patients presenting 21 days after the initial event.
9. Scenario 3 repeated for a cohort of patients presenting 7 days after the initial event.Key assumptions of the modelling exercise
The following key assumptions apply to all component parts of the model:
(a) The time horizon of the model is 20 years. All patients entering the model are 70 years of age. The
total number of model cycles is 243; the first four cycles are weekly and the remainder are monthly,
giving 15 cycles in the first year, and 228 over the remaining 19 years. The impact of adopting a
30-year time horizon is also explored through sensitivity analysis.
(b) Patients remain recurrence free within the first 24 hours after imaging.
(c) Baseline risks of stroke in the model are assumed to represent risks in patients not being treated with
statins and antiplatelet drugs.
(d) It is assumed that all patients who enter the model prior to imaging are not being treated with statins
and antiplatelet drugs. After imaging the RR of recurrence is lower for those patients treated with
these drugs.
(e) The risk of stroke recurrence is initially high [particularly in the first 7 days but then the risk attenuates
over time (see Table 63)]. In the longer term, we assume a constant risk of stroke as per the risk for the
last observed interval.
(f) The utility of the health outcomes after TIA, minor stroke, stroke and MI can be appropriately
measured with six distinct health states: (1) good health with no further stroke recurrence after
treatment (secondary prevention successful); (2) alive and independent after stroke recurrence;
(3) alive and dependent after stroke recurrence, (4) alive after MI; (5) alive after being diagnosed as
a non-stroke (no subsequent stroke events explicitly modelled); and (6) death, either due to fatal
stroke or fatal MI or other causes.
(g) In the base case it is assumed that patients present to the NV clinic for assessment within a few hours
of symptom onset (cost-effectiveness in later presenting cohorts is also modelled).
(h) The use of CT or MRI within the diagnostic pathway does not differentially influence the proportion of
patients with stroke mimics that receive the correct diagnosis, and as such subsequent treatment and
outcomes for these patients is assumed to be the same between the MRI and CT arms of the model.
(i) Secondary prevention for ischaemic stroke is implemented after imaging unless a final diagnosis of
haemorrhagic stroke or mimic is received.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The prevalence and epidemiological data that are used in the model were discussed earlier in the report
and the sections above. This section presents studies that are relevant for the assumptions made regarding
the costs of imaging, the length of hospital stay associated with recurrent stroke and MI, the costs per
bed-day, the costs of treatment, and the utility of health states.Cost-analysis studies
Luengo-Fernandez and colleagues3 conducted a review of the costs of stroke using patient-level data. They
considered the cost of CV diseases within developed country settings. A total of 120 studies were reviewed;
these included studies that estimated the costs for stroke and ischaemic stroke, TIA, subarachnoid
haemorrhage and cardiovascular diseases (CVDs). Costs were subdivided into direct medical costs, direct
non-medical costs and productivity costs. The direct medical costs included cost of diagnostics, inpatient care,
outpatient care, day care, community health care and medication. The direct non-medical costs included social
care, social benefits, travel costs and out-of-pocket care. The productivity costs included loss of productivity
owing to illness, death and caregiving. Most of the studies provided information on inpatient costs (93%).
However, only 40% of studies reported costs of diagnostic tests, 46% reported on costs of outpatient care,
34% on costs of medication, 40% on social care costs, and only 8% on travel costs. Only 14 studies reported
estimates of productivity costs, with six studies reporting on productivity costs owing to illness, and a further
eight studies reporting productivity cost due to informal caregiving. In terms of reporting of costs of different
subgroups, some of the studies (39%) reported costs in relation to event severity and about 31% reported on
event type. After having accounted for heterogeneity across studies, the authors compared costs in 71 studies,
and converted the costs adjusting for purchasing power parity (PPP), expressing the costs in US dollars (US$) at
2006 prices. The mean cost of stroke was estimated at US$28,252 (median US$19,635) per patient for a
follow-up period of 12 months. On average, the mean cost from all was estimated at US$19,018 per patient
and the median cost was estimated at US$14,571 per patient. Not surprisingly, cost estimates were influenced
by the length of the follow-up period; the mean cost for the groups with follow-up duration of between
3 and 6 months was estimated at US$10,216, whereas for the groups with follow-up duration of between
6 and 12 months it was US$16,973. The authors also noted that costs were significantly higher if charges
were used to value resources rather than actual unit costs (US$27,835 vs. US$16,102). The types of stroke
(overall stroke or ischaemic stroke) and study design (prospective, retrospective or RCT) did not influence the
cost estimates. One of the important contributions of the study was comparison across countries and regions.
There was a 10-fold difference in cost of stroke or ischaemic stroke between the studies conducted in Eastern
Europe and those in the UK or the USA. The mean cost estimate for the studies in Eastern Europe was
US$2822 (range from a minimum of US$468 to a maximum of US$11,523), US$9438 (US$1448–25,909) in
countries in Western Europe other than the UK, US$22,377 (US$5206–107,860) in the UK, and US$28,253
(US$7309–146,149) in the USA. This study therefore reinforces the importance of only considering UK sources
of costs data in stroke, as our cost-effectiveness modelling is conducted from the NHS perspective.
Grieve and colleagues367 reported significant differences in cost of acute stroke care across Europe. They
conducted a study using patient-level data from 13 centres (hospitals) in 13 different countries across
Europe, and analysed costs using multiple regression. The acute stroke costs were found to vary due to
differences in clinical practices, such as the number of brain scans undertaken, the average staff time per
contact and LOS. The study367 found that the mean number of scans ranged from 0.24 (at a centre in
Lithuania) to 2.35 (at a centre in Austria). The average number of scans carried out at the participating UK
centre was reported to be 0.98 and the mean LOS was 35.4 days (median 20 days), the highest among
centres included in the study. There were no patients referred to the rehabilitation unit from this hospital.
The shortest LOS was found to be for a centre in Spain (8.8 days), despite the fact that this centre was not
referring patients to a rehabilitation unit. The study367 provided estimates of the predicted mean total cost
(adjusting for purchasing power parity) of acute care for patients of > 74 years of age. For those who
survived the stroke, the mean total cost, in 1995 prices, were estimated at $PPP5202 (95% CI $PPP 4423 to
$PPP 6120) in Austria (highest), $PPP 3250 (95% CI $PPP698 to $PPP3916) in the UK, and $PPP240205
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DEVELOPMENT OF THE ECONOMIC MODEL(95% CI $PPP210 to $PPP274) in Latvia. This again highlights the importance of using UK data sources for
costing the acute care received after stroke.Cost data relevant for the economic modelling
In light of the above discussion, this section considers the cost data that are available in the literature for
different brain imaging modalities, and acute and ongoing care for stroke. Owing to the large number of
estimates that are available from different studies, we attempt here to provide justification for the sources
that are used in the economic modelling.Cost of imaging in stroke
Table 64 shows the range of UK estimates that are available for the costs of CT, MRI, ultrasound, MRA
and CTA. The cost estimates of CT imaging provided by Wardlaw and colleagues26 used a bottom-up
(microcosting) approach, i.e. measurement of actual resource use (staff time, expenditures and
depreciation of capital equipment, consumables, apportionment of overheads were applied for stroke
patients). The 2004 study26 is the most detailed microcosting study available on the costs of CT imaging;ABLE 64 Costs of imaging (UK studies)
Type of
imaging Description Cost (£) Source, price year
Inflated to
2009–10 (£)
CT Bottom-up approach 60.00 Author estimates, 2010 60.00
MRI Bottom-up approach 111.62 Author estimates, 2010 111.62
CT One area – no contrast 101.00 DOH, 2011368 101.00
MRI One area – no contrast 174.00 DOH, 2011368 174.00
Ultrasound
< 20 minutes
Unknown 55.00 DOH, 2011368 55.00
Ultrasound Bottom-up approach 54.08 Wardlaw and colleagues, 20065 61.95
DUS Unknown 120.00 DOH, 2011368 120.00
MRA Bottom-up approach 189.00 Wardlaw and colleagues, 2006,5 2004 216.58
CTA Bottom-up approach 122.94 Wardlaw and colleagues, 2006,5 2004 140.85





Teaching – out of
hours
79.35 92.54
RDGH – normal 81.02 94.48
RDGH – out of hours 126.30 147.29
UDGH – normal 69.47 81.02
UDGH – out of hours 72.57 84.63
CT 85.00 Saka and colleagues, 2009,369 2005 96.00
MRI 400.00 Saka and colleagues, 2009,369 2005 450.00
RDGH, rural district general hospital; UDGH, urban district general hospital.T
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addition, estimates are available for normal working hours provision and out-of-hours provision. However,
the estimate apply to only three Scottish hospitals, so they may not be generalisable to other settings
within Scotland or other countries of the UK. An alternative set of estimates are available from the NHS
reference costs;368 these are likely to include similar elements of resource use, but they are not specifically
estimated for stroke patients. The Saka and colleagues369 estimates are in the middle of the range of those
produced for CT by Wardlaw and colleagues.26 However, their costs for MRI are much higher than other
estimates and are based on data from one hospital trust in London; it is unclear why the estimate is much
higher than others, as no detail is provided of the costing methods used. Owing to the availability of cost
estimates for other techniques (MRA, CTA), for reasons of generalisability, and to enable comparisons with
other interventions where NHS reference costs are widely used, the model uses the NHS reference costs
for CT, MRI, MRA and CTA.368 For patients considered to have suffered a minor ischaemic stroke we
assume that they would receive appropriate blood pressure medication (£20.73) per annum), a generic
statin (£24.31 per annum), aspirin (£11.05 per annum) and dipyridamole (£37.31 per annum) (British
National Formulary, November 2012;370 www.medicinescomplete.com/mc/bnf/current). We assume that
patients diagnosed as having suffered a minor haemorrhagic stroke do not receive antiplatelet drugs.
Cost of stroke careAcute phase
The costs of stroke can be divided into those incurred in the acute phase (initial hospitalisation) and also
those incurred following discharge from hospital (chronic phase), including rehabilitation and ongoing
care. The model uses cost estimates of stroke in the acute phase, based on LOS data reported by Wardlaw
and colleagues26 combined with 2009–10 unit prices. The data reported by Wardlaw and colleagues26
were chosen as they provide LOS by stroke type (haemorrhagic and ischaemic) and severity (whether
patients end up independent or dependent), which is consistent with the model structure. The LOS
parameters used, along with other available estimates, are provided in Table 65. LOS in hospitals is
important too, as it is the main cost driver in any estimates of costs associated with the acute phase of
stroke. Table 65 shows the available estimates from UK and European studies. Given the wide variation in
the estimated costs of stroke in the acute phase, we assessed the sensitivity of model findings to variation
in this parameter.
Chronic phase
Table 66 shows that there is a vast amount of information available on the health-care costs of stroke in
the UK. In addition, there are now estimates of the social care costs and wider societal costs (productivity
losses and informal care time). It can be difficult ,therefore, to gauge which estimates are the most suitable
for estimating health service costs incurred beyond the initial acute phase. However, limited UK data are
available regarding costs incurred beyond the initial hospitalisation. Among the alternative sources, the
estimate of Lovibond and colleagues377 is chosen (£559 per 3 months) as the most suitable UK-based
source, based on earlier individual patient data reported by Youman and colleagues.361 As we were unable
to obtain ongoing costs by level of dependence following stroke, this estimate was applied to patients in
both the ‘alive and independent’ and the ‘alive and dependent’ states. However, an allowance was made
for likely increased primary care costs for those alive and dependent.207
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ABLE 65 Length of hospital stay for TIA and different stroke types
Type of stroke Description LOS (days) Range Source/comments
TIA Days in stroke unit 1.8 ± 2.2 Dodel and colleagues,
2004371
Days in ICU 0.3 ± 2.2
Days in regular ward 7.2 ± 5.6
Ischaemic Days in stroke unit 2.5 ± 2.9 Dodel and colleagues,
2004371
Days in ICU 0.6 ± 2.6
Days in regular ward 7.0 ± 5.6
Haemorrhagic Days in stroke unit 1.1 ± 2.4 Dodel and colleagues,
2004371
Days in ICU 5.4 ± 4.8
Days in regular ward 5.4 ± 6.8
TIA Days in stroke unit 9.4 ± 5.2 Epifanov and colleagues,
2007,372 Germany –
HospitalDays in ICU
Days in regular ward 11.1 ± 6.5
Ischaemic Days in stroke unit 10.2 ± 5.3 Epifanov and colleagues,
2007,372 Germany –
HospitalDays in ICU
Days in regular ward 11.1 ± 8.9
Haemorrhagic Days in stroke unit 11.9 ± 6.0 Epifanov and colleagues,
2007,372 Germany –
HospitalDays in ICU
Days in regular ward 16.9 ± 15.5
Independent
haemorrhagic
Average LOS, alive and
independent – after
haemorrhagic stroke




Average LOS, alive and
independent – after
ischaemic stroke




Average LOS, alive and
dependent – after
haemorrhagic stroke




Average LOS, alive and
dependent – after
ischaemic stroke
17.9 Wardlaw and colleagues,
200426
Ischaemic Average LOS in general
medicine
12.8 Christensen and Munro,
2008373
Average LOS in geriatric
ward
41.1
In readmission average 13.2
Haemorrhagic Average LOS in general
medicine
12.2 Christensen and Munro,
2008373




In re-admission average 11.6
Stroke
(ICD10 – 160–66)
Average LOS SLSR register,
South London, UK
34.4 (SD 30.2) Saka and colleagues,
2009,369 2005
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ABLE 65 Length of hospital stay for TIA and different stroke types (continued )
Type of stroke Description LOS (days) Range Source/comments
LOS by quality of care
Stroke
(WHO criteria)
Median LOS 13 Svendsen and colleagues,
2009,374 Denmark
Median LOS for 75–100%
of the quality of care
fulfilled
9 (IQR 5–20)
Median LOS for 0–24% of
the quality of care fulfilled
26 (IQR 13–58)
Stroke Mean LOS high
non-compliance to
guideline






LOS by Rankin score
TIA
Rankin score 0–2 LOS days 9.5 ± 5.1 Dodel and colleagues,
2004371
Rankin score 3–6 LOS days 8.1 ± 6.2
Ischaemic
Rankin score 0–2 LOS days 10.6 ± 4.4 Dodel and colleagues,
2004371
Rankin score 3–6 LOS days 9.8 ± 6.1
Haemorrhagic
Rankin score 0–2 LOS days 14.0 ± 2.9 Dodel and colleagues,
2004371
Rankin score 3–6 LOS days 11.6 ± 6.3
Mean Median
mRS 0 LOS days 9 17 Dawson and colleagues,
2007376
mRS 1 LOS days 17 25
mRS 2 LOS days 37 44
mRS 3 LOS days 64 58
mRS 4 LOS days 90 79
mRS 5 90 81
LOS for patients who died after stroke
Death from
haemorrhagic
Average LOS for those who
died after haemorrhagic
stroke




Average LOS for those who
died after ischaemic stroke
14 Wardlaw and colleagues,
200426
ICU, intensive care unit; SLSR, South London Stroke Register.
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TABLE 66 Costs of stroke care
Type of






Initial stroke 3-month costs 9630 Lovibond and
colleagues, 2011377





3-month costs 559 Lovibond and
colleagues, 2011377






HRG 1998–99, NHS DOH,
2001






HRG 1998–99, NHS DOH,
2001













Calculated on mean LOS
51 days, rehab cost £763







Calculated on mean LOS
14 days, rehabilitation cost





TIA Cost per admission with
LOS 9.4 (in stroke unit, ICU
and regular wards)






(Mean in £) 1926 2002 price
Calculated cost/day 258
Ischaemic Cost per admission with
LOS 10.2 (in stroke unit,
ICU and regular wards)






(Mean in £) 2,220 2002 price
Calculated cost/day 274
Haemorrhagic Cost per admission with
LOS 11.9 (in stroke unit,
ICU and regular wards)






(Mean in £) 3240 2002 prices
Calculated cost/day 342
TIA Cost per admission with
LOS 9.4 (in stroke unit, ICU
and regular wards)
€3020 Dodel and colleagues,
2004371
2421
(Mean in £) 1926 2002 prices
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TABLE 66 Costs of stroke care (continued )
Type of







Ischaemic Cost per admission with
LOS 10.2 (in stroke unit,
ICU and regular wards)
€3480 Dodel and colleagues,
2004371
2790
(Mean in £) 2220 2002 prices
Calculated cost/day 274
Haemorrhagic Cost per admission with
LOS 11.9 (in stroke unit,
ICU and regular wards)
€5080 Dodel and colleagues,
2004371
4072
(Mean in £) 3240 2002 price
Calculated cost/day 342





Ischaemic Average cost per initial
hospitalisation




on ISD Scottish Health
Services 2006 prices
Haemorrhagic Average cost per initial
hospitalisation




on ISD Scottish Health
Services 2006 price
Ischaemic Average cost per
re-admission




on ISD Scottish Health
Services 2006 prices
Haemorrhagic Average cost per
re-admission




on ISD Scottish Health
Services 2006 prices
Ischaemic Average cost per 12
months’ survivor initial
hospitalisation
10,893 (SD ± 15,767) Christensen and
Munro, 2008373
11,713
Total hospital cost for
survivors – 12 months
14,263 (SD ± 18,736) Cost estimates based
on ISD Scottish Health
Services 2006 price
15,336
Haemorrhagic Average cost per 12
months’ survivor initial
hospitalisation
18,026 (SD ± 24,218) Christensen and
Munro, 2008373
19,383
Total hospital cost –
12 months
21,493 (SD ± 26,222) Cost estimates based
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TABLE 66 Costs of stroke care (continued )
Type of



















Cost of an acute event:
mild stroke – 3 months






Cost of an acute event,
moderate stroke –
3 months






Cost of an acute event,
severe stroke – 3 months








Cost of an acute event,
fatal stroke – 3 months












Cost per IP day, large
general hospital
217 296.62
Cost per IP day, long-stay
hospital
116 158.56
HRG, Health Resource Group; ICU, intensive care unit; IP, inpatient.
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DEVELOPMENT OF THE ECONOMIC MODELCosts associated with myocardial infarction
For patients experiencing a MI, the initial acute costs associated estimated based on a previous UK study
by Palmer and colleagues,378 inflated to the 2010 prices. This estimate was chosen for its applicability to
the NHS setting. Palmer and colleagues,378 reported hospital costs associated with MI, and so we added
the cost of three GP visits to this estimate to allow for increased primary care costs in the period following
MI. Beyond the first 3-month period, we applied the cost estimate of £141 per 3-month period.377 For fatal
MI we applied the cost of £2225 taken from NICE Technical Appraisal 90.379 The costs applied to MI
events are provided in Table 67.ABLE 67 Costs of treatment and care for MI
Event Cost (£) Source
Non-fatal MI
(first-year hospital costs)
5437 Palmer and colleagues, 2004378 (hospital costs inflated to 2010 prices plus
allowance made for increased primary care costs) (see Table 61, box 80)
Cost of fatal MI 2225 NICE TA 90 review, 2010379
Post MI costs (3 monthly) 141 Lovibond and colleagues, 2011377T
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Post and colleagues380 reviewed literature published between 1996 and 2000 to obtain estimates of
health state utilities associated with stroke. They reviewed 23 studies where different methods were used
to assess the utility of stroke outcomes, such as the visual analogue scale (VAS), Health Utilities Index (HUI)
and the EQ-5D. They found the values/utilities elicited by the time trade-off (TTO) approach to be generally
lower than standard gamble (SG) utilities. The utility scores derived from studies using the VAS or HUI
instrument were found to be lower than those derived from studies using the TTO to directly elicit values
for stroke outcomes. Utility weights for major stroke assigned by healthy participants were fairly similar to
those assigned by patients at risk of stroke, however stroke survivors were found to have assigned higher
utilities. The estimated mean utility for survivors of major stroke was found to be 0.32 when the EQ-5D
was used, whereas it was 0.41 when the TTO was used to directly elicit values, and was 0.72 based
on the SG method. For survivors of minor stroke, the mean utility score was 0.72 using the TTO method
directly, and was 0.71 based on EQ-5D responses. These values were similar to those elicited from healthy
persons. The study by Post and colleagues380 also suggests that variation in the description of minor
stroke or major stroke influences the reported utilities. It needs to be noted here that estimates based
on the SG method are generally less favoured than TTO values owing to the possibility of loss aversion
and probability transformation causing upwards bias, whereas estimates derived using the VAS are less
likely to be accepted for decision-making because the method does not incorporate the concepts of
choice and opportunity cost. QALY weights derived from TTO scores are most frequently used to inform
decision-making in the UK, with a particular emphasis placed on using weights based on EQ-5D responses
scored using the UK TTO-based tariff.381
There is an increasing interest in transforming scores from disease-specific instruments to utility-based scores
to allow the estimation of QALYs. Mortimer and colleagues382 attempted to assess whether or not it would
be possible to transform stroke-specific measures of health status to a preference-based measure suitable
for generating QALY weights. Based on repeat responses of 859 patients suffering a stroke, they used a
regression approach to derive an empirical transformation of three commonly used descriptive measures of
health status in stroke – the NIHSS, the Barthel Index (BI), and the Short Form questionnaire-36 items (SF-36)
– to the Assessment of Quality of Life (AQoL) (a generic preference-based measure). They showed that a
transformation to the SF-36 could explain ≈72% of the observed variation in AQoL scores and concluded
that the BI and SF-36 could be adequately transformed to preference-based values suitable for generating
QALYs. Of course the SF-36 can also be used to generate utility weights in the UK setting through the
Short Form questionnaire-6 Dimensions (SF-6D) (Brazier and colleagues383).
Rivero-Arais and colleagues384 studied the association between mRS scores and preference-based EQ-5D
values using individual responses to both instruments collected as part of a large observational study
(OXVASC). Their study sample included 1283 stroke and TIA patients recruited between April 2002 and
March 2007 who were followed up at 1, 6, 12 and 24 months. The authors used ordinary least squares
regression to predict the preference-based EQ-5D score (based on the UK TTO tariff) from mRS scores, and
also tested a method whereby multinomial logistic regression (MLogit) was used to predict responses to
each EQ-5D question. Although both methods predicted the mean EQ-5D utility estimate reasonably well,
they also underestimated the uncertainty surrounding the observed mean EQ-5D score. They concluded
that their derived algorithms should not replace prospective collection of utility data.
Van Exel and colleagues385 examined the direct relationship between a conventional clinical scale of
functional status (BI) and the EQ-5D. Their findings were based on data collected in the Netherlands on
598 stroke patients who were followed over the period of 6 months. Using simple linear regression, they
found evidence for a significant relationship between these measures suggesting an EQ-5D score of –0.25
for patients with a BI of 0, and a 0.05 increase in the EQ-5D score for each point increase on the BI. With
this algorithm, independent patients (BI 20) received a utility weight of 0.75, which corresponded with the
age-/sex-specific EQ-5D population reference score for their sample.213
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DEVELOPMENT OF THE ECONOMIC MODELAlthough the above discussions highlight that a number of sources and approaches are available for
estimating utility weights associated with stroke, more relevant estimates are available in the form of
EQ-5D-based weights derived from the responses of individuals enrolled in the IST trial.112 Dorman and
colleagues’ study used the EuroQoL386 to measure the health status for 867 UK patients enrolled in the IST.
The utility values were 0.31 (95% CI 0.29 to 0.34) for dependent health states, 0.71 (95% CI 0.68 to 0.74)
for independent health states and 0.88 (95% CI 0.84 to 0.92) for fully recovered health states. Table 68
shows the mRS states and TTO weights based on EQ-5D updated with CLOTS trial data. These values were
used in previous modelling studies by Wardlaw and colleagues5,26 and are importantly based on the
responses of UK patients. We have now been able to update this with unpublished more recent EQ-5D data
from UK stroke patients enrolled in the CLOTS trial115 (see Chapter 10, Table 61, boxes 99 and 100,
and Table 68).ABLE 68 Modified Rankin Scale health states and TTO tariff weights based on EQ-5D (or other)
mRS CLOTS EQ-5D Prior data from IST/LSR (EQ-5D)
Alive and independent
n 1468 84
Mean (SD) 0.71 (0.24) 0.78
95% CI 0.70 to 0.72 0.73 to 0.82





Mean (SD) 0.20 (0.34) 0.34
95% CI 0.19 to 0.21 0.23 to 0.45




Further, the CLOTS trial estimates are based on the responses of a larger sample of patients, and as
such these values are used in the model. The values are very similar to those reported by Dorman and
colleagues,112 with the exception of a lower value obtained for patients alive and dependent following
a stroke. Table 69 below summarises available utility estimates for states of health associated with stroke
and TIA.
Model parameters
In light of the above discussions, the final cost and utility values incorporated in the economic model are
all provided in Table 70. The following chapter presents the results of the economic evaluation based
on the model described here.NIHR Journals Library www.journalslibrary.nihr.ac.uk




(95% CI) Source Comment
Recovered
(mRS score 0)








Recovered 0.88 (0.80 to 0.96) Dorman and colleagues, 2000112
using LSR data
Used LSR cohort
Independent 0.74 (0.69 to 0.79)
Dependent 0.38 (0.29 to 0.47)
Recovered 0.88 (0.84 to 0.92) Dorman and colleagues, 2000112
using IST data
Using IST data
Independent 0.71 (0.68 to 0.74)
Dependent 0.31 (0.29 to 0.34)
Fully recovered 0.88 (0.84 to 0.92) Wardlaw and colleagues, 20065 Used Dorman and
colleagues, 2000112
Independent 0.71 (0.68 to 0.74)
Dependent 0.31 (0.29 to 0.34)
Alive and independent
(mRS 0–2)








Minor stroke 0.87 Tseng and Lin, 2007,388 a review
of literature
A review of literature used





0.75 Tseng and Lin, 2007,388 a review
of literature
O’Brien and Gage, 2005,390
based on study published
in 1996




TIA 0.90 Tseng and Lin, 2007,388 a review
of literature
Matchar and colleagues,
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(95% CI) Source Comment
mRS 0 0.80 (0.80 to 1.00) Earnshaw and colleagues,
2009291
Used study by Stahl and
colleagues, 2003392
mRS 1 0.80 (0.8 to 0.95)
mRS 2 0.65 (0.68 to 0.9)
mRS 3 0.50 (0.45 to 0.65)
mRS 4 0.35 (0.10 to 0.40)
mRS 5 0.20 (0.00 to 0.32)
mRS 6 0.00
Ranking category
Mean and range Stahl and colleagues, 2003392 Used Tengs and Lin, 2003389
0. No symptoms 0.90 (0.85 to 0.95)
1. No disability 0.79 (0.70 to 0.90)
2. Slight disability 0.68 (0.35 to 0.90)
3. Moderate disability 0.65 (0.20 to 0.90)
4. Moderate to severe
disability
0.40 (0.12 to 0.54)
5. Severe disability 0.32 (–0.20 to 0.54)
Death 0
Utility value in MI
Non-fatal MI 0.76 (SE 0.018) Goodacre and colleagues,
2004393
Post non-fatal MI 0.76 (SE 0.018)
SE, standard error.
ABLE 70 Cost and utility parameter values used in the economic model
Parameter Value Low High Data source and assumptions
Cost parameters
Cost of drugs per month: British National Formulary no. 62 (September
2011)370
Pravastatin 40 mg £26.01
Aspirin 75 mg £0.31
Cost of CT (per scan) £101 £69 £108 DOH, 2011368 (CT one area, no contrast;
average + lower and upper quartile)
Cost of MRI (per scan) £174 £117 £199 DOH, 2011368 (MRI one area, no contrast;
average + lower and upper quartile)
Cost of ultrasound
(< 20 minutes)
£55 £40 £65 DOH, 2011368 (average + lower and upper
quartile)
Cost of CTA for detecting
stenosis
£116 £88 £126 DOH, 2011368 (average + lower and upper
quartile)
Cost of MRA for
detecting stenosis
£213 £180 £249 DOH, 2011368 (average + lower and upper
quartile)
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ABLE 70 Cost and utility parameter values used in the economic model (continued )
Parameter Value Low High Data source and assumptions
Cost per inpatient day £297 £180 £372 Wardlaw and colleagues, 2004;26 PSSRU,
2010394 (large general hospital inpatient cost,
inflated to 2009–10 prices)





31.3 days Wardlaw and colleagues, 200426





32.9 days Wardlaw and colleagues, 200426
LOS – alive and
independent
haemorrhagic stroke
11.6 days 8 days 19.6 days Wardlaw and colleagues, 200426





24.5 days Wardlaw and colleagues, 200426
LOS – death with
haemorrhagic stroke
53.0 days Wardlaw and colleagues, 200426
LOS – death ischaemic
stroke
33.3 days Wardlaw and colleagues, 200426
Cost of endarterectomy £3697 £2658 £4466 DOH, 2011368 (average plus lower and upper
quartile for HRG QZ04Z) (see Table 61, box 92)
Annual health care costs
following stroke (alive
and dependent)
£2648 Lovibond and colleagues, 2011;378 PSSRU,
2010394 (hospital costs £2236 + primary care




£2236 Lovibond and colleagues, 2011377
Initial MI costs (first
3 months)
£5437 Palmer and colleagues, 2004378 (hospital costs
inflated to 2010 prices plus allowance made for
medication and primary care costs) (see Table 61,
box 80)
Three-month health-care
cost following a MI (after
first 3 months)
£141 Lovibond and colleagues, 2011377
Cost of fatal MI £2225 NICE, 2010379
Utility – alive and
dependent following
stroke
0.20 CLOTS data (see Table 61, box 99)
Utility – alive and
Independent following
stroke
0.71 CLOTS data (see Table 61, box 100)
Utility recurrence-free 0.88 Wardlaw and colleagues, 20065 (see Table 61,
box 101)
Utility alive following MI 0.76 0.712 0.939 Goodacre and colleagues, 2004393 (see Table 61,
boxes 93 and 94)
Utility for non-stroke 0.88 Assumed same as for recurrence-free state
HRG, health resource group; PSSRU, Personal Social Services Research Unit.
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This chapter presents the results of the health-economic modelling study, the methods and developmentof which were described in the previous chapter.
The nine key scenarios that were examined are again outlined below. Each scenario was analysed for a
cohort of 70-year-old men and women over a 20-year time horizon:
1. Base-case scenario Immediate MRI for brain imaging plus immediate ultrasound for carotid imaging
compared with immediate CT for brain imaging plus immediate ultrasound for carotid imaging in an
immediate presenting cohort (within the first few hours of the event).
2. Delayed MRI and delayed ultrasound to within 7 days for those with ABCD2 score of < 4 (otherwise
immediate MRI plus immediate ultrasound) compared with immediate CT plus immediate ultrasound
for an immediate presenting cohort.
3. Immediate ultrasound for all, but delayed MRI to within 7 days, for those with an ABCD2 score of
< 4 and immediate MRI for those with an ABCD2 score of ≥ 4, compared with immediate CT plus
immediate ultrasound for an immediate presenting cohort.
4. Immediate MRI for brain imaging plus immediate ultrasound for carotid imaging compared with
immediate MRI for brain imaging plus immediate MRA for carotid imaging, compared with immediate
CT for brain imaging plus immediate ultrasound for carotid imaging, compared with immediate CT for
brain imaging plus CTA for carotid imaging (in immediate presenting cohort).
5. Repeat of scenario 1 but with secondary prevention for ischaemic stroke implemented only in the MRI
arm for those with a visible lesion on MRI brain imaging (immediate presenting cohort).
6. Secondary prevention implemented for all but MRI and ultrasound delayed to within 7 days for those
with a low ABCD2 score (immediate presenting cohort).
7. Scenario 1 repeated for a cohort of patients presenting 7 days after the initial event.
8. Scenario 1 repeated for a cohort of patients presenting 21 days after the initial event.
9. Scenario 3 repeated for a cohort of patients presenting 7 days after the initial event.Model analysisThe model was first of all run deterministically for the nine main scenarios identified above. Following this,
distributions were placed on parameters for which sufficient sampling information was available, and PSA
was conducted for scenarios 1, 7 and 8. The results of the PSA should be treated with caution, as data
limitations and availability precluded the estimation of distributions for a number of key model inputs.
Given the difficulty in assigning appropriate distributions to key diagnostic parameters, no formal value of
information analysis was conducted. However, cost-effectiveness acceptability curves were derived based
on the joint uncertainty surrounding those parameters for which distributions were assigned.
The parameters included in the PSA were the unit cost estimates for scanning, all of the utility estimates,
the RR reductions associated with appropriate treatment, and the standardised mortality ratios associated
with stroke and MI survival. Gamma distributions were fitted to cost parameters, beta distributions were
assigned to utility weights, and log-normal distributions were assigned to the RRs and standardised
mortality ratios. The results of the modelling study are presented in the following sections.Cost-effectiveness findings
Table 71 shows the mean cost and QALY estimates associated with each strategy for each of the nine
scenarios defined above. In each case, the more costly strategy is compared with the next less costly
alternative to estimate the incremental costs and incremental QALYs. Where strategies are more costly and
less effective an alternative strategy, they are said to be dominated. Where a strategy is more costly and219
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wardlaw et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.






1. Base case: immediate MRI and ultrasound vs. immediate CT and ultrasound
CT + ultrasound 3262 – 8.7313 – –
MR+ ultrasound 3340 77 8.7308 –0.0005 Dominated
2. Delayed MRI and ultrasound for those with an ABCD2 score of < 4 vs. immediate CT and ultrasound
CT + ultrasound 3262 – 8.7313 – –
MR+ ultrasound 3388 126 8.7122 –0.0191 Dominated
3. Immediate ultrasound but delayed MRI for those with ABCD2 score of < 4, vs. immediate CT and ultrasound
CT + ultrasound 3262 – 8.7313 – –
MR+ ultrasound 3340 78 8.7296 –0.0017 Dominated
4. Immediate MRI vs. immediate CT vs. immediate MRA vs. immediate CTA
CT + ultrasound 3262 – 8.7313 – –
CT + CTA 3323 61 8.7313 0.0000 Dominated
MR + ultrasound 3340 77 8.7308 –0.0005 Dominated
MR +MRA 3498 235 8.7308 –0.0005 Dominated
5. Only implement drug treatment for those with detected visible ischaemic lesion in MR arm
CT + ultrasound 3262 – 8.7313 – –
MR+ ultrasound 3669 407 8.5872 –0.1440 Dominated
6. Immediate implementation of drug treatments but delayed MRI and ultrasound for those with a
low ABCD2 score
CT + ultrasound 3262 – 8.7313 – –
MR+ ultrasound 3366 103 8.7214 –0.0098 Dominated
7. Immediate MRI vs. immediate CT for cohort presenting 7 days after initial event
CT + ultrasound 3230 – 8.7425 – –
MR+ ultrasound 3296 66 8.7442 0.0017 39,509
8. Immediate MRI vs. immediate CT for cohort presenting > 21 days after initial event
CT + ultrasound 3233 – 8.7419 – –
MR+ ultrasound 3296 63 8.7442 0.0023 27,751
9. Immediate ultrasound but delayed MRI for those with an ABCD2 score of < 4, vs. immediate CT + ultrasound in
the cohort presenting at 7 days after the initial event
CT + ultrasound 3230 – 8.742489 – –
MR+ ultrasound 3297 67 8.742934 0.000445 150,020
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represents the additional cost incurred per QALY gained over the next less costly alternative.
The base case considers the cost-effectiveness of immediate MRI plus ultrasound for patients presenting at
stroke prevention clinics within a few hours of symptom onset compared with a policy of immediate CT
imaging plus ultrasound. The results of this analysis indicate that a strategy of immediate MRI and
ultrasound is very unlikely to be considered cost-effective in the immediate presenting cohort. It works out
to be more expensive, primarily because the cost of MRI is higher than the cost of CT imaging and, if
anything, slightly less effective. The small difference in effectiveness is caused by a slightly greater
proportion of patients with haemorrhagic stroke being missed with MRI in the early presenting cohort, and
therefore receiving inappropriate antiplatelet treatment. This is a consequence of the lower sensitivity of
MRI for haemorrhagic stroke when used within a few hours of the event. At the same time, as individuals
without any visible lesion detected on imaging are modelled to receive secondary prevention for ischaemic
stroke, and ultrasound is used to detect carotid stenosis in both arms of the model, there is no benefit
associated with the higher sensitivity of MRI for identifying ischaemic stroke. Hence the estimated increase
in cost of £77 and the marginal QALY loss of 0.0005.
In scenario 2, MRI with ultrasound is again compared with immediate CT imaging with ultrasound.
However, in this scenario selective imaging is used in the MRI arm, with MRI and ultrasound being delayed
by 7 days for patients who have a low ABCD score; i.e. a score of < 4. This strategy also turns out to be
less cost-effective than the CT option and also less cost-effective than when immediate MRI and
ultrasound is carried out for all. The incremental costs are higher (£126) and the QALY losses greater
(0.0191) with this selective delayed MRI strategy as a significant proportion of patients with a low ABCD2
score still have high or moderate levels of carotid stenosis, which without timely diagnosis and surgery puts
them at high risk of suffering a recurrent stroke. The effect of delaying diagnosis and surgery for these
patients translates into higher mean incremental costs and QALY losses.
In strategy 3, instead of delaying both ultrasound and MRI by 7 days, the strategy tests the effect of
delaying only imaging with MRI for those with a low ABCD2 score (i.e. < 4). This strategy still costs
more than the CT base strategy and there is still a loss of QALYs, although to a lesser extent than with
strategy 2. However, the strategy is still dominated by CT plus ultrasound for all, i.e. it is more costly and
no more effective, and it is therefore less cost-effective. This is a consequence of patients with a low
ABCD2 score, but no stenosis, still having some degree risk for recurrent stroke that would benefit from
immediate secondary preventative treatment.
A further option for the immediate presenting cohort is considered in scenario 4. Here we simultaneously
compare four potential immediate imaging strategies: (1) CT for brain imaging plus ultrasound for carotid
imaging; (2) CT plus CTA for carotid imaging; (3) MRI plus ultrasound for carotid imaging; and (4) MRI plus
MRA for carotid imaging. The results for this scenario indicate that CT plus ultrasound dominates all of the
other strategies. These results are based on the assumption that neither CTA nor MRA is any more
sensitive for picking up carotid stenosis than ultrasound,83,84 whereas both are more costly.
Scenario 5 explores the impact of assuming secondary preventative drug treatment for ischaemic stroke
is implemented only for patients with an identified ischaemic lesion on DWI in the MRI arm of the model
(whereas treatment decisions remain unchanged from the base case in the CT arm). Under this scenario,
the MRI strategy is less costly than it otherwise is owing to saving on the cost of treatment, but it is also
significantly less effective owing to an increased incidence of recurrent stroke in the 66% of TIAs and 30%
of minor strokes patients with no visible ischaemic lesion on DWI. It remains dominated by the CT strategy.
A final scenario explored for the immediate presenting cohort, is one where it is assumed that preventative
drug treatment for ischaemic stroke is implemented for all patients upon presentation, but that brain and
carotid imaging are delayed for the group with a low ABCD2 score in the MRI arm of the model
(scenario 6). CT plus ultrasound remains the favoured strategy under this scenario.221
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RESULTS OF HEALTH ECONOMIC MODELLINGStrategies 7–9 assess the cost-effectiveness of MRI strategies compared with immediate CT plus ultrasound
in cohorts of patients presenting 7 days or 21 days after the initial event. Considering immediate MRI plus
ultrasound compared with immediate CT plus ultrasound in the cohort presenting at 7 days (scenario 7),
the MRI strategy turns out to be more costly but also slightly more effective than CT, with an ICER of
£39,509 per QALY. The increase in effect observed for MRI under this scenario results from its superior
sensitivity for haemorrhagic stroke (the sensitivity of CT for haemorrhages declines over time), whereas
the sensitivity of MRI for ischaemic stroke also declines over time, this has no impact on outcomes as
treatment for ischaemic stroke is still modelled to be implemented in this scenario unless an alternative
cause of symptoms is identified. Similar results are obtained when the same strategies are compared in a
cohort of patients presenting 21 days after the initial event. However, the QALY gains associated with the
MRI strategy are higher in this case as a result of a further decline in the sensitivity of CT for haemorrhagic
stroke and, as such, the ICER for MRI plus ultrasound is improved (£27,751 per QALY gained).
A final scenario explored for the cohort of patients presenting 7 days after the initial event was a repeat
of scenario 3: delayed MRI for those with a low ABCD2 score but immediate ultrasound for all compared
with immediate CT plus immediate ultrasound for all (scenario 9). Under this scenario the QALYs are again
higher with MRI but less so than when immediate MRI is implemented for patients presenting at 7 days.
This is, again, due to some patients with a low ABCD2 score and no carotid stenosis still being exposed
to a risk of ischaemic stroke that would benefit from appropriate treatment. In this instance, however,
the point estimate for the ICER is £159,325, which is well above the usually acceptable range of
£20,000–30,000 per QALY gained.
The QALY differences shown in Table 71 are primarily driven by small changes in the relative incidence of
recurrent stroke between the arms of the models. To illustrate this, Table 72 presents the modelledTABLE 72 Modelled cumulative incidence of stroke recurrence over a 20-year time horizon, expressed as the






recurrence of stroke QALYs
Incremental
QALYs
1. Base case: immediate MRI vs. immediate CT; immediate DUS for both
CT + ultrasound 0.172593 – 8.7313 –
MRI + ultrasound 0.172673 0.00007976 8.7308 –0.0005
2. Delayed MRI for those with an ABCD2 score of < 4 vs. immediate CT
CT + ultrasound 0.172593 – –
MRI + ultrasound 0.175366 0.002773 8.7122 –0.0191
3. Immediate ultrasound but delayed MRI for those with an ABCD2 score of < 4, vs. immediate CT + ultrasound
CT + ultrasound 0.172593 – 8.7313 –
MRI + ultrasound 0.172657 0.00006453 8.7299 –0.0014
5. Only implement drug treatment for those with detected visible lesion in MRI arm
CT + ultrasound 0.172593 – 8.7313 –
MRI + ultrasound 0.198549 0.0260 8.5872 –0.1440
7. Immediate MRI vs. immediate CT for cohort presenting 7 days after initial event
CT + ultrasound 0.171517
MRI + ultrasound 0.171223 –0.00029 8.7442 0.0017
8. Immediate MRI vs. immediate CT for cohort presenting > 21 days after initial event
CT + ultrasound 0.171621
MRI + ultrasound 0.171223 –0.0004 8.7442 0.0023
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over the 20-year time horizon. In each instance, the strategy associated with the QALY gains is also associated
with a lower cumulative recurrence of stroke. In the base case of immediate CT and ultrasound compared
with immediate MRI and ultrasound (in the immediate presenting cohort), for example, the difference in
recurrent stroke incidence between the strategies is very small, and would equate to an increase of one more
haemorrhagic stroke for every 12,500 patients imaged using the MRI strategy (1/0.00007976).
Sensitivity analysis
Table 73 presents the results of one-way sensitivity analysis on several key variables for the base-case
model specification: immediate MRI plus ultrasound compared with immediate CT plus ultrasound in an
immediate presenting cohort.
TABLE 73 Sensitivity analysis for immediate MRI plus ultrasound vs. immediate CT plus
Scenario/strategies Cost (£) Incremental costs (£) QALYs Incremental QALYs ICER
A. Immediate CT vs. immediate MRI with changes to the cost of the MRI scan
a. Cost of MRI: base case – £174
CT + ultrasound 3262 – 8.7313 – –
MRI + ultrasound 3340 77 8.7308 –0.0005 Dominated
b. Cost of MRI – £90
MRI + ultrasound 3255 – 8.7308 – –
CT + ultrasound 3262 8 8.7313 0.0005 16,740
c. Cost of MRI – £101 (making MRI the same cost as CT)
CT + ultrasound 3262 – 8.7313
MR + ultrasound 3265 2 8.7308 –0.0005 Dominated
B. Immediate CT vs. immediate MRI with changes to the sensitivity of CT for detecting haemorrhagic stroke
Sensitivity of CT for detecting haemorrhagic stroke: Base case – 0.99
a. CT + ultrasound 3262 – 8.7313 – –
MRI + ultrasound 3340 77 8.7308 –0.0005 Dominated
b. Sensitivity of CT for detecting haemorrhagic stroke: 0.3925 (equivalent to the estimated value at 7 days)
CT + ultrasound 3271 – 8.7296 – –
MRI + ultrasound 3340 68 8.7308 0.0012 55,123
C. Immediate CT vs. immediate MRI with changes to the increased RR of recurrent haemorrhagic stroke in
patients treated with anti–platelet medication following a minor haemorrhagic stroke
a. Increased risk of haemorrhagic stroke with inappropriate antiplatelet drugs – Base value 1.15
CT + ultrasound 3262 – 8.7313 – –
MRI + ultrasound 3340 77 8.7308 –0.0005 Dominated
b. 1.05
CT + ultrasound 3262 – 8.7313 – –
MRI+ ultrasound 3339 77 8.7311 –0.0002 Dominated
c. 1.2
CT + ultrasound 3262 – 8.7313 – –
MRI+ ultrasound 3340 78 8.7307 –0.0006 Dominated
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RESULTS OF HEALTH ECONOMIC MODELLINGUncertainty around cost of imaging
First of all we varied the cost of MRI to examine the effect of changes in this parameter on the results.
Immediate MRI and ultrasound remains dominated by immediate CT plus ultrasound unless we assume that
the cost of MRI is less than that of CT (e.g. £90). Although the MRI strategy is less costly than the CT strategy
at this price (holding the CT cost constant), it also remains marginally less effective. However, CT remains
relatively cost-effective in comparison with MRI, with an ICER of approximately £20,000 per QALY gained.Uncertainty around the sensitivity of computed tomography in detecting
visible haemorrhagic lesions
Lowering the sensitivity of CT for identifying haemorrhages in the immediate presenting cohort, the MRI
plus ultrasound option provides a greater number of QALYs compared with CT plus ultrasound. The
declining sensitivity of CT for haemorrhage over time is responsible for the improved cost-effectiveness of
MRI compared with CT in later presenting cohorts (see Table 71, scenarios 7 and 8). Here we demonstrate
how the cost-effectiveness of MRI improves in relation to CT if the sensitivity of CT for haemorrhage drops
in a more immediate presenting cohort (i.e. within a few hours of the initial event).Uncertainty around the increased risk of recurrence of haemorrhagic stroke
when incorrect treatment with antiplatelet therapy is given
With a reduced risk to 1.05 (the lower 95% CI on the risk of recurrent haemorrhage in patients with
haemorrhagic stroke treated with antiplatelet agents), the option of immediate MRI and ultrasound is still
dominated; however, there is a lower loss in QALYs than in the base case of immediate CT and
ultrasound. The opposite effect occurs with an increase in the hazard rate; a higher QALY loss is observed.
Table 74 presents the results of one-way sensitivity analysis on several key variables for the comparison of
immediate MRI plus ultrasound compared with immediate CT plus ultrasound in the later presenting
(day 7) cohort of patients. The results indicate that the cost-effectiveness of the MRI strategy is quite
sensitive to the cost of obtaining the MRI scan relative to the cost of CT, and also the relative increased risk
of recurrent haemorrhagic stroke in patients with a minor haemorrhagic stroke treated with antiplatelet
medication. When the cost of MRI is reduced or the RR associated with inappropriate antiplatelet
medication is increased, the cost-effectiveness of MRI improves in the cohort of patients presenting at
7 days. The relative cost-effectiveness of alternative strategies is much less sensitive to the costs of
recurrent stroke owing to only very small differences in the overall cumulative incidence of stroke between
strategies. Cost-effectiveness also improves slightly when running the analysis over a period of 30 years.Probabilistic sensitivity analysis
The results reported thus far are influenced by the mean values of the parameters. As each parameter
estimate is associated with a degree of imprecision, it is important to gauge the effect of the level of
imprecision on the reported values of cost-effective. To assess this, PSAs were conducted for the base-case
model specification (scenario 1) and also the comparisons of immediate MRI plus ultrasound compared
with immediate CT plus ultrasound in the later presenting cohorts (7 days and 21 days). In PSA the
imprecision surrounding a number of variables is explicitly modelled; the estimated mean value of any
random parameter has an associated measure of imprecision due to sampling variation; this is usually
represented by the standard error of the mean estimate or other measure such as a 95% CI. Within PSA,
this measure of imprecision is used to derive an empirical estimate of sampling distribution for each
random variable (parameter) in the model, with assumptions made regarding the appropriate functional
form distributions should take for different types of parameter. Monte Carlo simulation techniques are
then used to randomly draw a value for each parameter from its assigned distribution, and the model is
re-estimated using these values. This process is repeated a large number of times to build up a picture of
the joint uncertainty surrounding the modelled costs and effects of alternative strategies, and also the
ICER. By plotting the many estimates of incremental cost and effect pairs on the cost-effectiveness plane,
cost-effectiveness acceptability curves can be derived which depict the probability of alternative options
being preferred on grounds of cost-effectiveness by society’s per QALY gained.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 74 Sensitivity analysis surrounding key parameters that influence the cost-effectiveness of immediate MRI






A. Immediate CT vs. immediate MRI with changes to the cost of the MRI scan
a. Cost of MRI: base case – £174
CT + ultrasound 3230 – 8.7425 – –
MR+ ultrasound 3296 66 8.7442 0.0017 39,509
b. Cost of MRI £117 (lower quartile of NHS reference cost)
MRI + ultrasound 3230 – 8.7425 – –
CT + ultrasound 3238 8 8.7442 0.0017 4870
B. Immediate CT vs. immediate MRI with changes to the initial cost associated with recurrent
haemorrhagic stroke
a. Cost of haemorrhagic stroke: base case – (alive and independent £3445; alive and dependent £4841; fatal within 90
days £15,741)
CT + ultrasound 3230 – 8.7425 – –
MR+ ultrasound 3296 66 8.7442 0.0017 39,509
b. Initial 3 month costs for non-fatal stroke increased to £371373
MRI + ultrasound 3244 – 8.7425 – –
CT + ultrasound 3310 65 8.7442 0.0017 39,069
C. Immediate CT vs. immediate MRI with changes to the increased RR of recurrent haemorrhagic stroke
in patients treated with antiplatelet medication following a minor haemorrhagic stroke
a. Increased risk of haemorrhagic stroke with inappropriate antiplatelet drugs – base value 1.15
CT + ultrasound 3230 – 8.7425 – –
MR+ ultrasound 3296 66 8.7442 0.0017 39,509
b. Alternative value 1.05
CT + ultrasound 3227 – 8.7436 – –
MR+ ultrasound 3296 69 8.7442 0.0006 120,140
c. Alternative value 1.20
CT + ultrasound 3231 – 8.7420 – –
MR+ ultrasound 3296 65 8.7442 0.0022 29,438
D. Immediate CT vs. immediate MRI with changes to the modelled time horizon
a. Base case – 20 years
CT + ultrasound 3230 – 8.7425 – –
MR+ ultrasound 3296 66 8.7442 0.0017 39,509
b. 30 years
CT + ultrasound 3321 – 9.1987 – –
MR+ ultrasound 3387 66 9.2005 0.0018 36,156
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RESULTS OF HEALTH ECONOMIC MODELLINGThe above process was followed to assign sampling distributions to the model parameters shown in
Table 75. However, owing to limited availability of data illustrating the degree of precision surrounding
several key inputs, several parameters were omitted from the PSA. These included the majority diagnostic
performance parameters that were based to an extent on clinical opinion. Instead, we assessed the impact
of variation in the key diagnostic performance parameters using deterministic sensitivity analysis (above).
The other notable category of parameters omitted from PSA was to test variation in the baseline risks for
recurrent stroke. With the approach used to estimate stroke risks by ABCD2 score, level of stenosis and
time from event, it was not possible to assign distributions to these parameters. As such, the following
analyses will likely underestimate the degree of uncertainty surrounding the cost-effectiveness of
alternative options at different willingness-to-pay thresholds. Given the difficulty in assigning appropriate
distributions to key model parameters, no formal value of information analysis was conducted.
Figures 70–72 show the PSA results from scenarios 1, 7 and 8 in Table 71. Under scenario 1 (immediate








Sensitivity of CT for ischaemic stroke (< 7 days) 0.39 0.135 Beta
Cost of CT imaging £101.00 £29.10 Gamma
Cost of MRI £174.00 £61.19 Gamma
Cost per inpatient day £297.00 £104.48 Gamma
Cost of treatment for MI £4900.00 £1623.00 Gamma
Cost of endarterectomy £3697.00 £1349.00 Gamma
Health state utility for recurrence free 0.88 0.020 Beta
Health state utility for alive and independent 0.71 0.015 Beta
Health state utility for alive and dependent 0.20 0.005 Beta
Health state utility for post MI 0.76 0.058 Beta
Health state utility non-stroke 0.88 0.020 Beta
LOS (haemorrhagic stroke moving to alive and dependent) 16.3 days 22.39 Gamma
LOS (ischaemic stroke moving to alive and dependent) 17.9 days 22.39 Gamma
LOS (haemorrhagic stroke moving to alive and independent) 11.6 days 11.94 Gamma
LOS (ischaemic stroke moving to alive and dependent) 14.5 days 14.93 Gamma
RR of ischaemic stroke with medical treatment 0.53 0.148a Log-normal
RR of MI with medical treatment 0.65 0.120a Log-normal
Increased RR of recurrent haemorrhagic stroke with antiplatelet drugs
following a minor haemorrhagic stroke
1.15 0.022a Log-normal
Standardised mortality ratio for all cause mortality following a stroke 2.72 0.02a Log-normal
Standardised mortality ratio for all cause mortality following a TIA 1.40 0.126a Log-normal
Standardised mortality ratio for all cause mortality following a MI 2.68 0.041a Log-normal
SE, standard error.
a Estimated SEs reported on a log-scale for log-normal distributions.
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FIGURE 72 Scenario 8: CT plus ultrasound vs. MRI plus ultrasound for cohort presenting 21 days after initial event.
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RESULTS OF HEALTH ECONOMIC MODELLINGprobability of being cost-effective in comparison with MRI (90–95%). This is primarily due to its
significantly lower costs and very slightly improved effectiveness in comparison with the MRI strategy in the
immediate presenting cohort.
With scenario 7 [immediate CT vs. immediate MRI the later presenting cohort (7 days)], the probability of
MRI being considered cost-effective increases as the threshold willingness to pay (WTP) per QALY
increases. Above ≈£37,000, the MRI strategy has the higher probability of being cost-effective. In
scenario 7 (immediate CT vs. immediate MRI for a cohort presenting at 21 days), the probability of MRI
being cost-effective improves to ≈55% at the WTP threshold of £30,000 per QALY.
DiscussionStatement of principal findings
Magnetic resonance imaging strategies are generally found to be more expensive and no more
effective than CT. The exceptions to this are for those strategies that involve later presenting cohorts.
Here, MRI becomes more cost-effective, and its cost-effectiveness improves as its sensitivity for detecting
haemorrhages improves over time, although its ICER falls only within, and does not fall below,
conventionally accepted cost-effectiveness thresholds ranges (£20,000–30,000 per QALY) in the cohort
presenting 21 day after the initial event. The cost-effectiveness of MRI in late-presenting cohorts (7 and
21 days) was found to be sensitive to fairly small changes in the cost of MRI relative to the cost of CT, and
also the assumed relative increased risk of recurrent haemorrhagic stroke associated with inappropriate
antiplatelet treatment of those patients who have suffered a minor haemorrhage. It should also be noted
here that, although we present findings for the cost-effectiveness of MRI compared with CT at 7 days
and 21 days, this was primarily due to available evidence suggesting that CT has high sensitivity for
haemorrhagic stroke up to 7 days, and significantly lower sensitivity from day 7 onwards. However, if the
sensitivity of CT for haemorrhage drops off more quickly, MRI may become the more effective strategy
earlier than 7 days after the initial event.Strengths and limitations of the economic model
A strength of the model is that it offers an explicit framework for the synthesis of both evidence and
expert opinion. It uses structures developed in two previous HTA cost-effectiveness analyses that combine
assessment of brain imaging (cross-sectional diagnostic decision tree approach) with risks of stroke
(variable time-dependent approach), the former developed to assess the cost-effectiveness of brain
imaging in acute stroke26 and the latter to assess the cost-effectiveness of carotid imaging in stroke
prevention.5 From this combined approach, gaps in the evidence base are revealed. There is good evidence
from high-quality large RCTs on the effectiveness of different forms of medical and surgical management
on the probability of stroke recurrence and by extrapolation on health-related quality of life. The main
gaps appear to be in relation to the relative sensitivity and specificity of MRI and CT in TIA and minor
stroke, and the impact these imaging modalities have on subsequent treatment and outcomes; the
available evidence base is weighted towards sensitivity and specificity in moderate to severe stroke
patients, and so, as discussed in earlier chapters, some assumptions have been made with respect to how
these apply to TIA and minor stroke.
One potential limitation of the modelling strategy relates to the assumption regarding treatment of
patients following information provided by imaging results. In the modelled base-case scenario, the
sensitivity of MRI for detecting an ischaemic lesion is 0.63, whereas for CT it is 0.39. However, it is
assumed that implementation of preventative treatment (for recurrent stroke) is based on clinical
assessment as well as imaging, and not just the results from imaging in isolation, as is the case in clinical
practice. Where either CT or MRI is unable to rule out a minor ischaemic stroke or TIA (i.e. by identifying a
haemorrhage or mimic), we have assumed that implementation of secondary prevention for ischaemic
stroke will prevail based on clinical assessment in patients without a visible ischaemic lesion. This is current
practice. Further, we have assumed that CT and MRI, when combined with clinical assessment, areNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27essentially equivalent in their ability to appropriately identify and rule out mimics, and that they do not
result in different numbers of patients with true ischaemic stroke being misdiagnosed as mimics. The
available evidence on the contribution of CT or MR to establishing a diagnosis in most of the mimics is not
good but, on the other hand, there is information on the effect of MR in minor stroke on treatment
decisions and on detection rates of positive findings that confirm the type of mimic in many types of
mimics. There were no data on which to base other approaches, as mimics were excluded from all studies
of DWI in TIA/minor stroke (see Chapter 6). It could be argued that the assumptions used may underplay
the potential advantage that MRI offers through being better able to detect ischaemic lesions and
therefore differentiate some true TIAs/minor strokes with a DWI lesion (one-third/two-thirds) from the
two-thirds of TIAs/one-third of minor strokes without a DWI lesion and the mimics that make up 45% of
clinic attendances in most of whom DWI would be negative. However, some mimics can produce a
DWI-positive finding (migraine, hypoglycaemia, postictal, MS, etc.), so the impact on decision-making is
not transparent. Differentiating these categories essentially boils down to clinical expertise with careful
history and examination backed up by imaging. Thus, it is not clear whether that added advantage
changes treatment decisions, and previous studies suggested that the differences conferred by MR DWI
and T2* were small (< 10%),252 no treatment differences were modelled. It remains possible that in
settings where clinical assessments and further tests are less expertly applied – and particularly where there
was too much reliance on ABCD2 score-based filtering – the use of CT would result in more patients with
a true ischaemic stroke or TIA (e.g. those with low ABCD2 scores) being misclassified as a mimic or
haemorrhage, which could end up delaying appropriate preventative treatment for these patients. On the
other hand, if MRI were to be relied on in place of expert opinion, it would only help sift out the one-third
of TIAs and two-thirds of minor strokes with a DWI-positive lesion, leaving the two-thirds of TIAs/one-third
of minor strokes without a DWI lesion, but still with a high risk of recurrent stroke, with no protection
from stroke prevention therapy. Additionally, basing treatment decision more heavily on the findings of
MRI, could result in more patients with a mimic being misclassified as an ischaemic stroke, or with an
ischaemic event failing to receive treatment, which could lead to unnecessary or missed ischaemic stroke
treatment and delayed diagnosis and appropriate treatment for the true underlying problem. These
scenarios have been modelled by using ABCD2 score to triage the rapidity of imaging assessment and also
by assuming that only patients with a DWI-positive lesion would receive stroke prevention treatment,
neither of which was cost-effective.
Another issue that is problematic relates to estimation of the proportion of patients already on antiplatelet
therapy and other medical treatment. HR data from randomised trials will probably overestimate potential
benefits, as many patients who arrive with TIA or stroke may well already be on such therapy. The model
may therefore overestimate the benefits of diagnosing and treating ischaemic stroke, although such an
effect comes into play only in scenarios in which it is assumed that treatment is not implemented for those
patients with no visible ischaemic lesion on MRI. In fact, as the UK survey and other sources298 indicate
that many patients are started on stroke prevention treatment before they reach the clinic, and indeed this
is the recommendation in the NICE guidelines,97 the benefit of MRI becomes even less and the relative cost
even worse. Furthermore, the survey and other data indicate that MRI is often used in addition to CT,
further increasing costs, burdening imaging services and reducing the incremental effectiveness of MRI.
A further potential limitation is that health-related quality of life has been aggregated into three broad
categories: (1) alive and free from stroke; (2) alive and independent following a recurrent stroke; (3) and
alive and dependent following a recurrent stroke. This makes the model insensitive to changes in
health-related quality of life within particular categories; however, as the focus of the model relates to the
contribution of imaging to diagnostic accuracy and subsequent prevention of recurrent stroke, these broad
categories should be sufficient to capture the average expected impact of strategies on QALYs.
On the costs side, there is wide disparity in the available estimates for the costs of imaging. What is
important for cost-effectiveness, however, is the size of the difference in costs between CT and MRI, rather
than whether or not the exact values applied are too high or too low. In this case, there is a good deal of
evidence available to suggest that MRI uses more health-care resources than CT; in addition to its greater229
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RESULTS OF HEALTH ECONOMIC MODELLINGacquisition price, the test takes longer to perform and it uses more consumables and materials. The
important issue then is whether the cost increase is worth incurring in light of any expected health benefits
or downstream cost savings. Taking the cost of a medical consultant as £146 per patient-hour,394 an extra
20 minutes of a consultant radiologist time costs approximately £60. It is possible then that the £70
difference is an underestimate. The effect of a larger and smaller difference, however, is tested in
sensitivity analyses. In particular, the relative cost of MRI in comparison with CT is a key determinant of the
cost-effectiveness of MRI in later-presenting cohorts.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Chapter 13 Discussion
Stroke is a devastating illness. Prevention of stroke is very important to minimise its disabling physicaland cognitive consequences. Among those with a warning TIA or minor stroke, rapid assessment,
identification of potential stroke causes and appropriate treatment can prevent many of these
disabling strokes.
No one would question that the mild symptoms and signs of a TIA or minor stroke are difficult to separate
from other causes of mild neurological or cardiac symptoms or that the diagnosis of TIA/minor stroke is
difficult, particularly for non-experts. Or that identification of underlying risk factors, such as carotid
stenosis or cardiac abnormalities, for which we have established treatments based on evidence from large
multicentre randomised trials,395 should be a priority. Same-day clinics, where all priority investigations
are obtained and treatment decisions implemented, save time and are cost-effective.5,286 This much
is straightforward.
Transient ischaemic attack/minor stroke is very common. So are mimics. Any system trying to deliver
rapid assessment and treatment needs to be focused on priorities and streamlined to avoid becoming
overwhelmed with the sheer numbers of patients. Stroke is a government priority with targets and
incentives aiming to change practice to improve stroke prevention and treatment.360 Methods to identify
high-risk patients could quickly help streamline stroke services. Clinical risk prediction scores, particularly
the ABCD2 score, have achieved prominence in high impact journals, becoming the subject of entire
sessions at recent stroke conferences. Excitement about the sensitivity of MR DWI to detect ischaemic
lesions in patients with TIA/minor stroke and clinical risk prediction scoring have changed guidelines,97,360
the DOH guidelines adopting the ABCD2 score with a cut-point of ≥ 4 against < 4 for triage, and
suggesting that about 50% of TIA patients should have MRI to diagnose the TIA/minor stroke and triage
speed of treatment.
Coordinated outpatient services with rapid evaluation, identification of key risk factors and treatment to
prevent recurrent stroke are very important and, according to our survey, are now available in most parts
of the UK. However, some aspects of current practice introduced in the last decade are not evidence
based, may have been implemented rather hastily and may in fact not be as effective as was hoped, or
have unintended consequences due to problems with interpretation and use of some information on
which these practices are based. The rising use of MR in stroke in the last decade, often supplementing
rather than replacing CT scanning, as shown in the survey but also happening outside the UK, makes
neuroimaging the fastest growing component of hospital care costs for stroke in the last decade.298
Furthermore, several organisations, including the AHA,17 have endorsed a change in the definition of TIA
from time based to tissue based.
Many points relating to the gathering of evidence for this analysis have been discussed in detail in the
relevant chapters and we do not propose to repeat those here. Rather we will highlight general and
overarching points relevant to the use of imaging in stroke prevention in general and related issues that
this work has thrown up. There are some large holes in the evidence on which some practices are
currently based. That not so many clinics may actually be following these practices, as suggested in the
survey of UK clinics, may be beneficial.
In general, in every topic that we meta-analysed, there was substantial heterogeneity (I2-statistic values
typically in the 90s). We could not account for this heterogeneity by obvious causes such as retrospective
compared with prospective recruitment, diagnosis, risk score, year of publication, time to assessment, etc.
Second, despite this heterogeneity, the overall messages were clear.
The early risk of stroke after TIA may have been overestimated and certainly the pooled cumulative risk
(see Chapter 3) was inconsistent with the 20% suggested in the 2008 NICE guidance on stroke.97231
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DISCUSSIONAmong 53 studies (30,558 patients) the pooled cumulative recurrent stroke rate was 5.2% (95% CI 3.9%
to 5.9%) by 7 days, 6.7% (95% CI 5.2% to 8.7%) by 90 days and 11.3% (95% CI 7.5% to 16.6%) in
the few studies that provided information for > 90 days. Of course, within this are subgroups for which
recurrent stroke rate is much higher, notably those with symptomatic tight carotid stenosis. We applied
subgroup-specific recurrent stroke rates where appropriate in the model. We cannot tell to what extent
this lower stroke cumulative risk is a consequence of medical or surgical treatment of patients in these
observational studies as secondary prevention was rarely mentioned. All we can say is that there was little
evidence of any change in the rate over the last 20 years during which increasing awareness of stroke risk
after TIA has probably increased speed of initiation of treatment.
The ABCD2 score does not identify all patients with key underlying risk factors which we know cause most
recurrent stroke, particularly early recurrences, and for which there are well established evidence-based
treatments from large RCTs and meta-analyses.25 Symptomatic carotid stenosis and AF are the two
common and obvious ones that together are responsible for a large proportion of recurrent stroke. When
carotid stenosis is removed by successful endarterectomy, the stroke risk drops immediately to background
rates.169 Similarly, RCTs show that antithrombotic, cholesterol-lowering therapy and antihypertensive
therapy reduce stroke risk, although the immediacy with which the risk is reduced is based on
observational data24 rather than RCT evidence at present.
Use of ABCD2 scores, particularly by non-specialists, may in fact be failing , paradoxically, to prevent
stroke. ABCD2 does not differentiate mimic from true TIA/minor stroke (see Chapter 4).396 Mimics occupy
a substantial part of the stroke prevention service – nearly half (see Chapters 7 and 8). This will slow down
the access to services by true TIA/minor stroke. One-third of mimics have an ABCD2 score of ≥ 4 (see
Chapter 4) and so would go down the fast-track route and undergo MR. Meanwhile, one-fifth of true
TIA/minor stroke patients with low ABCD2 scores have carotid stenosis or cardiac embolic risk, and are at
risk of having a recurrence while waiting for investigation if put in the slow stream. That this is a real
problem has been amply demonstrated by some clinics in France164 and the UK,181 where patients with low
ABCD2 scores have had recurrent stroke either by waiting too long in the slow stream or missing out on
investigation altogether because of the creeping perception that patients with low ABCD2 scores do not
have recurrent stroke. Furthermore, in the economic modelling, delaying investigation in patients with
ABCD2 score of < 4 resulted in a fourfold reduction in QALYs over the QALY reduction that occurred with
immediate MR and ultrasound for all.
It is unfortunate that the reliability of the data on the ABCD2 score and MR DWI was undermined by study
methods, particularly factors such as nearly half of studies assigning the ABCD2 score or DWI findings
retrospectively from case note review. This and related methodological problems are not uncommon in
research on clinical risk prediction scores.397 Greater awareness of these problems should improve this type
of research. Many studies did not clearly differentiate TIA from minor stroke, yet the ABCD2 score may not
work in minor stroke.186 Few studies provided any information on treatment or identification of key risk
factors like carotid stenosis or AF or how these patients were handled in the analysis of risk prediction.
It would be unethical not to offer immediate treatment, but that would reduce by a large degree the
recurrent strokes that these studies were trying to observe. Another point was that a large proportion of
the data on several aspects of stroke prevention came from the same few research groups.
The ABCD2 score was not designed for, or tested for use by, non-specialists, yet DOH tariffs98,368 in
England relate to ABCD2 scores assigned by GPs or other non-specialist referring doctors. Also, in about
one-third of stroke prevention clinics, the assessments and ABCD2 score assigning are undertaken by
nurses. A full work-up achieved quickly can earn between £450 and £634 per patient when the ABCD2
score and DWI have been used and the patient is started on treatment within 24 hours of referral.98,99
Given that large proportions of patients arrive at the stroke prevention clinics having already been started
on secondary prevention treatment by their GPs, it is even more unlikely that further fast-tracking with
ABCD2 scores is going to add anything, although it could still detract by slowing endarterectomy in
patients with tight stenosis who are put in the slow stream. One can only conclude that at present, asNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27used in stroke prevention clinics, the ABCD2 score is unlikely to be contributing helpfully to prevention
of stroke.
The ROC curve for any stroke prediction score improves by adding results of brain imaging with CT or
DWI, but there are still patients with key risk factors who get low scores. In any case, it seems odd not to
look for the risk factors directly with ultrasound and cardiac investigations. The survey (see Chapter 8)
demonstrated that carotid imaging was widely available, mostly with ultrasound, on the same day as clinic
assessment in most centres. Therefore, why use an indirect, proxy method that will inevitably be less
accurate or effective than identifying the risk factor directly, particularly when the ultrasound or cardiac
tests would still need to be performed in patients with high ABCD2 ± CT or DWI scores? It seems that all
that the ABCD2 score ± brain imaging is achieving in this situation is delaying making the correct
diagnosis, the one thing that stroke prevention clinics are supposed to avoid!
There is probably more information to be derived from plain CT findings as most studies (and we found
about three times as many studies than in previous reviews, Chapter 5) did not specify if any infarct was
relevant, recent, old and irrelevant, or just a sign of leukoaraiosis. That CT may help predict recurrent
stroke is useful and not surprising, but getting the best information out of it may require knowing whether
the lesion is likely to be relevant to the recent symptoms or not. Prior irrelevant infarct or leukoaraiosis may
just indicate a vulnerability to infarction at some point in the future, for example, rather than a specific
early risk of recurrence.
Most patients with TIA (two-thirds) and a large proportion of patents with minor stroke (one-third) do not
have an acute ischaemic lesion on DWI, but equally they do not have any other cause of symptoms apart
from the TIA/minor stroke. This questions the sense in moving towards a tissue-based definition of TIA or
minor stroke. Reasons for substantial heterogeneity in rates of positive DWI (see Chapter 6) were not
obviously explained by time to scanning or other factors that we were able to address, and may reflect
variation in scanner technology, sequences used, expertise of the scan rater, etc. All of these are likely to
persist meaning that it will be difficult to standardise the DWI results enough to remove this heterogeneity.
However, it would probably be premature to change the definition of TIA if it leaves many patients
potentially undiagnosed or completely changes the epidemiology of the condition for reasons that we
cannot currently explain.
Ischaemic change on DWI disappears over a few days from lesions that produce mild symptoms such as
TIA, even although we were not able to show an obvious change in the positive rate with time lapse after
stroke in the published data (see Chapter 6). By extrapolation from ischaemic stroke where it is well
known that the DWI high signal normalises over several days,398 and faster in milder than in more severe
stroke, and faster in grey than white matter,44 the DWI-positive signal is likely to disappear in several days
from the one-third of TIA patients with positive findings. Hence, it is worrying that the average time to
undertaking MRI in TIA/minor stroke in the UK is 1 week or longer. Although late scans would detect
haemorrhage, if a T2* sequence was used they would be less likely to detect recent ischaemic change,
rendering the clinical value and cost-effectiveness even lower than with immediate scanning. If the
definition of TIA changes to tissue based then patients who arrived late after their TIA, by which time the
DWI acute lesion had disappeared, would be classed as not TIA or stroke. The public could use this
information to their advantage, for example if they were concerned about loss of insurance or loss of a
driving licence – simply delaying their attendance at clinic could avoid them being diagnosed as stroke or
TIA and their unfortunate and inconvenient consequences. That they might also miss out on important
secondary prevention measures, leaving themselves at high risk of recurrent stroke, would be
very unfortunate.
More worryingly, until imaging departments can routinely use the correct and minimum set of sequences
to diagnose stroke, whether haemorrhage or ischaemic and its mimics, wider use of MR should not be
encouraged as it may be dangerous. Only 45% of departments included a T2* sequence to detect
haemorrhage. This means that many departments are failing on the one established reason for performing233
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DISCUSSIONa MR scan in TIA/minor stroke – to identify haemorrhage in patients presenting too late for CT to
identify haemorrhage.31
As an approximation, among 1000 suspected TIA/minor stroke patients referred to stroke prevention
clinics, of whom about 45% would have a non-CV diagnosis, DWI would be positive in only 19% of
patients with suspected TIA and 38% with suspected minor stroke, leaving a large proportion of negative,
non-contributory scans and a large bill for the scanning.
In the UK, as elsewhere,298 MR seems to be used in addition to rather than instead of CT in many patients.
This renders the cost-effectiveness of any imaging in stroke prevention even less than it would be if one
or other were used alone. Reasons for this double use are unclear and may reflect ease of access. For
example, if CT is perceived to be easy to get and ‘better to have than nothing’ while waiting for the MR
then it is all too easy to request a CT immediately followed by a MRI. However, the point of this is unclear
except in a small proportion of unusual patients. Moreover this practice inflates workloads for staff in
imaging departments who have to perform and interpret the scans and perform receptionist and
secretarial duties, the porters who have to make two trips to the imaging department for inpatients,
and disrupts the recovery and lives of the patients themselves. Inpatients may have therapy sessions
interrupted or miss visitors (important emotionally for recovery after stroke and for discharge planning); for
outpatients, making two trips doubles the cost of transport and the time taken, and may disrupt relatives
and friends as well if the patient (as is often the case) relies on someone else for transport, which, in turn,
may disrupt other employment or child-care duties. This impact on inpatients and outpatients, and their
carers may be far more costly or disruptive than the impact on staff, but we were unable to quantify these
aspects of the effects of stroke prevention strategies in the modelling. It requires some thought on the part
of those who are requesting these duplicate investigations as to what is really in the best interests of the
patients and whether the additional information from a follow-up MR scan – performed, on average,
when it is too late to see many ischaemic lesions and when most departments are not including
blood-sensitive sequences and so will miss haemorrhage as well – is really worth the added cost and
disruption to the patients and imaging departments.
Delays to carotid endarterectomy are still too long: median of 21 days in the 2011 report from the Royal
College of Physicians of London,399 although this was a reduction from median 28 days in 2010400 or
30 days in Canada in 2009.401 Delays were blamed previously, among other factors, on lack of awareness
among the public and hence in presenting to medical attention. There is less reason for lack of awareness
now following many public awareness campaigns but there will be little point in patients presenting early
if they then encounter delays through being triaged inappropriately or waiting for imaging that is unlikely
to be contributory. It is too easy to put off a decision for endarterectomy while ‘waiting for the scan’.
If a CT scan can exclude a haemorrhage or a tumour/other important structural cause, the carotid
imaging shows a tight stenosis and the clinician finds no other cause for symptoms apart from TIA/minor
stroke then it is best to activate surgery (or other treatment) as fast as possible.
In the cost-effectiveness analysis, MRI strategies were generally more expensive and no more or even less
effective than those using CT in some cases. The exceptions to this were for those strategies that involve
later presenting patients. Here, MRI became more effective, and its cost-effectiveness improved as its
sensitivity for detecting haemorrhages remains with time, although even in that scenario, its ICER did not
fall below conventionally accepted cost-effectiveness thresholds (£20,000–30,000 per QALY). However,
this result was sensitive to fairly small changes in the cost of MRI relative to the cost of CT, and also the
assumed relative increased risk of recurrent haemorrhagic stroke associated with inappropriate antiplatelet
treatment of those patients with minor haemorrhage.
The lack of relevant evidence on the effect of diagnostic imaging on outcomes, in contrast with the
relatively large amount of data from randomised trials on the effects of medical or surgical interventions, is
not unique, being a common problem afflicting diagnostic imaging and other technologies. A previous
attempt in 2008 to calculate the cost-effectiveness of MR DWI in TIA was abandoned due to lack ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27relevant evidence.105 We would argue that there is still a substantial gap in relevant evidence but not such
that a reasonable attempt at estimating cost-effectiveness cannot be made. We would also emphasise the
importance of not introducing new technologies, be they diagnostic tests or risk scores, without proper
evaluation and an adequate evidence base on which to determine their risk and benefit and impact on
clinically relevant outcomes. It would be more or less unthinkable to introduce a new drug into clinical
practice without testing in large, generalisable RCTs in relevant patient populations. Diagnostic tests and
risk scores should be no different. They work, if they do, by enabling a series of steps that leads to
improvements in clinically relevant patient outcomes. Therefore, they should be tested in RCTs and there
should be adequate data on their sensitivity and specificity and accuracy, instead of virtually none.
The effect on numbers of strokes prevented was small between different strategies, but, when multiplied
across the population for such a common condition, should not be dismissed. In any case, no one should
have a stroke if we have the knowledge and means to prevent it. We may have underestimated the
number of recurrent strokes that would occur in some strategies because of the difficulty of introducing
enough granularity in the various streams of patients with various risk factors passing through the model.
Thus although we modelled an increased risk for patients with tight symptomatic carotid stenosis, we were
not able to do this across a range of stenoses and nor did we model the effect of failing to treat cardiac
sources of emboli, such as AF. However, regardless of the actual number of strokes not prevented, some
strategies clearly would fail by a larger degree to prevent strokes, and failing to prevent stroke through
failing to implement established evidence effectively and through the unintended consequences of
changes in health policy or strategies is unsupportable and against all of the principles of medical practice.
Limitations of the work not mentioned above should be discussed. In general, only one reviewer performed
the searches and initial checking of references. Having another reviewer to duplicate the searches and
undertake initial paper triage was well outside the resources available for the work. However, we did
other things to validate the searches and find all relevant papers, such as hand-searching of journals and
cross-checking where relevant with other systematic reviews. Two researchers assessed potential papers
and extracted data, so we are confident that these later steps have been as rigorous as possible. We did
not exclude any non-English papers except when we were completely unable to obtain a translation. Our
combined languages included Italian, Spanish, Portuguese, French, Japanese, Chinese and Russian, plus we
have colleagues in Scandinavian and other countries who could have provided translations from other
languages had we needed them. Thus in practice we excluded virtually no papers on the basis of being
non-English. We did not check the extracted data with the original authors or contact the authors for
unpublished data, as these steps were outside the staff resources and time limits available for the work. As
it was, the work benefited from the contribution of a full-time visiting fellow from Chile (HM) and, towards
the end of the project, a second health economist in Aberdeen (GS), without whom it would have been
impossible to complete. We could have modelled other strategies but there seemed little point. It was
already clear that MR was more costly than CT and (with one exception) no more effective, and the data
were inadequate to support modelling of further strategies. For example, we did not repeat all of the
strategies while assuming that all patients were already on stroke prevention treatment because use of MR
in patients who were already on treatment would simply reduce the
cost-effectiveness of MR even further.ConclusionsThe available data suggest that there is little justification for use of ABCD2 or other risk prediction scores
to triage patients, particularly as currently implemented in many clinics. Rather, the resources that are
already available across the UK according to the survey (see Chapter 8) should be focused on direct
identification of underlying key risk factors, identifying the small proportion of patients for whom
haemorrhage is the cause of the stroke, and differentiating mimics. This requires specialist input. Although
we did not test specialists compared with non-specialists directly, the available data point to large numbers
of mimics being referred as suspected TIA/minor stroke by non-specialists. The differentiation of many of235
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DISCUSSIONthe mimics from true TIA/minor stroke (see Chapter 7) require careful history and examination for subtle
features that generally take many years of experience to develop. It is unlikely ever to be something that
can be done by a non-specialist. The ABCD2 score and a MR scan do not replace the specialist. Patients
with non-CV diagnoses, who make up a large proportion of these clinics, should be managed
appropriately and sensitively. They need to be correctly distinguished from true TIA/minor stroke to avoid
the consequences of being incorrectly diagnosed as TIA/minor stroke (driving cessation; ineffective and
possibly risky drug treatment; insurance implications), as well as requiring correct treatment for the cause
of their mimic, many of which are not benign.
The cost-effectiveness evidence would suggest that MRI does not appear to be a cost-effective use of
resources for the routine diagnosis and management of TIA and minor stroke. However, in the
subpopulation of patients who present at > 1 week after stroke and in whom CT will not be able reliably
to identify haemorrhage, MR with T2* sequence is better than CT (thought to be still more expensive) and
should be reserved for these patients. MR DWI might also help in the occasional patient in whom it is not
clear if the symptoms are due to a tight carotid stenosis or are unrelated in the posterior circulation.
Separately, patients with suspected unusual causes of TIA/minor stroke (dissection, rare genetic variants,
etc., as are more common in young patients) are also more likely to benefit from MR. However, even the
use of MR in these minority subpopulations is limited as the advantage in terms of added QALYs remains
quite limited.
Detailed recommendations for current practice:
1. The evidence suggests that stroke prevention is more likely to achieve maximum effectiveness if
services are staffed primarily by specialists with experience in diagnosis and differentiation of TIA,
minor stroke and its mimics.
2. In all patients with probable TIA/minor stroke, evidence suggests that the focus should be on
performing appropriate, rapid, risk factor-directed investigations to identify tight symptomatic carotid
stenosis or AF/other cardiac embolic source and implementing appropriate treatment rapidly is likely to
prevent most strokes.
3. Patients thought not to have a true TIA/minor stroke after review by an expert, i.e. the 45% with a
mimic, many of which are cardiac or neurological, also require appropriate treatment including
avoiding the costly and potentially harmful effects of unnecessary antiplatelet, statin and
antihypertensive treatment.
4. Initial triage using the ABCD2 score alone risks relegating patients with key underlying causative
lesions but with low ABCD2 scores to ‘slow stream’ investigation and treatment exposing them to
high early recurrent stroke risk.
5. The benefits of the ABCD2 score on clinical practice and important outcomes have not yet been
demonstrated in reliable, generalisable studies.
6. The justification for routine use of MR in most TIA or minor stroke is unclear. Exceptionally, MR is
indicated in patients presenting at > 1 week after symptom onset when MR with T2* is better than
CT for identifying haemorrhage, possibly where an unusual cause of symptoms is considered, or
where there is doubt if a TIA/minor stroke is in the territory of a tight carotid stenosis. However, in
most ‘typical’ TIA/minor stroke patients presenting rapidly, use of MR inflates costs substantially,
confers no advantage in stroke prevention, may increase risk through increasing delays to treatment,
and disadvantages patients with other conditions for which there is clear evidence of benefit.
7. The evidence indicates that patients diagnosed as TIA/minor stroke by a stroke specialist, but who do
not have a visible ischaemic lesion on DWI, benefit from secondary stroke prevention treatment; not
implementing stroke prevention treatment will leave two-thirds of patients with TIA, and one-third of
patients with minor stroke who have no lesion on DWI, at high risk of recurrent stroke.
8. Failure to include T2* sequence as part of the MR examination for stroke or TIA, as currently happens
in 55% of UK services, will fail to diagnose haemorrhage and expose patients with haemorrhage to
the risk of recurrent haemorrhage if incorrectly diagnosed and treated with antiplatelet or
anticoagulant drugs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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mimic, identify haemorrhage or even correctly identify all true TIAs or minor strokes.
10. The use of MR in addition to CT is not justified, at least not at its current frequency: using either CT or
MR but not both would help streamline flow through TIA/minor stroke investigative pathways.
11. Ultrasound is cost-effective and its position as the most widely used investigation for carotid stenosis
continues to be justified; CT or MR angiography are not cost-effective alternatives, even when
combined into one examination session with brain CT or MR.
12. The justification for changing the definition of TIA from time based to tissue based is unclear, as
two-thirds of specialist-diagnosed TIAs and one-third of minor stroke do not have a DWI-visible lesion.
13. There are still many delays during assessment of patients with suspected TIA/minor stroke, including to
endarterectomy; efforts to identify and overcome the causes of those delays would increase speed of
investigation and prevent more strokes.Recommendations for researchAs stated in two prior analyses for the HTA on cost-effectiveness of imaging in stroke, more information is
needed on costs of stroke and of investigations – it seems increasingly bizarre that there is not better
information on how much it costs to deliver health care for common disorders.
No technology, including scoring systems of which there are now many in different areas of medical
practice, should be introduced into clinical practice without a thorough evaluation of the evidence
demonstrating its impact on clinically relevant outcomes, including comparisons of the score with the
best previous alternative,402,403 ideally from RCTs. Observational comparisons may be misleading or
uninformative.179 The principle of using the least biased evidence, which is most likely to come from
randomised trials, applies even more to technologies like diagnostic imaging – diagnostic imaging affects
treatment decisions and therefore clinical outcomes and should be regarded as no different to the testing
of a new drug. The methods required for testing diagnostic imaging may be a bit different but the
principle of identifying the benefit and hazard is the same as for drugs or surgical treatments.
More data are needed to determine which imaging strategy is best in routine stroke prevention, preferably
from a randomised trial on the subsequent treatment, health-care costs, health-related quality of life and
survival of patients with suspected TIA or minor stroke presenting at stroke clinics – randomised to initial
diagnosis and management with MRI or CT. Such studies could control for other confounding variables at
baseline, such as number of days delay between initial onset of TIA/minor stroke and time of imaging, and
number of days between imaging and initiation of treatment. Further microcosting studies on CT and MRI,
to gauge the size of the cost difference between the two techniques would also be beneficial. Information
on the cost of many other aspects of stroke care is also limited and needs to be improved.
The definition of TIA is being changed from a time-based to a tissue-based definition, because of
excitement around the ability of DWI to detect small ischaemic lesions in TIA and minor stroke.17 This may
be premature, given that two-thirds of TIA and one-third of minor stroke after assessment by a specialist
and in whom no other diagnosis is available, do not have a DWI lesion. Does this mean that they will no
longer be classed as TIA or minor stroke? What if the variation between stroke centres is as much as that
seen in the DWI meta-analysis (see Chapter 6)? Does that mean that the proportions of TIA or minor
stroke patients seen in different hospitals could vary so widely, and for as yet unaccounted for reasons? It
also means that a patient could be diagnosed as stroke if arriving early at one hospital with rapid access to
DWI but be diagnosed as TIA if admitted to another hospital that either had no MR scanner or limited
access or the patient just arrived to late for their lesion to still be visible. Basing the diagnosis of a common
condition, such as TIA or stroke on such a variable phenomenon as visible lesion on DWI, is likely to be
problematic? Redefinition of TIA with infarction on DWI as stroke will, overnight, increase the annual
incidence of stroke by about 15% and improve statistics on independent survival substantially, as these
new strokes will be mild and raise the overall average of good outcomes after stroke.404237
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DISCUSSIONFurther recommendations are as follows:
1. Reliable, relevant and generalisable data on use of MR in TIA/minor stroke is needed, preferably from a
RCT in which patients are randomly allocated to a policy of ‘early CT brain scan’ compared with ‘early
MR DWI and T2* brain scan’ with a primary outcome based on recurrent stroke and vascular death.
2. Data on accuracy of MR DWI and T2* in TIA/minor stroke and its mimics, in comparison with CT
scanning is required – there are no reliable data at present.
3. Use of the ABCD2 score by non-specialists including nurses and GPs should be tested against use by
stroke experts to determine the reliability of the ABCD2 score.
4. The effect of changing TIA definition from time based to tissue based is required in large populations
across multiple stroke centres and scanners in order to determine the effect on TIA/stroke incidence,
prevalence and outcome, preferably before the definition is changed.
5. Research should examine why MR is frequently used after CT as reducing the rate of duplicate
examinations and finding effective ways to triage patients to one examination would help to improve
efficient use of the staff and equipment resources.
6. Reliable data on all costs related to stroke including all different imaging modalities and the effect of
different operational settings, and their variation with different health-care scenarios are required.
7. Research into the reasons for substantial heterogeneity between studies on all topics related to TIA
assessed here is required to improve consistency of diagnosis. The wide variation observed is unlikely to
reflect true differences in disease frequency.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Appendix 1 Search strategiesChapter 3: stroke risk after transient ischaemic attackThe literature searches developed for Chapters 4 and 6 (below) have been combined for the purpose
of Chapter 3.Chapter 4: ABCD2 score to predict risk of stroke after transient
ischaemic attack/minor stroke
MEDLINE (Ovid) search strategy
Searched: January 2005 to November 2011.
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or brain ischemia/ or exp brain
infarction/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or
cerebral arterial diseases/ or exp “intracranial embolism and thrombosis”/ or stroke/ or Hypoxia-
Ischemia, Brain/
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
4. 1 or 2 or 3
5. (minor or mini or mild or warning).tw.
6. 4 and 5
7. Ischemic Attack, Transient/
8. (transient adj3 (ischemi$ or ischaemi$)).tw.
9. (transient adj3 attack$).tw.
10. (TIA or TIAs).tw.
11. 6 or 7 or 8 or 9 or 10
12. ABCD$.tw.
13. ((clinical or predict$ or risk$ or prognos$) adj3 scor$).tw.
14. (Predict$ adj3 (stroke$ or risk)).tw.
15. (stratif$ adj2 risk$ adj2 stroke$).tw.
16. exp risk/
17. “Predictive Value of Tests”/
18. 16 and 17
19. “Severity of Illness Index”/
20. age factors/ and blood pressure/ and time factors/
21. (age and blood pressure and clinical features and duration).tw.
22. 12 or 13 or 14 or 15 or 18 or 19 or 20 or 21
23. 11 and 22
24. limit 23 to human269
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APPENDIX 1Chapter 4: ABCD2 score to predict risk of stroke after transient
ischaemic attack/minor stroke
EMBASE (Ovid) search strategy
Searched: January 2005 to November 2011.
1. cerebrovascular disease/ or brain infarction/ or brain stem infarction/ or cerebellum infarction/ or brain
ischemia/ or exp carotid artery obstruction/ or cerebral artery disease/ or cerebrovascular accident/ or
exp occlusive cerebrovascular disease/ or stroke/ or stroke patient/
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
4. 1 or 2 or 3
5. (minor or mini or mild or warning).tw.
6. 4 and 5
7. transient ischemic attack/
8. (transient adj3 (ischemi$ or ischaemi$)).tw.
9. (transient adj3 attack$).tw.
10. (TIA or TIAs).tw.
11. 6 or 7 or 8 or 9 or 10
12. scoring system/ or ABCD$.tw.
13. ((clinical or predict$ or risk$ or prognos$) adj3 scor$).tw.
14. (Predict$ adj3 (stroke$ or risk)).tw.
15. (stratif$ adj2 risk$ adj2 stroke$).tw.
16. risk/ or cardiovascular risk/
17. exp “prediction and forecasting”/ or stratification/
18. 16 and 17
19. age/ and blood pressure/ and (disease duration/ or time/)
20. (age and blood pressure and clinical features and duration).tw.
21. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. 11 and 21
23. limit 22 to humanChapter 6: proportion of transient ischaemic attack
minor stroke patients with an ischaemic lesion on
diffusion-weighted imaging
MEDLINE (Ovid) search strategy
Searched: January 1995 to November 2011.
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or brain ischemia/ or exp brain
infarction/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or
cerebral arterial diseases/ or exp “intracranial embolism and thrombosis”/ or stroke/ or
Hypoxia-Ischemia, Brain/
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
4. 1 or 2 or 3
5. (minor or mini or mild or warning).tw.
6. 4 and 5NIHR Journals Library www.journalslibrary.nihr.ac.uk
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8. (transient adj3 (ischemi$ or ischaemi$)).tw.
9. (transient adj3 attack$).tw.
10. TIA.tw.
11. 6 or 7 or 8 or 9 or 10
12. exp Magnetic Resonance Imaging/
13. ((magnetic resonance or MR or NMR or diffusion weighted or T2-weighted) adj2 imag$).tw.
14. ((MR or NMR) adj2 tomograph$).tw.
15. (MRI or DWI).tw.
16. 12 or 13 or 14 or 15
17. exp Tomography, X-Ray Computed/
18. (CT or CAT).tw.
19. (comput$ adj3 tomograph$).tw.
20. 17 or 18 or 19
21. 16 or 20
22. (“1995$” or “1996$” or “1997$” or “1998$” or “1999$” or “20$”).ed.
23. 11 and 21 and 22
24. limit 23 to humansChapter 6: proportion of transient ischaemic attack
minor stroke patients with an ischaemic lesion on
diffusion-weighted imaging
EMBASE (Ovid) search strategy
Searched: January 1995 to November 2011.
1. cerebrovascular disease/ or brain infarction/ or brain stem infarction/ or cerebellum infarction/ or brain
ischemia/ or exp carotid artery obstruction/ or cerebral artery disease/ or cerebrovascular accident/ or
exp occlusive cerebrovascular disease/ or stroke/ or stroke patient/
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
4. 1 or 2 or 3
5. (minor or mini or mild or warning).tw.
6. 4 and 5
7. transient ischemic attack/
8. (transient adj3 (ischemi$ or ischaemi$)).tw.
9. (transient adj3 attack$).tw.
10. TIA.tw.
11. 6 or 7 or 8 or 9 or 10
12. exp nuclear magnetic resonance imaging/
13. ((magnetic resonance or MR or NMR or diffusion weighted or T2-weighted) adj2 imag$).tw.
14. ((MR or NMR) adj2 tomograph$).tw.
15. (MRI or DWI).tw.
16. 12 or 13 or 14 or 15
17. exp computer assisted tomography/
18. (CT or CAT).tw.
19. (comput$ adj3 tomograph$).tw.
20. 17 or 18 or 19
21. 16 or 20
22. (“1995$” or “1996$” or “1997$” or “1998$” or “1999$” or “20$”).em.271
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APPENDIX 123. 11 and 21 and 22
24. limit 23 to humanChapter 5: the addition of computed tomography brain and
carotid imaging to clinical risk prediction scores of recurrent
stroke after transient ischaemic attack
Search strategy in MEDLINE









9. 6 or 7 or 8
Restriction of the search with CT- or carotid-related search terms would have missed relevant references,
as some imaging was not a major part of the study.Chapter 7: transient ischaemic attack and minor stroke mimics
MEDLINE (Ovid) search strategy1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or brain ischemia/ or exp brain
infarction/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or
cerebral arterial diseases/ or exp “intracranial embolism and thrombosis”/ or stroke/ or
Hypoxia-Ischemia, Brain/
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
4. 1 or 2 or 3
5. (minor or mini or mild or warning).tw.
6. 4 and 5
7. Ischemic Attack, Transient/
8. (transient adj3 (ischemi$ or ischaemi$)).tw.
9. (transient adj3 attack$).tw.




14. 6 or 13
15. (mimic$ or misdiagnosis).tw.
16. (focal or atypical).tw.
17. (stroke?like or true stroke or pseudostroke).tw.
18. 15 or 16 or 17
19. 14 and 18NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2720. exp Mortality/ or Fatal Outcome/
21. exp Risk Factor/ or Cardiovascular Disease/
22. exp Secondary Prevention/
23. exp Prognosis/
24. 20 or 21 or 22 or 23
25. 19 and 24
26. limit 25 to yr = “1980-Current”Chapter 7: transient ischaemic attack and minor stroke mimics
EMBASE (Ovid) search strategy1. cerebrovascular disease/ or exp cerebrovascular accident/ or carotid artery disease/ or carotid artery
obstruction/ or carotid artery thrombosis/ or brain infarction/ or brain stem infarction/or cerebellum
infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
4. 1 or 2 or 3
5. (minor or mini or mild or warning).tw.
6. 4 and 5
7. transient ischemic attack/
8. (transient adj3 (ischemi$ or ischaemi$)).tw.
9. (transient adj3 attack$).tw.




14. 6 or 13
15. (mimic$ or misdiagnosis).tw.
16. (focal or atypical).tw.
17. (stroke?like or true stroke or pseudostroke).tw.
18. 15 or 16 or 17
19. 14 and 18
20. exp mortality/ or fatality/
21. exp risk/ or risk factor/ or cardiovascular disease/ or neurologic disease/
22. secondary prevention/ or prophylaxis/
23. prognosis/ or disease course/
24. 20 or 21 or 22 or 23
25. 19 and 24
26. limit 25 to yr = “1980-Current”273
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APPENDIX 1Chapter 9 and 11: costs and previous cost-effectiveness
analyses
EMBASE (Ovid) search strategy
Searched: January 1996 to 2011 week 8.
1. exp cerebrovascular disorders/ (228,191)
2. stroke$.tw. (107,527)
3. cerebrovascular$.tw. (23,460)
4. (cerebral or cerebellar or brainstem or vertebrobasilar).tw. (188,738)
5. (infarct$ or isch?emi$ or thrombo$ or emboli$).tw. (430,400)
6. 4 and 5 (51,042)
7. (cerebral or intracerebral or intracranial or parenchymal).tw. (199,114)
8. (brain or intraventricular or brainstem or cerebellar).tw. (429,046)
9. (infratentorial or supratentorial or subarachnoid).tw. (18,781)
10. or/7-9 (558,740)
11. (haemorrage or hemorrhage or haematoma or hematoma).tw. (70,777)
12. (bleeding or aneurysm).tw. (121,745)
13. 11 (70,777)
14. 10 and 13 (27,294)
15. carotid$.tw. (52,648)
16. thrombo$.tw. (163,020)
17. (intracranial or (venous adj5 sinus$) or (sagittal adj5 venous) or (sagittal adj5 vein)).tw. (44,254)
18. 16 and 17 (4464)
19. transient isch?emic attack$.tw. (6048)
20. reversible isch?emic neurologic$ defecit.tw. (0)
21. venous malformation$.tw. (986)
22. arteriovenous malformation$.tw. (5925)
23. 21 or 22 (6773)
24. 10 and 23 (3405)
25. exp aphasia/ (8498)
26. hemianopsia/ (1453)
27. hemiplegia/ (5357)
28. (aphasi$ or dysphasi or hemianop$).tw. (7902)
29. (hemiplegi$ or hemipar$).tw. (11,021)
30. or/25-29 (23,098)
31. or/1-3,6,14-15,18-20,24,30 (306,678)
32. leukomalacia, periventricular/ (1509)
33. cerebral anoxia/ (5821)
34. exp dementia, vascular/ (5570)
35. exp Vascular Headaches/ (145)
36. migrain$.tw. (18,258)
37. or/32-36 (31,090)
38. 31 not 37 (293,645)
39. exp Computer Assisted Tomography/ (328,357)
40. (computed tomograph$ or ct).tw. (206,560)
41. 39 or 40 (383,395)
42. 38 and 41 (36,930)
43. exp economics/ (103,662)
44. exp technology assessment, biomedical/ (8431)
45. exp health resources/ (39,605)
46. cost$.tw. (240,084)
47. charge$.tw. (81,504)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2748. economic$.tw. (97,136)
49. finance$.tw. (4768)
50. economic evaluation.tw. (4046)
51. cost effective$.tw. (55,597)
52. economics model$.tw. (15)
53. markov$.tw. (8779)
54. monte carlo.tw. (16,251)
55. (decision$ adj2 (tree? or anly$ or model$)).tw. (6411)
56. quality of life/ (146,257)
57. quality adjusted life years/ (7026)
58. quality adjusted life.tw. (4490)
59. or/43-58 (655,474)
60. 38 and 41 and 59 (862)
61. limit 60 to english language (749)
62. limit 61 to yr = “2000 -Current” (671)
63. Nuclear Magnetic Resonance Imaging/ (274,871)
64. mri.tw. (110,011)
65. 63 or 64 (291,418)
66. 38 and 59 and 65 (661)
67. limit 66 to english language (591)
68. limit 67 to yr = “2000 -Current” (548)Chapters 9 and 11: costs and previous cost-effectiveness
analyses
Ovid MEDLINE(R) without Revisions
Searched: January 1996 to February week 2 2011.
1. exp “cerebrovascular disorders”/ (126,102)
2. stroke$.tw. (76,361)
3. cerebrovascular$.tw. (17,086)
4. (cerebral or cerebellar or brainstem or vertebrobasilar).tw. (144,798)
5. (infarct$ or isch?emi$ or thrombo$ or emboli$).tw. (318,894)
6. 4 and 5 (36,596)
7. (cerebral or intracerebral or intracranial or parenchymal).tw. (150,327)
8. (brain or intraventricular or brainstem or cerebellar).tw. (337,459)
9. (infratentoriral or supratentorial or subarachnoid).tw. (13,217)
10. or/7-9 (434,276)
11. (haemorrage or hemorrhage or haematoma or hematoma).tw. (52,406)
12. (bleeding or aneurysm).tw. (88,982)
13. 11 or 12 (130,357)
14. 10 and 13 (26,725)
15. carotid$.tw. (39,004)
16. thrombo$.tw. (119,079)
17. (intracranial or (venous adj5 sinus$) or (sagittal adj5 venous) or (sagittal adj5 vein)).tw. (32,586)
18. 16 and 17 (2992)
19. transient isch?emic attack$.tw. (4465)
20. reversible isch?emic neurologic$ defecit.tw. (0)
21. venous malformation$.tw. (702)
22. arteriovenous malformation$.tw. (4383)
23. 21 or 22 (4987)
24. 10 and 23 (2478)275
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APPENDIX 125. exp aphasia/ (3078)
26. hemianopsia/ (825)
27. hemiplegia/ (2715)
28. (aphasi$ or dysphasi or hemianop$).tw. (5041)
29. (hemiplegi$ or hemipar$).tw. (7941)
30. or/25-29 (14,176)
31. or/1-3,6,14-15,18-20,24,30 (199,900)
32. leukomalacia, periventricular/ (800)
33. cerebral anoxia/ (2574)
34. exp dementia, vascular/ (3548)
35. exp Vascular Headaches/ (110)
36. migrain$.tw. (12,180)
37. or/32-36 (19,027)
38. 31 not 37 (192,528)
39. Tomography, X-Ray Computed/ (148,332)
40. (computed tomograph$ or ct).tw. (149,853)
41. 39 or 40 (222,171)
42. 38 and 41 (20,937)
43. exp economics/ (228,595)
44. exp technology assessment, biomedical/ (4949)





50. economic evaluation.tw. (2990)
51. cost effective$.tw. (41,336)
52. economics model$.tw. (12)
53. markov$.tw. (6964)
54. monte carlo.tw. (12,959)
55. (decision$ adj2 (tree? or anly$ or model$)).tw. (4942)
56. quality of life/ (73,130)
57. quality adjusted life years/ (4632)
58. quality adjusted life.tw. (3430)
59. Tomography, X-Ray Computed/ec [Economics] (726)
60. or/43-58 (537,088)
61. 42 and 60 (402)
62. limit 61 to english language (349)
63. Magnetic Resonance Imaging/ (177,270)
64. mri.tw. (78,522)
65. 63 or 64 (197,809)
66. magnetic resonance Imaging/ec (560)
67. or/43-58,66 (537,174)
68. 38 and 61 and 67 (402)
69. limit 68 to english language (349)
70. limit 69 to yr = “2000-current” (284)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Chapters 9 and 11: costs and previous cost-effectiveness
analyses
Database: Evidence-based Medicine reviews – Health Technology
Assessment first quarter 2011, EBM reviews – NHS Economic Evaluation
Database first quarter 2011
Search strategy1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or brain ischemia/ or exp brain
infarction/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or
cerebal arterial diseases/ or exp “intracranial embolism and thrombosis”/ or stroke/ or
Hypoxia-Ischemia, Brain/ (583)
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw. (164)
3. (isch?emi$ adj6 (stroke or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw. (159)
4. 1 or 2 or 3 (692)
5. (minor or mini or mild or warning).tw. (1233)
6. 4 and 5 (53)
7. Ischemic Attack, Transient/ (31)
8. (transient adj3 (ischemi$ or ischaemi$)).tw. (78)
9. (transient adj3 attack$).tw. (77)
10. TIA.tw. (25)
11. 6 or 7 or 8 or 9 or 10 (117)
12. exp Magnetic Resonance Imaging/ (386)
13. ((magnetic resonance or MR or NMR or diffusion weighted or T2-weighted) adj2 image$).tw. (14)
14. ((MR or NMR) adj2 tomograph$).tw. (0)
15. (MR or DWI).tw. (107)
16. 12 or 13 or 14 or 15 (424)
17. exp Tomography, X-Ray Computed/ (509)
18. (CT or CAT).tw. (491)
19. 17 or 18 or “19”.mp. [mp = ti, tx, hw] (13,868)
20. 17 or 18 or 19 (13,868)
21. 16 or 20 (14,085)
22. (“1995$” or “1996$” or “1997$” or “1998$” or “1999$” or “20$”).ed. (0)
23. 11 and 21 and 22 (0)
24. limit 23 to humans (0)
25. (di or du).fs. (3995)
26. 24 and 25 (0)
27. 24 not 26 (0)
28. exp basal ganglia hemorrhage/ or exp intracranial hemorrhages/ (86)
29. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraventricular or
infratentorial or supratentorial or basal gangli$ or subarachnoid or putaminal or putamen or
posterior fossa) adj15 (haemorrhage$ or hemorrhage$ or haematoma$ or hematoma$ or bleed$)).
tw. (183)
30. ((haemorrhag$ or hemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).
tw. (62)
31. 28 or 29 or 30 (208)
32. (minor or mini or mild or warning).tw. (1233)
33. 31 and 32 (43)
34. 21 and 22 and 33 (0)
35. limit 34 to humans (0)277
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APPENDIX 136. 35 not 24 (0)
37. (stroke adj5 (mimic$ or misdiagnosis)).tw. (1)
38. (stroke?like or true stroke or pseudostroke).tw. (1)
39. 37 or 38 (1)
40. 21 and 22 and 39 (0)
41. 40 not (24 or 36) (0)
42. exp “costs and cost analysis”/ (25,213)
43. economics/ (50)
44. economics, hospital/ (96)
45. economics, medical/ (122)
46. economics, pharmaceutical/ (635)
47. economic evaluation.mp. (23,416)
48. exp budgets/ (172)
49. exp decision theory/ (733)
50. monte carlo method/ (324)
51. markov chains/ (1161)
52. exp technology assessment, biomedical/ (528)
53. cost$.ti. (16,475)
54. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab. (0)
55. economics model$.tw. (3)
56. (economic$ or pharmacoeconomic$ or pharmo-economic$).ti. (5381)
57. (price$ or pricing$).tw. (7874)
58. (financial or finance or finances or financed).tw. (1250)
59. (value adj2 (money or monetary)).tw. (231)
60. markov$.tw. (1792)
61. monte carlo.tw. (946)
62. (decision$ adj2 (tree? or anly$ or model$)).tw. (2706)
63. or/42-62 (30,875)
64. 63 and 4 (568)
65. 63 and 11 (109)
66. 63 and 11 and 23 (0)
67. (4 or 6 or 7 or 8 or 9 or 10) and 47 (390)
68. quality of life/ (2132)
69. quality adjusted life years/ (2434)
70. “Value of Life”/ (271)
71. health status indicators/ (221)
72. health status/ (550)
73. sickness impact profile/ (101)
74. disability evaluation/ (198)
75. activities of daily living/ (299)
76. disability.mp. (796)
77. cost utility analysis.mp. (2106)
78. rating scale.mp. (171)
79. questionnaire/ (0)
80. (quality adj1 life).tw. (38)
81. quality adjusted life.tw. (3704)
82. disability adjusted life.tw. (107)
83. (qaly? or qald? or qale? or qtime? or daly?).tw. (2374)
84. (euroqol or euro qol or eq5d or eq 5d).tw. (539)
85. (hql or hqol or h qol or hrqol or hr qol).tw. (61)
86. (hye or hyes).tw. (2)
87. health$ year$ equivalent$.tw. (5)
88. (hui or hui1 or hui2 or hui3).tw. (50)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2789. (health adj3 (utilit$ or disutili$)).tw. (474)
90. (health adj3 (state or status)).tw. (1870)
91. (sf36 or sf 36 or short form 36 or shortform 36).tw. (240)
92. (sf6 or sf 6 or short form 6 or shortform 6).tw. (3)
93. (sf12 or sf 12 or short form 12 or shortform 12).tw. (32)
94. (sf20 or sf 20 or short form 20 or shortform 20).tw. (1)
95. willingness to pay.tw. (942)
96. standard gamble.tw. (177)
97. trade off.tw. (358)
98. conjoint analys?s.tw. (360)
99. discrete choice.tw. (376)
100. or/68-99 (7282)
101. 11 and 100 (53)
102. limit 101 to yr = “2000 -Current” (36)Chapters 9 and 11: costs and previous cost-effectiveness
analyses
Database: Evidence-based Medicine reviews – Cochrane Database of
Systematic Reviews (2005 to February 2011), Evidence-based Medicine
reviews – ACP Journal Club (1991 to February 2011), Evidence-based
Medicine reviews – Database of Abstracts of Reviews of Effects
(first quarter 2011), Evidence-based Medicine reviews – Cochrane Central
Register of Controlled Trials (first quarter 2011), Evidence-based Medicine
reviews – Cochrane Methodology Register (first quarter 2011),
Evidence-based Medicine reviews – Health Technology Assessment
(first quarter 2011), Evidence-based Medicine reviews – NHS Economic
Evaluation Database (first quarter 2011)
Search strategy1. (stroke or cerebrovascular or vascular or cerbral or subrachnoid)/All Fields OR dementia/Subject
Headings) AND (tomography OR ct OR magnetic OR mri/All fields {Including Limited
Related Terms} (281)
2. limit 1 to english language [Limit not valid in CDSR,ACP Journal Club,DARE,CCTR,CLCMR; records were
retained] (281)
3. limit 2 to yr = “2000 -Current” [Limit not valid in DARE; records were retained] (225)
4. limit 3 to humans [Limit not valid in CDSR,ACP Journal Club,DARE,CCTR,CLCMR; records were
retained] (222)Evidence-based Medicine Reviews – Cochrane Database of
Systematic Reviews
Searched: 2005 to January 2011.Search strategy1. [exp economics/] (0)
2. [exp Technology Assessment, Biomedical/] (0)
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APPENDIX 17. finance$.tw. (60)
8. economic evaluation.tw. (206)
9. cost effective$.tw. (1221)
10. or/1-9 (3821)
11. [exp cerebrovascular disorders/] (0)
12. stroke$.tw. (842)
13. cerebrovascular$.tw. (414)
14. (cerebral or cerebellar or brainstem or vertebrobasilar).tw. (811)
15. (infarct$ or isch?emi$ or thrombo$ or emboli$).tw. (1738)
16. 14 and 15 (429)
17. [exp Ischemic Attack, Transient/] (0)
18. or/11-17 (2350)
19. Magnetic Resonance Angiography/ ec {Including Related Terms} (71)
20. 18 and 19 (20)
21. 10 and 20 (16)
22. limit 21 to yr = “2000 -Current” (16)
23. from 22 keep 1-5 (5)
24. [exp economics/] (0)
25. [exp Technology Assessment, Biomedical/] (0)





31. economic evaluation.tw. (206)
32. cost effective$.tw. (1221)
33. or/24-32 (3821)
34. [exp cerebrovascular disorders/] (0)
35. stroke$.tw. (842)
36. cerebrovascular$.tw. (414)
37. (cerebral or cerebellar or brainstem or vertebrobasilar).tw. (811)
38. (infarct$ or isch?emi$ or thrombo$ or emboli$).tw. (1738)
39. 37 and 38 (429)
40. [exp Ischemic Attack, Transient/] (0)
41. or/34-40 (2350)
42. Tomography, X-Ray Computed/ec[Economics] {Including Related Terms} (8)
43. 41 and 42 (3)
44. 10 and 43 (3)
45. limit 44 to english language [Limit not valid; records were retained] (3)
46. limit 45 to yr = “2000-Current” (3)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Appendix 2 Critical appraisal toolsChapter 5: the addition of computed tomography brain and
carotid imaging to clinical risk prediction scores of recurrent
stroke after transient ischaemic attackItem Description Scoring
1 Patient recruitment
Were the patients a
consecutively recruited sample?
Y – Patients were recruited consecutively. In prospective studies, this means
that efforts were made to recruit all patients who met the eligibility criteria
over the time frame on the study. In retrospective studies, this means that
efforts were made to identify all patient records within the time frame
of the study
N – Patients formed, for example, a convenience sample
U – Insufficient detail reported in the study
2 Definition of a TIA Y – The definition of a TIA is given, for example the WHO definition of
sudden neurological deficits lasting <24 hours with full recovery
3 TIA status
Was the TIA status of the
patients defined?
Y – The TIA status of the patients was described in the study. For example,
patients are described as confirmed, probable, suspected TIA cases
N – For example, patients described as TIA only, with no indication of
whether this is suspected, confirmed, probable, possible
U – Unclear
4 Positive CT scan Y – The definition of a positive CT scan is described, for example a new
lesion apparent on CT consistent with the clinical symptoms
N – No definition given
U – Unclear
5 Positive carotid stenosis scan Y – The definition of a positive carotid stenosis diagnosis is given, for
example >70% stenosis by the NASCET method
N – No definition is given
U – Unclear
6 Definition of outcome Y – The definition of recurrent disabling stroke is given. For example, new
neurological symptoms lasting >24 hours, confirmed by a neurologist,
resulting in a mRS score of >2
N – No definition of recurrent disabling stroke is given. This includes studies
that state that the outcome was recurrent stroke but do not give an
indication of whether it was disabling or not
U – Unclear
7 Time interval between symptom
onset and scanning
Y – The time interval between presenting event and CT brain scan/carotid
imaging is given. This is coded as ‘Y’ if the maximum time is given (i.e. the
greatest possible time interval is known for all patients)
N – The time interval is not given
U – The time interval is given as a mean or some way such that it is not
possible to infer how many patients had late CT scans
281
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Item Description Scoring
8 Treatment Y – Description of treatments given, with some indication of the number of
patients undergoing treatment and relation to outcome
N – No description given
U – The treatments are described but with no indication of patient numbers
or how they might have affected outcomes
9 All patients included in analysis Y – The results refer to all or most (>80%) of patients recruited into the
study, or there is an explanation for any mismatch that does not indicate that
the subsample is a biased subsample
N – There is a mismatch between the number recruited and the number
included in the analysis, and the subsample is biased
U – There is a mismatch between the number recruited and the number
included in the analysis, but it is not clear whether the subsample is
biased or not
282
APPENDIX 2Chapter 7: diagnosis of transient ischaemic attack, minor
stroke and mimics: systematic review and meta-analysis of
frequency, differential diagnosis and prognosis of
non-cardiovascular eventsItem Description Data recorded
1 Sample size The number of patients recruited into the study
2 Study design – was the study
prospective or retrospective?
Recorded as prospective if data were collected from patients over time, at
time of recruitment outcomes had not occurred, retrospective if data were
taken from existing records or similar, and unknown if insufficient detail
reported in the study
3 Specialism of person making
final diagnosis of TIA
Recorded as neurologist, geriatrician, stroke physician, GP or nurse
4 Setting of study Recorded as TIA clinics, hospital, ED and population based
5 Did the study use predefined
criteria for a TIA
Recorded as having used predefined criteria if a description given, also noted
if the description was time based
6 Method of final diagnosis Recorded as having been made in person or by review of patient records
7 Method of follow-up Recorded as having been made in person or by review of patient records
8 Numbers of patients with a
final diagnosis of a non-CV
event
Recorded as the number of patients with a non-CV event and the total
number recruited, to enable the calculation of the proportion of non-CV
patients with associated CI
9 Other diagnoses The most frequent differential diagnoses for non-CV patients
10 Outcomes of non-CV patients The number of non-CV patients with further strokes, MI or vascular causes
of death
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transient ischaemic attack or minor stroke in the UK:
cover letter and questionnaire283
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RE: SURVEY OF SECONDARY STROKE PREVENTION SERVICES IN THE UK 
 
We are funded by the NHS R&D Health Technology Assessment (HTA) programme to determine the "Cost 
effectiveness of imaging investigations in secondary stroke prevention" in the UK. We seek accurate information 
on current provision of clinical services in the UK for secondary prevention of stroke, with particular regard to 
volume of work, capacity, professionals involved, and timing of investigations in TIA/minor stroke clinics.  
 
We understand that you are the Clinical Lead of the stroke services in your hospital/town. We are therefore 
inviting you to complete an on-line survey with respect to secondary stroke prevention services in your area. As 
this is a national project, funded by the NHS R&D programme, your response is crucial to ensuring that precise 
and reliable data are available for this research.  
 
The information derived from this survey will be treated in strict confidence. Your identity and location will be 
known only to the members of the research team who are bound by the Research Governance Framework for 
Health and Social Care (2005) to maintain confidentiality regarding all personal information collected in the 
course of this research. Any publications arising from this project, including the full HTA report, will contain 
only anonymised data. 
If you are not the right person to complete this survey (i.e. if you are not responsible for running the stroke clinic), 
we apologise for bothering you but would be extremely grateful if you could tell us who the correct person is or 
forward this message to him/her (but please let us know who he/she is for our records). 
 




The survey takes approximately 15 minutes to complete. You can exit it at any time, without the information 
entered thus far being saved or sent to us, by clicking on the ‘Exit Survey’ link in the top right corner of the 
survey page. 
 
We would be grateful if you could complete the survey by May 13th. We greatly appreciate your taking the time 
to contribute to this project.  
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APPENDIX 3If you have any questions or concerns, please do not hesitate to contact the project co-ordinator: Dr Miriam 
Brazzelli, Division of Clinical Neurosciences, University of Edinburgh, Telephone 0131 5372955, E-mail 
m.brazzelli@ed.ac.uk, myself (martin.dennis@ed.ac.uk), or the project principal investigator Professor Joanna 
Wardlaw, Division of Clinical Neurosciences, University of Edinburgh, E-mail joanna.wardlaw@ed.ac.uk. Thank 
you in advance for your help and co-operation. 
 




Professor of Stroke Medicine 
Chair of National Advisory Committee for Stroke 
Division of Clinical Neurosciences, University of Edinburgh NIHR Journals Library www.journalslibrary.nihr.ac.uk
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RE: ACCESS TO IMAGING FACILITIES FOR PATIENTS WITH SUSPECTED TIA OR 
MINOR STROKE IN THE UK 
 
 
We are funded by the NHS R&D Health Technology Assessment (HTA) programme to determine the 
"Cost effectiveness of imaging investigations in secondary stroke prevention" in the UK. We seek 
accurate information on current provision of CT and MR imaging services in the UK for secondary 
prevention of stroke, with particular regard to volume of work, capacity, and timing of investigations 
in radiology departments. 
  
We understand from the Diagnostic Imaging Clinical Network that you are the Clinical Director of the 
Radiology Department in your hospital/town. We are therefore inviting you to complete an on-line 
survey. The survey contains questions on your current imaging facilities, working hours, waiting 
times, and on the impact that any increase in demand for MR scanning would have on Radiology 
workload. As this is a national project, funded by the NHS R&D panel, your response is crucial to 
ensuring that precise and reliable data are available for this research. 
 
The information derived from this on-line survey will be treated in strict confidence. Your identity 
and location will be known only to the members of the research team who are bound by the Research 
Governance Framework for Health and Social Care (2005) to maintain confidentiality regarding all 
personal information collected in the course of this research. Any publications arising from this 
project, including the full HTA report, will contain only anonymised data. 
If you are not the right person to complete this survey we apologise for bothering you but would be 
extremely grateful if you could tell us who the correct person is or forward this message to him/her 
(but please let us know who he/she is for our records). 
 




The survey takes approximately 15 minutes to complete. You can exit it at any time, without the 
information entered so far being saved or sent to us, by clicking on the ‘Exit Survey’ link in the top 347
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APPENDIX 4right corner of the survey page. 
 
We would be grateful if you could complete the survey by May 13th. We greatly appreciate your 
taking the time to contribute to this project.  
 
If you have any questions or concerns, please do not hesitate to contact the project co-ordinator: Dr 
Miriam Brazzelli, Division of Clinical Neurosciences, University of Edinburgh, Telephone 0131 
5372955, E-mail m.brazzelli@ed.ac.uk, or myself (Division of Clinical Neurosciences, University of 
Edinburgh, E-mail joanna.wardlaw@ed.ac.uk).  
  
Thank you in advance for your help and co-operation. 
 
Yours sincerely,  
 
Professor Joanna Wardlaw 
 
Professor and Honorary Consultant Neuroradiologist Director, SINAPSE Collaboration, SFC Brain 
Imaging Research Centre 
Division of Clinical Neurosciences 
University of Edinburgh 
Western General Hospital 
Crewe Road 
Edinburgh EH4 2XU 
Tel 0131 537 2943 
Fax 0131 332 5150 
E-mail joanna.wardlaw@ed.ac.uk 
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NETSCC, Health Technology Assessment
Alpha House
University of Southampton Science Park
Southampton
SO16 7NS3. Project steering groupl Professor Joanna Wardlaw, Professor of Applied Neuroimaging and an Honorary Consultant
Neuroradiologist, at the University of Edinburgh and NHS Lothian
l Dr Paul McNamee, a Senior Research Fellow in Health Economics at the Health Economics Research
Unit (HERU), University of Aberdeen
l Professor Martin Dennis, Professor of Stroke Medicine and an Honorary Consultant Stroke Physician at
the University of Edinburgh and NHS Lothian
l Professor Peter Sandercock, Professor of Neurology and Honorary Consultant Neurologist at the
University of Edinburgh and NHS Lothian
l Ms Miriam Brazzelli, Research Fellow at the Division of Clinical Neurosciences, University of Edinburgh
l Dr Janet de Wilde, Medical Physicist and Project Co-ordinator of SINAPSE
l Professor Keith Muir, SINAPSE Professor of Clinical Imaging and Honorary Consultant Neurologist with
an interest in stroke, University of Glasgow and NHS Glasgow
l Professor Donald Hadley, Professor and Honorary Consultant Neuroradiologist, University of Glasgow
and NHS Glasgow
l Dr Peter Tothill, Lay representative
l Dr G Scotland, Health economics research fellow, University of Aberdeen
l Dr Francesca Chappell, Statistician, University of Edinburgh.4. Research objectives
Our primary research objective is to determine whether magnetic resonance (MR) including
diffusion-weighted imaging (DWI) as well as other relevant structural and blood-sensitive sequences is
cost-effective in the majority of patients with transient ischaemic attack (TIA) or minor stroke to guide
diagnosis and secondary stroke prevention, compared with the current alternative of computerised
tomography (CT) brain scanning.
Secondly to determine the cost and cost-effectiveness of increased use of MR including DWI and
blood-sensitive sequences in patients presenting more than five days after TIA/minor stroke when CT will
not be able to identify haemorrhage as the cause of stroke reliably.
Thirdly to estimate if ‘one-stop’ brain and carotid imaging is more cost-effective than individual separate
brain and carotid examinations, in what proportion of patients a ‘one-stop’ approach could be used, and349
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APPENDIX 5the practical and cost implications. Fourth, to determine physicians and radiologists current attitudes to
increased use of MR in TIA/minor stroke, the availability, barriers to greater use, costs of increasing
availability and net effect on other patient groups in whom MR is commonly used. We will do this by
modelling the effectiveness, cost-effectiveness and practical implications of using MR imaging in different
proportions of patients with TIA or minor stroke at different times after symptom onset, using systematic
reviews of the relevant literature, surveys of current practice and costs, existing stroke registry and cohort
data and data linkage. If MR cannot be justified in all patients, then we will also determine in which
subgroups of patients the use of MR is cost-effective. We will provide a range of options reflecting effect
of using MR in different proportions of TIA/minor stroke patients to guide decision-making by health
service purchasers.5. Background
Stroke remains a major public health burden: In the UK, about 150,000 people have a stroke each
year. About 30% die within six months and another 30% survive dependent on others for everyday
activities, making stroke the commonest cause of dependency in adults and the third commonest cause
of death in the world.1 Stroke costs the NHS in England around £7bn per year.2 Eighty per cent of
strokes are ischaemic and most ischaemic strokes are due to an artery in the brain becoming blocked by
atherothromboembolism. Treatment of stroke is limited, so prevention is vital. About 20–40% of people
have a warning TIA or minor non-disabling ischaemic stroke shortly before they have a major disabling
stroke.3,4 If these people can be assessed quickly, potential stroke causes identified and given the
appropriate treatment, then many of these disabling strokes can be prevented.5
TIA is defined as ‘a sudden loss of focal cerebral or monocular function lasting less than 24 hours and
which is thought to be due to inadequate cerebral or ocular blood supply as a result of low blood flow,
thrombosis or embolism associated with disease of the arteries, heart or blood’.6 While the definition
of TIA purely on the basis of clinical grounds is the subject of debate,7,8 for the present time we will use
this clinical definition. Patients with minor stroke, which only differs from TIA by symptoms or signs lasting
more than 24 hours, are also at high risk of early recurrent stroke and need the same assessment and
treatment as for patients with TIA to prevent a further disabling stroke or death. A small proportion of
TIA/minor stroke (less than 5%) are actually due to a small haemorrhage in the brain, but this can only be
distinguished by brain scanning.
TIA and minor stroke are common: In the UK, there are estimated to be 80,000 to 90,000 TIAs and
minor strokes per year.9 Therefore, the average regional hospital serving a population of 750,000 will see
about 1000 suspected cases per year, i.e. 20 per week. Delivering effective stroke prevention to this
number of people is challenging and requires highly organised stroke services that are able to respond
rapidly and precisely. However the personal, societal, public health and financial burden of stroke in the
UK is such that every effort should be made to limit the damaging effects of having a major disabling
stroke, and to determine how to make best use of our available resources.10–13
TIA and minor stroke is a medical emergency: The period of highest risk of disabling stroke is in the
first few hours and days after a TIA/minor stroke, thus making suspected TIA/minor stroke a medical
emergency:4,6,14,15 between 8% and 11.5% of patients will have a recurrent stroke by one week and
between 11.5% and 15% by one month after TIA/minor stroke unless effective secondary prevention is
started.9 In the USA, there are about 240,000 TIAs per annum, of whom 25% had had a further TIA, a
stroke or died by three months.16 Prevention of recurrent stroke is by rapid identification of underlying risk
factors (such as ipsilateral tight carotid artery stenosis, atrial fibrillation, hypercholesterolaemia,
hypertension) and implementation of optimal medical (antiplatelet agents, statins, antihypertensives or
anticoagulants where necessary)5,6,17 and surgical treatment (endarterectomy for symptomatic moderate to
severe carotid stenosis).18
Appropriate treatment of those whose symptoms are not due to vascular disease: The diagnosis
of TIA/minor stroke brings a threat of disabling stroke or death and causes much worry for patients.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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preventative therapy (antiplatelet, statin, angiotensin converting enzyme inhibitor and diuretic). In the light
of the EXPRESS study, many patients with suspected acute ischaemic cerebrovascular disease following
presentation with TIA/minor stroke are started on quadruple therapy pending specialist investigation and
treatment. It is therefore important to ensure that the patients, whose symptoms after due investigation
are proven not to be due to acute ischaemic cerebrovascular disease, particularly the small proportion
(< 5%) whose symptoms are due to a small haemorrhage, then avoid inappropriate or unnecessary and
possibly hazardous drug treatment. So, if MR imaging can reliably help exclude acute ischaemic
cerebrovascular disease as the cause of symptoms, then an additional benefit is that patients will avoid the
inconvenience and risk (of adverse drug reactions) and the health service will avoid the cost of unnecessary
drug treatment.
Clinical stroke risk prediction: Several scoring systems have been devised that aim to improve
identification of patients at high risk of disabling recurrent stroke after TIA/minor stroke: a score developed
in 469 patients with TIA seen in the 1980s based on clinical variables;19 a score developed in the European
Carotid Surgery Trial (1980s to mid 1990s) data;20 the ABCD score developed using data from a
population-based stroke and TIA registry conducted in the 1980s (Oxfordshire Community Stroke
Project – OCSP) and tested in a repeat study in the same population in the early 2000s (Oxford Vascular
Study – OxVasc);21 an updated version of this derived in the OCSP TIA patients and patients attending a
private health provider in the USA and tested in OxVasc and more USA patients, the ABCD2 score;22 the
Essen Stroke Risk Score which was derived from a subset of ischaemic stroke patients in the Clopidogrel
versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial and validated in two observational
studies and in data from another stroke prevention trial;23 the Stroke Prognosis Instruments I and II (SPI-I
and SPI-II) were developed in medical stroke prevention trials and validated in three independent cohorts;24
and the LIfe Long After Cerebral Ischaemia score (LiLAC), which was based on data from the Dutch TIA
trial (1986–1989), has not been externally validated.25 All except two20,24 of these scores use only simple
clinical features so are rapid and easy to apply without needing complex technologies.19,21,22,25 For
example, the ABCD2 score uses age, blood pressure, clinical features, duration of symptoms and diabetes
to derive a score from zero to seven. These scores could help to reduce delays to reaching medical
attention and to triage patients,26 so that those needing most rapid treatment such as carotid
endarterectomy would reach surgery more quickly. They might also improve the accuracy of clinical
diagnosis of TIA by non-stroke physicians, thereby also making better use of resources.
Problems with clinical stroke risk prediction: Many of these scores performed well in the population
from which they were derived and often also in initial testing in a different cohort,27,28 but then wider use
uncovered difficulties. For example, independent testing of the ABCD and ABCD2 scores22 has not been
universally positive.29,30 While in the OxVasc Study, the ABCD2 score was highly predictive of recurrent
stroke within 7 days of TIA (p < 0.01), it did not predict stroke between eight and 90 days, because in this
group, patients with lower scores had a higher risk of stroke than those with high ABCD2 scores
(p = 0.04).30 The ABCD2 score also did not predict recurrent stroke in patients with minor stroke (as
opposed to TIA). Thus TIA clinical risk prediction scores may not usefully predict stroke risk more than
7 days after TIA and may be of limited value in patients with minor stroke. Most scores were devised and
tested in highly selected populations of patients with definite TIA/minor stroke such as randomised
multicentre trials or observational studies where the patient had to have a definite TIA/minor stroke to get
into the study. However this is not the population of suspected TIA/minor stroke that typically presents to
the ‘front door’ of the hospital. In this unselected population, up to 50% do not ultimately turn out to
have had a TIA/minor stroke and therefore should have a low risk of recurrent stroke.31 However the net
effect of applying a clinical risk score in this mixed population was that many true TIA/minor strokes were
given a low ABCD2 score and therefore would have missed rapid access to stroke services.31 In this sense,
the use of a clinical risk score could have actually led to a net failure to prevent recurrent stroke. This
reflects a general limitation of low specificity scoring or screening systems – namely that while they may
detect the small proportion of patients with particularly high risk of recurrent stroke, many recurrent
strokes actually occur in patients deemed to be at moderate or low risk only (because there are many351
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APPENDIX 5more of them). Widespread use of clinical risk scores in this setting could therefore put at risk patients in a
‘slow stream’ who would then potentially not receive treatment quickly enough to prevent stroke.
Could stroke prediction scores be improved with imaging? Part of the problem may be that a) the
clinical diagnosis of TIA/minor stroke is difficult and b) the clinical findings have low specificity for the likely
underlying cause, but the future stroke risk is closely related to the cause. The clinical diagnosis of TIA and
minor stroke is made difficult, especially for non-experts, by the high proportion of patients (up to 50%)
11,31–34 that actually have common mimics of TIA/minor stroke. Common mimics include migraine, transient
global amnesia, epilepsy, simple faints, tumours, functional disorders, etc.31,33 It is not possible to
determine the cerebral pathological cause of symptoms, i.e. whether infarct, haemorrhage or mimic
(e.g. tumour), without a brain scan.35,36 The conventional brain scanning technique for stroke and TIA is
CT, now widely available in the NHS. While CT excludes tumours and haemorrhage if done acutely,37
it is insensitive to small infarcts, so does not ‘positively’ diagnose TIA/minor stroke.38 CT demonstrates an
infarct in a maximum of 50% of minor acute strokes39 and 43% of mixed minor stroke and TIA,40
although the sensitivity may be lower in older patients with brain tissue loss and leukoaraiosis.
Nonetheless, the presence of an infarct on CT in patients presenting with TIA is associated with increased
short term risk of stroke,41 CT has high specificity for ischaemia,42 visible infarction on CT is an
independent predictor of poor outcome (dependency or death) after any ischaemic stroke,39,43 CT is very
accurate for haemorrhage within the first five days of symptoms38,42 and for tumours and other
non-vascular causes of sudden neurological symptoms, giving it many advantages to balance its two
disadvantages – the low sensitivity for acute ischaemic stroke and for small haemorrhages that are more
than five days old.
Some have questioned the usefulness of scores that do not incorporate significant carotid disease or other
potential cardioembolic sources.44 However, only two scoring systems included carotid stenosis as part of
the risk prediction,20,24 and found, along with other studies,45 that adding tight carotid stenosis did
improve risk prediction. Carotid imaging is an integral part of the assessment of TIA and minor stroke. Its
cost-effectiveness was assessed in a previous HTA-funded project by our group.11 This work showed that
rapid access to carotid imaging to identify and measure carotid stenosis was the most cost-effective way of
using carotid imaging, and that the four non-invasive imaging methods functioned similarly in terms of
stroke prevention, although ultrasound was the most cost-effective of the four techniques if used early
after TIA/minor stroke.46 The focus of the present application is on how to improve stroke prevention
through use of brain imaging techniques, so comparative carotid imaging will not be considered further.
The alternative brain imaging test – advantages of MR:
a) Higher sensitivity for ischaemic lesions. MR imaging, if it includes DWI, is very sensitive to
ischaemia. MR imaging is widely used to investigate many neurological disorders, musculoskeletal
problems and in oncology. MR imaging is very versatile because different sequences can be used to
highlight different types of pathology relevant to stroke. For example, DWI is very sensitive to changes in
the mobility of water in the brain; one of the earliest changes in the brain at the onset of ischaemia is cell
swelling which reduces the extracellular space and hence restricts water movement. Thus, early ischaemia
shows up well on DWI, even very early after the symptoms start and even in very small lesions causing mild
symptoms.47 DWI primarily displays ischaemic areas as white on a dark background, so ischaemic lesions
are much more obvious than they are on CT scanning, where ischaemic lesions appear as dark on a dark
background. MR DWI shows even very tiny ischaemic lesions soon after symptom onset in 16% to 67% of
TIAs (mean 37%)48,49 and about 70% to 90% of minor strokes overall, even weeks after the event.42,47,49–52
Currently, with CT scanning, if the scan provides no positive evidence of an ischaemic lesion, the diagnosis
of ischaemia is often assumed if the scan has excluded haemorrhage and stroke mimics. By contrast, MR
including DWI could help make a ‘positive’ diagnosis of brain ischaemia in TIA/minor stroke in a larger
proportion of (but not all) patients.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27b) Higher sensitivity for haemorrhage in patients presenting late. MR, if it includes T2*-weighted
imaging (also known as Gradient Echo) or equivalent, is very sensitive to haemorrhage, even years after
the event. CT is very sensitive to acute haemorrhage but cannot reliably detect haemorrhage in patients
who first present more than five days after a minor ischaemic stroke. The high sensitivity of MR T2*
sequences for haemorrhage is clinically very helpful in such patients – and can avoid inappropriate use of
antiplatelet agents, anticoagulants and carotid endarterectomy in patients with haemorrhagic stroke.
c) Defining the arterial territory(ies) affected. MR can also help management in other ways. In some
patients with carotid stenosis it is difficult to decide if the clinical event occurred in the territory of that
artery if not.53 DWI is helpful, if it can confirm that a TIA/minor ischaemic stroke was in the territory of a
tight carotid stenosis, so leading to endarterectomy.53 The presence of lesions in several territories would
indicate a need to search a more proximal source of embolism, e.g. in the heart.54
d) Excluding acute ischaemic cerebrovascular disease as the cause. If MR is proven also to have both
high specificity, it will, by helping to exclude acute ischaemic cerebrovascular disease as the cause of
symptoms and if in a large enough proportion of patients, potentially have a greater role in avoiding
unnecessary or inappropriate treatment.
The evidence on the contribution of MR to diagnosis, stroke prediction and hence potential for patient
management and cost-effectiveness after TIA/minor stroke is conflicting. No studies have addressed the
cost-effectiveness of using MR including DWI and other relevant sequences in TIA/minor stroke. Most
studies of cost-effectiveness of imaging in stroke have either concentrated on hyperacute disabling
stroke35,55 or on carotid imaging for carotid stenosis11 as part of carotid endarterectomy.56 There are no
clinical trials of diagnostic accuracy or effect on prediction of prognosis of MR including DWI and other
relevant sequences, only smallish observational studies, from which it is unclear whether DWI adds
prognostic information to simple clinical scoring systems. The 29 studies of MR DWI in patients with TIA or
TIA and minor stroke published since 1999 include 2881 patients imaged between a few hours of onset
of symptoms and nearly three weeks after the event. DWI was positive for ischaemic change in 37%
(mean, ± 12% SD, range 16–67%).48,49,57–59 Note: some studies are by the same research groups (so there
may be some data duplication): all are single centre studies (so lack generalisability); some were
retrospective; and many only included a modest proportion of their TIA population (e.g. 53%)59 (so may be
prone to selection and small study bias). Many studies suggested that having a lesion on DWI (versus not
having a lesion) predicted increased risk of subsequent stroke,59–62 but others found that lesions on DWI
matched the same clinical features that are predictive of stroke after TIA and are already predicted by
clinical scoring.48,63 Whilst having a lesion on DWI was an independent risk factor for stroke in some
studies,59–62 several others failed to confirm this independent association63 and instead found that clinical
features and carotid stenosis were stronger predictors.58,62 However, the accuracy of the widely publicised
ABCD and ABCD2 clinical scores22 in predicting stroke risk has recently been questioned,30,64 so DWI
could add prognostic as well as diagnostic value after all. Furthermore, for the published literature of the
diagnostic and prognostic utility of MR, we cannot exclude the possibility of publication bias. Finally, the
focus on DWI has overlooked the contribution of other MR sequences to identifying recent and old
haemorrhage and its accuracy in detecting stroke mimics (which may be no better than CT).
The problems with MR. The available data are limited by the study methodological factors, listed above.
MR is also much more expensive than CT scanning (about £400 for MR versus £150 for CT brain
scanning.)11 It is still in very short supply in the UK, with long waiting lists even for patients with
established indications for MR. Thus, there is very limited capacity to provide rapid access to MR for people
with TIA and stroke (MR delayed even by a few days is of little value since the patient will miss the
window of opportunity to have preventative treatment during the early days of highest risk).65 Although
75% of UK hospitals had MR on site, less than 10% were able to scan patients early after stroke.65 The
UK is not alone in this as across the EU, only 5% of hospitals met criteria for stroke care which included
availability of MR for stroke (and surprisingly the UK had the highest proportion of hospitals with MR for
stroke).66 Any increase in use of MR for stroke prevention could result in reduced availability for – for353
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wardlaw et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
354
APPENDIX 5example – patients with cancer, where MR is of established benefit. Some patients cannot have MR
because of contraindications, e.g. having a pacemaker, claustrophobia or metal implant, so there would
always be a need for CT. In one recent study, only 90/904 patients [12%] considered for MR had
contraindications and only 477/904 (53%) of all patients presenting with TIA actually underwent MR; of
those having MR only 155/477 (33%, or 17% of the initial cohort) had a DWI-positive lesion. The accuracy
of MR for common mimics of TIA/minor stroke is unclear as most publications excluded patients who
turned out after further testing not to have had a stroke. Not all TIA patients have CT at present, so MR
including DWI would partly replace, and partly be an additional investigation, if it proved to be
cost-effective in improving the management of TIA.
Are guideline statements supported by robust evidence? The limited evidence has led some
reviewers to call for more data on imaging to guide physicians treating TIA patients.67,68 The NHS
Purchasing and Supply Agency 2008 report stated only that “DWI shows significant potential in the study
of TIA/minor stroke”, but also called for “more evidence”.69 Despite this – rather surprisingly – the 2008
UK Stroke Strategy guidelines and the National Institute for Health and Clinical Excellence (NICE) guidelines
advocate use of DWI in either 50% of70 or most71 TIA/minor stroke patients (www.dh.gov.uk/stroke). The
American Heart Association and related organisations stated that “TIA patients should undergo
neuroimaging evaluation within 24 hours of symptom onset, preferably with magnetic resonance imaging
including diffusion sequences”.72 The revised National Clinical Guidelines for Stroke,73 SIGN Guidelines
2008,74 and European Guidelines75 are more cautious but still advocate immediate brain imaging and use
of MR including DWI in large proportions of patients especially those with mild stroke. The guidance tends
to overlook the need for other sequences to identify haemorrhage and stroke mimics, hence there is a
need for further work to define the accuracy of MR for all aspects of stroke diagnosis and the incremental
difference, if any, from the accuracy of CT. Therefore, there is a ‘mismatch’ between national and
international guidance on the one hand,70,72 and convincing evidence to support this approach,48,49
information to guide precise usage,69 details of cost-effectiveness and available technology to deliver it on
the other,65,66 resulting in confusion about what to do in routine practice.
Summary: Potential benefits. MR including DWI and other relevant sequences, could make a substantial
impact as a positive diagnostic test for TIA/minor stroke by: improving diagnosis of the cause of stroke;
efficient patient selection for medical secondary prevention in patients with a proven diagnosis; conversely,
the avoidance of unnecessary treatment in patients in whom acute ischaemic cerebrovascular disease was
reliably excluded; and best use of carotid endarterectomy (especially where stroke expertise is limited).
Potential cost implications. TIA/minor stroke is so common that MR including DWI and other relevant
sequences would be in daily use in every hospital if such a strategy were adopted, but the direct costs to
the NHS would be substantial – £16 million per year to scan just the 50% of TIA patients suggested in
recent UK guidelines, not including the minor strokes and all the TIA mimics, assuming that MR were
available. Opportunity costs. The opportunity cost to meet the demand by increasing MR scanning
capacity, (without which there would also be substantial disadvantage to other MR users). Overall
cost-effectiveness unclear. It is not clear if the potential diagnostic and prognostic advantages of MR
outweigh the disadvantages of the obvious expense, limited availability, failure to make a positive
diagnosis of ischaemic lesion in up to 66% of TIA patients, unquantified accuracy for other stroke-related
diagnoses, and possibility that the strokes that we are trying to prevent might occur during the wait for a
scan if availability cannot be rapidly increased. Any strategy to increase MR usage would have to factor in
the effect of varying delays introduced because of waiting for MR. We are not aware of any large or
multicentre studies ongoing on this topic, although it is likely that single centre studies are ongoing. The
proposed study aims to resolve this controversy by summarising all available data on MR including DWI
and other relevant sequences, diagnosis and stroke prediction, and model the cost-effectiveness of
increasing MR including DWI and other relevant sequences usage to existing stroke prevention strategies.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 276. Plan of investigation
Design: The study is an evidence synthesis of literature data, surveys of practice and costs, and health
economic modelling with sensitivity analyses of important variables (see Diagram).
1) Systematic review: We will systematically review the literature to: estimate the sensitivity/specificity of CT
and MR including DWI and other relevant sequences in TIA/minor stroke, including the arterial territory; to
assess their role in prediction of stroke after TIA; to estimate costs of CT and MR (summarised to 2003 in35
but requiring updating); and to gather all data required to model stroke prevention after TIA. All aspects
of the systematic review, including literature searching, quality assessment, data extraction, and evidence
synthesis will be performed according to the Cochrane Collaboration and Stroke Group standards,
including recommendations from the Screening and Diagnostic Tests Methods Group, as in previous
work.11,42 The methods for evidence synthesis (meta-analyses performed according to the summary receiver
operator characteristic (SROC) curve methodology or separate meta-analyses of sensitivity and specificity
estimates) will be contingent on the data obtained and the most appropriate method will be used.76 We
will use a standardised quality assessment instrument (i.e. the Quality Assessment of Diagnostic Studies
tool – QUADAS),77 with modifications as appropriate as in previous work.35,78
2) We will obtain data on demographics, risk factors, medications, recurrent stroke and death in patients
with TIA/minor stroke relevant to the UK in order to construct the health economic model. We will use
existing datasets where possible, e.g. large stroke and TIA registries,79 individual patient datasets, and
routinely collected anonymised national audit data, as in previous work.11,35
3) We will systematically review the literature for data on costs of CT and MR in the UK and other
countries with relevant healthcare systems (data available to us from previous HTA-funded projects will
help this process but requires updating). We will obtain up to date imaging costs from the NHS
Department of Health NHS Reference costs database and NHS Scotland Information and Statistics Division
(ISD) Costs Book. We will also obtain specific up to date costs of diagnostic imaging for stroke with CT
and MR from individual radiology departments in a range of hospitals in the Scottish Imaging Network – A
Platform for Scientific Excellence (SINAPSE) Collaboration, which includes six University centres including
four regional specialist neuroscience centres and networks with district general hospitals in different
large and small cities. Together, these costs will provide a realistic range of current costs for the health
economics model and information on which to base sensitivity analyses of the effects of higher or lower
costs on the outcome of the health economics modelling as in previous work.11,35
4) We will survey UK stroke physicians through the British Association of Stroke Physicians as in previous
work11 to ask about stroke prevention clinics including current access to and use of MR sequences,
including DWI and other relevant sequences in patients with TIA/minor stroke in the NHS, aspirations and
consensus on role of MR, and to gather additional unpublished data on MR including DWI and other
relevant sequences in TIA/minor stroke.
5) We will survey UK radiology departments through the SINAPSE Collaboration in Scotland, and the
College of Radiologists and British Society of Neuroradiologists elsewhere in the UK to determine what
capacity there is for increased throughput of TIA and minor stroke patients, and to identify the perceived
major barriers to increased or faster throughput of TIA/minor stroke patients and what additional resources
would be required to provide additional access for these patients.
6) We will obtain UK data on the health care costs associated with management of stroke patients by
literature review of relevant electronic databases such as MEDLINE, EMBASE and SCOPUS,80 and
interrogation of specific sources such as stroke registry data as in previous work (see below for
specific details).11,35
7) We will obtain data on quality of life after stroke for key subgroups from the literature and from our
previous work and from our local stroke register data.81355
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APPENDIX 58) We will build a model that reflects key stages and outcomes in secondary stroke prevention after TIA/
minor stroke, including all data on assessments, medical and surgical interventions, outcomes, and timings,
populated with representative data from TIA/stroke services in the UK. The timelines in the model will be
stratified by time after symptoms, key patient characteristics, use of prognostic scores (ABCD2)22 including
conventional investigations (CT, carotid imaging) and treatment decisions, and key outcomes of
non-disabling and disabling stroke and death at six months, one and five years.
9) We will model the incremental cost-effectiveness of implementing MR including DWI and other
relevant sequences instead of usual care in the diagnosis of TIA/minor stroke. The clinical outcomes of
non-disabling stroke, disabling stroke and death will be summarised through the calculation of Quality
Adjusted Life Years (QALYs). QALYs will be calculated by the generation of quality of life weights for
disabling and non-disabling stroke, and the assignment of probabilities to these outcomes. Literature
review and statistical modelling of registry data will inform the calculation of probabilities of clinical
outcomes with and without MR including DWI and other relevant sequences. Quality of life weights will be
based on values from published literature and, where feasible, registry data. The definition of usual care
will be developed following literature review of current UK studies and interrogation of stroke registry
data; however, following previous work it is anticipated that it will be based on CT scanning varying
proportions of cohorts of 1000 patients presenting to hospital with suspected TIA/minor stroke. Modelling
will account for patient heterogeneity; e.g. in spite of increased efforts to raise awareness of the
importance of acting quickly on noticing stroke symptoms, a proportion of patients with TIA/minor stroke
may continue to present late after symptoms. In these patients, CT scanning will not identify the small
proportion (5%) who have a small haemorrhage as the cause of their stroke and MR scanning is
required.37 We have already analysed the sensitivity and specificity of CT and MR for haemorrhage in
patients presenting beyond five days after symptoms35 but did not perform a cost-effectiveness analysis
of increased use of MR in this predominantly out patient population. Therefore it is anticipated that
cost-effectiveness will be measured separately for both ‘early’ and ‘delayed’ presentation of symptoms,
with ‘delayed’ defined as presenting over five days after stroke. To test the robustness of the point
estimates generated and to quantify the degree of decision uncertainty, probabilistic sensitivity analysis
(PSA) will be conducted. This will involve taking repeated random draws from specific distributions of all
stochastic parameters (clinical outcome probabilities, relative risk reduction of associated events with MR
DWI and other relevant sequences, usual care quality of life score, disabling and non-disabling stroke
quality of life score, usual care health care costs, and imaging costs). The output from the PSA will then be
used to calculate the probability that the new diagnostic strategy is more cost-effective than usual care.
Value of information analysis will be conducted to investigate the worth of commissioning further research
on the cost-effectiveness of MR DWI imaging and inform the design of any future research. Population
Expected Value of Perfect Information (EVPI) will be computed to assess whether the benefits of future
research in the form of reduced uncertainty exceed the likely costs of research, and to assess which
parameter, or set of parameters, should be the focus for any future research; analysis of covariance
techniques will be used to explore the proportionate contribution of each parameter to variation in
incremental cost and QALYs. Further, the EVPI for parameters will be calculated, in which repeated model
simulations will be run with each parameter held constant in turn, whilst allowing other stochastic
parameters to vary, so as to provide clinically-relevant data on key age groups, stroke risk strata and MR
availability. All modelling work will be performed according to recommended guidance (http://www.
equator-network.org/).82
10) Finally, using information on investigation costs, we will estimate the effect of using MR or CT also to
diagnose carotid stenosis as a ‘one-stop’ investigation, instead of performing the MR or CT brain scan and
separately performing carotid imaging with, for example, ultrasound. This will reflect the reality that
different imaging modalities are used in different centres for reasons of equipment availability. We have
already determined the accuracy and cost-effectiveness of different carotid imaging tests in the diagnosis
and management of carotid stenosis in stroke prevention.11,46 However, we have not assessed the cost and
practicality of performing ‘one-stop’ brain and carotid imaging. Obtaining all the information required
from imaging in one scan is attractive, but factors such as increased machine occupancy, radiation doseNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27(CT), patient unacceptability (MR), and contraindications to contrast agents required for the carotid
imaging (both CT and MR) will limit the number of patients who can actually have ‘one-stop’ brain and
carotid imaging. We will use data from our previous HTA report11 combined with updated information on
accuracy of carotid imaging,83 data on practicality from Glasgow Neuroradiology where CT with CTA
(rather than CT plus ultrasound) is the routine investigation for suspected carotid stenosis and the cost
information that we will obtain in the present work, to examine the effect of replacing traditional separate
brain and carotid imaging tests with ‘one-stop’ CT or MR imaging. In this analysis, the base case scenario
will be CT brain scan and carotid ultrasound.
Planned inclusion/exclusion criteria: We will model a typical population of patients presenting with
suspected TIA/minor stroke based on existing data as in previous work, updated to reflect current
demographic, pre-stroke medications, and stroke treatments using information from the literature and a
large national stroke audit. These include: the North Edinburgh Stroke Study and Lothian Stroke Register
(n = 2598, a hospital-based registry of all in and out patients with TIA and stroke presenting to our hospital
between 1990 and 2000 with demographic information, imaging and laboratory investigations, past
medical history, medications prior to and following the TIA/stroke, and quality of life data) and followed up
to four years for recurrent stroke, cardiac events and death and used in two previous HTA reports;11,35 the
Edinburgh Stroke Study (n = 1367, a hospital-based registry of all in and out patients with TIA and stroke
presenting to our hospital between 2002 and 2005 with the same information except quality of life) and
so far followed up to four years after the stroke;79 and the Incidence of Stroke in the Lanarkshire Area
(ISLA) study (K Muir). We will obtain longer term follow-up for stroke, other major vascular events and
death for both cohorts at the start of the project through data linkage with the ISD (http://www.
isdscotland.org). We also have data from other studies of stroke and TIA with more detailed imaging,
including a study comparing CT and MR scans in minor stroke between 1998 and 2001 (n = 230),37 a
study of patients with mild cortical and lacunar stroke between 2005 and 2007 (n = 250),84 and a study of
practicalities and workload implications of increased use of MR imaging in patients with TIA in Glasgow
(K Muir ongoing). Other population-based studies of TIA/minor stroke which may provide additional details
are available to us and additional new data may become available from other stroke prognosis studies. The
Scottish Stroke Care Audit (SSCA) routinely collects data from hospitals across Scotland that provide stroke
services (PI M Dennis). Data from SSCA will be routinely linked through ISD to provide anonymised data on
the process of stroke care across the Scottish population in late 2009 (project currently under way jointly
run by SSCA and ISD, with a research governance committee to guide access and usage). We will apply to
use anonymised data from the linked audit to provide up to date population-based data that reflect
current stroke care. We will stratify data in the model by age, underlying vascular risk factors, sex, prior use
of medical treatments, and other factors which may affect stroke risk and therefore require data with this
degree of granularity for the model.
Ethical arrangements: The use of existing anonymised data to populate the model and perform other
analyses does not require additional ethics approvals. We will apply to the ISD Privacy Advisory Committee
for permission to link the LSR and ESS data (this has been done previously and no current problems are
anticipated with repeating this request). We will also apply to the new committee which is being formed
to review requests for use of ISD-linked data from SSCAS (see above). All data used in the proposed
modelling will be anonymised.
Proposed sample size: We will model the effect of incremental change in proportions of TIA/minor
stroke patients undergoing MR imaging for a typical UK population of 1000 patients as performed
previously in HTA-funded projects assessing the cost-effectiveness of CT scanning in acute stroke35 and of
carotid imaging in stroke prevention.11 We have several existing datasets including several 1000 patients
with TIA, minor and major stroke, with initial clinical and imaging assessment, and data on functional
status, stroke recurrence and death at six months, one year and four years, which we propose to data link
with centralised health care statistics as details above. We will provide the results in the form of “events
per a cohort of 1000 patients presenting to hospital with suspected TIA and minor stroke”.357
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APPENDIX 5Statistical analyses:
Systematic review of diagnostic accuracy: Indices of diagnostic performance will be extracted or derived
from data presented in each primary study for each imaging test. Where data are available, we will
construct 2 × 2 contingency tables of test results versus reference standard to show the cross-classification
of disease status and test outcome. We will calculate sensitivity and specificity with 95% confidence
intervals for each imaging test for each study. To describe and visualise the data, we will draw forest plots
showing the pairs of sensitivity and specificity estimates for each study. For a descriptive analysis we will
also plot the imaging test results on a receiver operating characteristic (ROC) plot of true positive rate
(sensitivity) against false positive rate (1 – specificity). The choice of statistical methods to combine studies
will depend upon the pattern of heterogeneity observed between study results. Where appropriate, we
will pool data from included studies using SROC curve methods,84 which are based on a random effects
approach and take into account the degree of heterogeneity between studies. Where possible, co-variates
will be incorporated in the SROC model to examine the effect of potential sources of heterogeneity on
sensitivity and specificity estimates. If the SROC model proves inappropriate we will summarise results
using univariate meta-analyses of true and false positive rates.76
Economic modelling: Data from included studies will be appraised, summarised, and interpreted alongside
the results of the systematic review of diagnostic accuracy so that conclusions will be drawn on the effect
of MR including DWI and other relevant sequences compared with the current alternative of CT brain
scanning, as detailed in 9 above.
Proposed outcome measures: The primary outcome will be the incremental cost-effectiveness of MR
scanning compared with the reference standard. Proposed secondary outcome measures include: the
estimates of sensitivity/specificity of ‘MR including DWI and other relevant sequences’ versus ‘conventional
clinical assessment plus CT’ to diagnose TIA/minor stroke; the proportion of patients with TIA/minor stroke
with a visible ischaemic lesion on ‘MR including DWI and other relevant sequences’ and CT brain scanning
and the association with key clinical variables; whether adding information from brain scanning to clinical
risk scoring improves prediction of future risk of stroke or death; the association between a positive or
negative brain scan and risk factors for stroke such as carotid stenosis; delays to diagnosis, delays to
starting medical or surgical treatment if MR including DWI and other relevant sequences were to replace
CT brain scanning; the number of disabling strokes prevented at six months, one and five years after
TIA/minor stroke if ‘MR including DWI and other relevant sequences’ were to be used in most patients for
a cohort of 1000 patients; quality adjusted life years stratified by key patient groups (e.g. elderly); the
cost-effectiveness of substituting MR including DWI and other relevant sequences for CT brain scanning
in patients with TIA/minor stroke in important demographic subgroups and by different times to
presentation; and an estimate of the increase in availability of MR for TIA/minor stroke that would be
required (if any) to accommodate TIA/minor stroke patients rapidly after the index event. We will provide a
range of options reflecting effect of using MR in different proportions of TIA/minor stroke patients to
guide decision-making by health service purchasers.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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We anticipate that the project will take 18 months to be completed.
Month 1–2: Appoint staff, develop a protocol, develop literature searches, design data extraction forms,
discuss structure for model;
Month 3–8: Diagnostic review, economic review and model development, design survey questionnaire,
survey stroke prevention clinics;
Month 9–12: Test model, writing up diagnostic review;
Month 12–14: Modelling (run model and sensitivity analyses);
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Project timetables and milestones
Start date: 1 October 2010
We anticipate that the project will take 18 months to be completed (see chart below):
l Months 1–2: Appoint staff, develop a protocol, develop literature searches, design data extraction
forms, discuss structure for model.
l Months 3–8: Diagnostic review, economic review and model development, design survey
questionnaire, survey stroke prevention clinics.
l Months 9–12: Test model, writing up diagnostic review.
l Months 12–14: Modelling (run model and sensitivity analyses).




Design data extraction forms
Discuss structure for model
Diagnostic review, economic review
and model development
Design survey questionnaire
Survey stroke prevention clinics
Test model
Writing up diagnostic review
Modelling (run model and sensitivity
analyses)
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Professor Joanna Wardlaw – Edinburgh, Neuroradiologist, PI
Dr Paul McNamee – Aberdeen, Health Economist
Professor Martin Dennis – Edinburgh, Stroke Physician
Professor Peter Sandercock – Edinburgh, Neurologist and Cochrane Stroke Group Lead
Ms Miriam Brazzelli – Edinburgh, Research fellow
Dr Janet de Wilde – SINAPSE co-ordinator
Professor Keith Muir – Glasgow, Neurologist
Professor Donald Hadley – Glasgow, Neuroradiologist
Dr Peter Tothill (Public representative)
Dr G Scotland – Aberdeen, Health Economics research fellow
Dr Francesca Chappell – Edinburgh, Statistician
The full Project Steering Committee will meet three monthly, starting in October 2010 until the end of the
project. A core group made up of J Wardlaw, M Brazzelli, P McNamee, and G Scotland will meet at least
monthly partly in person and partly by teleconference to reduce time wasted in travelling. Web
teleconferences will be used where possible to reduce in person meeting frequency.Expertise and resources available
Professor Joanna Wardlaw will lead and co-ordinate all aspects of the project. She is Professor of Applied
Neuroimaging and an Honorary Consultant Neuroradiologist at the University of Edinburgh and NHS
Lothian. She is an internationally recognised expert on imaging in the diagnosis and prevention of stroke,
in the use of imaging to study pathophysiology of large artery and lacunar ischaemic stroke, systematic
reviews of diagnostic test accuracy in stroke, and has conducted several cost-effectiveness analyses of
imaging in stroke. She has performed two HTA-funded studies of effectiveness and cost-effectiveness
of imaging in stroke (CT in acute stroke; carotid imaging for secondary prevention) which have changed
UK, European, North American and Australasian stroke guidelines. She is a member of the Cochrane
Diagnostic Tests Methods Group, helped to evaluate methods for meta-analysis of diagnostic tests,76 and
helped to pilot two Cochrane Diagnostic Tests Reviews. She was a European Editor of the AHA journal
STROKE, from 2005 to 2010. She is an executive member of the Scottish Stroke Research Network (SSRN)
and was founding director of a large imaging collaboration between six Scottish universities, the Scottish
Imaging Network – A Platform for Scientific Excellence (SINAPSE).
Dr Paul McNamee is a Senior Research Fellow in Health Economics at the Health Economics Research Unit
(HERU), University of Aberdeen. He is Director of the Preference Elicitation and Assessment of Technologies
(PEAT) Research Programme within HERU, and has over 15 years of research experience in health
economics, mainly in studies investigating the cost-effectiveness of new forms of health-care delivery.
Among current grants, he is a co-investigator on the NIHR HTA funded multicentre Surgical Trial In
Traumatic intraCerebral Haemorrhage (STITCH).NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18270 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 27Professor Martin Dennis is Professor of Stroke Medicine and an Honorary Consultant Stroke Physician at
the University of Edinburgh and NHS Lothian. He is an expert on stroke services, models of stroke
prevention and prediction. He was the founding President of the British Association of Stroke Physicians
and has been the Chairman of the Advisory Committee on Stroke to the Scottish Government (i.e. the
Scottish Stroke ‘Czar’) for nearly 10 years. He is an executive member of SSRN, the PI of the SSCA, and the
PI of the FOOD (HTA funded) and CLOTS (MRC funded) multicentre trials.
Professor Peter Sandercock is Professor of Neurology and Honorary Consultant Neurologist at the
University of Edinburgh and NHS Lothian. He was PI of the world’s largest ever acute stroke treatment
trial, the MRC-funded International Stroke Trial, and is currently PI of the world’s largest trial of
thrombolysis in acute stroke, the Third International Stroke Trial. He has been the Coordinating Editor of
the Cochrane Stroke Group since 1998. He has worked with the Cochrane Diagnostic Tests Methods
Group, tested the methods for systematic reviews of diagnostic tests, and helped pilot one of the first
Cochrane reviews in the field. He was lead author of an HTA review of effectiveness and cost-effectiveness
of thrombolytic and neuroprotective therapies for acute stroke, is currently joint Director of the Edinburgh
MRC Trials Methodology Hub and Director of Edinburgh Neuroscience, and jointly with Professor
Wardlaw, has previously surveyed availability of MR for patients admitted to UK hospitals with
acute stroke.
Ms Miriam Brazzelli is a Research Fellow at the Division of Clinical Neurosciences, University of Edinburgh.
She is experienced in systematic reviews of interventions and cost-effectiveness analyses of diagnostic
imaging. She has conducted and published several Cochrane systematic reviews as well as Technology
Assessment Reviews (TAR) and Interventional Procedures Reviews commissioned by NICE and worked on
systematic reviews for the Royal College of Radiologists Guideline ‘Making the Best Use of a Radiology
Department 5th Edition’. She has also been awarded a Chief Scientist Office (CSO), Scottish Executive
Health Department, fellowship to study the methodology of systematic reviews of diagnostic accuracy
studies and she is currently completing her PhD on this topic. She is a member of the Cochrane Screening
and Diagnostic Tests Methods Group and of the Stroke Group and has recently completed, together with
J Wardlaw and P Sandercock, a Cochrane review of diagnostic accuracy studies on CT and MR for
acute stroke.
Dr Janet de Wilde, Medical Physicist, is the Project Coordinator of SINAPSE, a joint imaging network set
up between six universities and funded by the Scottish Funding Council. She is also a very experienced
MR physicist having authored several papers and books on MRI and is the former Director of MagNET
(the UK’s central MR advisory body). She recently led a successful bid, on behalf of SINAPSE, to become a
UK Centre for Evidence-Based Purchasing (CEP) now part of NICE, and now leads the first CEP-
commissioned work.
Professor Keith Muir, SINAPSE Professor of Clinical Imaging and Honorary Consultant Neurologist with
an interest in stroke, University of Glasgow and NHS Glasgow is an experienced clinical investigator in
trials in acute and secondary prevention studies in stroke since 1992 (e.g. SAINT 1&2, ECASS 3, lubeluzole
programme, MATCH, PRoFESS), UK chief investigator for phase 2 trials, and member of the steering
committees for IMAGES, EPITHET, ENOS, and others. He is experienced in brain imaging analysis and
interpretation for acute stroke trials and in research (e.g. SELESTIAL trial, CT perfusion studies). He runs an
acute stroke treatment and prevention service for south Glasgow and adjacent regions and has been
piloting practicalities in the use of MR DWI for TIA.
Professor Donald Hadley, Professor and Honorary Consultant Neuroradiologist, University of Glasgow and
NHS Glasgow, is one of, if not the most, experienced neuroradiologists in the UK in MR, has co-ordinated
the SW Scotland regional neuro-MR service since the early 1980s as well as research uses and has
extensive experience in applications and practicalities of MR in general and in particular for stroke.
Dr Graham Scotland is a health economics research fellow in Aberdeen at HERU.367
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APPENDIX 6Dr Francesca Chappell is a statistician specialising in assessment diagnostic tests including meta-analyses
and use of Summary receiver operator characteristic curves and other methods for data synthesis.
Dr Peter Tothill is a retired medical physicist who will act as public representative on the Steering
Committee. As a medical physicist, he has very valuable insight into medical imaging as well as being able
to bring experience of stroke investigations from a lay perspective to the project.
Infrastructure: The SINAPSE network of six Scottish university research imaging centres and NHS imaging
facilities, offers an unparalleled ‘virtual clinical imaging laboratory’ facilitating many aspects of the project
(www.sinapse.ac.uk). The network members have considerable experience of systematic reviews and
health economic assessments of diagnostic imaging as evidenced by the recent award Centre for Evidence
Based Purchasing status. The HERU, together with the Health Services Research Unit (HSRU) and the
Department of Public Health at the University of Aberdeen, are one of only seven academic groups that
hold contracts to conduct TARs and Single Technology Appraisals (STAs) for NICE, as well as other
customers. Further, HERU provides an external quality assurance function to the work of the Scottish
Medicines Consortium (SMC). The Cochrane Stroke Groupbased at the University of Edinburgh is one of
the longest established Cochrane disease groups and has been proactive in piloting and implementing
diagnostic tests systematic reviews into the Cochrane Library.
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